Company Stories  N-O

Stories that earlier appeared in Nelson's News 
Note 1: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed.
(Note 2: Carl Nelson Consulting does not endorse these companies or organizations or their activities.) 
Looking for other older stories? Visit the archives


N12 Technologies .... N30 Pharmaceuticals .... NABsys ...Nalas Engineering ... Nammi Therapeutics ... NanOasis Technologies ... NanoBio ... Nano-C ... Nanobiosym ... NanoCellect (formerly NanoSort) ..... Nanochon ... Nanocomp Technologies ... NanoCoolers ... Nanocopoeia ... NanoCor Therapeutics ... Nanodynamics (Buffalo) ... Nano DX ..... Nanodynamics (NYC) ... NanoeXa ..... Nanofiber Solutions ... Nanogen ... NanoGraf (formery SiNode) .... NanoGram ... nanoGriptech ... NanoGuard Technologies ..... NanoH2O ... Nanohmics ... NanoLab ... NanoLite Systems ... NanoLogix .... NanoLumens ... Nanomaterials Research ... NanoMatrix ... NanoMedex ... Nanomix ... nanoMR .... Nanophase Technologies ... NanoPhotonica ... Nanopore Diagnostics ..... Nanoptek ... Nanoramic Laboratories (formerly FastCap Systems) .... nanoRETE ... Nanoscale Components ... Nanoscale Materials ... Nanoscope Technologies .... Nanosolar ... Nanosonic .... Nanospectra Biosciences ..... Nanosphere ... NanoSteel ... Nanostim .... NanoString Technologies ... Nanosys ... NanoSystems ... Nano Tailor .... Nanotech Energy .... Nanotek Instruments .... Nano-Terra ... Nanotherapeutics ..... NanoTune Technologies ... Nanova ... Nanovation Technologies ... NanoVault Medical .... NanoVibronix .... NanoViricides ... NanoVision Diagnostics .... NantCell ..... Nantero ... NantHealth .... NantKwest ..... Napo Pharmaceuticals ... Narus Biotechnologies ..... Nascentric ... Nastech Pharmaceutical ... Natera .... National Technical Systems ... Natural Molecular Testing .... NaturalNano ... Nature's First ... Natus Medical ... Naveris ... Naverus ... Navidea Biopharmaceuticals ... Navini Networks ... Navire Pharmaceuticals .... Navitor Pharmaceuticals ... Navmar Applied Sciences ... NBD Nanotechnologies ... NCD Technologies ... nContact Surgical ... Neah Power ...Near Infinity ... Neato Robotics ... Neoci .... Netezza ... NetLogics Microsystems ... Nektar Therapeutics ... Nekton Research ... NemaMetrix .... NeoChord ... Neogen ... NeoGenomics ..... Neograft .... Neoleukin Therapeutics .... NeoLight ..... Neon Therapeutics ..... NeoPhotonics ... Neoprobe ... Neos Therapeutics ..... NeoSync ..... Neothetics .... Neotron ... NephroGenex .... Nereus Pharmaceuticals ... Nerites ... Nest .... Netcentric .... Netspeed Systems .... Net Watch Solutions .... NetworkFab ... Neurable ..... NeurAccel Biosciences ... Neurala ..... Neural Analytics .... Neuralstem ... Neuraly ..... NeuraMedica .... Neuraptive Therapeutics ..... Neuro Amp ... Neurobiological Technologies ...NeuroBo Pharmaceuticals .... NeuroChaos Solutions .... Neurocrine Biosciences ... ... NeuroDx Development ... NeuroDyne Medical ... NeuroEM .... NeuroFlow ..... Neurofluidics ... Neurogastrx ..... Neurogen ... Neurogene .... NeurogesX ... Neurognostics ... NeuroHabilitation ..... Neuro Kinetics .... NeuroLogica .... NeuroLutions .... NeuroMap ... NeuroMetrix ... Neurona Therapeutics ..... Neuronetics ... Neuronex .... ... Neuron Systems .... NeuroOne ... NeuroPace..Neurophage Pharma (now Proclara Biosciences) ..... NeuroPointDX ..... Neuroptix .... NeuroPace ... NeuroRecovery Technologies .... NeuroSigma .... NeuroTek .... Neurotrack .... NeuroTronik ... Neurovance .... ... Neurovascular Diagnostics ..... NeuroVigil ... NeuroVision Imaging .... NeuroVista ... NeuroVive .... NeuWave Medical ... Nevro ... ... New Dominion Enterprises ..... New England BioLabs ..... New Era Technology ... NewLeaf Symbiotics ... NewLink Genetics ... Nexant .... NexBio ... NexImmune .... NextIO ..... NexPlanar ..... NextCODE Health .... NextCure .... NEXTracker .... Nextreme Thermal Solutions ... NextStep Robotics ..... Nexus Biosystems ... NFlection Therapeutics .... NG1 Technologies ..... NGM Biopharmaceuticals .... Nico (Indianapolis, IN) ..... Nido Biosciences .... Night Vision ... Nimble Storage ..... NimbleGen Systems ... Nimble Therapeutics .... Nimbus Discovery ... Nimbus Therapeutics ..... NinePoint Medical ... Niowave ... NIRvana Sciences .... Nitero ... Nitric BioTherapeutics ... Nitride Solutions .... NitricGen ... Nitrogenics .... Nitrome Biosciences .... NitroMed .... Nitronex ... Nivalis Therapeutics formerly N30 Thera .... NKT Therapeutics ... nLight ... NMT Medical ... Noah Technologies ... Noble Fiber ... Nocion Therapeutics .... Nohla Therapeutics .... Noitavone ... Nok Nok Labs .... Nomadics ... NONA Composites .... Noninvasix .... Nonvolatile Electronics .. Nora Therapeutics .... .... Norian .. NorMedix ..... Norse .... Northeast Photosciences .. Northstar Neuroscience ... Northstar Battery ... Northstar .... MedicalRadioisotopes ... ..Northstar Photonics ... ..Northwest Biotherapeutics ... ..Norwich Technologies ...Nostopharma ..... Notice Technologies ... ... Novalux ..... Novan Therapeutics ..... .NovaScan ...Nova Scientific ...Novasenta ..... Nova Synthetix .... Novatek...NovaTract Surgical.... Novavax ... Novazyme Pharmaceuticals ..... Novecon Technologies ... .Novella Clinical .... Novel Microdevices ....Novelos Pharmaceuticals ... .Novelos Therapeutics .... Noveome Biotherapeutic ..... Novian Health .... Novira Therapeutics ...Novocell ... ..Novogy .... Novome Biotechnologies .... Novomer.. ..Novophage... Novo Sol-u-tions MD .... NovoSource ... ..Novus Biologicals .... NoxilizerM .. Nox Technologies ... NP Photonics.... NRGindependence .... NSS Labs .... Nucelis ..... Nuclea Bioechnologies ... Nucleus Biologics .... Nufern ... NuGEN Technologies .... NuMat Technologies ..... NuMedii ... NumereX ... NUMiX Materials ..... NuPathe.. ..Nurel (now PeriphaGen) .... Nurix Therapeutics .... Nuron Biotech ... Nutrabiotix ... ..Nutrient Recovery and Upcycling .... Nuvaira .... NuVant ... NuVascular Technologies .... Nuvation Bio .... Nuve ..... Nuventix... ..Nuvera Biosciences ... .Nuvera Fuel Cells .... Nuvotronics ..... Nuvox Pharma ..... Nu Waves ..... NxThera.... Nvision Biomedical Technologies ..... NZ Applied Technologies .... ..Oak-Mitsui .... Oasys . ...Object Video .... Obsidian Therapeutics ..... OBS Medical ...Ocarina Networks .... Ocata Thera ..... Occipital .... Ocean Bio-Chem .... Ocean Power Technologies ... Ocean Renewable Power .... Ocera Thera ..... .OCI..... Ocugen ..... Ocular Therapeutix .....Oculeve ...Oculogica .... Oculus .. ..ddpost.. .Odyssey Systems Consulting Group .. ..Oil Chem Technologies .. ..OLEDWorks .... Olema Oncology .... Omega Therapeutics ..... Omeros .... .OmniGen Bioproducts... ..OmniGuide ...OmniLytics ... Omniox ... Omnis PharmaRebiotix .... OmniSonics Medical Technologies ....Omni Water Solutions ... ONCE Innovations .... Onboard Dynamics ..... OnChip Power ... Oncobiologics .... Oncoceutics ..... OncoCyte .... Oncogenex .... Oncolmmune ..... Oncolinx ..... Oncolix ...... Oncolytics Biotech .. ..OncoMed Pharmaceuticals.. .. OncoNano Medicine ... Onconova Therapeutics ... OnCore Biopharma ..... OncoResponse ...... Oncorus ..... OncoSec Medical .... Oncoscope..... OncoTartis ..... Oncothyreon ... .. Oncovista Innovative Therapies ..... Oncternal Therapeutics ... One Resonance Sensors ..... Onduo ..... Onexio Biosystems ... Onko Solutions .... OnKure Therapeutics ..... ONL Therapeutics ..... On-Q-ity ..... Onspira Therapeutics ..... On Target Laboratories .... Ontela ..... On-X Life Technologies .... Onyx Pharmaceuticals .. ..Oorja Protonics .. .Open Algae ..... Open Monoclonal Technology .... Open Silicon ...... Opertech Bio .... Opexa Therapeutics ... ..OpGen ....OPNET Technologies.... Opsonix ..... .OptTek Systems ...Optelecom .. ..Optelecom-NKF .....Optical Concepts ... ..Optigain...Optimal Technologies .... .Optimer Pharmaceuticals... ..Optivision ... Optofluidics ... OptoLum ..... Opto Technology.. ..Biotech...Orasi Medical ... OraSure Technologies ....Orbital Insight .... Orbital Sidekick .... Orbital Technologies .... Orbotix ... Orca Bio .... Orchestra BioMed ... Orchid Cellmark ... Oregon Iron Works .... Orexigen Therapeutics ..... Organic Research ... Organogenesis....Organovo. .. ORIC Pharmaceuticals .... Oricula Therapeutics .... Origin Medsystems ..... Oroboros Bio ..... OriginOil ....Orologic.. ..Ortel...Orion Energy Systems.. .Orion Genomics...Ormet Circuits.... OrphoMed ..... Ortho Kinematics....Oryx Technology. ..Oscient Pharamceuticals...Oscilla Power .... Osiris Therapeutics. ..OSI Pharmaceuticals%...Ossianix ..Oso Biopharmaceuticals Manufacturing .... OSSIO ..... Ostendo Technologie...Osteotech ... OtoNexus Medical Technologies .... Otonomy..... OtoSense .... Ottomatika ..... OvaScience...Oxford Performance Materials..... Oxis International ..... Oxygen Biotherapeutics ObjectVideo ... OBS Medical ... Ocarina Networks ... Ocean Power Technologies ... OCI ... Ocular Therapeutix ... Oculeve ... Oculus ... Oddpost ... Oil Chem Technologies ... Omeros ... OmniGen Bioproducts ... OmniGuide ...OmniLytics ... OmniSonics Medical Technologies ... Omni Water Solutions ... OnChip Power ... Oncogenex ... Oncolytics Biotech ... OncoMed Pharmaceuticals ... Onconova Therapeutics ... OncoSec Medical ... Oncoscope ... Oncothyreon ... OnLume .... eOn-Q-ity ... Onyx Pharmaceuticals ... Oorja Protonics ... Open Algae ... Open Silicon ... OpenWater Power ..... Opexa Therapeutics ... OpGen ... OPNET Technologies ... OptTek Systems ... Optelecom ... Optelecom-NKF ...Optical Concepts ... Optigain ... Optimal Technologies ... OptiMedica .... Optimer Pharmaceuticals ... Optimus Technologies ..... OptiNose ....Optivision... Optomec ... Optonicus .... Opto Technology ... OPX Biotech ... OragenicsOrasi Medical ... Orbital Technologies ... Orchard Therapeutics ..... Orchid Cellmark ... Orexigen Therapeutics ... Organogenesis ... Organovo ... OriginOil ... Orologic ...Ortel ... Orion Energy Systems ... Orion Genomics ... Ormet Circuits ... OrthoAccel Technologies ... Ortho Kinematics ... Oryx Technology ...Osazda Energy ..... Oscient Pharamceuticals ... Osiris Therapeutics ... OSI Pharmaceuticals ... Osprey Medical .... Ossianix ... Ostendo Technologies ... Osteotech ..... Osterhout Design Group .... Otonomy ... Outset Medical .... OvaScience ... Ovid Therapeutics ..... Oxalo Therapeutics .... Oxford Performance Materials ... Oxygen Biotherapeutics

N12 Technologies

N12 Technologies (Cambridge,MA; no SBIR) is currently testing its lightweight-composite technology in products ranging from hockey sticks, airplanes and bicycles to automobiles and satellites. ... Late last year, the company landed a $2.5 million loan from the state's Advanced Manufacturing Collaborative, which will help the company ramp up its pipeline of customers from 50 to about 200 by the end of the year.  ...  "The demand from customers has exceeded our production capacity," [CEO Brad Berkson] said in an interview.  [Sara Castellanos, Boston Business Journal, Jan 21, 15]

Two area clean technology startups have won grants under a new local program, U-Launch, that aims to turn university research into commercial cleantech solutions.N12 Technologies (Cambridge, MA) and  iBLogix (Waltham, MA)  Dollar values for the awards were not disclosed. N12 is commercializing advanced materials technology at MIT ...  iBLogix is developing building information software that employs data-aggregation and analysis technology, with the aim of commercializing a system developed to remotely profile the energy performance of buildings. ... U-Launch is partially funded by a three-year, $1.1 million award from the U.S. Department of Energy’s Innovation Ecosystem Development Initiative.  [Kyle Alspach, Mass High Tech, Mar 15, 11]

N30 Pharmaceuticals (now Nivalis Therapeutics; Boulder, CO)

Nivalis Therapeutics  (formerly N30 Pharmaceuticals, Boulder, CO; no SBIR) pharmaceutical company, filed [IPO] to continue its cystic fibrosis research and treatment development. ...  said it intends to raise as much as $60 million.  ...  is currently creating the compound "N9115" to treat the disease, which affects the lungs and digestive system. ... The Denver Post reports that the company last year raised $30 million in a mezzanine round    [Caitlin Hendee, Denver Business Journal, May 14, 15]

N30 Pharmaceuticals (Boulder, CO; no SBIR, founded 2007) a clinical stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis (CF), has raised $30 million in a mezzanine round of financing. [company press release, Nov 19, 14]   developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis.  [Company website]

NABsys (Providence, RI)

NABsys (Providence, RI; one SBIR)  has completed a $10 million round of venture capital financing ... working on electronic, solid-state DNA sequencing that, the company said, could ultimately be used in whole-genome sequencing  [Michelle Lang, Mass High Tech, Sep 15, 11]

NABsys (Providence, RI; $500K SBIR), developer of DNA-sequencing technology, has closed a $4 million equity round that will be used to grow the company’s solid-state DNA sequencing platform. ...  has won a $1.3 million federal grant, awarded by [NIH] in 2007 [Mass High Tech, May 5, 09]

Nalas Engineering (Essex, CT)

Five Connecticut companies have qualified for more than $1 million in grants and loans through the Small Business Express Program. ... a bi-partisan effort created last year to help small businesses with 50 or fewer workers boost their payrolls and fund capital investments. Innovation companies: Nature's First (Orange, CT; no SBIR); Nalas Engineering (Essex, CT; one SBIR);    [Janice Podsada, Hartford Courant, Apr 13, 12]

Nammi Therapeutics (West Los Angeles,CA)

Nammi Therapeutics (West Los Angeles,CA; no SBIR) Looks to Raise $20M BIOTECH: UCLA spinoff developing cancer treatment [Dana Bartholomew, Los Angeles Business Journal, May 10, 19] focused on optimizing cancer immunotherapy by using nanocarriers to deliver synergistic anti-tumor and immune activating agents to the tumor. [, May 10, 19]

NanOasis Technologies (Richmond,CA)

ARPA-E winners in San Francisco Bay area: Envia Systems (Hayward); NanOasis Technologies (Richmond); Pax Streamline, (San Rafael); and Stanford University. None had SBIR. official list of winners

NanoBio (Ann Arbor, MI)

NanoBio (Ann Arbor, MI; $300K SBIR) said it signed a licensing deal with the University of Michigan to help commercialize a vaccine against urinary tract infections (UTI).  ... wants to use its NanoStat platform technology to deliver through the nose an antigen developed by U-M scientists designed to kill E. coli bacteria in the urinary tract.  [Thomas Lee,, Apr 20, 11]

Nano-C (Westwood MA)

nanotech manufacturer NANO-C (Westwood, MA; $1.2M SBIR) raised $4.8M in a $9M funding round, according to an SEC filing. [Boston, Jun 5, 19]

MassDevelopment has issued a $2.4 million Emerging Technology Fund loan to Nano-C (Westwood, MA; $1.3M SBIR, founded 2001), a leading developer of nanostructured carbon for use in electronics and energy applications. Nano-C will use loan proceeds to upgrade its manufacturing facility. [company press release, Jan 16, 19] prior funding $17M []

Nano-C (Westwood, MA; $1.3M SBIR, founded 2001) announced it has completed an $11.5 million round of funding  .... Customers, working in partnership with Nano-C, have already incorporated these nanostructured carbon materials and are getting ready to launch exciting new products based on Nano-C’s unique materials. [company press release, Apr 18, 18]

Nano-C (Westwood, MA; $600K SBIR) announced today that it has been issued US patents that cover the manufacturing of its core products. [Boston Globe, Sep 16, 08]

Nano-C (Westwood MA; one SBIR Phase 2) got a $2.9M ATP award to go with its $5.5M in VC since its 2001 birth.  [press release, Oct 16, 07]

Nanobiosym (Medford, MA)

Nanobiosym(Medford, MA) got a $2M DOD contract to develop its genetic-detection technology to sense biological threats after multiple rounds of funding from AFOSR DARPA, and DOE SBIR Phase 2. Dr. Anita Goel, Founder, Chairman, & CEO was named in 2005 as one of the world's “Top 35 science and technology innovators under the age of 35 by MIT’s Tech Review. BS in Physics from Stanford, PhD in Physics from Harvard, MD from the Harvard-MIT Joint Division of Health Sciences and Technology [press release, Sep 26, 07]

NanoCellect (San Diego, CA)

NanoCellect Biomedical (San Diego, CA; at least $9.2M SBIR, founded 2009) announced the completion of a $10 million Series B financing round [led by Illumina Ventures] [company press release, Nov 28, 17] ... [NIH SBIRs] to introduce upgraded functionality to the company’s WOLF Cell Sorter and N1 Single-Cell Dispenser, [company press release, Nov 22, 17]

NanoCellect (San Diego, CA; one SBIR as NanoSort) startup developing innovative technology for microfluidic cell analysis technology, said it has landed a $700,000 [NIH SBIR]. ....  founded in 2009 with technology developed at UC San Diego. In a statement, the company says it’s now seeking industrial partners and investors to advance development of its technology, which works much like a coin sorting machine for cells.  [Bruce Bigelow,, Nov 8, 13]

Nanochon (Washington,DC)

Nanochon (Washington, DC; $200K SBIR) just got a step closer in its quest to get a 3D-printed implant to market — thanks to $2 million in fresh funding and the potential to raise more. [company press release, Dec 10, 21]

Nanochon (Washington, DC; one SBIR) is aiming to close a $3.5M seed round in January to fund the first human study of its product, an alternative to joint replacement surgery. The new funding would position the med-tech company to start its first clinical trial in Q4 2021 of its tech — licensed from George Washington University — that replaces lost or damaged cartilage and will target a lower cost than existing options. [DCInno, Dec 22, 20]

Nanocomp Technologies (Concord, NH)

Nanocomp Technologies (Merrimack, NH; $5.7M SBIR including one for $4.6M) which has developed proprietary processes involving carbon nanotubes that are the width of a strand of DNA and a millimeter long, secured $139,521. The company, which raised $7.7 million of a $25 million Series C round from investors including DuPont, says it’s the only commercial producer of carbon nanotube-based products. [Patricia Resende, Boston Business Journal, Mar 27, 13]

Nanocomp Technologies (Merrimack, NH; $5.4M SBIR) announced that global chemical company DuPont will participate in a $25 million round expected to close later this year, and that the two companies will partner to create armor as well as lightweight, corrugated sheets used in airplanes, cars and boats.  ....  based on Nanocomp’s proprietary processes involving carbon nanotubes, which are the width of a strand of DNA and a millimeter long. The company says it’s the only commercial producer of carbon nanotube-based products. From its brand new, 100,000-square-foot manufacturing facility in Merrimack, the company manufactures quadrillions of the tubes, which can be formed into yarns and sheets which are being used for components U.S. Department of Defense and NASA programs, according to the company.  .... now has 53 employees  [Don Seiffert, Mass High Tech, Jun 11, 12]

Nanocomp Technologies (Concord, NH;  $5.4M SBIR) nanomaterials company, has raised $7.7 million of a planned $25 million new financing round, federal documents show.  ... In November, Nanocomp was chosen to supply its yarn and sheet material made from carbon nanotubes to the U.S. government under a Department of Defense program that helps manufacturing companies meet anticipated federal needs for their products.[Rodney Brown, Mass High Tech, Jan 6, 12]

Nanocomp Technologies (Concord, NH; $600K SBIR) announced that it has been awarded a multi-million dollar [SBIR] contract to continue research into new materials for Air Force aircraft.   .... makes sheets of tissue-thin, super-tough carbon nanotubes that can be used in things like lightweight vehicle bodies or flexible body armor. ...  plans to move into a 100,000-square-foot manufacturing facility within the next year [Kyle Alspach, Mass High Tech, Aug 24, 10]

Nanocomp (Concord, NH; $1.5M SBIR) a maker of carbon-nanotube-based materials, has landed a government contract aimed at using its material in the aerospace industry. ... just weeks after Nanocomp announced two other (SBIR) government contracts with the USAF. ... Originally spun out of Lebanon, N.H., technology incubator Synergy Innovations Inc., the 30-person Nanocomp has made its way with small amounts of funding, while maintaining high expectations. The company first landed $2 million in funding from the U.S. Army’s Natick Soldier Systems Center in 2004 for the development of advanced armor products.  [Mass High Tech, Jun 5, 09]

The EZ-IO device from Vidacare (San Antonio, TX; $1M SBIR), the company Dr. Larry Miller co-founded in 2001, is the Gold winner in The Wall Street Journal's eighth annual Innovation Awards competition. ... The Silver award went to Audience(no SBIR), a maker of voice processors, for a noise-suppression technology designed to block annoying background noise in mobile-phone calls. ... A team of scientists at the Lawrence Berkeley National Laboratory won the Bronze for their work in developing a microchip that, by analyzing DNA, is able to identify thousands of different varieties of bacteria that might be present in air, water, soil, blood or tissue samples. ...The PhyloChip [not currently available commercially. It is manufactured by Affymetrix], developed by staff scientist Gary Andersen and a team of researchers at the Lawrence Berkeley National Laboratory in Berkeley, Calif., won in [environment] category. ...Nanocomp Technologies (Concord, NH, no SBIR), the winner in [materials and other base technologies] category, has developed a process to create large sheets of fabric and lengths of yarn using carbon nanotubes -- synthetic carbon molecules prized for their exceptional strength and conductivity. [Michael Totty, Wall Street Journal, Sep 29, 08]

NanoCoolers (Austin, TX)

Fourteen startups that received a total of more than $17 million from [Texas Emerging Technology Fund managed by Gov. Rick Perry’s office... which has backed 143 startups] have failed or gone bankrupt.   ....   [ MIT professor Bill Aulet, who is managing director of the Martin Trust Center for MIT Entrepreneurship] said the number of failed ETF companies would be higher if state officials took the chances they needed when investing in startups. "They really haven't taken any risk," he said. "Governments aren't good at being venture capitalists because governments aren't good at risk." ....  a partial list of the ETF-backed startups in Texas that have since closed, followed by the grant amounts they received:  • NanoTailor, $250,000;  • Star Vision Technologies, $750,000; • Terrabon, $2.7 million;  • Thrombo Vision, $1.5 million;  Nanocoolers, $3 million;  • Advanced Receiver Technologies, $250,000;  • Bauhaus Software, $500,000;  • Net Watch Solutions, $500,000;  • Sunrise Ridge Algae, $250,000;  • SeprOx, $750,000; • Speer Medical, $2.5 million   [Christopher Calnan, Austin Business Journal, Jan 9, 14] None of these had SBIR.

From the Texas Emerging Technology Fund, Image Trends (Austin, TX; no SBIR) which develops image correction and enhancement products for commercial and amateur photographers will receive $1 million, and RFMicron (Austin, TX; no SBIR) $250,000 to speed development of its microchip technology  [Lori Hawkins, Austin American-Statesman, Jul 14, 08]  Of ten central TX companies fed from the fund, only one has failed so far: Nanocoolers (no SBIR) Tried to create a thermoelectric cooling system that would help cool semiconductors. Closed in 2007. The others: Molecular Imprints Inc. Nanotechnology company that makes advanced equipment used in producing computer chips, disk  drives and other products. Monebo Technologies (no SBIR) Heart monitoring device called CardioBelt that enables users to obtain their own electrocardiogram while at home.  Quantum Logic Devices  ($1+M SBIR, moved from NC) Developing a system that uses single-electron devices to analyze  DNA, protein and other molecular interactions. Receptor Logic Ltd. (no SBIR) Developing antibodies to improve understanding of the immune system and lead to better drugs and vaccines. Xitronix (no SBIR) Developing advanced semiconductor testing technology. XTreme Power (no SBIR) Developing electrical storage systems that are used to cut energy bills for commercial and industrial plants.

Money Wasn't Enough. An Austin company that received $3M from the Texas Emerging Technology Fund to develop a high-tech cooling device has shut down.  NanoCoolers Inc., founded in 2002, was working on a thermoelectric cooling system that would help cool semiconductors, which generate increasing heat as they become more powerful. "the technical challenges have proved to be substantial, and after many years of trying, we just have not been able to solve the problem," said Krishna Srinivasan, a partner with Austin Ventures, which was an investor in company. Before receiving money from the state fund in March, NanoCoolers raised about $19M [VC] [Lori Hawkins and Robert Elder, Austin American-Statesman, Dec 6]

Nanocopoeia (St.Paul, MN)

NanoReturn.Will any of this stuff translate into an economic windfall for Minnesota? So far, the U has licensed nanotechnology to three companies, two of them local, with mixed results.  Nanocopoeia (St. Paul , MN; $1M SBIR) is trying to divest its original medical device coating business to focus on pharmaceuticals. Rushford Hypersonic (no SBIR) next month will open the world's first hypersonic plasma particle disposition plant in southeastern Minnesota. Innovalight, (Austin, TX to St. Paul, MN to Sunnyvale, CA; $900K SBIR in TX), which originally focused on light bulbs, is now making solar cells. ...  The U's uneven experience with nanoscience mirrors corporate America's teasing and often frustrating flirtation with a technology that's failed, so far, to match hype with reality. Despite millions of dollars in government research money and venture capital, making big bucks off nanotechnology remains an elusive dream. [Thomas Lee, Minneapolis Star Tribune, Jun 28, 09]  Nanostuff, GaAs, CVD diamond, SiC substrates, and such, are the kind of futures that SBIR should invest in until economic barriers show that it has only a long term possible future. Then it should be turned over to long term investors with long green, not slogged away in a small high tech nursery program. SBIR's goal should be economic visibility for a technology, not long term development a few bucks at a time in life-style companies.

Two Minnesota startups are joining forces to debut what they claim is a faster and more effective way to test drug-coated stents at the nation's premier biotechnology conference this week.  Nanocopoeia(St. Paul, MN; $0.9M SBIR)  and the Integra Group (Brooklyn Park, MN; no SBIR)  will announce today a new company called NanoInterventions whose core technology is a mouse-based testing system for drug-coated stents. [Minneapolis Star Tribune, Jun 17, 08]

Nanocor Therapeutics (Chapel Hill,NC)

NanoCor Therapeutics, (Chapel Hill, NC; no SBIR) secured a $2.5 million infusion from medical technology company Medtronic, the company announced  [Frank Vinluan, Triangle Business Journal, Jul 1, 09].  spun off from Asklêpios BioPharmaceutical, Inc. in November 2005...  to create the first viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF). ... Medtronic invested  $3.75 million in 2007 [company website]

NanoCor Therapeutics (Chapel Hill,NC; no SBIR) got a $3.75M investment from medical-device giant Medtronic to work on a gene-therapy-based treatment for congestive heart failure. [Raleigh News & Observer, Sep 8]

Nano DX (Albany, NY)

 Two nanotechnology companies affiliated with the SUNY Polytechnic Institute in Albany have joined the state's Start-Up New York program [which] allows businesses to operate tax free for a decade.  .... Glauconix (Albany, NY; no SBIR), co-founded by Ph.D student Karen Torrejon, develops a more effective drug screening to prevent glaucoma. It won $100,000 in the state's business competition in 2014. That company will create 14 new jobs and invest $1,272,500. ...  Nano DX is a new biotechnology company that is a spinoff of Nuclea Biotechnologies (Pittsfield, MA; no SBIR). That company develops, produces and markets nanoscale diagnostics to provide patients and physicians with better ways to manage and care for chronic disease like cancer. NANO DX will create 15 new jobs and invest $265,000.  [Chelsea Diana, Albany Business Review, Jul 23, 15]

Nanodynamics (Buffalo,NY)

Nano IPOs. NANOTECHNOLOGY companies, nurtured on billions of dollars in government grants and venture investments through most of this decade, are getting ready to go public. ... NanoGram (Milpitas, CA; no SBIR), Unidym (Menlo Park, CA; no SBIR), NanoDynamics (Buffalo, NY; $1M SBIR).    Unidym is a subsidiary of the Arrowhead Research Corporation, a public investment company that was founded in 2003 to back small companies engaged in nanotechnology research. [James Flanigan, New York Times, Dec 20]

Nanodynamics (New York City)

C9 will make a new generation of silicon carbide chips at the Saratoga (NY) Technology & Energy Park. .... with help from the state's $1.75M ... C9's products now are made at the facilities of FALA and Nanodynamics (New York City; $6M SBIR) and the firms already have invested $11M into silicon carbide research. [Alan Wechsler, Albany Times-Union, Jul 28]

NanoeXa (Santa Clara, CA)

Thievery charged.    Envia Systems  (Newark, CA; no SBIR), a battery startup, made a big splash in early 2012 when it claimed it had achieved a milestone: a rechargeable lithium-ion battery with the highest "energy density" ever recorded. The company had been awarded a $4 million grant from ARPA-E, the innovation arm of the Department of Energy, and General Motors invested in the company with the hopes of licensing the technology.  Now, in an explosive and highly detailed lawsuit, three of Envia's top former executives allege that Sujeet Kumar, the company's co-founder and chief technology officer, created the company using intellectual property that he stole outright from NanoeXa  (Santa Clara, CA; no SBIR), his previous employer. [Dana Hall, San Jose Mercury News, Dec 4, 13]

Nanofiber Solutions (Columbus, OH)

A tissue engineering company developing materials to heal wounds and grow new blood vessels has raised $4.1 million in a round led by a "startup nursery." ParaGen Technologies LLC (Columbus, OH; no SBIR) is a parent company for medical device subsidiaries that use its core microfilament technology for specific applications. The first four are for healing skin, treating sports injuries, growing blood vessels and repairing hernias. company is a joint venture of Nanofiber Solutions LLC ($150K SBIR), which invented the technology, and Ikove Capital Partners. [Carrie Ghose, Columbus Business Journal, Dec 15, 17] three subsidiary companies are RenovoDerm, Atreon Orthopedics, and Vascular Genesis. [ParaGen website]

Ohio State University spinoff Nanofiber Solutions (Columbus, OH; one SBIR) is putting off a potential patent fight with a Harvard University spinoff over an artificial windpipe – and even finding a silver lining in the dispute.  ....surgeon, Dr. Paolo Macchiarini, used [his] model [artificial] trachea made by Nanofiber, and stem cells were seeded in the device in a bioreactor by Harvard Bioscience (Holliston, MA; $800K SBIR)  that fully credited its Columbus partner’s role in the operation.  A year later, Harvard Bioscience was marketing its own combination of a replica trachea and the bioreactor to grow cells, and preparing to spin off a company to make them. Nanofiber warned Harvard Bioscience in December 2012 that the product may infringe on its technology. .... A consultant [said] the trachea market is too small to merit suing, and there’s no way to prove economic damages in court. ....  Nanofiber is focusing instead on research on other organs, such as a joint project with Columbus-based Nationwide Children’s Hospital to make small intestines for infants  ... Harvard Bioscience, meanwhile, spun off Harvard Apparatus Regenerative Technology  Nov. 1 and gave it $15 million for operations.  [Carrie Ghose, Columbus Business First, Jan 7, 14] Nanofiber now says that its technology attracted $15M. ...also was awarded a $1.5 million Third Frontier loan under a new loan program that allows the proceeds to be used for operations and commercialization instead of only physical capital. ...also is in line for up to $1 million in angel and venture investment over the next year based on hitting milestones  [Carrie Ghose, Columbus Business First, Dec 12, 13]

Nanogen  (San Diego, CA)

Nanogen that filed for bankruptcy protection in May, said it has completed the sale of nearly all its assets to the French company Elitech Group. The sale brought $25.7 million, but Nanogen said it did not think holders of common shares would receive anything in the bankruptcy.  ... founded in 1993, was among San Diego's older biotech companies, with a stock that neared $100 in the biotech frenzy early this decade. [San Diego Union Tribune, Jul 13, 09]

Nanogen (San Diego, CA; $1M SBIR) said that it has filed for bankruptcy protection with plans to sell off nearly all its assets to the French company Elitech Group. The Chapter 11 filing culminates a scramble for survival at a company once considered one of the county's more promising biotechs, with technology focused on diagnostics. ... In the heat of the biotech frenzy early this decade, its stock neared $100 a share.   [Thomas Kupper, San Diego Union Tribune, May 15, 009]

Sweet Technology, But. Molecular diagnostics maker Nanogen (San Diego, CA; $800K SBIR) will try to sell its 15-year-old founding technology, or close the money-losing program, as part of an aggressive plan to achieve profitability. [San Diego Union Tribune, Sep 18]  Must be suitable for endless federal research contracts, but company has higher goals.

Nanogen Goes Public   Nanogen (San Diego, CA) raised $42M in an IPO without the help of any SBIR. Nanogen combines microelectronics with molecular biology to identify and test samples containing charged molecules. Using semiconductor microchips, Nanogen's system allows molecules to be identified and analyzed as they move around designated sites on the chips, depending on their positive or negative charge. Nanogen believes its system will have uses in medical diagnostics, biomedical research, genomics, genetic testing, and drug discoveries. The company is establishing corporate alliances with biotechnology companies such as Becton Dickinson and Elan to commercialize products using its proprietary microchip technology.[Hoovers] It's certainly the type of R&D that SBIR is supposed to help. Why didn't Nanogen need it while a parade of beneficiaries troops before Congress pleading inability to get started with new technology?

NanoGraf (formely SiNode,(Chicago, IL)

NanoGraf (formerly SiNode, Chicago, IL; $1.2M prior SBIR) Northwestern University and Argonne Nat'l Lab spinout enabler of the world’s most energy-dense 18650 lithium-ion cell, announced it won a $1 million development contract from the [DOD] to produce a more powerful, longer-lasting 4.3Ah lithium-ion battery. [company press release, Mar 28, 2022]

A Northwestern University spinout has hauled in more funding from the Department of Defense for its technology that makes stronger lithium-ion batteries. NanoGraf announced Monday that it won a $1M development contract from DoD to create a longer-lasting battery for the Army. The stronger battery will be used to improve the communication equipment used by soldiers in the field, the company said. U.S. soldiers have as much as 20 pounds of lithium-ion batteries in their equipment, which powers things like helmets, goggles and other communication devices, NanoGraf said. A stronger battery can reduce that weight and improve the efficiency of their equipment. It's the second award NanoGraf has received from the DoD. In 2020 it got a $1.65M grant, and the following year it developed what the company said is the world’s longest-running 3.8Ah lithium-ion cell. NanoGraf's new cell, a 4.3Ah lithium-ion battery, is expected to be ready by 2024. Founded in 2012 and formerly known as SiNode Systems, NanoGraf's technology was initially developed at Northwestern University and Argonne National Laboratory. The startup was founded by Samir Mayekar, who is now Chicago's deputy mayor for economic and neighborhood development. NanoGraf is led today by CEO Francis Wang. [Jim Dallke,Chicago Inno, Mar 28, 2022]

NanoGraf (Chicago, IL; no SBIR) advanced battery material startup, announced a breakthrough in its lithium-ion battery that enables it to be longer-lasting, lighter weight, and have a shortened charge cycle. The company said its battery now has the highest energy density 18650 cylindrical lithium-ion cell in the world, providing a 28% longer run time than traditional cell chemistries. [Jim Dallke, ChicagoInno, Jun 14, 21]

Battery tech startup NanoGraf (Chicago, IL; one $1M SBIR as Sinode) has landed a $1.65 million [DOD] grant to develop longer-lasting batteries to power military equipment. The grant from the DoD is meant to develop silicon anode-based lithium-ion technology that is compatible with all portable batteries. [company press release, Jul 22, 20]

SiNode Systems (Chicago, IL; no SBIR) is using a new $4.5 million investment from Tokyo-based chemical company JNC to rebrand its company in a joint venture with the investor. SiNode is now calling itself NanoGraf Corp., and is using JNC’s tech and resources to help it commercialize its Lithium-ion battery tech, the companies announced ...makes a battery technology that was initially developed at Northwestern University. The startup’s battery tech utilizes a composite of silicon and graphene in a layered structure to create higher cell level energy density and faster charging in lithium ion batteries. [Katherine Davis, ChicagoInno, Dec 3, 18]

NanoGram (Milpitas, CA)

Nano IPOs. NANOTECHNOLOGY companies, nurtured on billions of dollars in government grants and venture investments through most of this decade, are getting ready to go public. ... NanoGram (Milpitas, CA; no SBIR), Unidym (Menlo Park, CA; no SBIR), NanoDynamics (Buffalo, NY; $1M SBIR).    Unidym is a subsidiary of the Arrowhead Research Corporation, a public investment company that was founded in 2003 to back small companies engaged in nanotechnology research. [James Flanigan, New York Times, Dec 20]

nanoGriptech (Pittsburgh, PA)

Carnegie Mellon University spinoff nanoGriptech (Pittsburgh, PA; $3.4M SBIR), [with] the first commercially available gecko-inspired adhesive, announced $1.7M investment from Taiwan-based Industrial Technology Investment Corporation. [company press release, Dec 10, 18]

Breakout Labs, a four-year-old program of San Francisco-based Thiel Foundation, is providing $350,000 in funding to  nanoGriptech  (Pittsburgh, PA; $1.1M SBIR)  A Carnegie Mellon University spinoff, nanoGripTech recently launched Setex, a microfiber adhesive material that’s dry, reusable, can grip surfaces lightweight without leaving residue and is inspired by geckos.  Breakout Labs provides additional support to portfolio companies such as introductions to potential follow-on funders and refinement of business plans and presentations.   [Patty Tascarella, Pittsburgh Business Times, Oct 6, 15]

NanoGuard Technologies (Creve Coeur, MO)

NanoGuard Technologies (Creve Coeur, MO; no SBIR, founded 2014) startup with technology that could make the world's food supplies safer, has raised $6 million [VC] ... has a plasma technology that kills bacteria, molds and other toxins in grain, nuts, meat and other foods. [David Nicklaus, St Louis Post Dispatch, May 14, 19]

NanoH2O (Los Angeles, CA)

NanoH2O (Los Angeles, CA; no SBIR) uses nano materials to improve the performance of reverse osmosis membranes in making dirty water clean or in desalination. Two years ago, the company licensed the membrane research of Eric Hoek, a professor of environmental engineering at U.C.L.A. Then it leased lab space in the NanoSystems Institute, which opened in 2007, because being at U.C.L.A. allowed the company to use expensive electron microscopes and other equipment. .... helped attract $20 million in venture capital  [James Flanigan, New York Times, Jul 16, 09]  Founded in 2005 by proven entrepreneurs and backed by leading venture investors, [company website]

Nanohmics (Austin,TX)

Nanohmics (Austin, TX; $16M SBIR)  was among 44 companies nationwide recognized for success in commercializing science and technology innovations with the help of [SBIR] Nanohmics President and co-founder Mike Mayo was at the White House last week to receive the Tibbetts Award, which recognizes companies that have achieve excellence using SBIR. ... founded in 2002, created two new companies to commercialize unique technologies. ... The SBIR program "allowed three first-time entrepreneurs to take the risk of creating a new venture," Mayo said. So far, he said, that has led to the creation of 30 jobs in the Austin area.  Faradox Energy Storage develops high-performance capacitors that can operate in high temperatures. GlideLine Systems develops parachute navigation systems for military special forces personnel.  [Austin American Statesman, Feb 22, 11] Believe what you will about what the Tibbetts Award actually recognizes.  Roland Tibbetts had an interesting idea of an SBIR for NSF which had never funded much small for profit business. But by the time the politicians and the federal agencies captured SBIR for their purposes, the idea had been mangled by self-serving federal management. Nearly thirty years later, it still cannot show any net economic gain over what would have happened if the federal agencies just spent their R&D unmolested by such social programs. Nevertheless, the SBIR advocates hold the principle that anecdote is the singular of data, and if you accept the anecdotes, the whole data must be a mere multiple of them. 

NanoLab (Newton, MA)

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners:  Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary;  OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems  secondary, twice;  Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary

NanoLite Systems (Austin, TX)

NanoLite Systems (Austin, TX; no SBIR) is the newest company to join the Austin Technology Incubator. The company licensed technology from the University of Texas last year to develop microimaging and sensing devices to diagnose cancer and assist doctors during cancer surgery.  CEO and co-founder Dr. Ting Shen said his company "is at a critical point to capture the market opportunity and build our presence quickly." [Austin American Statesman, Apr 26, 11]

NanoLogix (Hubbard, OH)

NanoLogix (Hubbard, OH; no SBIR) will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio. ... with the closing of BioStart, the high-tech business incubator in Avondale where NanoLogix operated a lab for five years  [Cincinnati Business Courier, Sep 6, 11]

NanoLumens (Norcross, GA)

Display maker NanoLumens (Norcross, GA; no SBIR, founded 2006, 20-30 employees) has raised about $3 million — capital the company will use for sales and marketing, and overseas expansion. ... raised more than $10 million from 2006-2009 from angel investors [Wikipedia, seemingly wriiten by the company] [Urvaksh Karkaria, Atlanta Business Journal, Apr 12, 13]

Nanomaterials Research (Tucson, AZ)

Eleven Awards. Nanomaterials Research Inc (Tucson, AZ) says it has won eleven awards - in addition to the three BMDO Phase 2 SBIRs. But the eleven are all for its Website. The Website does have a page that could help its competitors - it reports happenings in the nano-world. Meanwhile, in April, the top investor pulled out his 50%.

NanoMatrix (Baton Rouge, LA)

Organogenesis (Canton, MA; $200K SBIR) a life sciences firm focused on regenerative medicine, has acquired NanoMatrix(Baton Rouge, LA; $300K SBIR), a maker of biologically compatible materials.[Mass High Tech,  Feb 27, 08]

NanoMedical Systems

The Texas Emerging Technology Fund is pumping more money into Central Texas technology startups.  Six more Austin companies have won grants totaling $5.3 million.  Among the six new grant winners is year-old NanoMedical Systems (no SBIR) which will use its $3.5 million to develop a tiny implantable capsule that delivers drugs a few molecules at a time, with the dosage controlled precisely for each patient. The company is completing a prototype using $4 million from a private investor, said co-founder and chief executive Randy Goodall. The grant will help fund it through the complex and time-consuming process of seeking Food and Drug Administration approval, Goodall said. ...... Farodox Energy Storage  (no SBIR), which has developed a new fabrication process for high-performance electrical capacitors, $250,000; ...  Ironbridge Technologies (no SBIR), which is developing self-heating food packaging technology, $250,000;  ... Merkatum (no SBIR), which is developing fingerprint and facial recognition identity technologies, $250,000;   .....  Stellarray (no SBIR), which is commercializing flat-panel radiation source technology, $750,000; ...  Sunrise Ridge Algae (no SBIR), which is commercializing technology to turn algae into a renewable energy source. [Lori Hawkins, Austin  American-Statesman, Nov 17, 08]

Nanomedex  (Fitchburg,WI)

At least 14 [Wisconsin] biotech companies have received more than $3 million in grants ($240K each) from the Internal Revenue Service as part of a federal program to spur job growth at smaller firms and advance the country's life sciences prowess, according to a BioForward survey. ....  More than 5,600 companies applied for the grants and at least 4,000 companies were expected to receive them, according to BIO, the national trade organization for the biotech industry. .... The Qualifying Therapeutic Discovery Project was part of health care reform legislation passed earlier this year. The program provides grants or tax credits to companies of fewer than 250 employees to help create and sustain high-paying jobs and to advance the nation's competitiveness in life sciences. [Kathleen Gallagher, Milwaukee Journal Sentinel, Nov 2] Flex Biomed (Madison, WI; one SBIR) ;  NanoMedex Pharmaceuticals (no SBIR); FluGen (no SBIR).  BTW, BIO is the political champion of VC in SBIR awards, a barrier to House-Senate agreement on SBIR re-authorization, which will be up in the air again as the House committees change leadership.

NanoMedex Pharmaceuticals (Fitchburg, WI; no SBIR) is being awarded a $2.23 million [SBIR] grant from NIH to back the company's new anesthetic drug. .... focuses on the development of drug formulations that allow fat-soluble pharmaceutical products to be dissolved in water or saline-based solutions to allow for intravenous administration of drugs. In 2009 NanoMedex was seduced by WI grants and potential tax credits to move from FL. [Business Journal of Milwaukee, Dec 8, 09]

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] ....  founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers.  ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

Nanomix  (Emeryville, CA)

Nanocompany Nanomix (Emeryville CA) collected an oversubscribed $16M funding  .. The company is a spinoff from a venture founded in 2000 by two physics professors on the campus of the University of California-Berkeley. It develops nanotechnologies.  Killer app?  its sensors can detect subtle changes in the concentration of carbon-dioxide gas in a person's breath, revealing respiratory diseases in children and adults, and allowing anesthesiologists to monitor a patient's breathing during surgery.  [San Jose Mercury News, Apr 2, 05]

nanoMR (Albuquerque, NM)

Semiconductor DNA sequencing technology firm DNA Electronics (UK) today announced the completion of its acquisition of rare cell isolation firm nanoMR (Albuquerque, NM; no SBIR,  founded 2007, 25 employees)  for a total cash consideration of $24 million. ...  DNAe's sequencing technology is licensed to Thermo Fisher Scientific and serves as the core of Ion Torrent's next-generation sequencing system. DNAe also licenses the technology to Geneu  [, Jan 22, 15]    has raised about $30 million since it started   [Dan Mayfield, Albuquerque Business First, Jan 22, 15]  has developed the first system for rapid isolation of rare cells from complex matrices at levels of 1 cell/mL or lower  [company website]

US Health and Human Services has contracted with nanoMR (Albuquerque, NM; no SBIR) to create a device to quickly test for biological hazards. ...  a three-year contract with $5.9 million in funding in the first year. ...  According to the company's website, nanoMR has developed a system for rapid isolation of rare cells from complex matrices at levels of 1 cell/mL or lower.   [Gary Gerew,  Albuquerque Business First, Nov 10, 14]

Nanophase Technologies (Burr Ridge, IL)

Nanophase Tech  down 14% [Jul 23, 08]<

Nanophase Tech up 28% for the week ending Jul 11, 08

Nanophase Tech down 14% [Jun 26, 08]

Nanophase Tech down 12% [Feb 8, 08]  2007 was another solid year of revenue growth, gross margin expansion, and technical progress, said CEO Cross. Revenue was up a third and loss down a third for the fiscal year.

Nanophase down 11% [Jan 17, 08]

Nanophase Tech down 11% [Dec 31, 07]

Nanophase Technologies

Nanophase Technologies up 10%  [Dec 18, 07]

Nanophase Technologies down 13% [Dec 17, 07]<

Nanophase Technologies down 14% after reporting a wider loss in the third quarter due to a weakness in the housing market, [AP, Oct 19]

Nanophase Technologies up 12%. [Jul 23, 07]

Nanophase Tech sold stock for $10M with which it will acquire and install equipment and expand the Company's Romeoville facility to support anticipated increases in nanomaterial product demand[ Jun 07]

Nanophase Technologies up 12% on reporting its highest quarterly revenue in company history. [Apr 13, 07]

Nanophase jumped 14% on record revenueand gross profit margin even though it is still losing money. [Oct 26. 06]

Nanophase jumped 18%  [Jun 27, 06] and another 15% [June 29].

NanoPhase Sued
(June 8) The Litigious Investor. So, you like the startup company's prospects; the CEO makes the right optimistic noises and files an IPO registration. The stock goes public and then nowhere. Didn't make your expected bundle in a frothy market? Take the American way - sue 'em for false statements without which you would not have bought the stock. Thus stands Nanophase accused of deception for issuance of false and misleading statements concerning Nanophase's business and true financial condition. Most IPO registrations already say everything possible to alert the reader that the investment is an almost infinite risk with nothing being certain. But lawyers are one class of practitioner that can generate its own business. Doctors at least wait until you get sick.

A Nano-Profit (Mar 3) Nanophase Technologies made $230K for the quarter and a loss of only $3.1M for the year. The stock price hovers below its IPO price waiting for profits to appear regularly.

Incomprehensible The stock went from 8 [at IPO] to 15 based on I don't know what," said one analyst [Wall Street Journal, Jan 15] trying to explain the rise and fall (to 6) of Nanophase Technologies (Burr Ridge, IL). Any capitalist's concern, of course, is always a growing profit business, not the sweetness of "atom-sized, super tough ceramic particles" which itself is inaccurate in granting sub-micron particles atom-sized status. And the more an R&D company emphasizes what it bests understands - the technical details - the more it turns off investors as incomprehensible and the more dependent it becomes on government dole. So, practice your elevator speech for the day you meet a possible investor in a hurry. Investors are always in a hurry to bet on some company and if yours sounds incomprehensible, you lose. Actually, that rule would help SBIR proposals get through to the spirit of proposal judges.

Nanophase Goes Public
(Dec 5) Nanophase Technologies (Burr Ridge, IL) went public Nov 26 to raise $32M for a third of the company. IPO Central says, Nanophase develops and markets nanocrystalline materials -- ceramic and metallic materials with nanometer particle sizes. Its products are used as ingredients and components in electronics (semiconductor polishing and high-performance electrodes), structural ceramics and composites (ceramic mechanical seals and medical device housings), cosmetics and skin care (sunscreens and cosmetic colorants), and industrial catalysts. The company has collaborative relationships with Dow Chemical, DuPont, Medtronic, Philips Electronics, and Schering-Plough. From government subsidy programs it had little: three Phase 1 SBIRs (Army, Navy, and its first from BMDO in 1993) and one ATP award for $900K. Although its 50 employees average only $12K sales per employee, it nevertheless is valued at $100M. Compare that valuation with, for example, Spire which has had over $30M of SBIR, has 140 employees who average $100K sales per employee and over half of that from SBIR contracts, and still has a $50M valuation after 20 years, and 25% fewer employees than when it got its first SDIO SBIR in 1986. IF the government had any economic sense, it would put more of its SBIR into firms like Nanophase (instead of power company profit analysis). Hah!

NanoPhotonica (Orlando,FL)

NanoPhotonica (Orlando, FL; no SBIR, founded 2011) inked an overseas research and development deal with Japan Display Inc. the Orlando Sentinel is reporting.  .... specializes in creating display screens for devices such as phones and TVs — a $60 billion market — which help lock out moisture, oxygen, use less power and are resistant to UV rays.    [Matthew Richardson, Orlando Business Journal, Jul 14, 14]  technology called S-QLED that allegedly has superior picture quality, uses 30 percent less power, and costs three-quarters less than its OLED competition. [engadget, 2011]

Nanopore Diagnostics (St Louis, MO

Nanopore Diagnostics  (St. Louis, MO; no SBIR) startup developing a medical device that physicians can use to detect bacterial infections, raised nearly $600,000 from a group of investors led by the Missouri Technology Corporation  [Brian Feldt, St. Louis Business Journal, Jan 22, 16]   The test Nanopore Diagnostics is developing will move beyond diagnoses made on symptoms alone by determining if an infection present, and then providing comprehensive details on the infection, in only 30 minutes. This will inform physicians first seeing a patient what antibiotic, if any, is needed.  [company website]

About 100 startups launched out of a Washington University class called The Hatchery have raised $33.8 million since 2008, according to the university's research.  That figure is about double what the university reported at this time two years ago.  including  Sparo Labs (St. Louis, MO; no SBIR)and Nanopore Diagnostics  (St Louis, MO; no SBIR). [Brian Feldt, St. Louis Business Journal, Oct 27, 15]....   Sparo Labs  startup developing technology for asthma patients, launched a $50,000 Indiegogo campaign for its Wing medical device that measures lung function  [Brian Feldt, St. Louis Business Journal, Oct 23, 15] [Nanopore is] developing a rapid and portable bacterial diagnostic assay.  []

Nanoptek (Maynard, MA)

Nanoptek (Maynard, MA; $400K SBIR) has developed a new way to make hydrogen from water using solar energy. The company says that its process is cheap enough to compete with the cheapest approaches used now, which strip hydrogen from natural gas, and it has the further advantage of releasing no carbon dioxide.  ... recently completed its first venture-capital round, raising $4.7M [Kevin Bullis, MIT Tech Review, Jan 30, 08] The company claims a proprietary nano-engineered photocatalyst (patents pending).

Nanoramic Laboratories formerly FastCap Systems (Boston,MA)

Nanoramic Laboratories (formerly FastCAP Systems, Boston, MA; $1.3M SBIR), specializing in material solutions based on nano-carbons, closed a $5 million investment round inckluding strategic investments by NGK SPARK PLUG CO., LTD. and Marubun Corporation, both Japan. [, Sep 13, 18]

Nanoramic Laboratories ; $1.3M SBIR as FastCap Systems, founded 2010) said it closed a $5 million investment from two Japan-based firms—NGK Spark Plug Co. and Marubun Corporation—and earlier Nanoramic backers. The MIT spinout develops products using advanced materials, including energy-storage devices designed to withstand extremely hot temperatures and strong vibrations. [Jeff Engel,, Sep 19, 18]

nanoRETE (Lansing, MI)

the Michigan Economic Development Corporation announced its new Michigan Venture Match Fund, a $5 million pot of money from the Michigan Strategic Fund for early-stage companies in the state that have already gotten funding commitments from at least one venture firm. The fund just invested $2.76 million in six companies across a variety of sectors: Stik (social networking website, no SBIR), Livio (internet car radios, no SBIR), Amplifinity (manage advocacy programs; no SBIR), Gema Diagnostics (Ann Arbor, MI; no SBIR, human embryo screening), nanoRETE  (Lansing, MI; no SBIR, real-time detection of pathogens), and Tissue Regeneration Systems (Ann Arbor, MI; no SBIR, bone reconstruction). [Sarah Schmid,, Mar 12, 13]

Nanoscale Components (Hudson,NH)

Nanoscale Components (Hudson, NH; no SBIR) raised $600,000 out of a $950,000 round of equity financing, according to federal filings.  CEO Ronald Wohl [said] the company has developed technology to improve the capacity of batteries to be used in consumer electronics as well as automobiles. He said the company is now working with several companies to integrate its technology. [Don Seiffert, Mass High Tech, Nov 30, 12]

Nanoscale Materials (Manhattan, KS)

Nanoscale Materials (Manhattan, KS;  $3.7M SBIR) was awarded $375,000 [by the Kansas Bioscience Authority] as a partial match of a $1.5 million [DOD SBIR] to develop substances that can neutralize biological warfare agents. ..... also will receive $50,000 as a partial match of a $150,000 [NSF SBIR] to research the synthesis and delivery of nanoparticles. [Kansas City Business Journal, Nov 10, 09]

Nanoscope Technologies (Bedford, TX)

Nanoscope Technologies (Bedford, TX; $2.6M prior SBIR, founded 2009) announced receiving a $2 million multi-year [NIH SBIR] to advance its therapeutic gene and delivery platform. “Through laser delivery, we have now overcome the limitation on size of the therapeutic genes that can be delivered”, said Subrata Batabyal, co-investigator of the grant. [Kevin Cummings, North Texas Inno, Jun 1, 20]

Nanosolar (Silicon Valley, CA)

CVD diamond revives.  Diamond Foundry (San Carlos, CA; no SBIR) is not the first company to try to use chemical vapor deposition, to grow diamonds by depositing layers of carbon atoms in a high-energy plasma field.  ....  spent years developing a new manufacturing technique based on a plasma source with a new “shape” that is 10 times as powerful as what has previously been used by manufacturers of synthetic diamonds, R. Martin Roscheisen, a founder of Nanosolar  (San Jose, CA; $1.7M SBIR) said.   By modifying the shape of the plasma field to what he described as a pancake, the group was able to make the reaction that formed the diamond structure more efficient  ...  the founders of Nanosolar, a large start-up that raised about half a billion dollars in its first six years, began exploring ways to build that would apply their expertise to new technologies. ...   A group of engineers and scientists, led by , announced that they had developed an advanced approach to making diamonds, using technology derived in part from making silicon chips and solar cells, to be used by a new company.   [JOHN MARKOFF, New York Times, Nov 11, 2015]  SDIO/BMDO/MDA SBIR funded several CVD diamond projects starting in the late 1980s.

Nanosolar (Silicon Valley, CA; $1.9M SBIR) [ambitious CIGS solar startup] laid off part of its staff and is now in a “quiet period,” according to a company representative. Two reports suggest the cuts were significant, as much as 75 percent of the staff. ...  raised more than $450 million from venture investors  ....Another Silicon Valley CIGS startup, Miasole  (no SBIR), last year was acquired at a great loss to investors to Chinese energy project developer, Hanergy Holdings, which also acquired CIGS startup Solibro from QCells in Germany.  Heliovolt (Austin, TX; one SBIR) attracted funding from SK Innovations in Korea to fund its initial production and Stion has also forged deals with Asian manufacturers. These deals suggest that the CIGS technology is still viable, even if the company ownership has changed.    [Martin LaMonica, MIT Technology, Feb 19, 13]  Difficult technoology losing out to falling solar market prices.

Nanosolar raised $70 million in venture funding. .... makes "thin film" solar technology, which prints metal "inks" onto a type of aluminum foil. Besides its head office in San Jose, where it has a solar cell printing factory, it also has an assembly factory in Luckenwalde, Germany.   [Steven EF Brown, San Francisco Business Times, Jun 1, 12]

Army's venture venture.  The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs;  Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries;  Integrated Fuel Cell Technologies  (Burlington MA; no SBIR) next generation fuel cell systems for portable devices;  Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates,   PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets;  Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell.  []  No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

Nanosolar announced that it has raised $300 million to help it complete its production lines in Silicon Valley and in Germany.  [San Jose Mercury News, Aug 27]

Thin Is In. from the Southwest to Silicon Valley to Germany. Everywhere you look, thin-film solar companies are opening new, more efficient factories. .... As First Solar scaled production up, it was able to bring its costs down. Solar producers measure their costs in terms of dollars per watt of energy produced, a formula that's a combination of the cost of producing a module and its power efficiency. Right now the best crystalline-silicon makers can sell modules at $3 to $4 a watt; First Solar can sell at around $2.40 a watt, a price the company expects to reduce steadily. ... Nanosolar announced it would begin profitably selling thin-film panels at $1 a watt. ... says he can achieve radical cost savings by directly applying photoactive chemicals with an ink composed of nanoparticles. ... [dubious] competitors pointing out that the cost of raw materials alone should make it impossible to produce $1-a-watt panels profitably.   [Bryan Walsh, Time, Jun 23, 08]

Nanosolar (San Jose, CA; $1M SBIR) , whose backers include Google co-founders, said it has started to sell what it calls "the world's lowest cost solar panel."  [for freefield deployment in Eastern Germany]...uses a thin-film technology that requires only a fraction of the amount of silicon needed in conventional solar cells.  ... make panels profitably for less than $1 per watt.  [Franklin Paul, Reuters, Dec 18] In June 2006 if said it had $100M to enter volume production.

Nanosolar will open one of the world's largest solar cell manufacturing facilities in South San Jose by spring, placing the city at the forefront of an emerging technology. [Katherine Conrad, San Jose Mercury News, Dec 12] Listen for the complaints from the "flyover states" that the government and the establishment are ignoring them.

Nanosolar (Palo Alto, CA) has decided to build the world's largest factory for making solar power cells in the Bay Area -- a move that would nearly triple the nation's solar manufacturing capacity and give a significant boost to a growing source of clean energy. ... founded in 2001 with seed money from Google founders Larry Page and Sergey Brin ... the planned annual production could power about 325,000 homes. The technology is thin, thin, thin CIGS. [Paul Rogers, San Jose Mercury, Jun 21] SBIR - one 2004 Phase 1.

 Nanosonic (Blacksburg, VA)

What substance can conduct electricity like a metal, yet also stretch like a rubber band?  Earlier this year,  NanoSonic (Blacksburg, VA) found the answer in Metal Rubber, a filmy brown material that can extend to three times its original length and conduct electricity as well as a bar of steel, says NanoSonic founder Dr. Rick Claus. ... Like many inventions, NanoSonic's team didn't so much set out to create this new material explicitly, but more stumbled across their big find while working on other projects for the U.S. Air Force. "No one would actually fund you to make Metal Rubber," Claus says. [Karen Hoffman, MIT Tech Review, Dec 20] Indeed, NanoSonic has had about $12M in SBIR, mostly DOD, in the past four years which was enough to support the entire company in a variety of projects on creating new materials through molecular self-assembly.  So far, potential customers are still scratching their heads for a first application of such a surprise. If you make such a startling invention, you can help your case by also inventing applications that can make money for someone else.

Nanospectra Biosciences (Houston,TX)

Nanospectra Biociences (Houston, TX; $5M SBIR) a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, announced that it has closed on an initial $3 million in a Series B-1 financing [to] to further develop AuroLase, including full completion of the ongoing pivotal study for prostate cancer tissue ablation, filing of a 510(k) with the U.S. Food and Drug Administration (FDA) for marketing clearance, and preparing for commercialization [company press release, Sep 8, 20]

Nanospectra Biosciences (Houston, TX; no SBIR) raised nearly $1 million as it moves into a human clinical study, according to [SEC] filing. [Joe Martin, Houston Businesss Journal, Dec 21, 15]    has an exclusive license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles ...  to evaluate the safety and efficacy of AuroLase Therapy for the treatment of refractory or recurrent head and neck cancers.  [company website]

Nanosphere (Northbrook IL)

Nanosphere (Northbrook, IL; $3M SBIR) up 18% [May 11, 15] achieved record revenues for the first quarter of $4.6 million compared to $3.3 million in the first quarter 2014. This 41% year-over-year revenue growth was driven by U.S. based microbiology laboratories' continued adoption of our Gram Positive (BCGP) and Gram Negative (BCGN) blood culture tests, which grew more than 100% over the first quarter of 2014. ...  Net loss for the first three months of 2015 was $7.5 million    [company press release]   had reverse stock split last month

Nanosphere up 12% [May 24, 13]

Nanosphere up 11%  [Sep 21, 12]

Nanosphere up 12%  [Sep 18, 12]

Nanosphere up 17% [May 16, 08] although still down 44% over 52 weeks.

Nanosphere (Northbrook, IL; $4M SBIR) rose 25% [Mar 27, 08]. 

A week on, Nanosphere is up 41% from its IPO price. [Nov 7, 07]

Nanosphere (Northbrook IL; $4M SBIR) going public this week to raise $120M.  [Oct 07]

NanoSteel (Providence, RI)

Nanotech-based coatings company NanoSteel (Providence, RI; no SBIR) has taken on $8 million of a planned $11 million funding round, federal documents note.... licensed its technology from the Idaho National Engineering and Environmental Lab, moved to Providence from Florida in 2006  [Mass High Tech, Aug 21, 09]

Nanostim (Milpitas, CA)

St. Jude Medical said  it has bought Nanostim (Milpitas, CA; no SBIR), which has developed an implantable pacemaker that does away with wires leading to the heart because it's implanted inside the heart. [Mark Reilly, Minneapolis / St. Paul Business Journal , Oct 14, 13] St Jude has had much ugly press recently on degraded pacemaker lead wires to the heart.

NanoString Technologies (Seattle, WA)

NanoString Technologies  (Seattle, WA; no SBIR, 450 employees), a provider of life science tools for translational research and molecular diagnostic products, announced the closing of its previously announced underwritten public offering of ... approximately $56.5 million.  [company press release, Jun 6, 17]

biotech NanoString Technologies (Seattle, WA; no SBIR, 330 employees) will get $12 million in an immediate payment when it begins its expanded partnership with Merck, NanoString’s CEO said.  Under the agreement the company will develop and commercialize a diagnostic test for a Merck cancer-fighting drug, Keytruda, used on patients with melanoma and lung cancer  [Rachel Nielsen, Puget Sound Business Journal, Mar 1, 16]

NanoString Tech  down 19% [Jun 26, 13] after IPO

 NanoString Technologies (Seattle, WA; no SBIR) priced its [IPO below their target] set in mid-June before world stock markets got shaky.  The developer of life-science research tools raising $54 million ....  sells analytical systems that cancer researchers and other scientists use to study the activity of genes in small tissue samples.  [Seattle Times, Jun 25, 13]

NanoString Technologies (Seattle, WA; no SBIR) bioinformatics company, is planning an [IPO] to raise more than $86 million. [Ben Miller, Puget Sound Business Journal, May 21, 13]

genomic-analysis company NanoString Technologies (Seatle, WA; no SBIR) aims to sell up to $86 million in [IPO], the company said in a regulatory filing.   .... founded in 2003, a “spinout” from the Institute for Systems Biology in Seattle, according to  [Seattle Times, May 20, 13]

NanoString Technologies Seattle, WA; no SBIR) got a $15.3 venture investment [for] developing a patent pending platform for single molecule identification and digital quantification. The NanoString system uniquely barcodes individual target molecules, scans them, and delivers a literal inventory of target molecules in the biological sample.  [, Dec 3, 12]


Nanosys (Milpitas, CA; $4.4M SBIR) is suing -based QD Vision (Lexington, MA;  $1.7M  SBIR) for allegedly infringing upon 13 patents that Nanosys says it exclusively licensed from MIT and the University of California system, which are both also listed as plaintiffs in the lawsuit filed last week ... produce quantum dots—tiny semiconductor crystals that, among other things, can help deliver high-definition images on device screens, including TVs and tablets.  [Jeff Engel,, Apr 19, 16]

Nanosys (Palo Alto, CA, $4.7M SBIR) has raised $25 million in new capital and will license its technology and co-develop products with Samsung   [San Francisco Business Times, Aug 10, 10]

Nanosys (Palo Alto, CA; $4M SBIR) made a deal with In-Q-Tel (CIA's VC) to further expand collaboration ... to apply its novel electronics technology for innovative uses in the area of high-performance communications.  [In-Q-Tel press release, Aug 22,07] Does that mean allowing W to talk even more directly to whatever the thinks "God" is?

Nanosys, a (self-proclaimed) leader in the development of nanotechnology based products utilizing inorganic nanostructures, got a DARPA contract for up to $14M for "flexible low cost" solar cells. The press release makes no mention of the growing concern that nano-particles will be a long term health problem as they bypass the body's defenses against foreign stuff. The military has already scattered a lot of dangerous stuff - depleted uranium, perchlorate, oils and solvents in ground waters, radionuclide fission products - in the pursuit of national security. [Sep 04]

Nanosys got a Phase 1 NIH SBIR to continue research and commercialization on semiconducting nanowires that could add up to $1.6M, says Jeff Miller [Mass High Tech, Sep 4].The company hopes to use nanowires, filaments that are one-ten-thousandth the width of a human hair, to create molecular electronic detection systems with a wide range of applications in the medical, environmental and defense industries. Nanosys has already got $17M million VC from a large syndicate. Charles Lieber, a Harvard professor and a luminary in nanotech research, founded the company last year along with Larry Bock, a serial entrepreneur who has founded 11 now-public companies.

NanoSystems (Oxford, CT)

A Senatorial Visit
(Aug 20) The potential success of NanoSystems (Oxford, CT) attracted a politician. Surprise! Joe Lieberman went to see how Charlie Beetz's startup is using BMDO SBIR help to develop silicon wafers machined to include sieve-like microscopic opening and groves in the quest for ever smaller scale in chip details. The Hartford Courant story implies that NanoSystems got five Phase 1s since starting up last year. Beetz pursues the American dream - his own company. He left GM to join ATMI in its extreme youth, and now with three other pioneers has bet their savings and a little government money (so far) on what will be a risky high-impact strategy - just what SBIR was invented for. Lots of people out there, especially in Silicon Valley have similar dreams and a few will actually see them come true.

Nano Tailor (Austin, TX)

Fourteen startups that received a total of more than $17 million from [Texas Emerging Technology Fund managed by Gov. Rick Perry’s office... which has backed 143 startups] have failed or gone bankrupt.   ....   [ MIT professor Bill Aulet, who is managing director of the Martin Trust Center for MIT Entrepreneurship] said the number of failed ETF companies would be higher if state officials took the chances they needed when investing in startups. "They really haven't taken any risk," he said. "Governments aren't good at being venture capitalists because governments aren't good at risk." ....  a partial list of the ETF-backed startups in Texas that have since closed, followed by the grant amounts they received:  • NanoTailor, $250,000;  • Star Vision Technologies, $750,000; • Terrabon, $2.7 million;  • Thrombo Vision, $1.5 million;  Nanocoolers, $3 million;  • Advanced Receiver Technologies, $250,000;  • Bauhaus Software, $500,000;  • Net Watch Solutions, $500,000;  • Sunrise Ridge Algae, $250,000;  • SeprOx, $750,000; • Speer Medical, $2.5 million   [Christopher Calnan, Austin Business Journal, Jan 9, 14] None of these had SBIR.

A third company [Nano Tailor, Austin, TX; no SBIR] awarded taxpayer dollars through Gov. Rick Perry's business-hatching Emerging Technology Fund has filed for bankruptcy, folding after the state cut off money that was tied to hitting milestones not in the original contract, the president of the startup said Thursday.  ... [company president] Perales said NanoTailor used licensed technology from NASA to make carbon nanotubes for industries ranging from aerospace to pharmaceuticals. He said the company had six employees and about 20 investors, but [Perry spokeswoman Lucy] Nashed said filings with the state indicate the startup lagged in attracting outside dollars.  ...   The awards are not grants, because the state takes equity positions in each company, but the stakes are not made public  [Paul Weber, AP, Jun 14, 12]

Nanotech Energy (Los Angeles, CA)

Investors have just pumped $27.5 million into Nanotech Energy (Los Angeles, CA; no SBIR) Because the company claims its graphene based lithium batteries can charge 18 times faster than conventional lithium-ion batteries. [Steve Hanley, Cleantechnica, May 25, 20]

Nanotek Instruments (Dayton, OH)

G3 (Global Graphene Group, Dayton, OH), a holding company for subsidiaries Angstron Materials  ($150K SBIR) , Honeycomb Battery (no SBIR) and Nanotek Instruments  ($3M SBIR), announced that it has secured the first $10 million of a Preferred Series A investment ... with conditions for a second close of an additional $13 million for a total $23 million Series A investment.  G3 is engaged in commercializing graphene raw materials, and graphene-enabled applications including nanocomposites, thermal interface materials, and advanced batteries.   [Roni Peleg,, Jul 20, 16]

Angstron Materials (Dayton, OH; one SBIR in 2009) attracted $5 million to boost its commercialization efforts....  to increase manufacturing capacity and bring key technologies to market.  Angstron makes graphene, a material that is strong, lightweight and a considered one of the best conductors of heat and electricity. ...  touts itself as the world’s largest volume producer of graphene, with a capacity of 300 metric tons per year. Angstron and its sister company, Nanotek Instruments ($3M SBIR), have about 20 employees and operate in 22,000 square feet. [Joe Cogliano, Dayton Business Journal, Jul 28, 15]


Pentair (NYSE) and Nano Terra (Cambridge, MA; two SBIRs) said they are forming a strategic alliance in water treatment. ...  will "deploy its technology for functionalizing surfaces through chemistry and structuring to develop new solutions for the treatment of water."  [Boston Globe, Mar 31, 09]

Nanotechnology firm Nano-Terra and German drug maker Merck KGaA have upgraded their product development partnership to a commercialization deal. Cambridge-based Nano-Terra helped co-develop Merck’s “printable electronics” using nanometer-sized materials and a soft lithography technique called micro-contact printing. [Mass High Tech, Oct 9]

Nanotherapeutics (Alachua, FL)

Down-but-not-out biotech Xoma ($500K SBIR in the 1980s) will sell its Berkeley antibodies manufacturing plant to Agenus (Lexington, MA; no SBIR) in a $6 million cash and stock offer, unload its biodefense program and trim its workforce by more than half. ...  Xoma six years ago employed 350 people but that had fallen to 180 this year, in part because it sold its large-scale manufacturing facility in Berkeley three years ago to CMC Biologics (no SBIR). Now it will have less than 100 employees.  ....  Also, Xoma said it will divest its biodefense program to Nanotherapeutics (Alachua, FL; $2.7M SBIR)  .... The company has an accumulated deficit of nearly $1.2 billion and its one-time savior-to-be antibody, gevokizumab, failed in a clinical trial for the eye disease Behcet's uveitis.   [Ron Leuty, San Francisco Business Times, Nov 5, 15]

Jettisoned.  Baxter International announced that it has entered into a definitive agreement to sell its proprietary Vero cell technology and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics  (Alachua, FL; $2.6M SBIR). Financial details were not disclosed.   [Business Wire, Dec 15, 14]|

Nanotune Technologies(Mountain View,CA)

NanoTune Technologies (Mountain View, CA; no SBIR) raised $3M VC ... claims a unique tailoring process based around silica nanomaterials, capable of modifying the surface chemistry and precisely controlling the porosity of nanomaterials, a technology that could potentially have applications in numerous fields. [Matt Marshall, San Jose Mercury News, Dec 19, 07]

Nanova (Columbia, MO)

Nanova Biomaterials (Columbia, MO; no SBIR) will receive more than $1 million in Missouri Quality Jobs tax credits and $50,000 in Development Tax Credits.  .... adds nano materials to dental fillers and bone screws in order to improve their mechanical and biological properties, according to the Columbia Missourian.  The company's first dental product, which will go on the market next year, can enhance tooth cavity resistance for children and adults, according to the Missourian. ... must create 50 or more jobs to get the tax credits. [St. Louis Business Journal, Nov 27, 13]

Nanova (Columbia, MO; $1.7M SBIR) a high-tech biomaterials firm started by MU engineering faculty, received a $6 million investment from Chinese investment firm Summitview Capital to help commercialize its products.  ...  designs, patents and sells medical products [St Louis Business Journal, Mar 27, 13]

Nanovation Technologies (Northville, MI)

Nanovation Technologies (Northville, MI), a maker of integrated optical components for the telecom market tossed in the towel and filed for Chapter 11 when it could not satisfy all the present investors for a new round of financing. One investor, a Canadian firm, blocked the deal long enough to discourage the others and then offered to infuse cash for control of the board. Nano said nano-thanks. [Laser Focus World] Maybe it could now try for a government handout from SBIR.

NanoVibronix (New York, NY)

NanoVault Medical (St Paul, MN)

LifeScience Alley, the regional trade association that represents life science and health technology companies, announced that 10 organizations will be exhibiting cutting-edge products as part of the association’s New Technology Showcase at the 2013 LifeScience Alley Conference, Nov. 20 at the Minneapolis Convention Center.   Featured will be:  (Rochester, MN;  no SBIR), developing a cancer-selective virus particularly suited to destroy relapsed or metastatic cancer cells; Omnis PharmaRebiotix (Roseville, MN; no SBIR), which will present something called Microbiota Restoration Therapy, which delivers live, human-derived microbes to patients’ intestinal tracts to restore balance and treat certain diseases; and (Naperville, IL; no SBIR) will demonstrate its remote patient monitoring and predictive analytics system, which converts patient vital signs into information to aid in care.    VGBioCogCubed (Minneapolis, MN;  no SBIR) will exhibit an approach to diagnosing and treating cognitive health by analyzing game play data; Datuit (Roseville, MN; no SBIR) will display a platform allowing patients, family and clinicians to confidentially share medical information; Imanis Life Sciences   (Rochester, MN; no SBIR) will show a gene-based platform for promoting non-invasive, long-term imaging technologies in living beings; Mednology Solutions (Excelsior, MN;  no SBIR) will exhibit a system designed to improve efficiency in the management of medical emergencies; NanoVault Medical (St. Paul, MN; no SBIR) will show a cellular and biotherapeutic delivery technology to treat autoimmune diseases. ReMind Technologies of Houston, Tex., will exhibit a smartphone-based medication dispensing device and Skyline Medical, Inc. of Eagan will show an automated surgical fluid disposal device with unlimited capacity and real-time fluid volume data. For more information.  [James Walsh, Minneapolis Star Tribune, Sep 25]

NanoViricides (West Haven, CT)

NanoViricides (no SBIR) up 63% [Sep 21, 21]

NanoViricides (Shelton, CT; no SBIR) up 58% [Mar 2, 21] reported on the strong pan-coronavirus effectiveness of its two COVID-19 clinical drug candidates for which the Company is preparing a pre-IND application. [company press release, Mar 2, 21]

Nanoviricides up 42% [Sep 2, 20] said Our current COVID-19 drug development candidates have shown efficacy against multiple different coronaviruses in our BSL2 virology lab. The Company believes this research provides scientific support that the virus would not be able to escape our drug candidate despite mutations, unlike many other drugs, antibodies and vaccines. [company press release, Sep 2, 20]

Nanoviricides down 19% [Aug 24, 20]

Nanovircides up 26% [Jul 8, 20] announced that excellent safety and tolerability of the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases was observed in an animal model. The nanoviricides drug candidates tested in this safety/tolerability study have previously shown strong effectiveness against lung infection by a SARS-CoV-2 like coronavirus, namely, hCoV-NL63, in an animal study as previously reported by the Company. [company press release, Jul 8, 20]

Nanoviricides up 20% [Jun 25, 20]

Nanoviricides down 16% [May 21, 20]

Nanovircides down 17% [May 15, 20]

Nanoviricides up 28% [May 12, 20] announced that it has developed drug candidates that have demonstrated very high anti-viral effectiveness in cell culture studies against multiple coronaviruses. [company press release, May 11, 20]

Nanoviricides up 34% [Apr 21, 20] announced that it will provide an [Apr 22] update of its drug development programs for the treatment of Shingles and for COVID-19 when it presents an overview of the Company at the Planet MicroCap Showcase 2020 [company press release, Apr 21, 20]

Nanoviricides down 21% [Mar 10, 20]

Nanoviricides up 38% [Mr 6, 20] Reports Discovery of Broad-Spectrum Virus-Binding Ligands; Expected to Counter COVID-19 [company press release, Mar 5, 20]

Nanoviricides up 16% [Feb 26, 20]

Nanoviricides up 38% [Feb 24, 20]

Nanoviricides up 17% [Feb 10, 20]

Nanoviricides down 35% [Feb 3, 20]

Nanoviricides up 40% [Jan 31, 20]

Nanoviricides up 27% [Jan 30, 20]

Nanoviricides down 47% [Jan 28, 20]

Nanoviricides down 31% [Jan 27, 20]

Nanoviricides up 54% [Jan 24, 20]

Nanoviricides up 43% [Jan 23, 20]

Nanoviricides up 38% [Jan 22, 20]

Nanoviricides (Shelton, CT; no SBIR although President Anil Diwan won has won several NIH SBIR awards, founded 2005) up 153% [Jan 21, 20] in apparent reaction to the spread of an unknown respiratory virus in China that has claimed six livesannounced the pricing of an underwritten public offering with gross proceeds to the Company of $7.5 million [company press release, Jan 21, 20] develops therapeutics for patients suffering from life-threatening viral infections. Total funding $48M []

NanoViricides (SBIR) biotech focused on nanomaterials for antiviral therapy, has closed out a $5 million financing with a $2.5 million tranche from Florida firm  

NanoViricides< (West Haven, CT; no SBIR) has landed $2.5 million from a stock offering under another shelf registration with Seaside 88 LP. The offering follows a similar transaction in April.  ... developing treatments for seasonal Influenza, H1N1 swine flu, oral and genital herpes and H5N1 bird flu. [Michelle Lang, Mass High Tech, Jul 27, 11]

NanoViricides (West Haven, CT; no SBIR) biopharmaceutical firm, has raised $2.5 million in a shelf offering  .... focuses on discovering, developing, and commercializing nanotechnology-based targeted anti-viral therapeutics (nanoviricides) to advance the care of patients suffering from life-threatening viral infections.  [Mass High Tech, Dec 22, 10]

Drug maker NanoViricides (West Haven, CT; no SBIR)  has filed documents stating that it will look to raise up to $40 million through the occasional sale of company stock ... working on antiviral drugs for bird (avian) influenza, seasonal flu, HIV, Dengue fever and rabies  [Mass High Tech, Mar 5, 10]

NanoVision Diagnostics (Pittsburgh, PA)

NanoVision Diagnostics (Pittsburgh, PA; no SBIR) life sciences startup, has raised $1.5 million ... spun out of the University of Pittsburgh late last year, is the developer of an early cancer detection system ...  conducts an optical analysis of a standard biopsy slide which detects cancer earlier and more accurately  [Patty Tascarella, Pittsburgh Business Times, Jan 15, 14]

NantCell (Culver City, CA)

NantCell (Culver City, CA; no SBIR), a subsidiary of NantWorks, raised $30 million in investor funding after a similar injection late last year, according to a March 14 securities filing. [Dana Bartholomew, LA Business Journal, Mar 14, 19]

NantCell (Culver City, CA; no SBIR, founded 2014) biotech founded by [LA] billionaire Patrick Soon-Shiong, has raised $30 million in investor funding, according to [SEC] filing. ..., a subsidiary of the NantWorks conglomerate controlled by Soon-Shiong, sold $30 million in securities to one investor, ..... conducts cell-based research at the molecular level to develop treatments that harness the immune system to fight cancer. The latest funding round follows more than $230 million raised since 2015. [Dana Bartholomew, LA Business Journal, Dec 28, 18]

Nantero (Woburn, MA)

nanotechnology startup, Nantero (Woburn, MA; $900K SBIR) raised $2 million in an equity offering, according to a Form D notification. [Srividya Kalyanaraman, BostInno, Nov 1, 18]

Nantero (Woburn, MA; $900K SBIR) snagged another $7.4 million from investors as part of a round first announced in December, SEC filings show. That brings the round’s total to $29.4 million, although it could still grow to an estimated $35 million .... developed computer memory technology using carbon nanotubes.  [Jeff Engel,, Mar 21, 17]

Nantero (Woburn, MA; $900K SBIR) has raised $10.6 million in Series D financing ... to push its product out of development and into commercialization. ....  The company’s focus has been to commercialize a product that will replace all current forms of memory including DRAM (dynamic-random access memory), SRAM (static random-access memory) and flash memory with its nonvolatile Random Access Memory or NRAM. [Patricia Resende, Mass High Tech, Nov 28, 12]

Nanotechnology company Nantero (Woburn, MA; $800K SBIR) sold its government and military business unit to Maryland-based Lockheed Martin Corp. for an undisclosed amount. [Mass High Tech, Aug 14, 08]

Nantero (Woburn, MA, one SBIR) and its partners Carbon Nanotechnologies (no SBIR) of Houston and the Roy Blunt Jordan Valley Innovation Center (JVIC) at Missouri State University (one politician) have been awarded a $6.2M (ONR) grant to develop carbon-based satellite components, ... Privately held Nantero has raised at least $31.5 million in funding. [Mass High-Tech, Feb 27] Sniff a pork project?  In fiscal years 2005 and 2006, Blunt also helped secure more than $14M for defense-related research projects at the Center for Applied Science and Engineering (CASE), which will relocate much of its work to the new building. The Fiscal Year 2007 Department of Defense budget includes almost $8M in funding for CASE research projects. [Missouri State University news, Dec 15, 06] Didn't the Dem revolution of '06 stop such pork? Not for DOD whose appropriation was already law.

NantHealth (Culver City, CA)

NantHealth (Culver City, CA; no SBIR) healthcare technology company received [FDA] approval to market a genetic mapping tool that measures the rate of cell mutations in tumors. [Howard Fine, LA Business Journal, Nov 22, 29]

NantKwest (Cardiff-by-the-Sea, CA)

NantKwest (Cardiff-by-the-Sea, CA; no SBIR) shares surged 39% on first day of trading following [IPO] that valued the company at $2.6 billion.

Napo Pharmaceuticals first named Shaman Pharmaceuticals (San Francisco, CA)

When Salix Pharmaceuticals and Napo Pharmaceuticals (no SBIR) inked a deal to develop the diarrhea drug crofelemer in late 2008, Raleigh-based Salix had a market cap of about $250 million.   Today Salix, buoyed in large part by growing sales of its best-selling drug Xifaxan, has a market cap approaching $3 billion with a number of promising drug indications in the pipeline.  Napo, meanwhile, is in a very different place. Having soured on its relationships with Salix and another of its crofelemer partners, India-based Glenmark Pharmaceuticals, it is seeking to terminate those agreements and retake control of the drug, which would be the San Francisco-based company’s first revenue-generating product.[David Bracken, Raleigh News & Observer, Jul 5, 12]

[Lisa Conte' s drug development] quest has spanned two decades, two initial public offerings, a stock delisting, a bankruptcy and an ultramarathon of fundraising to pay for rigorous testing required by the [FDA] ... Conte may be nearing the finish line. In November her company,  Napo Pharmaceuticals  (San Francisco, CA; first named Shaman Pharmaceuticals ; one SBIR)  completed its first successful Phase III study of crofelemer [Helen Coster, Forbes, Jan 17, 11]

Narus Biotechnologies (San Francisco, CA)

Narus Biotechnologies (San Francisco, CA;  no SBIR) [focused on creating RNA diagnostic tests for neurological diseases] has been acquired by [biotech] Cofactor Genomics  (St. Louis, MO; no SBIR, $300K NIH grant, 19 employees) [which provides DNA and RNA sequencing services], the companies announced  ...  Cofactor was one of several companies founded after the completion of the Human Genome Project— supported by $900 million in research funding — by technology development scientists from Washington University’s Genome Center. ...  recently went through the Silicon Valley-based Y Combinator accelerator program, which invested $120,000 in the company. ..  Y Combinator is considered the best startup accelerator in the world having funded more than 800 startups that have a combined valuation of more than $30 billion. [Brian Feldt, St Louis Business Journal, Feb 5, 16]

Nascentric (Austin TX)

Nascentric (Austin TX; no SBIR), which develops software for analyzing complex circuits designed at the nanometer level,  raised another $7.2M of venture capital, especially from Intel Capital.  [Austin American-Statesman, Sep 15]

Nastech Pharmaceutical

Nastech Pharmaceutical shares plummeted [Apr 25, 08] after the company announced it was raising $7.9 million through an equity offering to unidentified new and existing investors.

Natera (formerly Gene Security Network, (San Carlos, CA)

Prenatal testing startup Natera (previously Gene Security Network, San Carlos, CA; $4M SBIR, founded 2004) set a target range for an IPO [for] $100 million.  ...  offers non-invasive testing for such prenatal concerns as gender, genetic carrier screenings, miscarriages and paternity ...  has raised $154 million over seven rounds [Gina Hall, Silicon Valley Business Journal, Jun 22, 15]

Natera  (San Carlos, CA; no SBIR) which is developing non-invasive DNA tests including a prenatal version, this week raised $55.5 million in Series F funding ...  also working on non-invasive cell-free DNA-based tests for the early detection and therapeutic monitoring of cancer.  [Cromwell Schubarth, Silicon Valley Business Journal, Apr 8, 15]

Natera (San Carlos, CA; $4M SBIR as Gene Security Network) announced that it has completed a $54.6 million financing round to support the expansion and continued global rollout of Natera’s non-invasive prenatal test, Panorama™  ....   raised $20 million in funding in January 2012   [Business Wire press release, May 1, 13]

National Technical Systems (Calabasas, CA)

National Technical Systems (Calabasas, CA; $400K SBIR (all DOD))  up 38% [Aug 16, 13] agreed to be taken private by private equity firm Aurora Capital Group for about $267 million in cash. [Saabira Chaudhuri, Wall Street Journal, Aug 16, 13]

Natural Molecular Testing (Renton, WA)

Natural Molecular Testing (Renton, WA; no SBIR) that was once the largest genetic testing company in the country will be liquidated and its assets handed over to creditors as part of a bankruptcy settlement. In October 2013, just four months after Natural Molecular Testing   ... In October 2013, just four months after Natural Molecular Testing's CEO Beau Fessenden was named a regional Ernst & Young Entrepreneur of the Year, the company filed for Chapter 11 bankruptcy protection. ... The company must pay back $71 million in payments Medicare made for claims related to genetic tests performed on patients. ... In a review by a Medicare contractor cited in the settlement, Natural Molecular's billing practices were found to be insufficient for reimbursement through Medicare.  [Annie Zak, Puget Sound Business Journal, Jul 31, 15]

NaturalNano (Pittsford, NY)

NaturalNano (Pittsford, NY; no SBIR) has extended its patent licensing agreement with the U.S. Naval Research Laboratory covering the commercialization of products based on five patents for extended-release technologies  [Smriti Jacob, Rochester Business Journal, Feb 10, 11] the stock trades under a penny with one full time employee

NaturalNano (Pittsford, NY; no SBIR) said that Noble Polymers, a division of Michigan-based Cascade Engineering purchased its halloysite nanotubes material. .... Cascade Engineering is a manufacturer that markets to a mix of industries such as the estimated $40 billion polymer composites industry.  [Rochester Business Journal, Jul 29, 08]

NaturalNano said it has entered an exclusive development and testing agreement with France-based cosmetics supplier Fiabila S.A.    The deal will involve exploring the use of halloysite natural tubes in nail polish and other nail-care products. [Rochester Business Journal, Jun 20]

NaturalNano (Pittsford, NY, no SBIR) announced a partnership with Philadelphia’s Rohm and Haas Co. to explore the development of polymers with enhanced properties.   ... another major milestone in NaturalNano’s drive toward sustained revenue and validating it investments and patents in halloysite natural tubes enabled materials   [Smriti Jacob, Rochester Business Journal, Jun 9, 08]  NaturalNano has used nanotechnology to develop a type of paint that stops cellphone signals. It's done by blending particles of copper that are inserted into nanotubes, and then mixing and suspending these tiny particles into a can of paint. [Gizmodo, Mar 06]

NaturalNano (Pittsford, NY; no SBIR) jumped nearly 28% [May 20, 08] following news the company has begun work with an undisclosed Fortune 50 chemical firm on two funded projects for uses of Pleximer and its halloysite nanotube technology. [Smriti Jacob, Rochester Business Journal, May 21] The stock reached six cents although the company's cash is barely enough to cover a fifth of its average annual loss for the past two years, and the company told the SEC that it might no longer be able to continue operations because of debt and growing losses.

Nature's First (Orange, CT)

Five Connecticut companies have qualified for more than $1 million in grants and loans through the Small Business Express Program. ... a bi-partisan effort created last year to help small businesses with 50 or fewer workers boost their payrolls and fund capital investments. Innovation companies: Nature's First (Orange, CT; no SBIR); Nalas Engineering (Essex, CT; one SBIR);    [Janice Podsada, Hartford Courant, Apr 13, 12]

Natus Medical

Natus Medical down 20% [Apr 4, 16]  after announcing lower quarterly revenue [compny press release]

Natus Medical up 24%  [Oct 24, 13]

Natus Medical down 13% [Jul 8, 13]

Natus Medical up 11% [Feb 28, 13]

Natus down 12% [Jul 28, 11]

Natus Medical down 10% [Jul 7, 11]

Natus Medical up 10% [Apr 29, 10]

Natus Medical agreed to acquire Fountain Valley, Calif.-based Alpine Biomed Holdings, which makes devices for the diagnosis of neurological disorders, for $43.2 million. [Wall Street Journal, Sep 15, 09]

Natus Medical, which makes medical devices used for newborn care, said Monday it bought privately held Hawaii Medical LLC, of Pembroke, for $2.9 million in cash.  [Boston Globe, Jul 6, 09]

Natus Medical  up 14% [May 1, 09]

Natus Medical down 26% [Jan 20, 09]

Natus Medical down 15% [Jan 5, 09]

Natus Medical up 11% [Dec 31, 08]

Natus Medical  up 13% [Dec 2, 08]

Natus Medical  down 12% [Dec 1, 08]  On a stock bloodbath day

Natus Medical up 13% [Nov 25, 08]

Natus Meidcal down 12% [Oct 30, 08]

Natus Medical up 11% [Oct 13, 08]

Natus Medical down 10% [Mar 12, 08]

Natus Medical down 10% as it reported growth in both sales and profit for the quarter ended September, but also said regulators warned it about process problems at one of its plants in Seattle. [, Nov 1, 07]

Natus Medical up 10%  on inclusion in new neuro index. [Sep 27, 07]

Natus Medical rose 14% on better than expected profits. One Phase 1 SBIR long ago.

Naveris (Natick,MA)

Naveris (Natick, MA; no SBIR) which aims to detect virus-related cancers early, closed its expanded Series A round [BostInno, Dec 15, 20]

Naverus (Kent, WA)

Last November, GE acquired Naverus, (Kent, WA; no SBIR) which has pioneered the use of satellite technology and on-board aircraft avionics to design precise pathways in the sky to guide airliners to their destination.... Fulton, a former Alaska Airlines pilot, co-founded Naverus after working with the technology in the 1990s at Alaska. The company designs precise paths for specific planes into specific airports. [Dominic Gates, Seattle Times, Jul 24, 10]

Navidea Biopharmaceuticals (Dublin, OH)

Navidea Biopharmaceuticals (no SBIR) is raising $2.5 million in a funding round led by the former principal of its largest institutional investor in a deal that places the valuation of its new disease-hunting subsidiary at $500 million. ...  for the Macrophage Therapeutics subsidiary (of Navidea)  [formed Dec 2014] to further explore therapeutic applications for the Manocept™ platform.   [Carrie Ghose, Columbus Business First, Jan 21, 15]

Navidea Biopharmaceuticals (Dublin, OH; no SBIR) took a first step toward developing radioactive drugs to treat disease instead of just detect it with the formation of a joint venture with an early stage pharmaceutical company [Rheumco LLC (no SBIR,a startup backed by private equity firm )] focused on arthritis.  ... seeking new uses for its compound that attaches to a specific receptor on macrophages, a type of white blood cell. That’s what attaches to lymph nodes in Lymphoseek, and in the new venture targets the errant immune cells that attack joints in debilitating rheumatoid arthritis. [Carrie Ghose. Columbus Business First, Jul 11, 14]

Navidea Biopharmaceuticals (Dublin, OH; no SBIR) radioactive diagnostic drug Lymphoseek has had about $2.5 million in sales in the 12 months since Cardinal Health [ the drug’s exclusive U.S. distributor] launched it one year ago, indicate sales figures released   ...  Medicare’s approval of separate payments for the drug in October boosted sales.   [Carrie Ghose, Columbus Business First, May 7, 14]

Navidea Biopharmaceuticals (Dublin, OH; no SBIR) the new identity of the former Neoprobe, has obtained $10 million in debt financing from a life sciences investment fund following a nearly $30 million infusion a few months ago, while hinting at another possible acquisition. ....The company’s most recent acquisition was the rights to AZD4694, which is being researched for use in detecting Alzheimer’s disease.   [Carrie Ghose, Columbus Business Journal, Jan 5, 12]

Navini Networks (Richardson,TX )

Cisco Systems will buy privately held Navini Networks (Richardson, TX, 260 employees; no SBIR) for $330M, extending the networking equipment maker's acquisition streak and providing the latest validation for the new wireless network technology called WiMax.  [San Jose Mercury News, Oct 23]

Navire Pharmaceuticals (Houston, TX)

The University of Texas MD Anderson Cancer Center and BridgeBio (Palo Alto, CA) announced the launch of Navire Pharmaceuticals (Houston, TX), a biopharmaceutical company aimed at developing novel small-molecule inhibitors of a tyrosine-protein phosphatase called SHP2 for genetically-driven and treatment-resistant cancer.  BridgeBio has committed $30 million and a team of senior business managers to the company, while MD Anderson, through its Institute for Applied Cancer Sciences (IACS), provides intellectual property and an oncology drug development team to advance SHP2 inhibitors toward clinical studies.  [BridgeBio press release, Oct 4, 17]

Navitor Pharmaceuticals (Cambridge, MA)

David Sabatini helped discover the kinase mTOR, or “mammalian target of rapamycin,” two decades ago. Now the work on the molecule at his lab at the Whitehead Institute is the foundation for a Cambridge-based startup called Navitor Pharmaceuticals  (Cambridge, MA; no SBIR), which just raised $23.5 million from Polaris Partners, Atlas Venture, and the venture arms of GlaxoSmithKline (SR One) and (Johnson & Johnson Development Corp.). ... is looking to create drugs that target proteins in a complex mTOR is a part of called mTORC1—which gets thrown out of whack in a whole variety of diseases.  [Ben Fidler,, Jun 20, 14]

Johnson & Johnson Innovation said it has formed alliances with six Massachusetts-based life science and research companies to further innovation in pharmaceuticals, medical devices and diagnostic and consumer healthcare. .... • Minerva Neurosciences (Cambridge, MA; no SBIR)– Partnering with Janssen Pharmaceutica N.V., Johnson & Johnson Innovation and the Janssen neuroscience therapeutic area, Minerva has begun a program that will focus on the treatment of patients with primary and secondary insomnia and potentially treating other related neuropsychiatric disorders.Rodin Therapeutics (Cambridge, MA; no SBIR)- With initial investment from Johnson & Johnson Development Corporation, Rodin’s will work in collaboration with Johnson & Johnson Innovation in studying the inheritable changes in gene activity for the treatment of cognitive disorders, including Alzheimer’s disease.Energesis Pharmaceuticals (Cambridge, MA; no SBIR) - Janssen Pharmaceuticals Inc. and Johnson & Johnson Innovation have established a collaboration with biotechnology company Energesis to identify biological compounds that stimulate the formation of brown fat for use in treating metabolic diseases. The company’s approach is a novel strategy, leveraging recent scientific insights in BAT biology to increase the body’s ability to burn stored fat and lower insulin resistance.Navitor Pharmaceuticals (Cambridge, MA; no SBIR) - Johnson & Johnson Development Corporation has made an equity investment in Navitor, which will work in collaboration with Johnson & Johnson Innovation to develop highly-specific modulators to regulate a cell’s response to nutrient availability, including cell growth and function.Ascelegen Therapeutics (Cambridge, MA; no SBIR)– With an equity investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Ascelegen is working on developing novel therapies for cardiovascular diseases, including heart failure. Ascelegen’s work builds on research conducted at the Harvard Stem Cell Institute and Brigham and Women's Hospital. Padlock Therapeutics (Cambridge, MA; no SBIR) – With an investment from Johnson & Johnson Development Corporation, and in collaboration with Johnson & Johnson Innovation, Padlock is developing new therapies targeting a protein that mediates how protein conversions lead to rheumatoid arthritis and how it drives inflammation and immune complex formation in active autoimmune disease.  [Boston Business Journal, Jun 19, 14]

Navmar Applied Sciences (Warminster, PA)

Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]

Navmar Applied Sciences  (Chester, PA; $18M DOD SBIR) won three orders totaling roughly $37 million against a previously issued [Navy] basic ordering agreement  [Peter Kay, Philadelphia Business Journal, Sep 30, 11]

Navmar Applied Sciences (Warminster, PA; $11M SBIR) won a Phase III Small Business Innovative Research contract worth nearly $10 million from the Naval Air Warfare Center Aircraft Division in Lakehurst, [Philadelphia Business Journal, Sep 18, 08]

NBD Nanotechnologies (Boston, MA)

NBD Nanotechnologies (Lexington, MA; $1.6M SBIR) which develops advanced liquid repellant surface coatings and additives, raised $1.4M in debt in a $1.5M funding round, per an SEC filing. [Rowan Walrath, BostInno, Apr 2, 21]

NBD Nanotechnologies (Boston, MA; no SBIR, founded 2012) landed $5.2 million in Series A equity funding for its beetle-inspired technology that helps make products waterproof or helps products attract water.  ....  brings total funding for the company to $6.5 million ....  could be used for products that need to attract water — such as those used in fog harvesting — and products that need to repel water, such as electronic devices.  [Sara Castellanos, Boston Business Journal, Aug 14, 14] 

NCD Technologies (Madison, WI)

Six Madison [WI]-area tech startups are receiving grants from the SBIR Advance program, a collaboration between the Wisconsin Economic Development Corp. and the UW System Administration's Center for Technology Commercialization, to grow their businesses.  Onexio Biosystems, Madison $75K, Equipment used to quickly screen potential drug compounds during the drug development process. Pyran, Madison $75K: Using wood and crop waste to make a key chemical used to manufacture paints and plastics; Stem Pharm, Fitchburg, $75K: Biomaterials for cell and tissue manufacturing; NCD Technologies, Madison $100K: Diamond and diamond-like coatings for medical devices and other industries. PhylloTech, Middleton $100K: A process to engineer plants to produce proteins that will help them resist agricultural diseases. [Judy Newman, Wisconsin State Journal, Mar 27, 19]

NCD Technologies (Madison, WI; one SBIR) is the only SBIR user of the seven new firms qualifying for a state handout by the Wisconsin Economic Development Corp ...  commercializing its nanotechnology diamond coating product, initially to the micro-tools market, which includes makers semiconductors, imaging and video equipment and industrial medical software.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Feb 22, 12]

CVD Diamond Again.  NCD Technologies (Madison, WI) start-up company aiming to use thin diamond coatings to improve the performance of cutting tools and other devices said  it has received a $150,000 [NSF SBIR] ...  Heaney founded NCD in October, after graduating in August with a doctorate in materials science from the University of Wisconsin, he said. The company is negotiating with the Wisconsin Alumni Research Foundation for an exclusive license for its technology involving nanocrystalline diamond coatings and applications, which Heaney developed while earning his degree.  [Kathleen Gallagher, Milwaukee Journal Sentinel, May 12]  Prospective costs as a market barrier?  Again.

nContact Surgical (Morrisville,NC)

medical device company nContact (Morrisville, NC; no SBIR) has agreed to be acquired by AtriCure (West Chester, OH; no SBIR) in a deal valued at up to $149 million.  Both companies are developing treatments for atrial fibrillation, an abnormal and often rapid heart rhythm that affects more than 33 million people worldwide and significantly increases the risk of stroke.  ...   In November 2014, nContact secured $20 million in [VC] financing [David Ranii, Raleigh News & Observer, Oct 5, 15]

Excelleration Medtech LLC has raised $4.2 million to invest in a medical device maker, nContact (Morrisville, NC; no SBIR) technology company developing so-called "aepicardial ablation devices" for the arrhythmia market, according to James Kay, an Excelleration Partners founder. [Christopher Calnan, Austin Business Journal, Jun 13, 13]

nContact Surgical (Morrisville, NC; no SBIR) raised $16 million in new funding. ....  developing devices for minimally invasive treatment of heart ailments, plans to use the money to hire new staffers and for product development, including support of three clinical trials.  Since it was founded in 2005, nContact has raised $42.4 million  [David Ranii, Raleigh News & Observer, Nov 11, 10]

Neah Power (Bothell, WA)

Neah Power's (Bothell, WA) $8M round of venture capital brings investment to $20M to develop new fuel cells small enough for mobile devices like laptop computers and DVD players. From an expected product release in 2006, the marketeers project that by 2012, micro fuel-cell technology will power 13% of laptops. [story Seattle Times, Aug 20] No sign of any SBIR money.

Near Infinity

Invertix (McLean, VA; $1M SBIR) and Near Infinity (no SBIR) are now operating as Altamira Technologies. .....  announced it was teaming up with Ball Aerospace & Technologies to go after one of four prime contractor spots on an eight-year, $960 million deal to support the National Air and Space Intelligence Center at Wright-Patterson Air Force Base. [Joe Cogliano, Dayton Business Journal, Jun 19, 13] 

Neato Robotics

Neato Robotics  (Newark, CA; no SBIR), a startup that competes with Roomba (by iRobot) for automatic vacuum cleaners, disclosed that it raised $14 million in new funding ......  says that its cleaning robots are better than Roomba because they automatically map a room before starting and are laser-guided to sweep floors in overlapping lines.   [Cromwell Schubarth, Silicon Valley Business Journal, Aug 13, 13]  Commercial success induces competitors.

In its fourth round of venture funding, Neato Robotics (no SBIR) raised $12.2 million.   [San Francisco Business Times, Apr 19, 12]

Nektar Therapeutics (San Carlos, CA)

The 27-0 vote against approval followed questioning of Nektar’s decision to run one pivotal trial and the extent to which it assessed the abuse risk. .... . The unanimous rejection followed the publication of a FDA briefing document that questioned the reliance on a single pivotal trial [Nick Paul Taylor, Fierce Biotech, Jan 15, 2020]

A gene therapy delivered to the liver delayed progression and reversed symptoms of early-stage multiple sclerosis in mice. With improvements, the approach could be a potential treatment for the autoimmune disease, which has no cure, [say] University of Florida-led researchers ...  The team is working on viral vectors to deliver other proteins implicated in MS, and are exploring other autoimmune disease targets for this approach. Eli Lilly recently forked over $150 million to Nektar Therapeutics (San Francisco, CA; no SBIR) to codevelop a drug that increases the number and activity of Tregs in up to 10 disease areas.   [Amirah Al Idrus, Fierce Biotech, Sep 21, 17]

Nektar Therapeutics (San Francisco, CA; no SBIR) up 43% [Mar 20, 17] after the drugmaker cites success in latest clinical trials for pain reliever NKTR-181.  [San Jose Mercury News, Mar 20, 17]

Nektar Therapeutics (San Francisco, CA; no SBIR) announced that it has entered into an agreement with Daiichi Sankyo Europe for Nektar's investigational drug therapy, ONZEALD (etirinotecan pegol, NKTR-102), which has completed a Phase 3 clinical trial (the BEACON study) in patients with advanced breast cancer.  The agreement grants Daiichi Sankyo Europe exclusive rights to market ONZEALD in Europe (EEA), Switzerland and Turkey. Nektar Therapeutics will retain rights to ONZEALD in the United States and the rest of the world. Under the terms of the agreement, Nektar Therapeutics is entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments, based upon the achievement of European regulatory milestones and European sales of ONZEALD.  Nektar is also entitled to significant double-digit royalties on net sales in Europe. [company press release, Jun 1, 16]

[VC] firm Clarus Venures has invested in $18 M dollar financing of Pearl Therapeutics (no SBIR), a California-based biopharmaceutical company developing products for major respiratory diseases. ..... Pearl, founded in 2006, has raised $36 M of VC and other funding to date.  Nektar Therapeutics (no SBIR) has licensed advanced particle technology to Pearl, and the company it is using to develop technology that will give patients and their health care providers a choice of formulations and dosage strengths of respiratory treatments.  [Mass High Tech, Jul 7, 08]

Large-cap Pfizer's report of increased lung-cancer cases among users of its inhaled-insulin product weighed on Nektar Therapeutics  (San Carlos, CA, no SBIR) which fell 25%. The company developed the delivery system used with the product and said it has stopped talks with potential partners for its inhaled-insulin programs.  [Wall Street Journal, Apr 10, 08]

Nekton Research (Durham, NC)

iRobot agreed to buy Nekton Research (Durham, NC; $4M SBIR, 24 employees), an unmanned underwater robot and technology company...  for $10M+.  [Boston Globe, Sep 9, 08]  Nekton has grown into an aquatic robotic power with customers that include defense agencies. ... iRobot already gets about 45 percent of its sales from the military and industrial segment. ...  traces its history to Duke University, where Wainwright was a biology professor. He wanted to understand how fish swim. [Jonathan Cox, Raleigh News & Observer, Sep 9]

NemaMetrix (Eugene OR)

(Oregon) Gov. Kate Brown announced that five companies would receive a combined $300,000 to fund innovation from Business Oregon, the state's economic development arm, and act as follow-on funding for awards from [SBIR]: DesignMedix (Portland, OR; $1.4M prior SBIR): makers of a drug to improve malaria treatment, $75,000;  Energy Storage Systems (Portland, OR; no SBIR): makers of a new kind of battery for utility-scale energy storage, $75,000;   SupraSensor  (Eugene, OR; no SBIR, founded 2012): makers of a testing device that helps farmers use fertilizer more efficiently, $61,875; NemaMetrix  (Eugene OR; $200K SBIR, founded 2011): makers of an advanced drug screen for cheaper, faster testing, $49,100HM3 Energy (Gresham, OR; one SBIR): developers of a technology that converts forest debris into briquettes that can replace coal in power plants, $40,171.  [Mason Walker, Portland Business Journal, Apr 17, 15]

NeoChord (Minneapolis, MN)

NeoChord  (St Louis Park, MN; no SBIR, founded 2007) leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation,announced that it has secure dadditional funding as anextension of its SeriesD equity financing, ... bringing the ttal for the last 12 months to $32M [comapny press release, Apr 30, 19] prior funding $67M []

heart device maker NeoChord (St. Louis Park, MN; no SBIR) announced closing a $25 million [Series D] funding - its largest to date—that received contributions from several out-of-state investors. .... develops products for surgical use to treat patients suffering from mitral valve regurgitation. [Sam Schaust, Twin Cities Business, November 9, 18]

Med-tech company NeoChord (St Louis Park, MN; no SBIR, founded 2007) announced that it has completed a $25 million Series D equity financing ... to accelerate the development of the company’s transcatheter chordal repair and edge to edge programs. [company press release, Nov 5, 18]

NeoChord (St. Louis Park, MN; no SBIR, founded 2007, Mayo Clinic spinoff) nabs $10 million  [Minneapolis / St. Paul Business Journal, Sep 20, 17] ....   medical technology company leading the advancement of minimally invasive repair for degenerative mitral regurgitation (DMR). [company website]

NeoChord (Eden Prairie, MN; no SBIR) completed its most recent round of funding with $20 million to pursue U.S. regulatory approval of its heart-valve-repair technology. ... makes artificial “heart strings” — tendons that close heart valves — and an accompanying device that together treat mitral valve regurgitation, a condition that causes heart valves to not close tightly enough.  Surgeons at Mayo Clinic invented the company's technology.  [Katharine Grayson Minneapolis / St. Paul Business Journal, Jun 9, 15]

Mayo Clinic spinoff NeoChord (Eden Prairie, MN; no SBIR) has landed nearly $13 million  [Katharine Grayson, Minneapolis / St. Paul Business Journal, May 29, 15]   is investigating minimally invasive technology intended to transform the treatment of mitral regurgitation.  The company has an exclusive worldwide license to the technology and is currently working on additional minimally invasive technologies for the treatment of structural heart disease. ... has developed a proprietary device which allows mitral valve repair to be performed on a beating heart through a 2- to 3-inch incision between the ribs in patients with severe mitral valve regurgitation (“MR”). In contrast, most mitral valve repair procedures are performed through a 3 to 10 inch chest incision (sternotomy) that involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on cardio-pulmonary bypass (CPB).   [company website]

NeoChord (Eden Prairie, MN; no SBIR) that makes artificial "heart strings," is seeking $1.5 million in capital, according to a regulatory filing.... has already raised about $457,000.  ...  makes artificial versions of tendons that close heart valves. Its technology, first invented by Mayo Clinic, treats mitral-valve regurgitation.  [Katharine Grayson, Minneapolis / St. Paul Business Journal, Feb 27, 15]

Clarian Health Ventures -- an investment company owned by Indianapolis hospital system Clarian Health -- said Tuesday it has invested an undisclosed amount in  startup NeoChord  (Minneapolis, MN; no SBIR) developing a minimally invasive procedure to treat mitral-valve regurgitation for cardiac patients. [Indianapolis Star, Oct 8, 08]

>Neoci (Miami, FL)

Neocis (Miami, FL, one SBIR) raised $30M [Emon Reiser, South Florida Business Journal, Jul 16, 2019] transforming dental implant surgery with advanced robotics [company website]

Neogen (Lansing, MI)

Neogen (Lansing, MI; $1M SBIR) up 21% [Jul 21,15]

In Forbes 2014 list of 100 best small companies: iRobot, Neogen (Lansing, MI; $1M SBIR).

Neogen (Lansing, MI; $1M SBIR)., which makes food and animal safety products, bought the assets of Scidera Genomics (Davis, CA; no SBIR). .... Scidera started life as MetaMorphix (no SBIR). and MMI Genomics (no SBIR), working in the area of genetic tests for cattle, poultry, pigs and dogs [Stephen EF Brown, San Francisco Business Times, Jan 2, 13]

Forbes's 2009 list of best 200 small companies includes Aerovironment, American Science and Engineering (paying a dividend and with nearly $600M market cap), Argon ST, Hittite Microwave, II-IV, Meridian Bioscience, Neogen, NVE, and Synaptics.

NeoGenomics (Ft Myers, FL)

NeoGenomics (Ft Myers, FL; no SBIR), a leading provider of cancer-focused genetic testing services, announced that it [will] acquire Genoptix (Carlsbad, CA; $1.1M SBIR) for $125 million in cash and 1 million shares of NeoGenomics common stock. Genoptix is a leading clinical oncology laboratory, specializing in hematology and solid tumor testing. Genoptix’s strong capabilities complement NeoGenomics’ leadership position with hospitals and pathologists. [NeoGenomics press release, Oct 23, 18]

Neograft (Taunton, MA)

Medical device startup Neograft Technologies (Taunton, MA, (born at the University of Pittsburgh); (no SBIR) closed on a $5 million funding round ... to complete preclinical testing and development of the company’s Angioshield technology for use in structural support of veins during heart bypass procedures.  [Rodney Brown, Mass High Tech, Aug 11, 11]

Neoleukin Therapeutics (Seattle, WA)

Neoleukin Therapeutics (Seattle, WA; no SBIR) up 22% [Nov 25, 19]

NeoLight (Scottsdale, AZ)

NeoLight (Scottsdale, AZ; no SBIR, an Arizona State University spinout in 2014) announced it has received [FDA] clearance to market the Skylife™ portable phototherapy system [which] delivers a narrow band of high-intensity blue light via blue light emitting diodes (LEDs) to provide treatment for neonatal unconjugated hyperbilirubinemia (jaundice).  [company press release, Nov 1, 17]

Neon Therapeutics (Cambridge,MA)

Neon Therapeutics (Cambridge, MA; no SBIR) closed 2019 by curtailing its cancer vaccine programs and laying off 24 percent of its workforce. The new path will now be as a division of cancer drug developer BioNTech (Germany) [which] announced that it has agreed to acquire Neon in a $67 million stock deal. [Frank Vinluan, Jan 16, 20]

A little more than a year after its launch, immuno-oncology firm Neon Therapeutics (Cambridge, MA;  no SBIR) secured $70 million in new financing to fuel its efforts to develop drugs that teach the immune system to fight cancer.  ... The vaccine, called NEO-PV-01, targets neo-antigens — markers that are uniquely present on the surface of tumor cells, but completely absent on normal, healthy tissue .... launched in 2015 with a $55 million investment, announced a Series B financing ...   brings the total amount raised by the company to $125 million.    [Max Stendahl,  Boston Business Journal, Jan 5, 17]

Third Rock Ventures and Len Blavatnik, the richest man in the U.K., poured $55 million in Series A cash into a a new  immuno-oncology startup called Neon Therapeutics (Cambridge, MA; no SBIR). Neon is pursuing a new type of cancer vaccine that would train the immune system to spot so-called “neoantigens,” or, pieces of tumor cells that result from new mutations as the tumor grows.  [Ben Fidler,, Oct 2, 15]

NeoPhotonics (San Jose, CA)

NeoPhotonics down 15% [Oct 5, 17]

Neophotonics down 12% [Dec 20, 16]

NeoPhotonics , (San Jose, CA; no SBIR) maker of components for communications networks, said it has agreed to acquire Santur(Fremont, CA; no SBIR) in a deal potentially worth up to $46.7 million. Santur designs and manufactures indium phosphide-based products, such as tunable laser arrays and packaging technologies for communications. [AP, Sep 29, 11]


Neoprobe (Dublin, OH; no SBIR) medical device developer says it could be on its way to joining a major national stock exchange after striking a debt-to-equity swap with its largest investor. ... 12 years ago failed to clinch approval for the cancer-detecting drug upon which it was founded, called Rigscan. It was a devastating blow that led to the departure of its CEO and delisting from NASDAQ. More than a decade later, Neoprobe has rebooted its efforts on Rigscan and is moving closer to commercialization on Lymphoseek, a product executives have said could have a $370 million market potential. [Business First of Columbus, Jun 23, 10]

Neos Therapeutics (Grand Prairie, TX)

Neos Therapeutics (Dallas, TX; no SBIR, IPO 2015) developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, announced that [FDA] approved Cotempla XR-ODT, the first and only methylphenidate extended-release orally disintegrating tablet for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients 6 to 17 years old. [company press release, Jun 19, 17]

Neos Therapeutics (Grand Prairie, TX; no SBIR) announced the pricing of its IPO to raise $60M focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are XR medications in patient-friendly ODT or liquid suspension dosage forms. [company press release, Jul 23, 15]

Neos Therapeutics (Grand Prairie, TX; no SBIR) filed for [IPO]. ...  develops medication for Attention Deficit/Hyperactivity Disorder  ... has a place holder value of $69 million.  [Korri Kezar, Dallas Business Journal, Jun 23, 15]

Neos Therapeutics (Grand Prairie, TX; no SBIR) completed a round of financing totaling $20.6 million for its late-stage pipeline of extended-release products for Attention-Deficit Hyperactivity Disorder, the firm announced.  ...  support its efforts during the regulatory review of its ADHD drug candidate. The company has been raising late-stage funding in the past year ... Last year, the company raised $18 million in funding and also completed a $20 million loan facility.   [Bill Hethcock,  Dallas Business Journal, Feb 25, 15]

NeoSync (South Boston, MA)

NeoSync (South Boston, MA; no SBIR) raised $13 million for a registration trial of its magnetic stimulation technology in treatment-resistant depression  [Amirah Al Idrus, Fierce Biotech, Aug 11, 17]

Neothetics (San Diego, CA)

Neothetics (San Diego, CA; no SBIR) sold 4.65 million shares in its pre-Thanksgiving IPO and raised $65 million. The company is trying to repurpose an approved asthma drug as a means of reducing belly fat. [Alex Lash,, Dec 4, 14]

Neotron (Boston, MA)

Neotron (Boston, MA; no SBIR) is looking for $1.5 million to develop a Lithium-6 neutron detector, add personnel and buy space and equipment. [Mass High Tech, Apr 14, 10]

NephroGenex (Durham, NC)

NephroGenex (Raleigh, NC;  SBIR), which announced last month it had fired its CEO and was working to sell its assets, has filed for Chapter 11 bankruptcy.

NephroGenex (Raleigh, NC; no SBIR, IPO in 2014) fired its CEO and chief scientific officer as the cash-strapped  company works to sell its assets  [Raleigh News & Observer, Apr 14, 16]

NephroGenex shares plunged 37 percent after the company said it had paused a clinical trial of its experimental treatment for kidney disease while it moves to restructure its operations.  [Raleigh News & Observer, Feb 24, 16]

drug developer NephroGenex (Raleigh, NC; no SBIR) finalized a plan to raise $7.5 million, a disclosure that sent the stock tumbling 18 percent.  ... After changing the offering five times, it settled on a plan to sell shares on the open market for $5 each ... in the process of testing Pyridorin, an experimental drug under development for the treatment of diabetic nephropathy, a common complication of diabetes and in cases of acute kidney injury (AKI).  [Jason deBruyn, Triangle Business Journal, Jul 17, 15]

kidney disease treatment developer NephroGenex (Research Triangle Park, NC; no SBIR) closed on a $12 million loan to bolster the company's finances and give it more working capital.  ...  has dramatically stepped up research and development this year, causing the company to burn through cash at a higher rate than in 2013.  ... ...  as we execute on our pivotal Phase 3 program with Pyridorin in diabetic nephropathy," said CEO Pierre Legault. [Jason deBruyn, Triangle Business Journal, Nov 24, 14]  

NephroGenex (Research Triangle Park, NC; no SBIR) down 4% after an IPO to raise about $37M  .... developing Pyridorin, an experimental treatment aimed at slowing the progression of a chronic, degenerative disease of the kidneys caused by diabetes called diabetic nephropathy. About 6 million people suffer from the disease  [David Bracken, Raleigh News & Observer, Feb 11, 14]

NephroGenex (Durham, NC; no SBIR) which is developing kidney disease treatments, filed [a $46M IPO] ... to further develop its therapeutics.  [Jason deBruyn, Triangle Business Journal, Dec 24, 13]

Nereus Pharmaceuticals (San Diego, CA)

Nereus Pharmaceuticals (San Diego, CA; $800K SBIR) says it has secured as much as $20 million in commitments for additional funding from its existing investors to fund a mid-stage trial of a drug candidate for treating non-small cell lung cancer. The company, which specializes in developing drugs from marine microbes  [Bruce Bigelow,, Jul 1, 10]

Nerites  (Madison, WI)

Nerites (Madison, WI; one previous SBIR) got a $134,000 SBIR grant from NIH to develop alternative methods of tendon repair ...  Nerites' hydrogel technology - which the company says can be used to close internal tears and incisions or to affix medical devices - was described in a June 2007 cover article in the journal Nature and was called one of the top 100 scientific developments of 2007 by Discover magazine  [Kathleen Gallagher, Milwaukee Journal Sentinel, Feb 21, 09]

Nest (Palo Alto, CA)

Most people thought Matt Rogers and Tony Fadell were crazy to leave Apple in 2010 to try and start-up a small company- Nest -  focused on wireless home automation. Without any initial startup funding, the two bootstrapped a prototype thermostat that they eventually used to raise money from Google and other investors. Over the next three years, the two grew the company to over 200 employees and shipped between 40,000 and 50,000 thermostats per month.  In January, Google acquired the wireless “internet of things” company for a lofty $3.2 billion. [Ryan Allway,, Feb 19, 14]

[Tony] Fadell, who left Apple at the age of 40, became convinced that his [dream house] thermostat needed to be built like a smartphone and controlled from one.  ....Nest  (Palo Alto, CA; no SBIR)’s first model, a striking stainless-steel-ringed disc with a circular display, went on sale in October 2011 to widespread acclaim. The HVAC industry, a sector as unexciting as the thermostats it sold, was astonished by the fresh ideas behind the device, which learned from its owners’ behavior and could be controlled with a polished mobile app. [Tom Simonite, MIT Tech Review, Feb 15, 13]  If Fadell lived in [anywhere outside eastern Mass or Silicon Valley], could he have put together the organization to develop, market, and sell the new idea in jiffy time?  Would he have been helped with an SBIR and a governmnt provided commercialization consultant?


Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]


Battery Ventures, Waltham MA VC firm, has two IPOs in the next two weeks: Netezza (Framingham, MA) and  BladeLogic (Waltham, MA). [Boston Globe, Jul 13, 07] Neither did SBIR.

NetLogics Microsystems

Two employees at NetLogics Microsystems, a computer chip design and development company,  have been indicted for allegedly trying to steal trade secrets on computer design that they were going to use in a company they were starting on their own. [Sharon Gaudin, Info Week, Oct 1]

Netspeed Systems (Mountain View, CA)

Intel has acquired NetSpeed Systems (San Jose, CA; no SBIR, founded 2011) for an undisclosed price. The big chip maker said the acquisition will help improve its tools for creating chip designs. NetSpeed has highly configurable and synthesizable offerings that could help Intel more quickly and cost-effectively design, develop, and test new system-on-chips (SoCs), or all-in-one chips that put a full working system on a single piece of silicon. [Dean Takahashi, Venture Beat, Sep 10, 18] total funding $13M []

Disruptive innovation has become the single biggest worry for many firms. Setting up VC arms is a way to identify life-threatening changes to their business early, so that they can adapt or, better yet, get in on the act, says Ben Veghte of America’s National Venture Capital Association, whose membership has mushroomed in recent years.  ... Intel Capital, the venture-capital VC unit of the American technology giant, is not quite sure yet but it wants to find out. It recently announced it was taking stakes in 16 startups, including the firms making these products. Intel has been in the venture-capital business for over 20 years, and has invested in more than 1,300 companies in 56 countries. Over that time corporate enthusiasm for venture capital has waxed and waned—but has seldom been greater than it is now.   [The Economist, Nov 12, 14]  Included in Intel's investment are:  Netspeed Systems  (Mountain View, CA; no SBIR) has developed a system-on-chip design platform and advanced on-chip network solutions. It says this lets system-on-chip designers create smaller and more power-efficient chips more quickly than usual; AnDAPT (Santa Clara,CA; no SBIR)  stealth-mode company working on hardware for multifunction sensor integration and integrated system power management. The aim is to lower power consumption and cost while providing high reliability.  [Intel said] we expect to invest a total of $355 million this year.  [Cromwell Schubarth, Silicon Valley Business Journal, Nov 4, 14]

Net Watch Solutions

Fourteen startups that received a total of more than $17 million from [Texas Emerging Technology Fund managed by Gov. Rick Perry’s office... which has backed 143 startups] have failed or gone bankrupt.   ....   [ MIT professor Bill Aulet, who is managing director of the Martin Trust Center for MIT Entrepreneurship] said the number of failed ETF companies would be higher if state officials took the chances they needed when investing in startups. "They really haven't taken any risk," he said. "Governments aren't good at being venture capitalists because governments aren't good at risk." ....  a partial list of the ETF-backed startups in Texas that have since closed, followed by the grant amounts they received:  • NanoTailor, $250,000;  • Star Vision Technologies, $750,000; • Terrabon, $2.7 million;  • Thrombo Vision, $1.5 million;  Nanocoolers, $3 million;  • Advanced Receiver Technologies, $250,000;  • Bauhaus Software, $500,000;  • Net Watch Solutions, $500,000;  • Sunrise Ridge Algae, $250,000;  • SeprOx, $750,000; • Speer Medical, $2.5 million   [Christopher Calnan, Austin Business Journal, Jan 9, 14] None of these had SBIR.

Six Madison [WI]-area tech startups are receiving grants from the SBIR Advance program, a collaboration between the Wisconsin Economic Development Corp. and the UW System Administration's Center for Technology Commercialization, to grow their businesses.  Onexio Biosystems, Madison $75K, Equipment used to quickly screen potential drug compounds during the drug development process. Pyran, Madison $75K: Using wood and crop waste to make a key chemical used to manufacture paints and plastics; Stem Pharm, Fitchburg, $75K: Biomaterials for cell and tissue manufacturing; NCD Technologies, Madison $100K: Diamond and diamond-like coatings for medical devices and other industries. PhylloTech, Middleton $100K: A process to engineer plants to produce proteins that will help them resist agricultural diseases. [Judy Newman, Wisconsin State Journal, Mar 27, 19]

Networkfab (Santa Clara, CA)

Agilent Technologies will acquire private defense contractor NetworkFab [Santa Clara, CA; one Phase 2 SBIR]  [San Jose Mercury News, Aug 14]

Neurable (Ann  Arbor, MI)

 Last month, two University of Michigan startups took home a total of $107,000 from the Rice Business Plan Competition, the largest and most lucrative graduate-level business competition in the world. Neurable (Ann  Arbor, MI), which has developed a human-brain interface that allows people to control objects using thoughts, and PreDxion Bio (Ann  Arbor, MI), a precision medicine diagnostics company, represented the university in the competition. [Sarah Schmid,, May 9, 16]

NeurAccel Biosciences (LaJolla, CA)

NeurAccel Biosciences (LaJolla, CA; no SBIR) is on the cutting edge of the effort to find new cures for brain diseases. The 2-year-old, privately owned La Jolla company uses a patented technology invented at the University of California San Diego to test the effects of experimental drugs in the brains of laboratory animals. [Keith Darce, signonsandiego, Sep 7, 11]

Neurala (Boston, MA)

Artificial intelligence is swiftly becoming a commodity thanks to the rise of AI-as-a-Service offerings from Amazon and IBM. Today, Neurala (Boston, MA; no SBIR, founded 2006) is joining this list thanks to a $14 million Series A. The team is looking to put AI in the hands of toy makers, drone enthusiasts and IoT engineers alike. [John Mannes, techcrunch, Jan 17, 17]

Neural Analytics (Los Angeles, CA)

Neural Analytics (Los Angeles, CA; $3M SBIR, founded 2013) a medical robotics company developing and commercializing technologies to measure and track brain health, announced it has raised approximately $22 million Series C  [company press release, May 8, 19] prior funding $51M []

Neural Analytics (Los Angeles, CA; $4M SBIR, founded 2013), a medical robotics company, announced FDA 510(k) clearance for its NeuralBot™ System, a robotic assistance technology which automatically adjusts orientation and position of its ultrasound products under the guidance of a healthcare professional. When used with its previously cleared Lucid™ M1 Transcranial Doppler Ultrasound System®, can assist clinicians to non-invasively monitor a patient’s brain blood flow characteristics and can provide information to diagnose a variety of neurological disorders. [company press release, May 30, 18] raised $15 million in Series B financing January 2018, raised $10M Apr 2017 .... US Army awarded [it] $10 million contract to develop and supply a portable, point of injury device for assessing combat-related traumatic brain injury (TBI). [company press release, Oct 24, 17]

Neuralstem (Rockville, MD)

Neuralstem down 36% [Jul 26,19] announced the pricing of its underwritten public offering [to raise] $7,500,000 [company press release, Jul 25, 19]

Neuralstem down 26% [Jul 25,19]

Neuralstem down 18% [Jul 22,19]

Neuralstem (Rockville, MD; $1.9M SBIR) down 31% [Jul 19,19] two days after 1-20 reverse split

Neuralstem (Germantown, MD; $1.8M SBIR) received notice that it could be delisted from the Nasdaq after failing to elevate its stock price consistently above $1 over the past six months. [Washington Business Journal, Jun 2, 19]

Neuralstem (Germantown, MD; $1.1M SBIR) developing treatments for serious nervous system conditions, faces a [NASDAQ] delisting threat due to a low [under $1] stock price. [Sara Gilgore, Washington Business Journal, Dec 4, 18]

Neuralstem down 50% [Jul 25, 17] on news of a mid-stage clinical trial miss for its major depressive disorder drug. The drug, NSI-189, did not meet its primary endpoint of a statistically significant reduction in depression symptoms.  [DowJonesNewswire, Jul 25, 17]

Neuralstem (Germantown, MD; $600K SBIR) down 10% [Jun 27,17]

Neuralstem up 36% [May 10,17]

Neuralstem down 28% [May 9,17]

Neuralstem (Germantown MD; $600K SBIR) up 10% [Mar 14, 17]

Neuralstem (Germantown MD; $600K SBIR) up 18% [Feb 16,17]

Neuralstem (Rockville, MD; $600K SBIR) up 7% on the NYSE after filing an application with the FDA to begin early-stage testing of a chronic spinal-cord injury treatment using stem cells. [Wall Street Journal, Aug 26, 10]

Neuraly (Germantown, MD)

Johns Hopkins School of Medicine-born biotech startup Neuraly (Germantown, MD; no SBIR, founded 2016) recently raised $36M in Series A financing as it plots trials for its first drug candidate. [DCInno, Jul 19, 18]

NeuraMedica (Oregon, City, OR)

NeuraMedica (Oregon, City, OR; $1.7M SBIR) received 510(k) [FDA] clearance for DuraFuse™ Dural Clips ... DuraFuse Dural Clips allow neurosurgeons and orthopedic spine surgeons to close incidental and planned spinal durotomies in a fraction of the time it would take to suture the dura. [company press release, Aug 30, 2022]

Neuraptive Therapeutics (Lafayette, CO)

Neuraptive Therapeutics (Lafayette, CO;  no SBIR) announced that it has obtained $1 million in seed round led by the Central Texas Angel Network  [to] further develop its flagship product, the AxoFuse Nerve Repair SystemTM (AxoFuse®) and expand operations.... AxoFuse® utilizes a well-understood method, along with a proprietary drug delivery system, to induce the fusion of cells called PEG-fusion  [company press release, Aug 21, 17]

Neuro Amp

start-ups in the drug field within the Milwaukee 7 economic development region suggests another strategic direction for the regional economy. Those new ventures come as Concordia University of Wisconsin mounts an impressive campaign to build a new pharmacy school in southeastern Wisconsin, possibly in downtown Milwaukee. ... New ventures  in the emerging drug-making concentration:  MPP Group  (no SBIR),a venture headed by serial entrepreneur Frank Langley that is building drugs aimed at alcoholism. James Cook, a University of Wisconsin-Milwaukee researcher, developed the compounds.  Neuro Amp (no SBIR),a spin-off from PhysioGenix (Wauwatosa, WI; $3M SBIR) that is aiming at diseases of the central nervous system and Alzheimer's.  Promentis (no SBIR),a collaboration between Marquette University's David Baker and UWM researchers and former Schwarz Pharma managers who are targeting schizophrenia and central nervous system disorders.  Cytometix (no SBIR),a 2004 start-up headed by Lane Brostrom that is developing drugs for the treatment of pain and asthma. Endece  (no SBIR),a 2006 Mequon start-up headed by James Yarger that is developing compounds for treating cancer, sepsis, learning and memory. [John Torinus, Milwaukee Journal Sentinel, Jan 31, 09]

Neurobiological Technologies (Richmond, CA)

NeuroBo Pharmaceuticals down 43% [Apr 14, 20]

Neurobiological Technologies (Richmond, CA; two SBIRs) reported a fiscal fourth-quarter loss of $3.5 million, compared with a loss of $4.2 million in the same quarter a year earlier. [East Bay Business Times, Sep 16, 08]

Neurobiological Technologies up 33% [Oct 15, 07]

NeuroBo Pharmaceuticals (Boston, MA)

NeuroBo Pharmaceuticals down 43% [Apr 14, 20]

NeuroBo Pharmaceuticals (Boston, MA; no SBIR) up 104% [Feb 12, 20]

Gemphire Therapeutics (Livonia, MI; no SBIR), a clinical-stage biopharmaceutical focused on developing therapies for the treatment of dyslipidemia as well as nonalcoholic fatty liver disease, and NeuroBo Pharmaceuticals (Boston, MA; no SBIR) clinical-stage biotech focused on novel, disease-modifying therapies for neurodegenerative diseases, jointly announced that they have entered into a definitive agreement whereby NeuroBo will [reverse] merge with a wholly-owned subsidiary of Gemphire in an all-stock transaction. [joint press release, Jul 24, 19]

NeuroChaos Solutions (Austin, TX)

medical technology company, NeuroChaos Solutions (Austin, TX; no SBIR) secured $1.1 million in funding from angel investors and expects to close more than $500,000 in additional investments in the next 30 days. ... The funding will also help NeuroChaos build a sales staff and marketing channels to get the product in a marketplace that is estimated to be worth $2 billion a year. [Chad Swiatecki, Austin Business Journal, Aug 27, 14]  developing products to objectively identify and monitor brain abnormalities. We are developing novel, portable, easy-to-use products that provide valuable information regarding brain dysfunction, and the post-injury or disease recovery period. [company website]

Brain injury specialists NeuroChaos Solutions (Austin, TX; no  SBIR) raised $280,000 of a planned $500,000 financing.
.... from six investors  .... founded in 2012, is a medical technology company developing products to identify and monitor traumatic brain injury. The products are designed to provide information about the presence of such an injury, its severity and the projected recovery period.  [Christopher Calnan, Austin Business Journal, Sep 25, 13]

Neurocrine Biosciences

Neurocrine Biosciences announced that Although disappointed that our essential tremor data was not what we hoped to see, we look forward to the continued advancement of our pipeline with the recent FDA approval to initiate a Phase 2 proof-of-concept study for the treatment of schizophrenia with our selective M4 agonist." [company press release, Aug 5, 22]

Neurocrine Biosciences (San Diego, CA; $10M SBIR) and Sosei Heptares (Japan) announce the signing of a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders. ... Sosei Heptares will receive a total of $100 million USD in upfront cash up to $2.6 billion USD upon achieving certain global sales milestones. [joint companies press release, Nov 22, 21]

In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences (San Diego, CA; $10M SBIR) bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics (no SBIR) ). Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold. [Amirah Al Idrus, Fierce Biotech, Feb 3, 21]

Neurocrine Biosciences and Takeda Pharmaceutical announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia. ... Takeda will receive a total of $120 million USD in upfront cash. Additionally, Takeda will be entitled to development milestones of up to $495 million USD, commercial milestones of up to $1.4 billion USD and up to double-digit royalties on net sales. [joint press release, Jun 16, 20]

Neurocrine Biosciences announced that [FDA] approved once-daily oral ONGENTYS® (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes. [company press release, Apr 28, 20]

Neurocrine Biosciences (San Diego, CA; SBIR)is doubling down on epilepsy, striking its second agreement in as many months with a new deal that grants it the option to license an investigational treatment for a rare form of the disease. [, Jan 12, 20]

Neurocrine Biosciences (San Diego, CA;$11m SBIR) is paying $30 million cash and taking a $20 million equity stake in Xenon Pharmaceuticals (Canada) to license a clinical-stage epilepsy drug and collaborate on other potential treatments for the seizure-causing brain disorder. Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in Potential Development, Regulatory and Commercial Milestone Payments [joint companies press release, Dec 2, 19]

Neurocrine Biosciences down 14% [Dec 12, 18]

Neurocrine Biosciences has teamed up with Jnana Therapeutics to develop drugs that target solute carrier (SLC) metabolite transporters. The collaboration gives Neurocrine a potential source of small molecules to treat disorders of the central nervous system. [Nick Paul Taylor, Fierce Biotech, Oct 10, 18]

Neurocrine Biosciences up 13% [Aug 1, 18]

AbbVie in cooperation with Neurocrine Biosciences (San Diego, CA; $11M SBIR, founded 1992) announced that [FDA] approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.1,2 [joint companies press release, Jul 26, 18]

Neurocrine Biosciences up 19% [Nov 2, 17]  AbbVie in cooperation with Neurocrine Biosciences announced detailed results from two replicate Phase 3 extension studies evaluating the long-term efficacy and safety of elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being evaluated for the management of endometriosis with associated pain. [AbbVie press release, Nov 1, 17]

Neurocrine Bioscience up 10% [Aug 4, 17]

Neurocrine Biosciences up 25% [Apr 12, 17]

 Neurocrine Biosciences received marketing approval for its movement disorder drug Ingrezza, the company said. Ingrezza was approved for adults with tardive dyskinesia, which causes people to have involuntary movements. This condition is a common side effect [San Diego Union Tribune, Apr 11, 17]

Neurocrine Biosciences  submitted a marketing approval application to the Food and Drug Administration for its drug to treat tardive dyskinesia, a movement disorder. [San Diego Union Tribune, Sep 2, 16]

Neurocrine Bio up 14% [Jan 14, 16]

Neurocrine Bio up 12% [Oct 8,15]

Neurocrine Bio up 11% [Sep 30, 15]

Neurocrine Biosciences down 13% [Sep 28,15]

Neurocrine Bio down 12% [Sep 25, 15]

Neurocrine Biosciences has suspended two clinical trials of its drug NBI-77860, for congenital adrenal hyperplasia. The  biotech said safety concerns caused the halt, but no patients had yet been treated, in a statement  [Bradley Fikes,, Jun 9, 15]

NeurocrineBio down 11% [Mar 25,15]

Neurocrine Biosciences ($10M SBIR; market cap $2.8 billion) said it has begun a $225 million secondary stock offering to fund research and development and drug commercialization.  ...  is performing late-state clinical trials of two drugs.  [Bradley Fikes,, Feb 18, 15]  Could DOD learn anything about investment from NIH's experience with SBIR seed funding to get private capital to exploit tech success to eventually fulfill NIH's mission?  Of course, but it won't.  DOD does not think that way.  DOD focuses on winning wars and budgets in the present.

Neurocrine Biosciences  up  26%  [Jan 8, 15] An experimental drug being developed by AbbVie  and Neurocrine Biosciences successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies.   Neurocrine's stock soared [Reuters, Jan 8, 15]

Neurocrine Bio up 10% [Dec 17, 14]  

Neurocrine Biosciences  up 11% [Dec 10, 14]

Neurocrine Biosciences  up 10% [Aug 11, 14]

Neurocrine Biosciences said it is offering 7 million shares in a secondary offering.  [Bradley Fikes,, Feb 25, 14] Trading at $18.

Neurocrine Bio up 90% [Jan 7, 14]

Neurocrine Biosciences said its movement disorder drug showed a reduction in symptoms compared to a placebo in a mid-stage study, sending its shares up 56 percent after the bell. [Reuters, Jan 6, 13]

Neurocrine Bio down 30% [Sep 10, 13] after reporting mixed results from a clinical trial of its movement disorder drug. The drug showed some indication of efficacy but failed to achieve its primary endpoint. [Bradley Fikes,, Sep 10]

Neurocrine Biosciences  up 12% [Feb 5, 13]

Neurocrine Biosciences said it has started a Phase 2b clinical trial of its drug for moderate to severe tardive dyskinesia. The neurological disease causes involuntary, repetitive movements.[Bradley Fikes,, Dec 19, 12]

Neurocrine Biosciences down 13% [Mar 27, 12]

Neurocrine Bioscience up 16% [Nov 1, 11]

Neurocrine Bio up 11% [May 31, 11]

Neurocrine Biosciences  up 12% [Apr 5, 11]

Neurocrine Biosciences  up 16% [Oct 8, 10]

Neurocrine Biosciences received  up to $235 million from Germany's Boehringer Ingelheim in a drug-development deal for a Type 2 diabetes treatment. Under the agreement with Boehringer, the San Diego drug developer will get $10 million upfront and up to $225 million in payments for reaching development, regulatory and commercial goals, as well as royalty payments on future product sales.  [Wall Street Journal, Jun 18, 10]

Neurocrine Biosciences  up 14% [Jun 16, 10]  after large-cap Abbott Laboratories agreed to pay as much as $575 million as part of a deal to help develop and commercialize the San Diego company's endometriosis treatment, designed to reduce nonmenstrual pelvic pain and other symptoms. [Wall Street Journal, Jun 17, 10]

Neurocrine Biosciences up 11% [Jun 2, 10]

Neurocrine Biosciences up 20% [May 26, 10]

Neurocrine Biosciences up 11% [Jul 10, 09]

Neurocrine Biosciences   up 11% [May 18, 09]

Neurocrine Biosciences  down 11% [Mar 26, 09]  company said some data in its fourth Phase II study on endometriosis pain treatment Elagolix require additional dialogue with advisers and regulators.  [Wall Street Journal, Mar 27]

Neurocrine Biosciences up 14% [Mar 23, 09]

Neurocrine Biosciences down 11% [Feb 25, 09]

Neurocrine Biosciences up 10% [Jan 21, 09]

Neurocrine Biosciences up 12% [Dec 31, 08]

Neurocrine Biosciences  down 11% [Dec 29, 08]

Neurocrine Biosciences up 14% [Dec 24, 08]

Neocrine Biosciences up 12% [Dec 5, 08]

Neocrine Bioscience  down 24% [Dec 1, 08]  On a stock bloodbath day

Neocrine Bioscience up 35% [Nov 24, 08]

Neurocrine Biosciences down 17% [Nov 12, 08]

Neurocrine Biosciences down 10% [Oct 15, 08]

Neurocrine Sciences up 11% [Sep 19, 08]

Neurocrine Biosystems up 11% [Sep 3, 08]

Neurocrine Biosciences up 11% [Jul 11,08]

Neurocrine Bioscience was  up 16% for last week but down 54% for 52 weeks. [Jan 14, 08]

Neurocrine Loses Sleep Over Insomnia Drug, down 48% [Market Scan, Dec 13, 07]

Neurocrine Biosciences  up 12% [Nov 29, 07]

Neurocrine Biosciences hit the skids 30% after announcing a delay in the re-submission for approval of its experimental sleep drug indiplon to summer 2008 and reporting losing $39M in the quarter. [Nov 3, 06]  $11M+ in SBIRs.

NeuroDx Development (Bensalem,PA)

Political Help Claimed.  NeuroDx Development(Bensalem, PA; no previous SBIR) received a $143,000 SBIR to continue its development of improved diagnostic tests for children and adults with brain injuries and diseases. ...  “This grant supports the vital research that NeuroDx is conducting to help those suffering from this brain condition, as well as supporting employment in this cutting-edge field,” said U.S. Rep. Patrick Murphy, D-Bucks, who helped the company secure the funding.  [Philadelphia Business Journal, Mar 1, 10]

NeuroDyne Medical (Cambridge, MA)

NeuroDyne Medical (Cambridge, MA; no SBIR) has received a letter of intent from Zynex (Lone Tree, CO; no SBIR) which plans to buy substantially all of the assets of NeuroDyne, for undisclosed terms.  [Mass High Tech, Aug 25, 11]

NeuroEM (Scottsdale, AZ)

NeuroEM Therapeutics (Phoenix, AZ; no SBIR, founded 2013) and Arizona State University have received a $255,000 [NIH SBIR] grant [Angela Gonzales, Phoenix Business Journal, Jan 8, 17]....   has developed a first-in-class, self-contained head device (the MemorEM 1000) to prevent and treat AD with electromagnetic waves – a therapy that we have pioneered and tested successfully in AD animal studies with no adverse events seen in the animals. [company website]

NeuroEM (Scottsdale, AZ; no SBIR) is a virtual early-stage medical device research and development company.... So far, the company is being funded by its parent, NeuroEM Therapeutics ...  The company will develop a head garment most likely using a cloth system that would fit snugly onto the head so an array of antennas can radiate electromagnetic treatment to certain areas of the brain.  [Angela Gonzales, Phoenix Business Journal, Apr 17, 14]

NeuroFlow (Philadelphia, PA)

NeuroFlow (Philadelphia, PA; $1M SBIR) said the company raised a $20 million Series B funding round led by a customer, an independent psychologist in Philadelphia who used its software with his patients. The deal brings the firm's total back to date to $31 million. [Michelle Caffrey, Philadelphia Business Journal, Jan 13, 21]

Neurofluidics (Menlo Park, CA)

Medical-device company Minnetronix (St Paul, MN; no  SBIR) has acquired Neurofluidics (Menlo Park, CA; no SBIR) developing technologies for treating neurological diseases. [Katherine Grayson, Minneapolis / St Paul Business Journal, Jul 10, 13]

Neurogastrx (Campbell, CA)

Neurogastrx (Campbell, CA;no SBIR, founded 2012) focused ondiscovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system, today announced a transformative $45M Series A financing [company press release, Jan 4, 18]

Neurogen (Bramford, CT)

Neurogen (Branford, CT; two SBIRs) will be sold to Ligand Pharmaceuticals for $11M plus a possible $7M to shareholders later. [Mass High Tech, Aug 24, 09]

Neurogen(Branford, CT; two Phase I SBIRs in 1988)  a pioneering member of Connecticut's small but lively biotech industry, has hired an adviser to help sell the company or its assets and has laid off half of its already shriveled workforce, the company said Tuesday. To save cash, Neurogen — which in 22 years never brought a drug to market or made a profit — has also stopped enrolling new patients in the Phase 2 trials of its most advanced drug, aplindore, for Parkinson's disease and restless legs syndrome. ... By the start of this year, the company's total net losses had reached $322 million  [Eric Gershon, Hartford Courant, May 13, 09]

Neurogen (Branford, CT; no SBIR) the struggling  biotech company, said that its deal to raise cash by selling four of its five buildings for $6 million has fallen through. ...  still trying to raise cash by selling "non-core assets," including its chemical library, which a "global pharmaceutical company" has agreed to buy for $3 million.  The company, which has been developing drugs for psychiatric and neurological disorders, is facing delisting from the Nasdaq Global Market   [Hartford Courant, Dec 3, 08]

Biotech firm Neurogen (Brookline,MA; tiny SBIR long ago) said it plans to raise $30.6 million in a private placement and cut 45 workers to focus resources on clinical development.  [Mass High Tech, Apr 9, 08]

Neurogen filed to sell filed papers with U.S. regulators to sell $100M of securities at its convenience. [May 30, 07]

Neurogene (New York, NY)

Neurogene (New York, NY; no SBIR, founded 2018) is breaking into gene therapy with $68.5 million in new funding to support research on experimental treatments for rare, genetic brain disorders, the first of which could start human testing next year. [Frank Vinluan, xconomy,con, Feb 12, 19]

NeurogesX (San Carlos, CA)

NeurogesX (San Mateo, CA; no SBIR) cut eight of its 11 employees and is seeking a buyer for its pain patch Qutenza. ....Although NeurogesX built its own U.S. sales force leading up to Qutenza's April 2010 launch, sales of the roughly $700 pain patch apparently never matched the company's hopes for its highly concentrated synthetic form of capsaicin, the active ingredient in chili pepper.   [Ron Leuty, San Francisco Business Times, Mar 8, 13]

NeurogesX (San Mateo, CA; no SBIR) cut a deal that gives it $40 million in exchange for all European royalties and milestones that it would have received for its new pain patch from Astellas Pharma.  [Ron Leuty, San Francisco Business Times, Apr 30, 10]

NeurogesX(San Carlos, CA; no SBIR) is a biopharmaceutical (founded 2000; 37 employees)developing novel pain therapies. Its chief product, NGX-4010, a skin patch containing synthetic capsaicin, is in phase III trials for treating patients with post-therpetic neuralgia, a side effect of shingles.Gene Marcial (Business Week, Sep 24, 07) likes its prospects for European markets as well. SBIR? Who needs it? The six-person Board has three VCs.

NeurogesX (37 employees in San Carlos CA; no SBIR) up 16% after noting promising results from a late-stage trial of a pain patch.

Neurognostics (Wauwatosa, WI)

Neurognostics (Milwaukee WI; one SBIR) signed an agreement to provide its functional MRI (fMRI) system to researchers at the Cleveland Clinic and the University of Iowa for a National Institutes of Health-funded Huntington's disease study. [Milwaukee Journal-Sentinel, Sep 18]

Neurognostics (Wauwatosa, WI; one SBIR) said it has installed its functional magnetic resonance imaging system at the University of Southern California. The technology, which enhances images by including information about the functionality of brain tissue, will be used initially by USC to study therapies in multiple sclerosis patients.  [Milwaukee Journal-Sentinel, Jun 20]


Army researchers soon will begin testing a new treatment for traumatic brain injury, or TBI, that involves sending nerve-impulses directly to the brain through the tongue.   A soldier would bite down on the battery powered device for about 20 or 30 minutes while carrying out a series of physical, occupational or cognitive exercises tailored specifically to treat his impairments, according to the Army. The idea is to improve the brain’s organizational ability and allow the patient to regain neural control.Researchers say the tongue is an efficient sensory link to the brain because of the thousands of nerve fibers that make up its surface.The device, which was developed by NeuroHabilitation Corporation (no SBIR; funding the commercial development of the device) with support of Marine veteran turned TV celebrity Montel Williams,   [Bryant Jordan, Defense Tech, Feb 15, 13]

Neuro Kinetics (Pittsburgh, PA)

Neuro Kinetics (Pittsburgh, PA; $1.3M SBIR) has been awarded a patent (its 19th) by the U.S. Patent and Trademark Office for an eye tracking assessment for early indicators of diseases and medical conditions such as concussions.  [Patty Tascarella, Pittsburgh Business Times, Mar 30, 17]

The National Football League has awarded a $500,000 grant to Neuro Kinetics (Pittsburgh, PA; $1.4M SBIR)  and two universities to test the effectiveness of the company's concussion detection device. ...  measures how eyes move in response to a range of stimuli. In early trials, the device provided improved concussion detection by measuring post-injury eye movements against controls.   [Kris B. Mamula, Pittsburgh Business Times, Nov 13, 14]

medical device firm Neuro Kinetics (Pittsburgh, PA; $1.4M SBIR, employs 17) has raised $885,434 from private investors  .... support our research and product development for concussion detection. ....  announced it contracted with Allegheny General Hospital to collaborate on the analysis of clinical trials underway at two military medical facilities.   [Patty Tascarella, Pittsburgh Business Times, Jan 15, 14]

NeuroLogica (Danvers, MA)

NeuroLogica (Danvers, MA; no SBIR) developer of medical imaging products, has raised $12 million in a funding round intended to support the company's higher-than-expected orders of its BodyTom scanner, CFO Jeff Cohen said.  ...... BodyTom is the company's portable, full body, multi-slice CT scanner, which landed 510(k) clearance from the U.S. Food and Drug Administration in March. The device is designed to be transported from room to room in a manner similar to existing chest X-ray systems.    [Michelle Lang, Mass High Tech, Jan 11, 12]

NeuroLutions (St Louis, MO)

NeuroLutions (St Louis, MO; no SBIR) raised $1.15 million from a group of investors ... to help the medical device company continue its clinical study of its first product, called IpsiHand, which could help patients recover from stroke.  NeuroLutions is developing medical devices that use Brain Computer Interface (BCI) technology to help restore function in patients disabled by neurological injury. The device is based on research from Washington University professors Drs. Eric Leuthardt and Dan Moran. ... To date, the company has raised approximately $2 million    [Brian Feldt, St. Louis Business Journal, Jun 11, 15]

NeuroMap (San Diego, CA)

a trio of nascent biotechnology firms with San Diego ties from trying. Each of the companies in recent weeks has won fans and thousands of dollars in prize money as they’ve moved through the annual circuit of business-plan competitions ... NeuroMap is working on a way to test the effectiveness of antidepressant medications in a patient. ... NeuroVigil, the San Diego-based winner of the second UCSD business-plan contest, announced last month that it had completed its first round of outside investment fundraising, which was led by an unnamed “American industrialist” and included investors from both U.S. coasts. ... Oculeve’s experimental device is designed to treat dry eye disease, a painful and debilitating condition that affects tens of millions of people in the United States and Europe. As many as 1.5 million Americans have the most severe form of the disease, Smith said. Most patients are treated with the tear production drug Restasis, but the therapy doesn’t work well in many patients, Smith said. In an initial test of the Oculeve device on a patient, its effectiveness was 10 times better than Restasis, he said.   [Keith Darce,, Jun 24]


NeuroMetrix down 22% [May 20, 22]

NeuroMetrix (Woburn, MA; $600K SBIR) up 76% [May 19, 22]

NeuroMetrix (Woburn, MA; $600K SBIR in 1985) after announcing that the FDA granted the Breakthrough Designation for its Quell technology designed to address symptoms in chemotherapy-induced peripheral neuropathy (CIPN). Under the designation, NeuroMetrix is entitled to priority review and more interactive communications with the regulator during the development of the device. [Seeking Alpha, Jan 18, 22]

NeuroMetrix up 27% [Sep 21, 21]

NeuroMetrix (Woburn, MA; $600K SBIR in the 1980s) down 14% [Aug 31, 21]

NeuroMetrix (Woburn, MA; $600K SBIR in the 1980s) down 16% [Aug 30, 21]

NeuroMetrix (Woburn, MA; $600K SBIR in the 1980s) up 66% [Aug 27, 21]

NeuroMetrix (Woburn, MA; $600K SBIR) up 19% [Jul 21, 21]

NeuroMetrix (Woburn, MA; $600K SBIR) up 107% [Jul 21, 21]

Chembio Diagnostics (Hauppauge NY; $7M SBIR) up 159% [Jul 21, 21] announced receipt of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio's DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil's Ministry of Health in addressing the COVID-19 pandemic [company press release, Jul 20, 21]

NeuroMetrix (Woburn, MA; $600K SBIR) up 208% [Jul 20, 21] announced that its Quell(R) d evice has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treating the symptoms of fibromyalgia in adults. [company press release, Jul 20, 21]

NeuroMetrix (Waltham, MA; $600K SBIR in 1980s, IPO 2004) raised $3.5M ...focused on the diagnosis and treatment of the neurological complications of diabetes. [, Oct 31, 17]

NeuroMetrix has started marketing efforts in Japan for its test to detect the most common complication of diabetes, peripheral neuropathy, saying approval is expected in the next month.  [Don Seiffert, Boston Business Journal, May 27, 14]

NeuroMetrix announced that it had entered into an agreement with Omron Medical Devices, a subsidiary of Omron Healthcare China, to be the exclusive distributor for NC-stat® DPNCheck® in China. Earlier this year NeuroMetrix and Omron Healthcare Co. Ltd. announced a partnership for the exclusive distribution of NC-stat DPNCheck in Japan.  NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test for early detection of diabetic peripheral neuropathy (DPN), which affects over half of people with diabetes  [company press release, Dec 10, 13]

NeuroMetrix did a 1:6 reverse split. [Feb 19, 13]

NeuroMetrixsaid it has gotten regulatory clearance to market a device that helps manage chronic pain in the lower leg or foot. [Boston Globe, Nov 30, 12]

NeuroMetrix (Waltham, MA; no SBIR, 55 employees) said its Sensus pain management device has been approved by the [FDA]. The company added that it now hopes that the device should reach the US market before the end of the year. ... a non-invasive electrical nerve stimulator that is designed to provide relief from chronic pain. People likely to benefit from the device are diabetics with nerve-related complications.  [Chris Reidy, Boston Globe, Aug 7, 12]  Founded in 1996 as MIT/Harvard Medical School spinoff [company website]

NeuroMetrix said that that it will support a clinical study of 50 obese patients with diabetes at the Joslin Diabetes Center. The patients will participate in a weight and lifestyle management program as the study seeks to determine whether weight loss and improved diabetes management can impact the progression of diabetic peripheral neuropathy, or DPN. DPN affects more than 50 percent of people with diabetes and causes significant morbidity including pain and increased risk of falling.  [Chris Reidy, Boston Globe, Apr 23, 12]

NeuroMetrix (Waltham, MA;  no SBIR) medical device firm, is seeking $10.5 million from a public offering of stock and warrants. The company said it expects to apply the proceeds to commercializing its nerve conduction test and developing its pain therapy device.[Michelle Lang, Mass High Tech, Feb 8, 12]

If at first you don't succeed, try a different target.  NeuroMetrix, developer of medical devices and therapies to treat neurological and spinal conditions, has announced a shift in business strategy to focus on the detection and monitoring of diabetic neuropathy, a complication of diabetes that results in nerve damage. The new strategy entails a 27 percent cut in its workforce and a subsequent $2.2 million charge.  [Michelle Lang, Mass High Tech, Jan 5, 11]

NeuroMetrix a developer of medical devices to treat nerve and spinal-cord injuries, has filed paperwork to register roughly 4.3 million shares — or 20 percent of its common stock outstanding — for public sale. ... will not receive any proceeds from sales of the newly registered shares. [Craig Douglas, , Mass High Tech, Dec 21, 09] Hedge fund exit.

NeuroMetrix up 12% [Sep 21, 09]

NeuroMetrix up 30% [Sep 10, 09]

NeuroMetrix agreed to pay a criminal penalty of $1.2 million and change its business practices to avoid prosecution for illegal kickbacks to doctors ... $2.5 million to settle civil charges that it encouraged doctors to improperly bill Medicare  [Todd Wallack, Boston Globe, Feb 9, 09]

NeuroMetrix has been granted 510(k) clearance from the FDA for three of the company’s Universal Electrodes. The single-patient, disposable electrodes are used in nerve conduction studies, in conjunction with the company’s Advance NCS/EMG System.  [Mass High Tech, Oct 2, 08] 

NeuroMetrix says it plans to cut about 15% of its workers to reduce costs. [Mass High Tech, May 14,08]

NeuroMetrix Inc. and Cyberkinetics Neurotechnology Systems report the two medical devices firms have formed a limited liability company to expand an existing joint venture to develop a product for peripheral nerve injury. [Mass High Tech, Feb 19, 08]

NeuroMetrix  lost nearly half its value [Feb 11, 08] after a prediction that one of the company's medical devices would not receive a positive rating, likely prohibiting federal reimbursement. [AP]

NeuroMetrix  down 11% more [Feb 14, 08]

pNeuroMetrix and SurModics appeared on the NASDAQ top ten short interest ratios. [Jan 08]

NeuroMetrix up 15% after an analyst upgraded the stock and said the company will be able to survive lower reimbursement rates for its NC-Stat monitor device, if necessary. [AP, Jan 3, 08]

Neurona Therapeutics (South San Francisco, CA)

Biotech startup Neurona Therapeutics (South San Francisco, CA; no SBIR) raised $23.5 million in Series A funding to develop therapies for neurological diseases.  ... has raised $31.14 million to date. ....  founded as a pre-clinical stage biotechnology company exploring the transplantation of selected neurons to treat intractable neurological diseases. The company focuses on unique compositions of cells that can be precisely targeted and integrated into damaged neural circuits.  [Gina Hall, Silicon Valley Business Journal, Dec 2, 15]

Biotech startup Neurona Therapeutics (South San Francisco, CA; no SBIR) raised $23.5 million in Series A funding  to develop therapies for neurological diseases.  ...  has raised $31.14 million to date.  ....   to create a novel class of therapeutics with the potential to permanently repair dysfunctional neural circuits," [CEO Tim] Kutzkey said. ... founded by neuroscientists and stem cell pioneers from the University of California, San Francisco. The company will use human stem cell derivatives as part of its treatment.  [Gina Hall, Silicon Valley Business Journal, Dec 2, 15]

Neuronetics (Malvern, PA)

Neuronetics down 11% [Oct 10, 18]

Neuronetics (Malvern, PA; no SBIR) maker of non-invasive depression [mgnetic] treatment system raises $15M [John George, Philadelphia Business Journal, Jun 7, 17]    NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.  [company website]

Neuronetics (Malvern, PA; no SBIR, founded 2003) that uses transcranial magnetic stimulation technology to treat depression raised $34 million in a private stock sale series F financing round included an investment from GE Ventures along with funding from its original investor base, which includes Pfizer Venture Investments ...  has now raised more than $160 million from private investors since its inception....   to broaden treatment accessibility for existing patient populations in need of a nondrug therapy option. [John George, Philadelphia Business Journal, May 1, 15]

Medical-device developer Intact Vascular (Wayne, PA; no SBIR) raised $3 million in a debt financing, according to [SEC] documents  ... focused on developing medical devices for minimally invasive peripheral vascular procedures. Its lead product candidate is the Tack Endovascular System, a minimal metal implant that is designed to improve peripheral balloon angioplasty results in patients treated for peripheral artery disease. ...  CEO Bruce Shook said the funds will be used to support late-stage testing of Tack Endovascular System. Shook took over as CEO last summer after previously leading Neuronetics (no SBIR), another suburban Philadelphia medical-device company.  [John George, Philadelphia Business Journal, Mar 20, 15]

Neuronetics (Philadelphia, PA; no SBIR) start-up, has tapped that deepening vein of knowledge to develop a therapy called transcranial magnetic stimulation (TMS). It uses a device that generates electrified magnetic impulses to stimulate the prefrontal cortex of the brain, the area that controls mood. ... Some 200 doctors and institutions have each spent $70,000 to buy treatment stations. Dr. Martha Koo, a psychiatrist in Hermosa Beach, Calif., is seeing positive responses in about 70% of her TMS patients  [Bob Diddlebock, Time, Sep 20, 10]

Neuronetics (Malvern, PA; no SBIR) raised $30 million in a fourth round of venture capital funding ...  makes a device that treats depression with magnetic pulses.  [John George, Philadelphia Business Journal, Sep 1, 09]

Neuronex (Morrisville, NC)

Jazz Pharmaceuticals plc (Ireland) and Aerial BioPharma, LLC (Morrisville, NC; no SBIR) announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy.  [Jazz website, Jan 13, 14]founded in January of 2011 by the management team from Neuronex  and Addrenex Pharmaceuticals, both successful start-ups based in the Research Triangle Park area.  Neuronex was acquired by Acorda Therapeutics in 2012 and Addrenex Pharmaceuticals was acquired by Shionogi Pharma in November of 2009  [Aerial website] a deal that could be worth up to nearly $400 million. Jazz paid $125 million up front [Jason deBruyn, Triangle Business Journal, Jan 17, 14]

Neuronex, (Morrisville, NC; founded 2010)  with the help of $1.5 million raised from investors plus a $250,000 loan from the N.C. Biotechnology Center, has agreed to be acquired by Acorda Therapeutics ... The centerpiece of the deal is Neuronex's proprietary nasal spray that the company is developing for the treatment of seizures, which is based on technology it licensed in 2010 from a Korean company.  [David Ranii, Raleigh News & Observer, Feb 17, 12]

Neuron Systems (Burlington, MA)

Neuron Systems (Burlington, MA; no SBIR) raised $9M in Series A funding, according to online reports. Investors in Neuron Systems include Johnson & Johnson Development ....working on treating retinal diseases, reports state. The company was founded in 2005 from Thomas A. Jordan and Harvard University researcher John Dowling. [Mass High Tech, Aug 11, 08]

Burlington-based biotech company Neuron Systems has raised $8.96 million in Series A funding, according to online reports. Investors in Neuron Systems include Domain Associates LLC and Johnson & Johnson Development Corp., both based in New Jersey. Neuron Systems is working on treating retinal diseases, reports state. The company was founded in 2005 from Thomas A. Jordan> and Harvard University researcher John Dowling, The pair have filed a patent application with the U.S. Patent & Trademark office for compounds and methods to both treat and prevent age-related macular degeneration. [Mass High Tech, Aug 11, 08]

NeuroOne (Eden Prairie, MN)

The Mayo Clinic acquired an 10.9% stake in epilepsy treatment neuromod startup NeuroOne (Eden Prairie, MN; no SBIR, founded 2009)’s parent firm, according an SEC filing.... is developing a “thin film” electrode technology, originally from the University of Wisconsin, designed to be implanted in the brain. The film can detect irregular brain activity, accurate to single neurons, to pinpoint the source of seizures and tremors, according to the filing, and has been used in testing at the Mayo Clinic. [Fink Densford,, Aug 7, 18]

NeuroPace (Mountain View, CA

NeuroPace  (Mountain View, CA; no SBIR, founded 1997) that developed the world’s first and only closed-loop brain-responsive neurostimulation system shown to significantly reduce seizure frequency, announced  that it closed a $74 million round of funding...  to rapidly expand commercialization of the NeuroPace RNS®  System, a device approved by FDA to treat adults with partial (focal) onset seizures that are not well controlled by medication alone.  [company press release, Oct 24, 17] $141M funding to date []

NeuroPace (Mountain View, CA; no SBIR) medical technology company that developed the world’s first and only closed-loop brain-responsive neurostimulation system shown to significantly reduce seizure frequency, announced that it closed a $74 million round of funding [to] rapidly expand commercialization of the NeuroPace RNS®  System, a device approved by FDA to treat adults with partial (focal) onset seizures that are not well controlled by medication alone. [company press release, Oct 24, 17]

NeuroPace  (Mountain View, CA;  no SBIR) which has developed implantable devices to treat neurological disorders, disclosed  it has raised about $18 million of a planned $50 million in new funding. ... initially focused on treating epilepsy, a which affects about 1 percent of the population worldwide ....has raised about $180 million since it was founded in 1997   [Cromwell Schubarth, Silicon Valley Business Journal, Jul 9, 13]

The Wall Street Journal's third annual ranking of the top 50 venture-capital-backed companies shows a crop of contenders that overall are focused less on online consumers than in years past. ....  Unlike in years past, none of the companies on this year's list are in the energy sector, underscoring the challenges faced by that industry. This year was also the first time that a health-care company didn't top the ranking.  [Zoran Basich and Emily Maltby, Wall Street Journal, Sep 27]  Companies with tech that might fit SBIR: 7. Glaukos (Laguna Hills, CA; $200K SBIRs)  $126M; 8. NeuroPace (Mountain View, CA; no SBIR) $180M;  35. Achaogen  (South San Francisco, CA; no SBIR) $103M; 48. Acceleron Pharma (Cambridge, MA; no SBIR) $307M.  The other 46 took VC to reduce business risk, a job not appropriate for government technology subsidy.

NeuroPhage Pharmaceuticals (now Proclara Biosciences, Cambridge, MA)

Despite a litany of high profile failures among drugs to fight Alzheimer’s disease, biotechs and pharma companies continue to pour billions of dollars into the fight. The latest firm to get a financial boost is a startup from , that until today has been known as Neurophage Pharmaceuticals  (Cambridge, MA; no SBIR).  ....    has raised $47 million from current backer Merieux Development and a group of high net worth individuals, and changed its name to Proclara Biosciences.   [Ben Fidler,, Sep 7, 16]

NeuroPhage Pharmaceuticals (Cambridge, MA; no SBIR) neurodegenerative disease company closed a $12.4M Series B round that it plans to use to get its lead compound to treat Alzheimer’s disease, NPT001, into a Phase 1 clinical trial in about a year and a half. ...  NeuroPhage, which has eight patents, of which one is granted, is based on technology licensed from the laboratory of Professor Beka Solomon at Tel Aviv University ...  The new funding brings to $19.6 million the total raised  [Lori Valigra, Mass High Tech, Mar 3, 11]

NeuroPhage Pharmaceuticals (Cambridge, MA; no SBIR) has landed $12.4 million in a Series B round of funding ... focusing on a disease-modifying phage approach for treating protein aggregation neurodegenerative diseases  [Rodney Brown, Mass High Tech, Mar 1, 11]


NeuroPointDX aims to change with a test that could potentially diagnose [hard-to-diagnose autism] by analyzing the metabolism of a child from a small blood sample. NeuroPoint, a business division Stemina Biomarker Discovery (Madison, WI; $1.3M SBIR) focused on diagnostics for neurological disorders, is now turning to the autism community to support its efforts to validate its blood test. The company is seeking to raise $50,000 or more through a new crowdfunding campaign. .... Last March, researchers at Rensselaer Polytechnic Institute conducting research independent from NeuroPoint’s work, said they had developed an algorithm that can accurately predict whether a child has autism spectrum disorder (ASD), based on levels of metabolites in a blood sample.   [Jeff Buchanan,, Jan 24, 18]

Neuroptix (Acton, MA)

Neuroptix (Acton, MA; no SBIR) said that it has closed the first approximately $4 million tranche of a Series C funding round as it continues clinical development of its diagnostic platform. ...  focused on the early detection of Alzheimer's disease through a non-invasive eye test.  [Boston Globe, Jan 10, 11]

Alzheimer’s disease detection company Neuroptix (Acton, MA; no SBIR) has taken in $18.5 million in a Series B round of funding, to help push its diagnostic test toward clinical trials.  In 2006, took in $500,000 from angels as a seed round. In 2007 a scant $1.6 million in its Series A round,   [Mass High Tech, Oct 22, 08]

NeuroPace (Chapel Hill, NC)

NeuroPace  (Mountain View, CA;  no SBIR) which has developed implantable devices to treat neurological disorders, disclosed  it has raised about $18 million of a planned $50 million in new funding. ... initially focused on treating epilepsy, a which affects about 1 percent of the population worldwide ....has raised about $180 million since it was founded in 1997   [Cromwell Schubarth, Silicon Valley Business Journal, Jul 9, 13]

NeuroRecovery Technologies(San Juan Capistrano, CA)

GTX Medical (Dutch and Swiss) is merging with NeuroRecovery Technologies (San Juan Capistrano, CA; no SBIR), a pre-revenue device developer the companies announced. [Dana Elfin,, Oct 22, 19] Two companies focused on restoring movement and the ability to walk in patients with paralysis and spinal cord injuries [Conor Hale, Fierce Biotech, Oct 22, 19]

NeuroSigma (Los Angeles,CA)

NeuroSigma (Los Angeles,CA; $6M SBIR, founded 2008), focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating neurological and neuropsychiatric disorders today announced that its Monarch® eTNS® System (Monarch) received FDA clearance as a non-drug treatment for attention deficit hyperactivity disorder (ADHD). [company press release, Apr 23, 19] total funding $13M []

NeuroTek (Dallas, TX)

Medical startup NeuroTek (Dallas, TX; no SBIR) is developing a battery-operated, self-administered, home-based device to relieve the [migraine].  .... affect more than 10 percent of the population — about 30 million people in the United States and 240 million worldwide.  The device, called Tones, works by electronic neuromodulation, stimulating the occipital nerve, so it's a non-surgical, drug-free solution  [Bill Hethcock, Dallas Business Journal, Nov 15, 13]

Neurotrack (Palo Alto, CA)

Neurotrack  (Palo Alto, CA; no SBIR), a startup that develops behavioral biomarkers to assist in diagnosing Alzheimer's disease, said it raised $2 million in Series A funding. ....  to develop and commercialize a visual cognitive test sensitive to damage in brain regions first impacted by Alzheimer's disease. ...  founded in 2012, holds an exclusive license for the technology behind the behavioral test from Emory University following the favorable outcome of an NIH-sponsored longitudinal study.   [Preeti Upadhyaya, Silicon Valley Business Journal, Sep 26, 13]

NeuroTronik (Chapel Hill, NC)

Medical technology startup NeuroTronik (Chapel Hill, NC; no SBIR) has nabbed nearly $1.7 million in equity financing from two undisclosed investors ... trying to bring a new approach to treat acute heart failure syndrome.  [Lauren Ohnesorge, Triangle Business Journal, Jun 12, 13]

NeuroTronik  (Chapel Hill, NC; no SBIR), which was spun out of a Chapel Hill business accelerator just 11 months ago, has raised its first round of outside funding: $13.1 million that is earmarked for continued development of a system to treat heart failure.  [David Ranii, Raleigh News & Observer, Jun 13, 13]

Neurotrope (New York, NY)

Neurotrope up 13% [May 3, 17]

Neurotrope up 17% [May 2, 17]

Neurotrope down 63% [May 1, 17]

Neurotrope (New York NY, no SBIR, founded 2012) up 24% [Apr 28, 17] a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, will issue a press release announcing results of top-line data from its 148 patient, Phase 2 clinical trial in moderate to severe Alzheimer's Disease, on Monday May 1[company press release, Apr 28, 17]

Neurovance (Cambridge, MA)

Neurovance (no SBIR, founded 2014) has raised another $5.5 million for its abuse-proof drug for adult attention deficit-hyperactivity disorder, bringing total Series A1 funding to $20 million. ...  has committed all previous funding to development of its ADHD drug, being made currently for adults and eventually slated to be marketed for adolescent and pediatric use.  [Jessica Bartlett,  Boston Business Journal, Mar 26, 15]

Neurovance (Cambridge, MA; no SBIR) said  it has secured $7 million in funding to advance the development of an experimental drug that aims to treat adult attention deficit hyperactivity disorder. The Series A1 funding round was led by existing investor Novartis Venture Fund  [Chris Reidy, Boston Globe, Oct 19, 12]

Neurovascular Diagnostics (Buffalo, NY)

(Buffalo, NY; no prior SBIR, 4 employees, founded 2016}, (spinout from SUNY Buffalo) awarded a Phase I SBIR grant worth $224,032 from the National Science Foundation (NSF) for “A Blood-Based Test to Identify Patients with Intracranial Aneurysm.” The goal of the SBIR project is to develop a novel blood diagnostic to detect unruptured intracranial aneurysms (IA) in asymptomatic patients. [ , Dec 20, 17]

NeuroVigil (San Diego, CA)

a trio of nascent biotechnology firms with San Diego ties from trying. Each of the companies in recent weeks has won fans and thousands of dollars in prize money as they’ve moved through the annual circuit of business-plan competitions ... NeuroMap is working on a way to test the effectiveness of antidepressant medications in a patient. ... NeuroVigil, the San Diego-based winner of the second UCSD business-plan contest, announced last month that it had completed its first round of outside investment fundraising, which was led by an unnamed “American industrialist” and included investors from both U.S. coasts. ... Oculeve’s experimental device is designed to treat dry eye disease, a painful and debilitating condition that affects tens of millions of people in the United States and Europe. As many as 1.5 million Americans have the most severe form of the disease, Smith said. Most patients are treated with the tear production drug Restasis, but the therapy doesn’t work well in many patients, Smith said. In an initial test of the Oculeve device on a patient, its effectiveness was 10 times better than Restasis, he said.   [Keith Darce,, Jun 24]

NeuroVision Imaging (Sacramento, CA)

NeuroVision Imaging LLC (Sacramento, CA; no SBIR, founded 2010) announced that a clinical trial shows the company’s imaging system does appear to detect Alzheimer’s disease using a noninvasive eye test [In an Australian clinical trial]. [Mark Anderson, Sacramento Business Journal, Jul 14,14]

Researchers in Perth, Australia, are doing trials on a eye test developed by NeuroVision Imaging (Sacramento, CA; no SBIR) to screen for Alzheimer’s. ...Founded in 2010, NeuroVision develops digital imaging and diagnostic solutions for Alzheimer’s disease and eye-care markets. To date, more than $3 million has been invested.   [Kathy Robertson, Sacramento Business Journal, Jun 14, 13] 

Neurovista (Seattle, WA)

NeuroVista (Seattle, WA; no SBIR) has raised $16.5 million in equity financing led by an Australian firm and $5 million through a convertible debt agreement ....  founded 2005 by local entrepreneur and medical device innovator John Harris, is developing an implantable device designed to predict epileptic seizures before they happen  [Seattle Times, Aug 24, 10]

NeuroVive Albuquerque, NM)

NeuroVive, a company that has its roots at Albuquerque’s Technology Ventures Corp., recently began trading on the [Swedish] NASDAQ. .... .That company has raised more than $15 million in angel funding, and investment funds, while trading on the Swedish version of an over-the-counter exchange.  ...  In 2000, Maas Biolab (Albuquerque, NM; $2M SBIR) [the largest single shareholder of NeuroVive] spun off NeuroVive Pharmaceutical in Sweden. .... Maas Biolab has two employees in Albuquerque, and NeuroVive has about 10 in Stockholm. [Dan Mayfield, Albuquerque Business First, May 8, 13]

NeuWave Medical (Madison, WI)

Ethicon, a medical device company that is a division of Johnson & Johnson acquired NeuWave Medical (Madison, WI; no SBIR; founded 2004) manufacturer of medical devices that use microwaves to destroy cancerous tumors.  ....   Ethicon said the acquisition was consistent with J&J’s strategy of investing in areas of medical need such as surgical oncology.  [Barrett J. Brunsman,  Cincinnati Business Courier, April 14, 16]

NeuWave Medical  (Madison, WI;  SBIR) med-tech company led by serial entrepreneur Dan Sullivan, has closed on $25 million[VC] and opened an office in Plymouth, MN. ...  to ramp up sales and marketing of its microwave technology for destroying cancerous tumors. It also plans to invest in development of a new product to treat lung cancer, Sullivan said.   [Katharine Grayson,Minneapolis / St. Paul Business Journal, May 28, 15]

Neuwave Medical (Madison, WI;  no SBIR) medical device company, has raised $25 million of equity funding from 38 investors, according to [SEC] document ....  brings to $72.8 the total amount the company has raised since May, 2009  ...  founded by University of Wisconsin-Madison scientists, makes the Certus 140 thermal ablation system. The system provides a minimally invasive treatment that uses microwave energy to destroy tumor cells. It is an alternative to surgery and is used in some cases with patients who are too sick to have surgery.  [Kathleen Gallagher, Milwaukee Journal Sentinel, May 21, 15]

NeuWave Medical  (Madison, WI; no SBIR, founded 2003)  medical device company, said it has raised $14 million in a second round of financing.  ....  to further develop its Certus 140 thermal ablation system and continue developing minimally invasive tools for surgery and other medical uses.  ....  founded by two University of Wisconsin-Madison professors  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 5, 12]  did have a $2M federal grant in 2009 [company website]

Other [Wisconsin] companies the MoneyTree report showed raising venture funding in the second quarter were: Aquarius Technologies (Port Washington, WI; no SBIR) developer of wastewater treatment technologies, $4 million; NeuWave Medical (Madison, WI; no SBIR) medical device company, $2.63 million; ProCertus BioPharm (Madison, WI; $1.6M SBIR) drug developer, $1.7 million; and Zurex Pharma (Madison, WI; no SBIR) drug developer, $1 million.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 19, 11]

Nevro (Menlo Park,CA)

Nevro (Menlo Park, CA; no SBIR, founded 2006) developing an implant that stimulates the spinal cord to treat back pain is seeking $125 million in [IPO].  ... hopes to commercially launch its Senza spinal cord stimulation device by early 2016, the company said   ... So-called neuromodulation uses mild electric currents to interrupt pain signals and replace pain with a tingling sensation known as paresthesia. Contacts are placed in the spine near the region that supplies nerves to the area in pain. ....    has raised $154.1 million ... received its CE Mark in Europe and is approved in Australia  [Ron Leuty, San Francisco Business Times, Oct 3, 14]

Mayo Clinic has joined in a $48 million round of financing for Nevro  (Menlo Park, CA; no SBIR), a startup developing a medical device that treats chronic pain.  .... the technology, a spinal-cord stimulator, is based on intellectual property licensed from Mayo.  [Katherine Grayson, Minneapolis / St Paul Business Journal, Mar 7, 13]    Nevro (Menlo Park, CA; no SBIR) which is developing a neuromodulation device for the treatment of chronic back and leg pain, said yesterday that it has raised $58 million in a Series B financing round led by new investor Johnson & Johnson Development Corporation. ...  said the funds will go toward a pivotal clinical study of the device’s effects in the U.S. and help support international commercialization. [Wade Roush,] Jul 22, 11]

New Dominion Enterprises (San Antonio, TX)

New Dominion Enterprises (San Antonio, TX; no SBIR) developing and commercializing a completed inorganic additive for lithium electrolytes (reduced fire hazard/longer lasting) batteries. ... holds IP for a 100% inorganic electrolyte [that would displace about 10 percent of the otherwise organic] for lithium batteries that will eliminate fire and explosion hazard as well as the material degradation leading to loss of charge and useful life of the cell. [@Jay Fisher, president/founder,, Jan 2, 18]

New England BioLabs (Beverly,MA)

A spinoff of New England BioLabs (Beverly, MA; $5M SBIR), Biohelix (Beverly, MA; also $5M SBIR) is leaving the nest and establishing its own headquarters after five years under its parent’s wing. ...  developing diagnostics for infectious and sexually transmitted diseases.  [Mass High Tech, Aug 28, 09]

New Era Technology (Gainesville, FL)

Alleged Fraud. Federal investigators are accusing a University of Florida professor and three members of his family of fraudulently receiving millions of dollars from NASA and then funneling money to their personal bank accounts, court documents show. .... the university’s Innovative Nuclear Space Power and Propulsion Institute ...  According to court documents, Dr. Anghaie and his family members set up a company called New Era Technology  (Gainesville, FL; $2.5+M SBIR) ...  Court documents assert that the company submitted fraudulent proposals to NASA for research contracts. As a result, the company received several NASA contracts. The company is also accused of submitting fraudulent invoices to NASA for hours it said were worked by employees. ... Dr. Anghaie has served on and been the chairman of several research advisory boards and review panels for the National Research Council, NASA, and the Departments of Energy and Defense.  Results of Dr. Anghaie’s research have been published in more than 500 papers and reports.  [AP, Feb 27, 09]

NewLeaf Symbiotics (St Louis, MO)

NewLeaf Symbiotics (St Louis, MO; no SBIR) announced that it recently completed the final close of its Series D [$22 million] financing as it broadens and accelerates product commercialization. [company press release, Dec 1, 20]

NewLeaf Symbiotics (St Louis, MO; no SBIR) announced that it has raised $20 million in a first close of its Series D financing as it broadens and accelerates product commercialization. [company press release, Feb 26, 20]

Joyn Bio (Boston, MA and Woodland, CA)

Joyn Bio (Boston, MA and Woodland, CA;  SBIR), an agtech company entered a partnership with NewLeaf Symbiotics (St. Louis, MO;  no SBIR, founded 2012) valued at up to $75M to bring innovation and sustainability to modern agriculture with a new class of microbes that benefit crop health and protection. Joyn will gain access to NewLeaf's library of proprietary, strains of plant colonizing microbes and will engineer those microbes to bring novel disease and pest control options to farmers. [Rowan Walrath, BostInno, Jul 22, 19]

NewLeaf Symbiotics (St Louis, MO, no SBIR) announced that it has completed the second close of its $30MM series C financing, accelerating plans to convert proven applications of its unique biologicals platform into products for large-scale agriculture. The company’s commitment to tapping the advantages of Methylotrophic bacteria has positioned it as a leader in agricultural biologicals. [company press release, Sep 8, 17] closed a $17 million Series B round in 2014 [company website] 

NewLeaf Symbiotics (St Louis, MO; no SBIR) announced  the close of a $24MM series C financing round, accelerating plans to convert proven applications of its biotechnology into products for large-scale agriculture. ... The company is tripling the size of its R&D and pilot production facility in St. Louis and is expanding its proprietary Prescriptive Biologics Knowledgebase™ bioinformatics platform.  [company press release, Jul 10, 17]  acquired Intuitive Genomics (St Louis, MO; no SBIR, founded 2010) in 2013

NewLeaf Symbiotics (St Louis, MO; no SBIR), a plant science startup operating closed a $17 million Series B financing round led by Palo Alto, California-based Otter Capital.  ... to accelerate NewLeaf’s research and development program to commercialize bacteria known as pink pigmented facultative methylotrophs, which are found in nature and have been shown to improve plant health, promote growth and increase crop yield. ...  and ramp up production and bring to market its first biological products. ...  raised $7 million through a Series A financing in January 2013.    [Brian Feldt, St. Louis Business Journal, Sep 15, 14]

NewLink Genetics (Ames,IA)

NewLink Genetics (Ames, IA; $1.1M SBIR) and Lumos Pharma  (Austin, TX; no SBIR) focused on development and commercialization of therapeutics for rare diseases, announced that the companies have entered into a definitive merger agreement. following the closing of the merger, Lumos Pharma will become a wholly-owned subsidiary of NewLink, and NewLink will be renamed Lumos Pharma,  [joint companies press release, Sep 30, 19]

NewLink Genetics has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing. [Phil Taylor, Fierce Biotech, Aug 1, 18]

NewLink Genetics down 16% [Aug 1, 18]

NewLink Genetics up 11% [Apr 17, 18]

NewLink Genetics down 43% [Apr 6, 18] after Merck and Incyte said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. NewLink has focused its research and development on IDO as a target for its cancer drugs, and its two lead therapies -- indoximod and NLG802 -- target the IDO pathway. [Emma Court, MarketWatch, Apr 6, 18]

NewLink Genetics down 10% [Feb 9,18]

NewLink Genetics down 11% [Jan 5, 18]

NewLink Genetics up 12% [Jan 4, 18]

NewLink Genetics announced that it has entered into a clinical collaboration agreement with AstraZeneca (UK) to evaluate the combination of indoximod, NewLink Genetics' small molecule IDO pathway inhibitor, and durvalumab, AstraZeneca's anti-PD-L1 monoclonal antibody, along with standard of care chemotherapy for patients with metastatic pancreatic cancer.  [NewLink press release, Sep 25, 17]

NewLink Genetics down 10% [Sep 12,17]

NewLink Genetics up 30% [Sep 8,17]

NewLink Genetics up 75% [Sep 7, 17]  announced updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics' IDO pathway inhibitor, in combination with the PD-1 pathway inhibitor, KEYTRUDA (pembrolizumab). ....  Updated Data for Indoximod Plus KEYTRUDA(R) (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma  [company press release, Sep 7, 17]

NewLink Genetics up 14% [Aug 31, 17]

NewLink Genetics up 10% [Jul 28, 17]

NewLink Genetics down 41% [Jun 8,17] announced that Genentech, a member of the Roche Group, informed NewLink Genetics that it intends to return the rights to IDO inhibitor GDC-0919 (navoximod) pursuant to the License Agreement dated October 16, 2014.  [company press release, Jun 8, 17]

NewLink Genetics down 12% [Jun 5,17] announces the presentation of results from a randomized Phase 2 investigator initiated study with indoximod in combination with the therapeutic cancer vaccine, PROVENGE (sipuleucel-T), for patients with metastatic castration resistant prostate cancer.  [company press release, Jun 5, 17]

New Link Genetics up 19% [Apr 19, 17]

New Link Genetics down 14% [Apr 5, 17] reported interim results from NLG2103, a Phase 2 study evaluating its IDO pathway inhibitor, indoximod, in combination with checkpoint inhibitors for the treatment of patients with advanced melanoma.  [company press release, Apr 4, 17] Meanwhile, a leading national securities law firm, is investigating potential securities fraud at NewLink Genetics Corporation ... on whether the Company and its executives violated federal securities laws by failing to disclose that NewLink's immunotherapy drug, indoximod, was not showing a meaningful benefit in its Phase 2 trial for patients with advanced melanoma. [law firm press release, Apr 4, 17]

New Link Geneticss down 10% [Mar 31, 17] 

New Link Genetics up 18% [Mar 2, 17]

NewLink Genetics up 18% [Jan 9, 17]

NewLink Genetics up 10% [Dec 23, 16]

NewLink Genetics up 13% [Sep 28, 16]

New Link Genetics laid off 87 people after a clinical trial failed on its new medication to fight a type of cancer.  The Des Moines Register reports ( ) that NewLink Genetics confirmed the layoff [AP, Jun 20, 16]

NewLink Genetics down 31% [May 10, 16] said its investigational immunotherapy for resected pancreatic cancer didn't meet its primary goal of extending overall survival of patients in a Phase 3 study.  [company press release, May 10, 16]

NewLink Genetics down 10% [Mar 15,16]

NewLink Genetics up 10% [Jan 20, 16]

NewLink Genetics down 24%  [Nov 6, 15]

NewLink Genetics up 11%  [Nov 4, 15]

NewLink Genetics down 21% [Sep 28,15]

New Link Genetics up 14% [Aug 17, 15]

NewLink Genetics  down 30% [May 12, 15]  said it would continue a clinical trial for a pancreatic cancer drug without modifying the study plan. ...   as some investors had hoped the study may be stopped at the interim analysis because it was showing enough efficacy.  [Wallace Witkowski, DJ Newswire, May 11, 15]

one small firm here is drawing notice for its cutting-edge research on Ebola and cancer, despite being far removed from the drug industry’s usual hubs. NewLink Genetics has recruited scientists from around the world to work in laboratories nestled between Iowa State University and crop fields. The company’s biggest shareholder [25%] is a large soybean company owned by Iowa’s sole billionaire ...  But ... Already, the 130-employee company is investing in locations far away from its core. Last year it leased space in Austin, Texas, because that city has better flight connections and is more appealing to sales workers. NewLink also opened a small satellite office near Boston for Ebola research. ...  “Trying to get very specialized people in a remote area may be very difficult.”    [Peter Loftus, Wall Street Journal, Apr 12, 15]  Small biz success in a small place is a politician's dream, but success as a large company needs a different world.

 The push to test Ebola vaccines is accelerating. Last fall, an international ethical panel convened by the World Health Organization (WHO) judged that the unprecedented threat made it acceptable to take Ebola vaccines straight from small, phase I safety studies to large phase III efficacy studies, while simultaneously conducting phase II studies. Two vaccines are now almost ready to make the leap. One, made by GlaxoSmith-Kline (GSK), contains a chimp adenovirus equipped with a gene that codes for the Ebola surface protein. The other, developed by NewLink Genetics but now manufactured by Merck, uses a livestock virus called VSV to carry an Ebola gene.  [Martin Enserink, Science, Jan 16, 15]

The U.S. Department of Health and Human Services (HHS) awarded contracts worth a total of about $43 million to NewLink Genetics and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine generates an effective immune response, the HHS said. ... The contract includes an option for additional funding of $41 million.  [Reuters, Dec 23, 14]

A clinical trial of the Ebola vaccine by Merck and NewLink [Genetics] has been interrupted in all 59 volunteers in Geneva a week early "as a measure of precaution" after four patients complained of joint pains in hands and feet, the University of Geneva Hospital said.  ...  The human safety trials are due to resume on Jan. 5 in up to 15 volunteers after checks to ensure that the joint pain symptoms were "benign and temporary", the hospital said.    [Reuters, Dec 11, 14]

Merck said it would buy worldwide commercial rights to NewLink Genetics experimental vaccine against the Ebola virus. NewLink, whose subsidiary licensed commercial rights to the rVSV-EBOV vaccine in 2010, said it would receive $50 million plus royalties from Merck.  [RANSDELL PIERSON, Reuters, Nov 24, 14]

NewLink Genetics up 13% [Nov 6, 14] a different picture emerged after NewLink broke its media silence following a high-level meeting on Ebola vaccines held by the World Health Organization on 23 October. At the meeting, NewLink executives said that, under a best-case scenario, the company might have 12 million doses of vaccine by April. That number would far outstrip GSK's estimate of 230,000 doses by that date.   [Jon Cohen, Science, Oct 31, 14]

Roche’s Genentech division and NewLink Genetics said Genentech will pay $150 million upfront for rights to NewLink’s cancer immunotherapy candidate NLG919, currently in Phase 1, that targets the IDO pathway. The companies will also collaborate on discovery of other compounds in that class. NewLink could earn up more than $1 billion in milestones and sales royalties if Genentech brings multiple products to market.   [Alex Lash,, Oct 23, 14]

NewLink Genetics up 15% [Oct 22, 14]

NewLink Genetics up 10% [Oct 21, 14]

NewLink Genetics up 17% [Oct 15, 14]

NewLink Genetics up 24% [Oct 13, 14]

Ebola vaccines racing forward at record pace.  Experimental Ebola vaccines started human tests last week and beginning in November may be rolled out to as many as 10,000 people in West Africa. The two vaccines being tested first must prove safe and capable of stimulating relevant immune responses in small trials taking place in four countries. No vaccine has ever moved more quickly into widespread use. Many issues remain on how to determine whether the vaccines actually protect people from Ebola. Because the vaccines are in short supply, they also will only be offered to health care workers and other first-line responders. One vaccine is being manufactured by a collaboration between the U.S. National Institute of Allergy and Infectious Diseases and GlaxoSmithKline, and the other is being made by NewLink Genetics.  [Jon Cohen, Science, Sep 15]

NewLink Genetics  up 12% [Aug 14, 14] is preparing to test a possible Ebola vaccine in humans, as scientists race to develop ways to prevent or fight a virus that has killed more than 1,000 people in a West African outbreak. ...    is planning an initial phase of testing involving up to 100 healthy volunteers and is talking with regulators about the study, said Brian Wiley, the company's vice president for business development. ....  There is no proven treatment or vaccine for Ebola, and the current outbreak, which also has sickened nearly 2,000 people, is the largest in history.   [TOM MURPHY , AP, Aug 14, 14]

NewLink Genetics down 14% [May 15, 14]

 NewLink Genetics up 10% [May 9, 14]

NewLink Genetics down 11% [Apr 11, 14]

NewLink Genetics  down 12% [Apr 10, 14]

New Link Genetics up 10%  [Mar 31, 14]

NewLink Genetics down 16%  [Mar 7, 14]

NewLink Genetics down 12% [Mar 3, 14]

NewLink Genetics (Ames, IA; $1.1M SBIR) up 12% [Feb 21, 14]

Newlink Genetics (Ames, IA; $1.1M SBIR)  up 10% [Jan 21, 14]

NewLink Genetics (Ames, IA; $1M SBIR, 94 employees) up 11% [Jan 15, 14]

NewLink Genetics  (Ames, IA; $1.2M SBIR) down 12% [Jun 26, 13]

NewLink Genetics  (Ames, IA; $1.1M SBIR) actually focused on the currently buzzy business of cancer immunotherapy. ... has more than doubled since its November IPO ... doesn’t have Phase III data to support its work yet, but its stock has been moving in the right direction.  [Luke Timmerman,, Jul 9 ,12]

Nexant  (San Francisco, CA)

Intel Capital said it's investing more than $30 million in four technology startups...  Adaptive Computing   (Provo, UT) developer of software for data centers and cloud computing; Ciranova, (Santa Clara, CA) maker of chip design software; Joyent, (San Francisco, CA) provider of cloud-computing infrastructure; Nexant a (San Francisco, CA) developer of energy-efficiency software and clean-energy services.  [FM Russell, San Jose Mercury News, Sep 15, 10]  None had SBIR.

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners:  Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary;  OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems  secondary, twice;  Planar Energy Devices>/span> (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

NexBio (San Diego, CA)

NexBio  (San Diego, CA; $9M SBIR)'s lead drug candidate, Fludase, significantly reduced the amount of influenza virus in patients receiving the drug as compared with those who took a placebo in a Phase 2 clinical trial, according to early results reported by the company .... Since its founding in 2003, NexBio has received as much as $73 million in grants and contracts from the National Institutes of Health to develop and test Fludase, according to agency records and a 2009 report from the San Diego industry group Biocom. AND federal agents raided the privately owned company's headquarters ...  to serve search warrants connected to a white-collar criminal investigation   [Keith Darce, signonsandiego, Aug 16, 11] Of that $9M SBIR, $6M came in one NIH grant.

NexImmune (Gaithersburg,MD)

NexImmune (GAITHERSBURG, MD; one SBIR) announced that Due to resource prioritization, and the evolving treatment landscape in relapsed refractory multiple myeloma, we plan to pause enrollment of NEXI-002 and provide an update on patients currently being treated. [company press release, Aug 15, 22]

NexImmune (GAITHERSBURG, MD; one SBIR) announced that Due to resource prioritization, and the evolving treatment landscape in relapsed refractory multiple myeloma, we plan to pause enrollment of NEXI-002 and provide an update on patients currently being treated. [company press release, Aug 15, 22]

NexImmune (Gaithersburg, MD; #300K SBIR) up 18% [Aug 10, 21] reported quarterly financial resuts

NexImmune (Gaithersburg, MD: $3300K SBIR) closed its IPO with $126.5M in gross proceeds for two product candidates, now in early-stage clinical trials for acute myeloid leukemia and multiple myeloma, and its preclinical pipeline, which includes candidates for solid tumor and autoimmune diseases. The funding would also fund manufacturing activities, further use of its tech platform, as well as working capital and general corporate purposes, the company said. [Sara Gilgore, DCInno, Feb 25, 21]

NexImmune (Gaithersburg, MD; $300K SBIR) up 49% [Feb 12, 21] after $110M IPO ; developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a specific, potent and durable immune response that mimics natural biology. [company press release, Feb 11, 21]

Gaithersburg’s NexImmune has filed for [IPO], developing immunotherapy treatments for cancer, will look to raise $86.25M [DCInno, Jan 21, 21]

immunotherapy startup NexImmune (Gaithersburg, MD; $300K SBIR) reported raising $7.7M in new equity funding.[Kieran McQuilkin, DCInno, Feb 25, 19]

Neximmune (subsidiary of a consortium led by Teva Pharma, Gaithersburg, MD; no SBIR in 2007, founded 2011) raises $21.7M  [Washington Business Journal, Feb 9, 2018]  developing immunotherapy treatments for cancer [Tina Hall, Washington Business Journal, Feb 2017]

NexImmune  (Gaithersburg, MD;  at least $300K SBIR), announced the completion of the acquisition of the company by a consortium of private investors led by [Teva; Sunflower Life Sciences, and Medtronic]. NexImmune’s AIM technology  was licensed from The Johns Hopkins University and is currently being applied in the field of immuno-oncology.  Specifically, the AIM technology deploys a novel process that simultaneously enriches, expands and activates multiple antigen-specific T cells that can be directed against a variety of tumor-relevant antigens, including shared tumor-associated antigens or patient-specific neoantigens. [company press release, Feb 14, 17]

NextCODE Health

Wuxi NextCODEthe Shanghai company formed out of Wuxi Pharmatech’s acquisition of Cambridge, MA, and Iceland-based genomic data startup NextCODE Health two years ago—closed a $75 million Series B round led by Temasek and Yunfeng Capital.  [Ben Fidler,, May 5, 17]

NextCure (Germantown, MD)

NextCure down 54% ,{jul 13, 20] Based on the current enrollment criteria and clinical response data, at this time the company does not plan to advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts into the stage 2 portion of the Simon 2-stage trial. [company press release, Jul 13, 20]

Eli Lilly has killed off its deal with immuno-oncology biotech NextCure after spending $25 million upfront on the pact just over a year ago. [Ben Adams, Fierce Biotech, Jan 13, 2020]

NextCure up 17% [Nov 29, 19]

NextCure down 53% [Nov 11, 19]

NextCure (Beltsville, MD; no SBIR, founded 2015) up 243% [Nov 5, 19] a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related diseases, announced that the company will host and webcast an event with its Chief Medical Officer [to]discuss updated clinical results from the Phase 1 portion of its ongoing trial with NC318 that are being presented earlier in the day at SITC. [company press release, Nov 5, 19]

NextCure (Beltsville, MD; SBIR) filed to go public three years after its founding, with a cancer-fighting drug in clinical testing and several local biotech veterans leading the charge. The startup projects $66 million to $77 million in net proceeds from the IPO. [DCInno, Jun 4, 19]

NextCure (Beltsville, MD; no SBIR) up 33% [May 9, 19] a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced the pricing of its [IPO] to raise $75M [company press release, May 8, 19]

Beltsville, Md.-based NextCure has filed to go public three years after its founding, with a cancer-fighting drug in clinical testing and several local biotech veterans leading the charge. The company plans to trade on the Nasdaq Global Market under "NXTC," offering 5M shares to the public at $14 to $16 per share. The startup projects $66M to $77M in net proceeds from the IPO that, along with its $135M in cash on the balance sheet, will go toward pushing its products through the clinical pipeline. [DC Inno, Apr 30, 19]

NextCure (Germantown, MD; no SBIR, founded 2015) raised $67 million from Eli Lily and Pfizer, among other investors, in hopes of producing its immune-therapy treatment. The company, formed from a partnership between a Yale University cancer physician and biotechnology company Amplimmune executives, does not currently have any drugs in development. However, NextCure does have a first-rights research and development deal in place with Yale.  [Aaron Gregg, Washington Post, Jan 8, 16]

NextIO (Austin, TX)

NextIO (Austin, TX; no SBIR) raised $18.8 M in venture investment to continue its development and sales of chips and systems that enable dozens of computer servers to work together at high speeds. [Austin American-Statesman, Feb 29]

NexPlanar (Hillsboro, OR)

NexPlanar (Hillsboro, OR; no SBIR) got a $10M venture round builds the next generation of chemical mechanical planarization (CMP) pads for the semiconductor device industry. Our propriety nano-domain technology coupled with patented molded grooves and the unique ability to tune the pads results in dramatically improved yields and lower cost of ownership with extended pad life. [,Jan 4, 13]

NEXTracker (Fremont, CA)

Smart solar startup NEXTracker (Fremont, CA; no SBIR, founded 2014) agreed to be sold to electronics manufacturer Flextronics (Singapore) in a deal worth close to $330 million. ... NEXTracker promises to deliver cost and time-saving innovations to large-scale solar projects. ... part of a spinoff from Solaria (no SBIR) ... had raised $40.5 million in total prior to the acquisition  [Gina Hall, Silicon Valley Business Journal, Sep 9, 15]

Nextreme Thermal Solutions

Nextreme Thermal Solutions (Durham, NC; one Phase 1 SBIR so far) has raised $8 million in funding for product development and to scale up production of its devices. ...  boosts the total capital raised by the company to $35 million ... tiny thermoelectric products can help electronic devices run longer, faster and more efficiently by performing two functions: They act as tiny heat pumps that cool equipment, and they convert heat into electricity.  ....  At the core of Nextreme's products is its patented thermoelectric film that is much thinner than a human hair. That technology enables its solid-state heat pump to be 20 times smaller than the conventional device it competes against. [David Ranii, Raleigh News & Observer, Jul 8, 09]

Thirteen NC companies will split $1 M from a new state fund intended to help businesses create environmentally friendly technologies. In the Triangle area: Ecocurrent of Raleigh received $100,000 to convert hog manure into electric power; Kyma Technologies of Raleigh received $60,000 to work with N.C. State University on a more efficient, cheaper electric switch.; 3F LLC of Raleigh received $100,000 to develop a natural fiber-reinforced concrete formula.; Piedmont Biofuels of Pittsboro received $75,000 to work on a reactor that more efficiently creates biodiesel.; Nextreme Thermal Solutions of Durham received $57,319 to manufacture a generator that converts waste heat into electricity.; Rain Water Solutions of Raleigh received $18,000 to develop a new rain barrel manufacturing process. [Raleigh News & Observer, Jul 1]

NextStep Robotics (Baltimore, MD)

NextStep Robotics (Baltimore, MD; no SBIR) will receive $250,000 from the Maryland Momentum Fund, part of a $750,000 total fundraising round for the startup. [Morgan Eichensehr, Baltimore Business Journal, Feb 6, 18] the first ever clinically proven option to effectively treat foot drop. [company website]

Nexus Biosystems (Chelmsford, MA)

Brooks Automation (Chelmsford, MA; no SBIR) has closed on a purchase of Nexus Biosystems (Poway, CA; no SBIR) in a cash deal worth $79 million. ...  Nexus makes automated compound and sample management solutions for life sciences companies  [Rodney Brown, Mass High Tech, Jul 26, 11]

NFlection Therapeutics (Wayne, PA)

The first drug for neurofibromatosis type 1 (NF1) is available to patients following the FDA’s approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection Therapeutics (Wayne, PA; $300K SBIR) is vying to be runner-up, but its founders say they can eventually win out with a drug that takes a different approach than the commercialized pill while also offering a safer and more effective way of addressing the tumors and skin bumps caused by the rare disease. NFlection is developing its drug as a topical gel. [Frnk Vinluan,, Jul 9, 20]

NG1 Technologies (Sarasota, FL)

NG1 Technologies (Sarasota, FL (moving to Atlanta); no SBIR) secured nearly $1.5 million in funding  ...  TechFlo Exhaust exists to manufacture and distribute cost effective, efficiency exhaust systems that solve problems for diesel engine users, namely by reducing high fuel costs.  [company website, Nov 26, 15]

NGM Biopharmaceuticals (South San Francisco, CA)

NGM Biopharma (South San Francisco, CA; no SBIR, founded 2008) down 20% [Oct 7, 19]

NGM Biopharmaceuticals (South an Francisco, CA; no SBIR, founded 2008) announced the pricing of its [IPO] to raise $107M. .... has generated a pipeline of seven experimental drugs for metabolic disorders, cancer, and eye diseases. For the past four years, NGM has been working with Merck in a partnership focused on developing drugs for diabetes, obesity, and nonalcoholic steatohepatitis (NASH), which is a type of fatty liver disease. [Frank Vinluan, Apr 3, 19]

NGM Bio (South San Francisco, CA; no SBIR),  joined the scrum of drug companies looking to treat the liver disease nonalcoholic steatohepatitis, or NASH. Its Phase 2 data showed a reversal in one factor of the disease and offered hints that other factors were reversed. Liver doctors were encouraged but cautious about the limited data. [Alex Lash,, Apr 28, 17]

The Column Group, the David Goeddel-led VC firm whose investments include up-and-coming companies like Igenica Biotherapeutics  (Burlingame, CA; no SBIR) , Immune Design  ( Seattle, WA; no SBIR) and NGM Biopharmaceuticals  (S San Francisco, CA; no SBIR) has raised $176 million toward a projected $250 million fund.  ....  Goeddel was the first scientist hired by Genentech and eventually went on to cofound Tularik (S San Francisco, CA;  $500K SBIR), which was sold to Amgen 10 years ago for $1.3 billion.  [Ron Leuty, San Francisco Business Times, Apr 17, 14]

Diabetes drug developer NGM Biopharmaceuticals (South San Francisco, CA; $500K SBIR, 60 employees ) pulled down $50 million in venture financing as the venture capital spigot pours down on biotech.  .... has spent much of the past five years uncovering the basic science around how hormones and receptors regulate cardiometabolic diseases like diabetes, obesity, muscle wasting and cardiovascular disorders, has inked drug development and research deals with Janssen Pharmaceuticals, Daiichi Sankyo, MedImmune (Gaithersburg, MD; $3.5M SBIR) and the Juvenile Diabetes Research Foundation.     [Ron Leuty, San Francisco Business Times, Jul 19, 13]

MedImmune (Gaithersburg, MD; $2.7M SBIR)  announced an agreement with NGM Biopharmaceuticals (South San Francisco, CA; no SBIR) to jointly develop treatments for obesity and type 2 diabetes based off a type of specialized cell found in the gastrointestinal tract.  ..... MedImmune will fund NGM's research, and will have the option to license promising candidates and bring them through development and commercialization. The collaboration centers on enteroendocrine cells (EEC), which are responsible for the production of gastrointestinal hormones. ....   MedImmune turns its focus to early-stage research, part of a broader set of changes by British pharma parent AstraZeneca [acquired in 2007]   [Bill Flook, Baltimore Business Journal, Jun 17, 13]  Medimmune sales have been in the $1B range [Wikipedia]

 NGM Biopharmaceuticals (South San Francisco, CA; no SBIR) led by veteran biotech innovators from Amgen, Genentech and Tularik, made a big bet five years ago that it could plumb the human digestive tract for new hormones and other agents that might help control metabolic disorders such as obesity and Type 2 diabetes. Private backers have put more than $76 million behind that vision. And now three pharmaceutical giants have lined up with their own endorsements, in the form of partnership deals that could hasten the company’s scientific progress.  The small private company announced a partnership deal this month with AstraZeneca’s biologics unit MedImmune, its third big collaboration in the last 15 months. Johnson & Johnson subsidiary Janssen Pharmaceuticals signed on in January, following a deal inked with NGM in March 2012 by Daiichi Sankyo. [Bernadette Tansey, xconomy,com, Jun 25, 13]

Nico (Indianapolis, IN)

Some 10 years ago, Hologic (Bedford, MA; no SBIR) bought Suros Surgical Systems (no SBIR), a maker of minimally invasive breast biopsy tools. Since then, Suros’s former executives have taken on a new venture, an  startup called Nico (Indianapolis, IN; no SBIR) with a much tougher task—to change how certain types of brain surgery are done. I spoke with Nico executives about their journey from Suros to Nico, and the crucial clinical trial they’re running to try to prove the worth of their brain surgery device, “Brain Path.”  [Ben Fidler,, Apr 28, 16]

Nido Biosciences (Boston, MA)

Nido Biosciences (Boston, MA; no SBIR) raised $4M in equity, according to an SEC filing (Rowan Walrath, BostInno, Sep 11, 19].

Night Vision

Night Vision lost its appeal that argued that the government was obligated to award the Phase III contract to Night Vision because the government orally promised to do so and that the SBIR law requires it to do so. The court rejected both arguments. Remember that the government does not make oral future contracts and that the SBIR law only allows sole-source procurement for Phase II but does not require it.  If you do a Phase 2, the government can award a subsequent contract to whomever it selects with your technology. The free money leaves the government free to do whatever it wants but just for government purposes. If you get a Phase 2, you should remember that the agency will act in its own interest with little if any regard for your interests beyond the expressly contracted terms of the Phase 2 contract.

NimbleGen Systems (Madison, WI

Invenra (Madison, WI; no SBIR) maker of pharmaceutical products, raised $2 million, its filing said. That brings to $6.2 million the total amount the company has raised since 2012, according to  Invenra was co-founded by Roland Greene and Emile Nuwaysir, both veterans of NimbleGen Systems (Madison, WI; $1.8M SBIR), which was acquired in 2007 for $272.5 million by the diagnostics arm of Roche Holding AG, the giant Swiss pharmaceutical company.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 29, 15]  Invenra's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies in phenotypic assays. [company website]. If you pay attention to emerging biotech companies, you might have heard of Sutro Biopharma. With a new way of making therapeutic monoclonal antibodies, the Northern California company has raised more than $90 million and just struck a major deal with Celgene. It’s a lot less likely you’ve heard of Invenra. But the Madison, WI-based company says it has a similar technology to Sutro: an antibody production system that doesn’t use genetically modified cells such as E. coli or Chinese hamster ovary cells as the factories, a break from the industry standard.  [Alex Lash,, Nov 15, 14]

NimbleGen Systems (Madison, WI; $1.8M SBIR)  got a $415K NIH grant to participate in its Cancer Genome Atlas pilot project and help develop innovative technologies for exploring the genomic underpinnings of cancer. using high-tech methods to select regions on the genome for DNA sequence analysis. NimbleGen is being acquired for $272M by the diagnostics arm of Roche Holding AG, the giant Swiss pharmaceutical company. [Milwaukee Journal-Sentinel, Jul 4]

Nimble Storage (San Jose, CA)

Nimble Storage (San Jose, CA; no SBIR) IT and hardware firm that planted operations in Raleigh earlier this year, filed for a $150 million initial public offering [Lauren Ohnesorge, Triangle Business Journal, Oct 18, 13] 

Nimble Therapeutics (Madison, WI)

Nimble Therapeutics (Madison, WI; no SBIR, spun off from Roche (Swiss)) raised a $10 million Series A round from three investors [to] to commercialize a “proprietary chemical synthesis technology for drug discovery and development” that was developed by a team led by Jigar Patel at Roche. [Molly Dill, Milwaukee BizTimes, Apr 30, 19]

a spinout of Roche called Nimble Therapeutics (Madison, WI; no SBIR), which licensed the drug discovery technology from the Swiss pharma giant, said it completed a Series A venture investment [undisclosed amount] ... according to a document filed with the SEC earlier this month, Nimble closed $10 million in equity funding. ... focusing on drugs formed from peptides, which are chains of amino acids. Such drugs have appealed to pharmaceutical developers because they are thought to combine desirable properties of both small and large molecule drugs, [Jeff Engel,, Apr 30, 19]

Madison-based Nimble Therapeutics has closed a $10M Series A funding round led by San Francisco's Telegraph Hill Partners. Nimble, based at the University Research Park at the University of Wisconsin-Madison, is developing chemical synthesis technology for drug development. More here. [Jim Dallke, WisconsinInno, Apr 30, 19]

Nimbus Discovery (Cambridge,MA)

Nimbus Therapeutics (formerly Nimbus Discovery, Cambridge, MA; no SBIR) will have $43 million [Series B investment led by Pfizer Venture Investments] to progress clinical trials of its non-alcoholic liver disease drug after the company successfully completed a financing round. ...  previously had only raised $24 million in Series A ... advancing its drug, a so-called acetyl CoA carboxylase inhibitor, which is designed to work to treat a common non-alcoholic liver disease estimated to affect 16 million Americans.  [Jessica Bartlett,  Boston Business Journal, Mar 19, 15]

Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013.  ... a spinoff company of the Fred Hutchinson Cancer Research Center  .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient.  .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising.   The other Fierce 14 are:   Acetylon Pharmaceuticals;   AnaptysBioCytomX  (Santa Barbara, CA; $500K SBIR); FibroGen  (South San Francisco, CA; $1.3M SBIR);  Immunocore; Jounce TherapeuticsKala PharmaceuticalsMacroGenics  (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; UltragenyxUniQure; and Visterra.  [Valerie Bauman,  Puget Sound Business Journal , Sep 24] 

Nimbus Discovery (Cambridge, MA; no SBIR), which uses computational technology to discover novel medicines, said today that it has extended its seed round with an investment by Microsoft Corp. founder Bill Gates ... follows a $10 million investment by Gates in Schrödinger [one of the other investors] to accelerate R&D. In addition, last April, Nimbus offered $3.5 million in securities. ... to advance Nimbus’ lead programs in diffuse large B-cell lymphoma, an aggressive blood cancer, as well as inflammatory disorders and metabolic disease.  [Lori Valigra, Mass High Tech, Mar 10, 11]

Nimbus Therapeutics (Cambridge,MA)

Nimbus Therapeutics (Cambridge, MA; no SBIR) earned a $200 million milestone from Gilead Sciences, which bought rights to Nimbus’s early-stage treatment for NASH, a type of fatty liver disease, in April. Nimbus could earn $600 million more if all goes well.  [Alex Lash,, Nov 4, 16]

NinePoint Medical (Cambridge,MA)

NinePoint Medical (Cambridge,  MA; no SBIR) an in vivo pathology device maker has closed a $33 million Series A funding ...  to support medical device development and commercialization, using the company’s in vivo pathology platform; to hire 25 new employees within a year; and eventually to begin manufacturing at its Cambridge facility [Mass High Tech, Oct 14, 10]

Niowave (Lansing, MI)

The rest of DOE,'s Phase II list also shows a preference for SBIR experience: Euclid Labs (Solon, OH; $18M SBIR since 2004, all DOE including one $10M award), four new Phase IIs;  Radiabeam Technologies (Santa Monica, CA, $10M SBIR since 2005  SBIR) three awards; Tech-x (Boulder, CO; something over $50M SBIR since 1994) three new awards;  Muons (Batavia, IL;  $13M since 2002 SBIR, all DOE) three awards; Far-Tech (San Diego, CA;$9+M SBIR since 2003) two awards; Ridgetop Group (Tucson, AZ; $10M SBIR since 2002) two awards;  Calabazas Creek Research (San Mateo, CA; $26M since 1994) two awards; Niowave (Lansing, MI;  $5M since 2007 SBIR) two awards;  Mesa Photonics  (Santa Fe, NM;  $0.8M since 2008 SBIR) two awards; Green Mountain Radio Research (Colchester, VT;  $5.7M SBIR)  two awards.  Of 104 awards, 33 went to multiple winners who already had collected $378M SBIR from the federal government.  Is DOE over-emphasizing contractor competence at the expense of companies and technologies with brighter futures?  No one knows becasue Congress shows little interest in the question, and the agency has a bias toward making itself smarter.  

NIRvana Sciences (Durham, NC)

NC IDEA has awarded more than $200,000 in grants to five North Carolina startups.  Three of them are: FokusLabs (Wake Forest, NC; no SBIR) has developed an intervention tool designed to remind individuals with autism and ADHD to get back on task when their attention wanders.  NIRvana Sciences (Durham, NC; no SBIR) is focused on novel fluorescent dyes developed at N.C. State University for use with medical diagnostic and imaging tests.   Panacea Solutions (Research Triangle Park, NC; no SBIR)  is using robotic technology to create low-cost, 30-day supply nutritional packets that are personalized for an individual’s needs.   [David Ranii, Raleigh News & Observer, Dec 10, 13]

Nitero (Austin, TX (and Australia)

Semiconductor startup Nitero (Austin, TX (and Australia); no SBIR, founded 2009) has raised $3.1 million in its latest investment round to support its development of high-speed Wi-Fi data communications technology for mobile devices. [Kirk Ladendorf, Austin American Statesman, Aug 5, 12]

When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes.  Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund.....  Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital.  [Lori Hawkins, Austin American Statesman, Jan 26, 12]  Graduates: Agile Planet,  Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar,  Savara Pharmaceuticals, Spredfast, Terapio ($500K  SBIR), Unwired Nation, 

Nitric BioTherapeutics (Bristol Borough, PA)

Nitric BioTherapeutics (Bristol Borough, PA; no SBIR)  raised $1 million in a debt offering, according to [SEC]documents ...  initially focusing on a treatment for toenail fungus based on a drug-delivery technology it acquired last year from Transport Pharmaceuticals of Framingham, Mass. ... also working on using use nitric oxide gas to treat infections.   [John George, Philadelphia Business Journal, Nov 29, 11]

NitricGen (Middleton,WI)

Start-up Wisconsin.  A start-up [NitricGen] with a patent pending on a portable device to treat chronic diabetic foot ulcers won first place in the Wisconsin Governor's Business Plan Contest.  .... founded in Madison in 2011 by Duncan Bathe, Frederick Montgomery and two others. Bathe and Montgomery previously created a Middleton medical device company called Sadasis LLC (no SBIR) that they sold to Ino Therapeutics (no SBIR), which was in turn bought by Ikaria (no SBIR), a critical-care company based in New Jersey. The pair has 19 patents and seven medical devices in use, Montgomery said.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 5, 13]

Eight start-up companies have been certified as qualified new business ventures by the Wisconsin Economic Development Corp., the agency said.  With the certification, the companies' financial backers will be eligible for a 25% tax credit on the amount they invest in the company.  The start-ups include:  InControl Medical LLC (Milwaukee, WI; no SBIR) has developed an FDA-cleared device designed to treat female urinary incontinence; NitricGen (Middleton, WI; no SBIR) has developed a medical device that uses plasma technology to electronically generate gaseous nitric oxide from the air and helps speed the healing process for individuals with chronic diabetic foot ulcers; SpeechTails (Elm Grove, WI; no SBIR) has an online speech therapy and learning system; Whole Trees (Stoddard, WI; no SBIR) has a technology for digitally engineering timber to make affordable commercial construction materials that can be substitutes for concrete, steel or milled lumber. [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 1, 12]

Nitride Solutions (Wichita, KS)

Nitride Solutions (Wichita, KS; no SBIR, founded 2009), a leading developer and manufacturer of advanced nitride substrates for LEDs, lasers, and power electronics, announced that it has successfully closed $2.75M in new funding. ...  to ramp up manufacturing capacity and staffing to meet rapidly growing customer demand for the company’s aluminum nitride products  [company press release, Apr 24, 17]

Nitride Solutions  (Wichita, KS; no SBIR) startup that manufactures aluminum nitride substrates for LEDs, lasers and power electronics, announced  that it has raised $1.75 million in its Series B round of financing, on top of more than $2.25 million raised previously.  ....   developed proprietary manufacturing processes and equipment to produce aluminum nitride substrates faster and with less cost than others in the market, according to CEO Jeremy Jones.  [Emily Behlmann, Wichita Business Journal, Oct 8, 13]

Nitrogenics (St Louis, MO)

Nitrogenics (St Louis, MO; no SBIR)  biotech startup incorporating enzymes into the genome of tobacco, has raised $175,000 from the BioGenerator and Missouri Technology Corporation.  ...   allows tobacco plants to absorb nitrogen directly from the atmosphere instead of from fertilized soil, which could decrease the cost and environmental impact of chemically fertilized farmland. ... BioGenerator is the investment arm of BioSTL, which has an annual budget of about $7 million   [Brian Feldt, St. Louis Business Journal, Dec 7, 15]

>Nitrome Biosciences (San Francisco, CA)

Nitrome Biosciences (San Francisco, CA; no SBIR) raised $38 million ... taking aim at a family of enzymes it discovered called nitrases. It’s working on treatments that target these enzymes to slow, or even stop, the progression of various diseases, starting with Parkinson’s. [Amirah Al Idrus, Fierce Biotech, Aor 22, 20]


NitroMed , the Lexington company that became known for marketing a heart medicine for blacks called BiDil, is attempting to reinvent itself.  The company -- which recently unveiled plans to sell the rights to BiDil, its only approved drug -- today said it will merge with Archemix  a small, privately-held Cambridge biotech company developing drugs for blood-related diseases.  [Boston Globe, Nov 19, 08]

NitroMed (Lexington, MA; no SBIR) said it’s suspending the sales force for its drug to treat heart failure in black patients, BiDil, and cutting 70 jobs while it conducts additional studies to gain approval of a once-daily form of the medicine. [Bloomberg, Jan 16]a research-based emerging pharmaceutical company [company website]

Who Needs Sellers? NitroMed, maker of a heart drug approved only for black patients said yesterday it fired its entire 120-member sales force and would replace it with a small team of heart specialists in a move to cut costs and improve marketing. [AP, Oct 12]


Nitronex (Durham, NC; one Phase 2 SBIR) got $7.5M in new funding. ... The company is working to fill 200 new manufacturing, engineering and administrative jobs and expects to invest $24 million into the new headquarters during the next five years. [Raleigh News&Observer, Jan 12]

A Raleigh nonprofit group opposed to business incentives filed a lawsuit Friday related to a $100,000 grant that Durham County promised Nitronex in March. [Raleigh News&Observer, Dec 22]

Nitronex (Raleigh, NC) will take $100K to move to Durham.

Gallium nitride valley. Bob Lynch CEO of Nitronex talks about GaN. GaNgallium nitride combines attributes of all different semiconductors, kind of all packaged into one. It has the frequency response, which is another way of talking about speed,of indium phosphide and gallium arsenide. ... it's the first time in a semiconductor that you have all the advantages of speed and power in one material. ... We put gallium nitride on just standard silicon, off-the-shelf silicon wafers. And that's one of our unique attributes, is the ability to put it on silicon.... the wireless base-station market. is a perfect application ... We have licensed it to other areas where we're not going to get into the products. Blue lasers, for instance, for the next generation of DVDs. There's a company in Japan that's licensed some [intellectual property] from us to build their blue lasers, which they're actually in production ... How valuable is a license like that to Nitronex? Very. Multiple six-figures kind of value. We've already written royalty checks to N.C. State in very high amounts. Very early on, too. So we're commercializing it. They're happy, we're happy.... In opto-electronics, things like blue light-emitters, either lasers or LEDs [light-emitting diodes] --we won't build those, we're going to license that technology. But for things like RF products for base stations and higher frequencies, we'll build those; high-temperature electronics, high-power switches, we're going to build those.... there's no reason to believe that this area can't be the Gallium Nitride Valley.......Our goal is IPO. Public markets are unpredictable, so we have the horsepower behind us to stay private and grow pretty substantially, and we also have the markets that will allow us to get retained earnings to grow with as well so you don't have to dilute and sell equity. But to grow at the rate we need to grow, we're going to need some pretty large capital infusions over the next few years.... [CHRISTINA DYRNESS, Raleigh Observer]

Nivalis Therapeutics formerly N30 Thera (Boulder,CO)

Alpine Immune Sciences (Seattle, WA; no SBIR), made its market debut [IPO] by merging with another biotech, Nivalis Therapeutics (Boulder, CO; no SBIR), which was rich in cash but had poor prospects after a drug trial failed last fall. ... Alpine, which describes itself as a developer of proprietary, protein-based immunotherapies to potentially treat cancers and inflammatory diseases, says it aims to apply for permission to begin its first clinical trial in the second half of 2018  [Seattle Times, Jul 25, 17]

Nivalis Therapeutics (formerly N30 Pharmaceuticals, Boulder, CO; no SBIR, founded 2007) and Alpine Immune Sciences  (Seattle, WA; no SBIR, founded 2015, 30+ employees), a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, jointly announced they have entered into a definitive merger agreement under which Alpine will merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology. [Yahoo Business Wire, Apr 18, 17]

Nivalis Therapeutics (Boulder, CO; no SBIR) focused on treating people with cystic fibrosis (“CF”), announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi™. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trial’s primary endpoint, or in sweat chloride reduction at 12 weeks. [company press release, Nov 29, 16]

Nivalis Therapeutics (formerly N30 Pharmaceuticals, Boulder, CO; no SBIR, 26 employees) said it's begun the second phase of a study of its N91115 drug targeting cystic fibrosis. ...  said results of the study, which will examine the efficiency and safety of the drug, will be available in the second half of next year. ... raised $88 million in its initial public offering in June  [Ben Miller, Denver Business Journal, Dec 1, 15]

biotech drug developer Nivalis Therapeutics (formerly N30 Pharmaceuticals, Boulder, CO; no SBIR) generated $77 million from an IPO. ....  formerly N30 Pharmaceuticals, is developing a cystic fibrosis treatment as its leading project  ... Late last year Nivalis raised $30 million from its investors to start clinical trials of its lead drug, called N91115.   [Greg Avery, Denver Business Journal, Jun 17, 15]

Nivalis Therapeutics  (formerly N30 Pharmaceuticals, Boulder, CO; no SBIR) pharmaceutical company, filed [IPO] to continue its cystic fibrosis research and treatment development. ...  said it intends to raise as much as $60 million.  ...  is currently creating the compound "N9115" to treat the disease, which affects the lungs and digestive system. ... The Denver Post reports that the company last year raised $30 million in a mezzanine round    [Caitlin Hendee, Denver Business Journal, May 14, 15]

NKT Therapeutics (Newton, MA)

NKT Therapeutics (Newton, MA; no SBIR) secured $8 million in a first funding round [Mass High Tech, Mar 19, 09]

nLight (Vancouver WA)

nLight Photonics (Camas, WA; $15M SBIR) down 19% [Feb 18, 22]

Baebies (Morrisville, NC; $22M SBIR) has [further] raised nearly $12 million [Zac Ezzone, Triangle Inno, February 22, 2022]

nLight up 25% [Nov 6, 20]

nLight up 16% [Apr 7, 20]

nLight (Vancouver, WA; $17M SBIR) up 22% [Nov 15, 19] announced the completion of the acquisition of Nutronics (Longmont, CO; $14M SBIR, founded 1995, 32 full-time employees) for $17.5 million in cash and $15.8 million of restricted stock units (RSUs) that will be issued as part of ongoing employment agreements. Nutronics is a leading developer of coherently combined lasers and beam control systems for high-energy laser (HEL) systems serving the defense market. [nLight press release, Nov 14, 19]

nLight down 10% [Oct 5, 18]

nLight down 17% [Jul 31, 18]

nLIGHTdown 10%  [Jun 8, 18]

nLight up 10%  [Jun 1, 18]

nLight up 22%  [May 24, 18]

nLight (Vancouver, WA; $20M SBIR), [which raised] $96 million in [April] IPO has reached market cap of $1 billion. [Jeff Buchanan,, May 16, 18]

nLight (Vancouver, WA; something like $20M SBIR) up 68%  [Apr 25, 18] on first day after $100M IPO.

nLIGHT (Vancouver, WA; something like $20M SBIR, founded Y2K,more than 1,000 employees) announced that it has filed for an IPO of value to be determined. [company press release, Mar 30, 18]

nLight (Vancouver, WA; $10M SBIR, 400 employees, founded Y2K) raised an additional $35 million to expand production, capitalizing on what the company says is a hot market for its technology.  "We are growing, growing over 30 percent a year, over $100 million in sales last year," said Scott Keeney, nLight's founder and chief executive. [Mike Rogoway, The Oregonian. May 11, 17]

nLight Photonics (Vancouver, WA; $12M SBIR) raised $25.3 million that will be used to expand its operation and build a new factory in its hometown.   ... has raised more than $150 million across nine funding rounds  ...  makes semiconductor-based, high-performance lasers that are used in materials processing, defense and medical device markets.  [Malia Spencer, Portland Business Journal, May 1, 15]

nLight Photonics (Vancouver,WA; $9.5M SBIR) raised $3 million, according to a securities filing, and it appears the round is related to an upcoming acquisition announcement. ... maker of semiconductor-based lasers, has already raised more than $110 million   [Erik Siemers, Portland Business Journal, Jan 3, 13]

NLight Photonics [Vancouver, WA; $12M SBIR) has raised a new $17.5 million round of venture capital, increasing its total to more than $110 million in its 11-year history. ...  manufacturer of semiconductor-based lasers fresh capital to finance a production expansion. [Eric Siemers, Puget Sound Business Journal, Aug 18, 11]

nLight (Vanouver,OR; $6M SBIR) has landed $10.7 million in new investment ... Founded in 2000, employs more than 200 in the Portland metro area and more than 300 altogether [The Oregonian, Jan 27, 09]

Semiconductor laser manufacturer nLight (Vancouver, WA; $1M SBIR) bought Liekki, a Finnish optical-fiber maker.   .... NLight started in 2000 with about a half-dozen employees. It now has close to 400. [Allan Brettman, The Oregonian, Oct 9, 07] 

nLight (Vancouver WA; $1M SBIR) got a $3M earmark (at the Appropriations Committee stage) to develop safe lasers to use at military checkpoints in Iraq and Afghanistan, boasts its Senator. [The Oregonian, Sep 13]

NMT Medical

Just weeks after announcing it did not have enough cash to file required federal documents, NMT Medical reports it is liquidating its business and selling assets to pay off creditors and has let go any employees left. [Mass High Tech, Apr 20, 11]

NMT Medical  developer of medical-implant technologies, has filed a shelf registration to sell up to $30 million in equity and debt. [Mass High Tech, Apr 6, 10]

NMT Medical  up 11% [Mar 22, 10]

NMT Medical  up 19% [Mar 19, 10]

NMT Medical up 10% [Mar 11, 10]

NMT Medical maker of medical implant technologies, has completed a private placement to bring in about $5.8 million. [Mass High Tech, Feb 17, 10]

NMT Medical up 13% [May 29, 08]

NMT Medical reports it has been awarded $2.25 million in damages from a federal court in its patent infringement lawsuit against a Minnesota company. [Mass High Tech, May 20, 08]

NMT Medical up 11% [Apr 29,08]

NMT Medical up 13% [Jan 25, 08]

NMT Medical down 26% [Jan 23, 08]  said it would close a trial testing a new migraine treatment after only a handful of patients met enrollment requirements and the study was becoming costly, pushing shares to a three-year low. [Reuters, Jan 23]

NMT Medical up 15% [Jan 3, 08]

NMT Medical down 12% [Nov 9, 07] despite winning a favorable patent ruling.

Noah Technologies (Milwaukee, WI)

Four water technology startups were named for an inaugural "seed accelerator program" at the soon-to-open Global Water Center business incubator facility in Milwaukee: Microbe Detectives (Madison, WI; no SBIR);  H2O Score (Milwaukee, WI; no SBIR),  Noah Technologies (Milwaukee, WI; no SBIR); and one with a parent company in France, called Vegetal i.D. Each company will receive a $50,000 WEDC grant to cover startup costs, and space in the Global Water Center, a seven-story warehouse that has been converted at a cost of $22 million.   [John Schmid, Milwaukee Journal Sentinel, Jul 17, 13]  A good deal for the warehouse converting business; value for the state economy TBD (don't expect to recover the cost of the warehouse conversion for perhaps decades).

Noble Fiber

The Ultimate Silver Lining   How Bill McNally turned his idea for an antibacterial fabric into a $50 million sensation. ..  McNally, an eight-year Marine Corps veteran, pitched X-Static to the Pentagon, and by 2004 every U.S. soldier was wearing X-Static socks, T-shirts, and gloves. ... Today the firm [Noble Fiber] has more than 300 licensing partners, including Adidas, Polartec, and Puma. ... More important, the company is on track to hit $50 million in sales in 2005. Noble has been profitable from the start, [Siri Schubert, Business 2.0, October 26, 2005 ] How did SBIR help? Not at all, no sign of any award.

Nocion Therapeutics (Cambridge, MA)

Nocion Therapeutics (Cambridge, MA; no SBIR), a biotech developing drugs that silence nociceptors, the neurons that send pain or itch signals when they are inflamed. The biotech is starting out with $27 million in series A funding [Amirah Al Idrus, Fierce Biotech, Apr 17, 19]

Nohla Therapeutics (Seattle, WA)

Nohla Therapeutics (Seattle, WA; no SBIR, founded 2015) a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignanies and other critical diseases, announced the second closing of its Series B financing, bringing the total amount raised in this round to $56 M. [company press release, Jul 11, 18] also announced that the U.S. Food and Drug Administration (FDA) has granted Nohla’s lead product candidate, dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT). [company press release, Jul 16, 18] total funding $120M []

Nohla Therapeutics (Seattle, WA; no SBIR, founded 2015) raised $45 million to continue mid-stage studies for its lead drug candidate, dilanubicel, an off-the-shelf cell therapy developed to provide bone marrow function. [Jeff Buchanan,, May 15, 18] total funding $109M []

Nohla Therapeutics (Seattle, WA; no SBIR) pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers,  announced the initial closing of a $43.5M Series A financing.... will support
the Company’s two lead programs (NLA - 101 and NLA - 102) generated by Nohla’s novel technology platform, which was spun
- out of the Fred Hutchinson Cancer Research Center in September 2015.  [company press release, Nov 29, 16]

Nohla Therapeutics  (Seattle, WA; no SBIR) cell therapy startup is raising $20 million and signed a licensing and collaboration agreement with the Fred Hutch to develop the use of umbilical-cord blood in medicine. ... says its proprietary platform multiplies the number of stem cells found in cord blood donations up to 500 times. This makes cord blood a viable alternative to adult bone marrow in the transplant setting [Steven Goldsmith, Puget Sound Business Journal, Dec 3, 15]

Noitavone (Houston, TX)

Spreading the "business focus".  Noitavone (Houston, TX; no SBIR) wants to be many different things for many different people.  The young technology company says it has six different branches with concepts ranging from creating mobile instruments to offering a wireless infrastructure network. It also wants to enter multiple different sectors, such as education, the prison system and utilities.  [Molly Ryan, Houston Business Journal, Sep 21, 12]

Nomadics (Stillwater, OK)

Nomadics (Stillwater OK; over $20M SBIR and STTR) is exploiting polymers that change colors in the presence of target molecules for sniffing explosives. MIT chemist Timothy Swager just won the $500K Lemuelson-MIT prize for the chemistry. The company also won a $16M DOD contract teaming with iRobot to put the detectors where they will do the most good with the least risk to the warrior. The company's elevator pitch (overview): ICx Nomadics pursues the research and development of emerging technologies focused on homeland security and force protection. The ICx Nomadics Technology Cultivation model creates value by applying the skills and creativity of a cross-disciplinary technical team to early stage technologies, driven by proper funding and professional management.

Nok Nok Labs (Palo Alto, CA)

Nok Nok Labs  (Palo Alto, CA; no SBIR) raised $16.5 million in Series B funding  .. brings the total raised by the Palo Alto startup to $31.5 million  ...  founded in November 2011 to unify the silos that plague current authentication technologies.  ....  leverages a new protocol—the Online Secure Transaction Protocol (OSTP), a scalable strong authentication protocol  [John Sailors, San Francisco Business Times, Feb 27, 14]

NONA Composites (Dayton, OH)

NONA Composites (Dayton, OH; no SBIR), a spinoff from Cornerstone Research ($35M SBIR) in the composites world has received the annual Soin Award for Innovation and $25,000 prize .... will be able to grow. ... a process engineering company for composite tooling and parts manufacturers. It provides a no-oven, no-autoclave composite fabrication solution to significantly reduce time and capital equipment investments.  [Tristan Navera, Dayton Business Journal, Apr 13, 15]

Cornerstone Research Group  (Beavercreek, OH; $32M SBIR, 80 employees) is looking to start a $2 million manufacturing operation that could create up to 50 new jobs.  ....  to make Metagraphite, a composite material it developed, for sale to the residential and civil construction market.  ....  Cornerstone has started to see success with some of its subsidiary companies. That includes:  NONA Composites LLC, a process engineering company for composite tooling and parts manufacturers. It provides a no-oven, no-autoclave composite fabrication solution to significantly reduce time and capital equipment investments; Advantic LLC, which provides an engineering service and product that acts as a lightweight alternative to pre-cast concrete, allowing customers to bid projects more competitively and eliminate heavy installation issues; and  Spintech LLC, which markets a forming system that allows composite structures to be built with a quickly removable and reusable mold.      [Joe Cogliano, Dayton Business Journal, Dec 3, 14]

Noninvasix (Houston, TX)

The Texas Medical Center, the largest medical complex in the world, announced the TMC Venture Fund, a $25 million initiative designed to support technologies and early-stage companies to flourish in Houston’s health care ecosystem and further the TMC’s mission to advance health, education and research.  Its awardees for 2017: Alleviant Medical (Houston, TX, founded 2017) developing a novel minimally-invasive device to treat congestive heart failureBriteseed (Chicago, IL; no SBIR, founded 2012)  commercializing a new class of smart surgical tools that have artificial-vision assistance; CNSDose (Australia, founded 2015, raised $1M) uses advanced genetic technology to fast-track finding the right antidepressant and dose; Noninvasix (Galveston, TX; no SBIR, founded 2007) developing a patient monitor to directly, accurately and noninvasively measure brain oxygenation in premature babies in the neonatal intensive care unit.   [TMC press release, Nov 8, 17]

Noninvasix (Houston, TX; no SBIR), a medical device company building a monitoring system for fetal wellness, took home $100,000 in cash at the Texas New Ventures Competition at Texas A&M University .... it plans to embark on the investor path again to raise a Series A round [around $3.75 million]  ...  2007 out of the University of Texas Medical Branch at Galveston, and was one of the first companies to be spun out of UTMB   [Joe Martin, Houston Business Journal, Jun 3, 15]

Nora Therapeutics (Palo Alto, CA)

Nora Therapeutics (Palo Alto, CA; no SBIR) startup will focus an $18 million VC investment on developing a drug to stop unexplained recurrent miscarriages.  ....    capitalizing on work started by cofounder Darryl Carter at Johns Hopkins University that led to development of Nora's lead drug, NT-100.  ....  Recurrent miscarriages affect 1 percent to 5 percent of all women of childbearing age, according to Nora.   [Ron Leuty, San Francisco Business Times, Apr 17, 14]

Norian (West Chester, PA)

Norian (West Chester, PA; one SBIR in 1991) illegally tested bone cement during spinal surgery on about 200 patients, three of whom died on the operating table, federal prosecutors in Philadelphia charged. A lengthy indictment accuses the [company] of training dozens of surgeons to conduct unofficial clinical tests of the product on humans, subverting FDA safeguards. The company is charged with conspiracy and 51 other felonies. Prosecutors say the surgeries took place from 2002 to 2004 but ended after the third death. [AP, Jun 16, 09]

NorMedix (Plymouth, MN)

SurModics (Eden Parairie, MN), a leading provider of medical device and in vitro diagnostic technologies. announced it has acquired NorMedix  (Plymouth, MN; no SBIR),  design and development company focused on ultra thin-walled, minimally invasive catheter technologies  [company press release, Jan 11, 16]

NormOxys (Wellesley, MA)

NormOxys (Wellesley, MA; no SBIR) has taken in a small amount of funding in its $600,000 financing of debt and secured convertible notes, the  company noted in a regulatory filing. ... develops drugs intended to treat cancer, cardiovascular disease, inflammatory airway disease and diabetic retinopathy. Its lead drug candidate, OXY111A, is in clinical trials for treating tumors related to pancreatic cancer, melanoma, hepatoma and colon cancer. [Michelle Lang, Mass High Tech, Nov 21, 11]

NormOxys (Wellesley, MA; no SBIR) has taken in a Series B round of financing to the tune of $17.5 million ... to move its lead drug candidate, OXY111A, into clinical trials in treating chronic heart failure and cancer. [Mass High Tech, May 24, 10]

NormOxys (Wellesley, MA; no SBIR), developer of small-molecule drug treatments for oxygen deficiency, has raised $1.1 million in a new round of debt financing, the company reported in a regulatory filing this morning. [Mass High Tech, Mar 25, 10]

Norse (St. Louis, MO)

Norse (St. Louis, MO; no SBIR) cyber security startup, has raised $10 million in a venture funding round, according to [SEC] documents ... from one investor, who was not made public   ...  Since being founded in 2010, Norse has secured close to $10 million in funding without relying on any venture capital or institutional investors.   ... one of five companies in the fall 2011 Capital Innovators class, when it received $50,000 in seed money from the St. Louis-based accelerator program.  [Brian Feldt, St Louis Business Journal, Dec 6, 13]

Northeast Photosciences (Holllis, NH)

Wanna read a BMDO SBIR project? Ludman et (many) al "Very thick holographic nonspatial filtering of laser beams", Optical Engineering, Jun 97 by Northeast Photosciences, Hollis, NH.

Into the Black HOLOS (May 22) The Keene Sentinel (NH) reports a black hole where HOLOS used to live with the building up for lease again. HOLOS got a great real estate deal when a previous tenant vacated the factory in rural (lots of rocks and trees) Fitzwilliam NH and made space for HOLOS to manufacture and sell the SBIR holographic and other products of Northeast Photosciences Inc (Hollis, NH). Despite the community's hopes for hundreds of employees, it got only to 18 before the capital ran out (presumably). In the booming economy the workers can probably land on their feet except for the imported Russian experts who will have a harder time negotiating the employment market. Northeast is the creation of Jacques Ludman, a retired technocrat from AF Rome Lab.

Northstar Battery (Springfield, MO)

orthstar Battery (Springfield, MO; no SBIR; founded 2000) plans to add 400 jobs (already has 316 employees at its first plant) with a new manufacturing plant it's building at home. ... makes batteries for industry, mainly for telecommunications uses such as cell phone towers.  ... Company officials said they considered putting the new plant in China but had quality concerns. They also looked at other states but decided that Missouri had the best incentives. ... expects to invest about $73M in the new plant. [AP, Mar 18]

Northstar Medical Radioisotopes (Madison, WI

NorthStar Medical Radioisotopes (Beloit, WI; no SBIR, founded 2006)  has federal approval to become the first U.S. supplier in 30 years whose technology can be used to produce a critical radioactive imaging product — technetium-99m — “the most widely used radioisotope in medical imaging,” according to [FDA] [which] approved NorthStar’s RadioGenix System to produce technetium-99m, used in more than 10 million diagnostic procedures a year in the U.S. to detect heart disease and cancer and to test lung, liver, kidney and brain function.  [Judy Newman, Wisconsin State Journal, Feb 9, 18]

Northstar Medical Radioisotopes (Madison, WI; no SBIR) planning to build a plant in Beloit that would make a commonly used medical isotope, has been awarded $22.2 million of matching funds from a federal agency [National Nuclear Security Administration]  .... brings to $25 million the amount of matching funding Northstar has received from the federal government. Northstar has also raised $16 million from outside investors .[Kathleen Gallagher, Milwaukee Journal Sentinel, Nov 19, 12]

Northstar Neuroscience

Northstar Neuroscience, whose technology for treating stroke patients failed a clinical trial last January, said Monday it plans to lay off most of its remaining employees and seek shareholder permission to liquidate the company.  [Seattle Times, Jan 5, 09]

The stock of Northstar Neuroscience (Seattle, WA; no SBIR), maker of a device for stroke patients, plunged nearly 84% after the company said a trial didn't meet a goal. [Seattle Times, Jan 23]

Northstar Photonics (Minneapolis, MN)

Northstar Photonics gets $11M venture capital funding. The financing, along with $10M raised in preliminary and first-round funding since mid-1999, is expected to carry the 26-employee firm until it begins selling its product, said Tom Oliverius, Northstar's finance vice president. But he said the company hopes to raise an additional $5M in this financing round. Northstar's device is a component of a fiber-optic telecommunications line that helps boost speed and carrying capacity. It is expected to begin producing revenue in 2Q 2002, Oliverius said. [Steve Alexander, Minneapolis Star Tribune, Oct 3] Northstar got started without SBIR but with the help of Minnesota Project Innovation whose business advisor Brian Schiffman joined the company.

Northstar Photonics (Minneapolis, MN) got an $8.5M investment from a Minneapolis VC. Although Northstar didn't do SBIR, one of its main players was an SBIR fan - Brian Schiffman who did the business help for Minnesota start-ups at Minnesota Project Innovation before plunging back into the private sector.

Northwest Biotherapeutics (Seattle, WA)

Northwest Bio unveiled interim phase 3 data showing its dendritic cell vaccine improved survival rates in patients with newly diagnosed glioblastoma, in some cases even doubling survival. [Amirah Al Idrus, Fierce Biotech, Jun 1, 18]

[CEO] Linda Powers of Northwest Biotherapeutics (Bethesda, MD; no SBIR) is loaning the company $4.4 million, [SEC] filing shows. the midst of a phase 3 clinical trial for its immunotherapy drug candidate for glioblastoma multiforme brain cancer, earlier this month entered into two separate note and loan agreements with Powers. (Washington Business Journal, Mar 26, 18)

Northwest Biotherepeutics (Bethesda, MD; no SBIR) raised $12 million as it continues its phase 3 clinical trial for its immunotherapy drug candidate for glioblastoma multiforme brain cancer. Northwest Bio officials said the funding would be used for general corporate purposes, which could include clinical trial expenses, but did not offer further specifics. [Washington Business Journal, Dec 7, 17]

Northwest Biotherapeutics (Bethesda, MD; $400K SBIR), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into definitive agreements with two new institutional investors for a registered direct offering with gross proceeds of $3.7 million.  [company press release, Jul 5, 16]  On June 24, 2016,  received a written notice from Nasdaq Staff that the Company is not in compliance with Nasdaq Listing Rule as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days.  [company press release, Jun 28, 16]

Northwest Biotherapeutics (Bethesda, MD; $400K SBIR) is raising $12.6 million in new funding as part of a direct offering to health care-focused investors, according to a company announcement.  ... developing products to stimulate the immune system to help fight tumors and kill cancer cells, had previously raised $27 million in a 2013 offering. [Andy Medici, Washington Business Journal, Dec 27, 15]

Northwest Biothera down 19% [Dec 23, 15

A major shareholder is urging biotechnology firm Northwest Biotherapeutics ($400K SBIR) to hold an inquiry into allegations about the governance of the company by Chairman and Chief Executive Linda Powers. .. [Whoever is appointed] would convene a special committee of nonexecutive directors to investigate the allegations, which were made largely by an equities research group, and which raise questions about what the research group says are the company’s financial dealings with vehicles related to Ms. Powers.  [Denise Roland, Wall Street Journal,  Nov 30]

Northwest Biotherapeutics up 13% [Oct 21,15]

Northwest Biotherapeutics (Bothell, WA; $400K SBIR) up 15% [Oct 19,15]

Northwest Biotherapeutics (Bothell, WA; $400K SBIR) down 29% [Oct 16,15]

Northwest Biotherapeutics (Bethesda, MD; $400K SBIR) down 22% [Aug 21, 15] [CEO] said the company has temporarily stopped screening new patients for the late-stage [international] trial of its experimental brain cancer drug.   [Ransdell Pierson, Reuters, Aug 21, 15]

Northwest Biotherapeutics (Bethesda, MD; $400K SBIR in Bothell, Washington), developing DCVax® personalized immune therapies for solid tumor cancers, announced that today the Company entered into agreement for financing of $40 million... from a British investor [company press release, Apr 2, 15]

Northwest Biotherapeutics (Seattle, WA; $400K SBIR) is attempting a comeback in the public marketplace, five years after being kicked off Nasdaq in 2002 when it ran out of cash. ... said it raised about 13.1 M pounds ($26 million) in net proceeds from foreign institutional investors as it began trading [Angel Gonzalez, Seattle Times, Jun 23, 07]

Norwich Technologies (Norwich, VT)

Norwich Technologies [Norwich, VT; no SBIR]. will get up to $300,000 [from DOE's SunShot Incubator program] for a project to design an innovative linear receiver that uses advanced geometries, upgrades insulation materials, and replaces expensive and failure-prone vacuums with cavities.  [Don Seiffert, Mass High Tech, Jun 14, 12]

Nostopharma (Bethesda, MD)

Nostopharma LLC (Bethesda, MD; no SBIR) is developing a treatment for pathologic bone growth, the formation of new bone following surgeries, burns, injuries and other traumas. The complication affects 100,000 patients every year, a patient cohort the company’s co-founders hope to benefit with their product. [Washington Business Journal, May 18, 18]

Notice Technologies (Texas)

When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes.  Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund.....  Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital.  [Lori Hawkins, Austin American Statesman, Jan 26, 12]  Graduates: Agile Planet,  Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar,  Savara Pharmaceuticals, Spredfast, Terapio ($500K  SBIR), Unwired Nation, 

Novacea (South San Francisco,CA)

Novacea (South San Francisco; no SBIR) lost 50% after announcing it has ended its Phase 3 ASCENT-2 clinical trial of Asentar(TM) (DN-101), the company's lead investigational cancer therapy for the treatment of patients with androgen-independent prostate cancer, or AIPC, due to an imbalance of deaths between the two treatment arms, as observed by the Data Safety Monitoring Board (DSMB) for the clinical study. [company press release, Nov 5, 07]

Novalar Pharmaceuticals (San Diego, CA)

dental medication developer Novalar (San Diego, CA; no SBIR) has sold its only commercial product, OraVerse, to one of the largest dental pharmaceutical companies in the world. Septodont,  in St. Maur, France, acquired the prescription local anesthesia reversal therapy  ... Novalar's 12 employees will be let go in the coming weeks as the company winds down operations, Janson said. Most of the 24 sales people hired by Novalar two years ago to launch the drug in the United States were laid off in anticipation of the sale of OraVerse, she said....  created in 2001, and OraVerse was approved in May 2008  [Keith Darce, signonsandiego, Mar 22, 11]

Novalar Pharmaceuticals (San Diego, CA; no SBIR) and its partner Sanofi-Aventis have filed papers seeking permission to sell Novalar’s dental anesthesia reversal therapy in Britain, Germany, Italy, France and Spain. [Keith Darce,, Jul 17, 10]

Novalux (Sunnyvale, CA)

Novalux (Sunnyvale, CA) found that adding a crystal of lithium niobate to a gallium indium arsenide laser would boost its light output and change its wavelength from infrared to the red, green, or blue that are the building blocks of color displays. The lasers shine on arrays of thousands of micromirrors that flip back and forth thousands of times a second to combine the light into new colors of different intensities, says inventor Aram Mooradian, founder of Novalux and former head of the quantum electronics group at MIT's Lincoln Laboratory. [MIT Tech Review, J/F07]  Mooradian had two Phase 2 SBIRs (with an co-investment extension) with his Massachusetts start-up Micracor before he sold it to Coherent in 1996 and started over in 1998 No SBIR (yet) for Novalux (the named investors sound like folks with allergic reactions to partnering with government) In the 1990s, co-investment highlighted SDIO/BMDO SBIR as company after company in Phase 2 found third-party investors to demonstrate enough market potential to merit more government investment. No, happy words didn't count; just money on the table, although the money could be used for any purpose that moved the product toward a market.  Note that such a scheme is entirely distinct from cost-sharing where a private entity pays for government R&D work. The SBIR advocates oppose the cost-sharing, which is fair comment, but also oppose the co-investment because it steers SBIR money away from the drone companies that just do government R&D work.

Aram Mooradian is back with $20M and more optically pumped lasers, this time as the founder of Novalux (Sunnyvale, CA). Aram founded Micracor in Boston in 1992 where he got one BMDO SBIR Phase 2 after which he sold out to Coherent in 1997. He plans to gather another $60M this summer. Is Aram an SBIR success story? Would he have $80M this year in development money if SBIR had not let him venture out from his perch at Lincoln Labs? Story in The Red Herring, Aug 00 (online sometime later). The management team comes from PARC, Intel, Livermore, E-Tek, Opto-Power, and AMD.

Novan Therapeutics (Durham, NC)

Novan up 18% [Jun 14, 21]

Novan (Morrisville, NC; $8M SBIR) up 62% [Jun 11, 21] announced positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum ("molluscum"). Molluscum is a common, contagious skin infection caused by the molluscipoxvirus, affecting approximately six million people in the U.S. annually, with the greatest incidence in children aged one to 14 years. [company press release, Jun 11, 21]

Novan’s antiviral SB206 has failed to beat placebo in two phase 3 trials in patients with molluscum contagiosum. The setback wiped 74% off Novan’s value and left its cash runway looking precariously short, but the biotech plans to start another trial in the belief it still has a path to approval. [Nick Paul Taylor, Fierce Biotech, Jan 3, 20]

KNOW Bio, a subsidiary of Durham's Novan, has raised nearly $12 million in equity during a financing round. [Triangle Business Journal, Sep 24, 18]

Novan down 11% [Dec 11, 17]

Novan announced that it has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via [unnamed] third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Drug Application (NDA).  The proposed Phase 3 trial would be executed by the third party’s dermatology drug development team which plans to utilize a clinical research organization with extensive dermatology clinical trial experience.  [company press release, Nov 7, 17]

Novan down 10% [Nov 6, 17]

Novan down 10% [Sep 15, 17]

Novan up 10% [Sep 8, 17]

Novan up 10% [Aug 30, 17]

Novan up 12% [Aug 4,17]

Novan down 17% [Aug 2, 17]

Novan up 13% [Jul 31, 17]

down 11% [Jul 31, 17]

Novan up 25% [Jul 28, 17]

Novan (Morrisville, N.C; $3.5M SBIR) makes wholesale managment shifts. To be exceedingly clear, the Company will require additional capital in order to proceed on broadening the potential application of the science (nitric oxide) and the underlying technology, and specifically to initiate and complete the planned phase 2 trials in both psoriasis and atopic dermatitis.  ...  Creating a longer term “runway” for the overall Novan business remains a central imperative for the executive management team and the Board of Directors.    [company press release, Jun 5, 17]

Novan down 10% [Apr 17, 17]

Novan up 21% [Apr 12, 17] announced positive topline results from the Company's Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. [company press release, Apr 12, 17]

Novan up 34% [Feb 15, 17]

Novan up 12% [Feb 14, 17]

Novan (Durham, NC; $3.5M SBIR) down 74% [Jan 24, 17] Novan's topical nitric oxide-releasing product candidate SB204 demonstrated statistical significance (p<0.05) compared to vehicle on all three co-primary endpoints in NI-AC302, but demonstrated statistical significance on only one of three co-primary endpoints in NI-AC301. [company press release, Jan 27, 17]

Novan (Morrisville, NC; $3.6M SBIR) announced top-line results from the Company's Phase 2 clinical trial with SB206 for the treatment of  genital warts caused by human papillomavirus, or HPV. The highest dose tested, SB206 12%, demonstrated a statistically significant improvement (p<0.05) in the incidence of complete clearance of all baseline warts compared to vehicle treatment after 12 weeks in both the intent-to-treat and per-protocol analyses.    [company press release, Nov 29, 16]

Novan up 17% [Sep 22, 16]

Novan (Durham, NC; $3.5M SBIR, 63 employees) up 65% [Sep 21, 16] after IPO raised $45 million  ....  The skin products company has no products on the market and is developing dermatological products to treat five conditions, including acne, genital warts and toenail fungus.   [John Murawski, Raleigh News & Observer, Sep 21, 16]

Novan (Durham, NC; $3.5M SBIR) pharmaceutical startup staffed and advised by prominent North Carolina and national business executives plans to raise a potential $60 million in an initial public stock offering.  [Raleigh News & Observer, Aug 25, 16] focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation.   [company website]

drug developer Novan Therapeutics (Durham, NC; no SBIR) has raised $30 million in another private placement. ...   just nine months after Novan announced it raised $50 million ... developing a treatment for acne that does not include antibiotics, an important distinction given the quickly rising rates of antibiotic resistance  [Jason deBruyn,Triangle Business Journal, Dec 21, 15]

Novan Therapeutics (Durham, NC; $3.7M SBIR as Novan) will add a center that can manufacture nitric oxide-based active pharmaceutical ingredients for use in the company’s experimental drugs.  Novan is developing a treatment for Acne vulgaris. using nitric oxide-releasing new chemical entities. This new facility, aptly named the Nitric Oxide Center of Excellence, is expected to be completed next summer. [Jason deBruyn, Triangle Business Journal, Oct 27, 15]

Novan Therapeutics (Durham, NC; no SBIR) reported positive Phase 2 clinical trial results for its experimental acne drug SB204. Novan’s drug harnesses the therapeutic properties of nitric oxide in a stable, topical gel. Earlier this year, Novan closed on $50 million in funding, which the company applied toward its acne drug, as well as mid-stage trials of SB206, a topical antiviral that the company is studying as a treatment for human papillomavirus infection.   [Frank Vinluan,, Oct 6, 15]

Biotech darlings.  Led by a huge surge in funding for life science companies, North Carolina’s entrepreneurial companies raised $426.9 million during the first half of this year – up 71 percent from a year ago and more than double the total from two years ago. ... CED officials labeled the funding total “blockbuster.”  ....  Novan Therapeutics ($3.7M SBIR as Novan) attracted more than $39 million.   [David Ranii, Raleigh News & Observer, Sep 15] When does a surge become a bubble? When it bursts.

Novan Therapeutics (Durham, NC; no SBIR) said it has completed raising $50 million, much of it from private investors in the Triangle, as the start-up continues developing its novel acne treatment. ... Novan’s lead medication, SB204, is being developed to treat acne vulgaris, a bacterial infection common in adolescence that results in red lesions, blackheads and whiteheads.  Novan says SB204 would be the first acne treatment to use nitric oxide  [John Murawski, Raleigh News & Observer, Mar 30, 15]

Novan Therapeutics  (Durham, NC; no SBIR, founded 2008) announced positive Phase 2 clinical trial results for its acne therapy.  .... has raised $20 million in private equity funding from individuals. The company has no drugs on the market  ... In August, the company was awarded a $7.8 million government contract to develop a treatment for thermal burns. [David Bracken, Raleigh News & Observer, Mar 19, 14]

startup Novan (Durham, NC; $3.5M SBIR) snagged a $3.5 million loan .... counts Cree founder Neal Hunter and GlaxoSmithKline veteran Bob Ingram among its investors .... is researching treatments based on nitric oxide - not to be confused with nitrous oxide, the laughing gas variety - with potential in wound care, acne and other areas of treatment  [Lauren K. Ohnesorge, Triangle Business Journal, Mar 10, 14]

Novan Therapeutics  (Durham, NC; no SBIR, a UNC-Chapel Hill spinoff) nitric-oxide therapy company, has nabbed a $7.8 million, two-year government contract to develop a medical countermeasure for thermal burns.  ....   issued by the Biomedical Advanced Research and Development Authority with the hope that a new treatment could make a difference in the event of a mass casualty emergency. The deal will advance the development of Novan’s technology, including formulation work, nonclinical toxicology and proof-of-concept studies. [Lauren Ohnesorge, Triangle Business Journal, Aug 26, 13]

Novan Therapeutics (Durham, NC; no SBIR)  that is developing nitric oxide-based skin therapies, has been awarded a $7.8 million government [HHS] contract to develop a treatment for thermal burns. ... Novan began operations in January 2008 and has raised $20 million in private equity funding from individuals. The company has no drugs on the market but is conducting Phase 2 clinical trials on a nitric oxide-based therapy for acne. ...  Also  getting grants from that part of HHS:  Chimerix ($600K SBIR)   $24.8M for smallpox; Cempra Pharmaceuticals  $58M; GlaxoSmithKline  $200M. [David Brfacken, Raleigh News & Observer, Aug 26, 13]

NovaScan (Milwaukee, WI)

Novascan (Milwaukee, WI;  SBIR) raised $50,000 as part of a funding round that could climb as high as $2 million, according to an SEC filing. The company develops tools designed to help customers detect forms of soft tissue cancer and reduce the length of surgical procedures they perform. Last year, Novascan participated in the TMCx accelerator for medical device startups, in Houston [Jeff Buchanan, xconomy,com, Aug 1, 17]

Two Wisconsin businesses will receive state funding for technology development:  NovaScan (Milwaukee) $50K for technology to measure the electrical properties of materials used to identify tissue types in the body, and Platypus Technologies (Madison) $50K for nanotechnologies for the life sciences. [Milwaukee Journal Sentinel, Oct 17]  Platypus has hauled in about $7M in SBIR.

Nova Scientific Sturbridge, MA)

Aerodyne Research (Billerica, MA; 199 SBIR Phase Is and something like $80M total SBIR) will receive five $1-million DOEnergy [SBIR Phase II] grants, and Radiation Monitoring Devices (Watertown, MA;  404 SBIR Phase Is and something like $150M SBIR) will receive three $1 million grants, the department said. ...  Other local companies in line to receive Energy Department grants: Conispire (Boston, MA: no SBIR) , Aspen Products Group (Marlborough.MA; $5.6M SBIR), Capesym (Natick, MA; $5.3M SBIR); Nova Scientific  (Sturbridge, MA; $9M SBIR); Beacon Power (Tyngsborough, MA; $1M SBIR), the department said.  [Chris Reidy, Boston Globe, Jun 29, 12] 

Novasenta (Pittsburgh. PA)

Novasenta (Pittsburgh. PA; no SBIR) focused on immunotherapy treatment for cancer, raised a $20 million seed round. [Patty Tascarella PittsburghInno, October 14, 2021]

Nova Synthetix (Chapel Hill, NC)

Nova Synthetix (Chapel Hill, NC; no SBIR) is just 6 months old and has raised about $50,000 so far, including a loan from the N.C. Biotechnology Center. The company doesn’t expect to have a commercial product before 2019, said David McElroy, the chief operating officer....  to help produce castor seeds that produce castor beans free of ricin, a lethal toxin that has to be removed from the beans by heat treatment or chemically. The company is conducting genetic experiments with the ultimate goal of creating a nontoxic variety of castor plant.   [John Murawski, Raleigh News & Observer, Feb 26, 14]

Novatek (Provo, UT)

Schlumberger acquired Novatek (Provo, UT; $1.8M SBIR, founded 1955 (as I began to study engineering) and Novatek IP LLC, which the oilfield services giant says will help improve drilling performance.  ...  Schlumberger [already] had an existing relationship with Novatek, which specializes in synthetic diamond technology primarily for the oil and gas industry. ...  value of the deal was not disclosed  [Olivia Pulsinelli, Houston Business Journal, Sep 2, 15]   has grown into a modern Edison labs ... to invent technologies that solve global-scale issues, and all work has the promise of expanding our portfolio of over 600 patents.   [company website]

Provo businessman named the top "Utah genius" ... . The Utah Genius 2009 Awards  honored individuals or companies that received the most patents in the state in 2008. Cities also were honored for the number of patents and the number per capita. Last year, Hall's company, Novatek (Provo, UT; $2.7M SBIR), which creates tools and machines for industries such as oil and gas drilling, mining and construction companies, received about 50 patents, while filing for another 100. [Tom Harvey, Salt Lake Tribune, May 12, 09]

NovaTorque (Sunnyvale, CA)

Boosting the efficiency of existing appliances is just as important as harnessing alternative energy sources to power them. That's why John Petro, founder of NovaTorque (Sunnyvale, CA; no SBIR), decided to redesign the electric motor, which consumes about half of all the electricity used today ... Though the motor was conceived in 2003, its development stalled for years because Petro didn't have the funds to manufacture it. The $40 billion motor industry is notoriously resistant to change  [Anita Hamilton, Time, Dec 15, 08]

NovaTract Surgical

Connecticut Innovations has invested for the third time in medical-device company NovaTract Surgical  (New Haven, CT; no SBIR) with a $1 million stake ... raised $2,375,000 in this round ... developing medical devices that would reduce the number of incisions in minimally invasive surgeries  [Mara Lee, Hartford Courant, Jun 15, 12]

A Yale University spinout, NovaTract Surgical LLC, will receive $20,000 in pre-seed support from Connecticut Innovations as it works to develop a device for use in minimally invasive laparoscopic abdominal surgery. [Mass High Tech, May 4, 10]

Novavax (Gaithersburg, MD)

Novavax slashed its full-year revenue outlook, citing a lack of demand for its Covid-19 vaccine from Covax and delays in winning expanded authorizations in the U.S. [Barron's, Aug 9, 2022]

Novavax down 26% [Jul 14, 22] after FDA approval of new Covid vaccine

Novavax is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck. "We will be filing within the next few days in the U.S.," Erck said. [company press release, Dec 20, 21]

Novavax up 29% [Dec 7, 21]

Novavax dwon 20% [Aug 6, 21] after it delays emergency use submission to FDA of COVID-19 vaccine [MarketWatch, Aug 6, 21]

Novavax up 19% [Aug 4, 21]

Because of development delays, Novavax should expect little uptake for its COVID-19 vaccine in the United States. But there's still a ready market globally, which the shot is well equipped to serve, GlobalData analysts report. [Kevin Dunleavy, Fierce Life Sciences, Jun 24, 21]

Novavax has linked its COVID-19 vaccine to 100% efficacy against severe disease in countries where variants of concern are prevalent. The final phase 3 data suggest NVX-CoV2373 may protect against the worst outcomes caused by the coronavirus variants, even though the mutations limit its efficacy. [Nick Paul Taylor, Fierce Biotech, Mar 12, 21]

Novavax has fully enrolled its late-stage clinical trial of its experimental Covid-19 vaccine with 30K participants at 118 sites across the U.S. and Mexico. The study population focuses on people across diverse populations in age, race and ethnicity, and co-morbidities most vulnerable to the virus. And it advances the candidate aiming to report data at the end of Q1 or in early Q2 — which, if positive, would pave the way for it to reach patients. The Gaithersburg vaccine maker also has a new MOU with Gavi, the Vaccine Alliance, to ultimately provide 1.1B doses of its vaccine to at-risk groups as part of an international initiative. [Sara Gilgore, DCInno, Feb 25, 21]

Novavax up 65% [Jan 29, 21] posted data on its own Covid-19 vaccine trial night that was stronger than the Johnson & Johnson data [Barron's, Jan 29, 21]

Novavax has locked in a deal with Australia to sell 51M doses of its experimental Covid-19 vaccine. It’s just the latest in a string of such deals as the candidate undergoes late-stage clinical trials, with data expected potentially this quarter. [Sara Gilgore, DCInno, Jan 13, 21]

Novavax has officially started advanced clinical trials of its Covid-19 vaccine candidate in the U.S. and Mexico, after they were delayed from mid-October. These trials kick off alongside late-stage trials in the U.K. and other studies in South Africa and Australia. [DCInno, Dec 29, 20]

Novavax up 22% [Nov 27, 20]

Novavax (Gaithersburg, MD; one 2009 SBIR) has received a crucial status for its Covid-19 vaccine candidate as the pandemic drags on and coronavirus cases once again soar across the country. The Gaithersburg company has earned fast-track designation from the FDA for NVX-CoV2373, a coronavirus vaccine candidate in late-stage development. It means the biotech can submit parts of its application on a rolling basis for a speedier review by the agency, and gives Novavax more direct and frequent access to the FDA. [DCInno, Nov 10, 20]

Novavax expects to start its pivotal trial for its Covid-19 vaccine candidate in the U.S. and Mexico by the end of November, rather than mid-October as originally planned, after both “significant progress in large-scale manufacturing” and “delays experienced versus original timing estimates,” the Gaithersburg biotech said [DCInno, Oct 29, 20]

If one is good, two is better. Novavax, developing next-generation vaccines for serious infectious diseases, announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell (Rip) Wilson, [to inter alia] the exploration of a combined influenza/COVID-19 vaccine that could be used in a post-pandemic setting. Novavax announced results of its successful NanoFlu pivotal Phase 3 clinical trial earlier this year and intends to seek regulatory approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway previously granted to the company. [company press release, Oct 12, 20]

Science to rule.  Novavax has joined with [eight] several other biopharmaceutical executives in a global pledge to prioritize safety over speed in the race to find a viable Covid-19 vaccine. [DCInno, Sep 8, 20] Don't bet against Trump's October surprise claiming his immunity success.

Novavax announced it has signed a [Term Sheet] with the [UK] Government for the purchase of 60 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine, and a Phase 3 clinical trial to assess the efficacy of the vaccine in the UK population. Novavax will also expand its collaboration with FUJIFILM Diosynth Biotechnologies, which will manufacture the antigen component of NVX-CoV2373 from its Billingham, Stockton-on-Tees site in the UK, in addition to its sites in North Carolina and Texas in the United States. The FUJIFILM Diosynth Biotechnologies site in the UK is expected to produce up to 180 million doses annually, which further boosts the global supply of NVX-CoV2373 for additional markets. [company press release, Aug 14, 20]

Novavax announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial, which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. [company press release, Aug 17, 20]

Novavax and SK bioscience, a vaccine business subsidiary of SK Group, announced a development and supply agreement for the antigen component of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, for supply to global markets including the COVAX Facility. In addition, the companies have signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to work toward broad and equitable access to NVX-CoV2373 for the global market as well as to make the vaccine available in South Korea. [company press release, Aug 13, 20]

Novavax down 17% [Aug 12, 20]

Novavax and FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced an agreement to manufacture bulk drug substance for NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. FDB’s site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373. This arrangement falls under Novavax’ recent $1.6 billion award by the federal government as part of Operation Warp Speed. [joint companies press release, Jul 24, 20]

Novavax up 17% [Jul 17, 20]

Novavax up 32% [Jul 7, 20]

The same week Annexon Biosciences (South San Francisco, CA; no SBIR) announced it had raised $100 million in private financing to advance its research of antibody drugs to treat neurodegeneration, the company filed paperwork with regulators indicating its intention to [IPO]. [Sarah de Crescenzo,, Jul 6, 20]

Novavax (Gaithersburg,MD; $250K SBIR in 2009) announced that it has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 in 2021. ... awarded $1.6 billion by the federal government to complete late-stage clinical development, including a pivotal Phase 3 clinical trial; establish large-scale manufacturing; and deliver 100 million doses of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate, as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using its proprietary nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant. [company press release, Jul 6, 20] total funding $777M []

Novavax announced that the company has been awarded a contract by the [DoD] for the manufacturing of NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate. NVX‑CoV2373 consists of a stable, prefusion protein antigen made using its proprietary the Defense Health Program, has agreed to fund up to $60 million to support Novavax in its production of several components of the vaccine that will be manufactured in the U.S. The agreement includes a 2020 delivery of 10 million doses of NVX‑CoV2373 for DoD that could be used in Phase 2/3 clinical trials or under an Emergency Use Authorization (EUA) if approved by the U.S. FDA. [company press release, Jun 3, 20] and the company inked a deal with Bothell, Washington-based AGC Biologics to manufacture an element of its Covid-19 vaccine candidate. And it tapped PolyPetide Group to also assist with production. [DCInno, Jun 4, 20]

Novavax up 15% [Jun 1, 20]

Novavax developing next-generation vaccines for serious infectious diseases, announced the acquisition of Praha Vaccines 9(Czech Republic) [for $167M] cash .... includes a biologics manufacturing facility and associated assets in Czech Republic. The facility is expected to provide an annual capacity of over 1 billion doses of antigen starting in 2021 for NVX‑CoV2373, Novavax’ COVID-19 vaccine candidate [compamy press release, May 27, 20]

Novavax filed a prospectus to sell up to $250 million of shares of common stock as it prepares to scale up production of its coronavirus vaccine candidate. [, May 20, 20]

Novavax up 30% [May 18, 20]

Novavax up 53% [May 12, 20] announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax' coronavirus vacccine against CoVid-19. [company press release, May 11, 20]

Novavax up 31% [May 11, 20] announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax' coronavirus vaccine candidate. [company press release, May 11, 20]

Novavax up 25% [Apr 20, 20]

Novavax is taking its coronavirus vaccine program to the next stage faster than expected, despite the remaining challenge of securing more funding and support for the program, forthcoming DC Inno Editor Sara Gilgore reports. The Gaithersburg biotech company has identified the candidate it will take to its first phase of clinical trials, now with an expectation of starting its first human study a few months sooner than planned, in mid-May, the company said today. The company is positioned to have preliminary data from this study, which will just test the candidate’s safety levels in humans, in July. [DCInno, Apr 8, 20]

Novavax said its NanoFlu treatment for seasonal flu achieved all primary endpoints in a phase 3 trial for adults 65 an older. NanoFlu was well tolerated and had a safety profile comparable to Fluzone Quadrivalent. [MarketWatch, Mar 24, 20]

Novavax up 37% [Mar 17, 20]

The [Norweigan] Coalition for Epidemic Preparedness (CEPI) is providing Novavax with an initial $4 million grant "to accelerate vaccine development to prepare for Phase 1" clinical trials of Novavax's COVID-19 vaccine, which are expected to start up in late spring of this year.  ... Separately, Novavax says it has "entered into an agreement with" Emergent BioSolutions to first manufacture and supply Novavax with vaccine product for use in said trials and, should these trials prove successful, to later "leverage Emergent’s rapid deployment capabilities and expertise that provide Novavax scalability and capacity to produce vaccine product for future stockpiling.  [, Mar 11, 20]

Novavax down 25 [Mar 2, 20]

Novavax up 35% [Feb 28, 20]

Novavax up 28% [Feb 27, 20]

Novavax up 16% [Feb 26, 20]

Novovax down 16% [Jan 28, 20]

Novavax down 16% [Jan 27, 20]

Novavax up 100% [Jan 21, 20]

Novavax (Gaithersburg, MD; $200K SBIR)  up 20% [Jan 17, 20] a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that [FDA] has granted Fast Track Designation for NanoFlu™, its recombinant quadrivalent seasonal influenza vaccine candidate, adjuvanted with Matrix-M™, in adults 65 years of age and older. [company press release, Jan 15, 20]

Novavaxs up 23% [Nov 29, 19]

Novavax up 20% [Sep 16, 19]

Novavax up 18% [Aug 16, 19]

Novovax up 40% [Aug 14, 19] on a market bloodbath day

Novavax, which develops vaccines for infectious diseases, announced yesterday that it's selling its manufacturing business to Catalent Biologics’ Baltimore-based Paragon Gene Therapy unit. The $18M deal will transfer leases of two product development and manufacturing facilities, sell off the equipment and transfer more than 100 Gaithersburg employees. For Novavax, the move frees up cash to advance its NanoFlu and ResVax products through clinical development and regulatory review, according to the company.  [DCInno, Jun 28, 19]

Novavax up 24% [May 14, 19]

Novavax’s RSV shot missed another phase 3 trial, causing the company’s stock price to lose about two-thirds of its remaining value premarket [Conor Hale, Fierce Biotech, Feb 28, 19]

Novavax  announced it plans to raise funds through a new public stock offering, though the news wasn't received as well on Wall Street. ... didn't reveal details of the offering  [Washington Business Journal, Apr 12, 18]

Novavax shares jump on positive news of flu vaccine trial. It was purely coincidental that federal experts released plans to develop a universal flu vaccine the same day Novavax released positive early data on its flu vaccine from its latest clinical trial. But it certainly was timely. Novavax's positive test results could be seen as a step toward that very goal of a universal flu vaccine. (Washington Business Journal, Mar 2, 18)

Common Cold Vaccine (again).  [Martin Moore, a paediatrician at Emory University]’s start-up, Meissa Vaccines  (San Mateo, CA; $225K SBIR), received [NIH SBIR] grant for work on rhinovirus. He is taking leave from academia to work on the vaccines.  ...  Moore [previously] secured funding from NIH and applied for samples of the different serotypes from the Centers for Disease Control and the American Type Culture Collection, a biological material repository.  ....  Successes have been rare, and there have been spectacular flops. Last year, shares in Novavax (Rockville, MD; $225K SBIR) fell by 83% after its vaccine for RSV, one of the virus families responsible for colds, failed in a late-stage clinical trial.   [Nicola Davison, The Guardian (UK), Oct 6, 17]

Novavax announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older).  [company press release, Jan 19, 17]

Novavax (Gaithersburg, MD; $250K SBIR) is retooling its drug pipeline after a failed clinical trial on one of vaccines, and now is reporting progress on the company's Zika program. Pre-clinical data shows that Novavax's technology can stimulate "uniquely neutralizing antibodies" above necessary levels for protection. The commercial opportunity is potentially quite large, according to the company.  [Washington Business Journal, Nov 14, 16]

Novavax down 85% [Sep 16, 16] announced  that its lead product candidate, a vaccine for a respiratory virus known as RSV-F, didn’t meet its primary endpoint. [Wall Street Journal, Sep 16, 16]

Novavax down 10% [Aug 10, 16]

BioCryst Pharma up 18% [Aug 9, 16]

Novavax  up 11% [Jun 28, 16]

vaccine maker Novavax to create 850 new jobs ....  will use $5 million in loans from the Maryland Department of Commerce to expand its development, research and clinical trials team to deal with the new vaccines expected from the company. Montgomery County also approved up to $2.5 million of grant money, and the city of Gaithersburg will chip in $50,000.  [WTOP-TV, Jun 8, 16]

Novavax up 10% [Mar 14,16]

Novavax down 16% [Jan 25, 16]

Novavax up 10% [Nov 30, 15]

Novavax up 14% [Nov 2, 15]

Novavax up 10% [Sep 30, 15] will receive a grant worth up to $89 million for its RSV work from the Bill and Melinda Gates Foundation. ...  as Novavax reveals positive top-line data from its Phase II clinical trial of its RSV vaccine candidate. ....  will support the company's Phase III clinical trials  ...  In 2014, the company raised $115 million by selling shares of its common stock   [Tina Reed, Washington Business Journal, Sep 29, 15]

Novavax  down 21% [Sep 29,15]

Novavax down 12% [Aug 24, 15]

A vaccine developed by Novavax [up 24% [Aug 11, 15]] was shown to prevent a common respiratory viral infection in a mid-stage study, taking it one step closer to becoming the first vaccine for the virus that affects almost all American children. [Natalie Grover, Reuters, Aug 10, 15]

Novavax (Rockville, MD; $250K SBIR) said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults. ...  Novavax has the means to make millions of doses per week, and is in "fairly advanced" talks over possible tie-ups with governmental and non-governmental entities to develop the vaccine further, executives told Reuters on Tuesday.   [Natalie Grover, Reuters, Jul 21, 15]

Novavax up 11% [Jul 9, 15]

Novavax up 12% [Jun 23, 15]

Novavax (Gaithersburg, MD) known for its work developing vaccine candidates for the flu, a pediatric respiratory illness and Ebola — has expanded into a new 54,000-square-foot research and development space where it plans to house its vaccine work. ... specializes in a process that it says creates new vaccine candidates more quickly than what's on the market now, has more than doubled in size in two years to 349 employees   [Tina Reed, Washington Business Journal, Jun 5, 15]

Novavax down 14% [Mar 25,15]

Novavax initiated its Phase 1 clinical trial of its Ebola vaccine, supported by significant non-human primate data, it was announced ...  plans to conduct the clinical trial of its Ebola GP Vaccine candidate in a randomized clinical trial of healthy adults in Australia.   [Tina Reed, Washington Business Journal, Feb 12, 15]

Novavax  up 10% [Jan 16,15]

Novavax up 13% [Oct 27, 14]

Novavax said it has raised $115 million in gross proceeds ... to pour into its pipeline.  .... advancing Novavax's Respiratory Syncytial Virus (RSV) nanoparticle vaccine into a Phase 2 trial in elderly subjects this year.  [Bill Flook, Washington Business Journal, Jun 11, 14]  

Novavax up 10% [May 19, 14]

Novavax (Gaithersburg, MD; one SBIR) believes it has created a vaccine against the Middle East Respiratory Virus, or MERS, which has been causing pandemic concerns. ....  published in the most recent issue of the journal Vaccine.  .....Last June, Novavax announced plans to acquire Swedish vaccine adjuvant maker Isconova AB in a stock deal valued at about $29.6 million.   [Tina Reed, Washington Business Journal, May 6, 14]

Novavax up 14% [Apr 29, 14]

Novavax (Rockville, MD; $250k SBIR] up 10% [Mar 16, 14]

Novavax (one SBIR) up 19% [Dec 16, 13]

Novazyme Pharmaceuticals (Oklahoma City, OK)

John Crowley co-founded Novazyme Pharmaceuticals  (Oklahoma City, OK; no SBIR) , a small biotech company in 2000 The Pompe disease eventually leaves patients confined to a wheelchair and threatens their ability to breathe. In 2001, Novazyme, which had grown to 80 employees, was acquired by Genzyme that had already struck major success in getting a rare-disease drug into the hands of patients. ... Genzyme rose to success under the guidance of its longtime (now former) chief executive, Henri Termeer, born in the Netherlands.  ... Though Genzyme bought Novazyme, it was not ultimately that company's version of the drug that was approved. Researchers compared several experimental therapies head-to-head in the search for the best drug. The most effective was one that Genzyme had developed itself  [Carolyn Y Johnson, Washington Post, Mar 3, 17]

Novecon Technologies (Reston,VA)

Sterling Semi Bought (Apr 19) Uniroyal Technology will pay 1.5M shares (trading around $20) plus assume $4M of debt for Sterling Semiconductor (Sterling, VA). Uniroyal describes Sterling as a leading developer of silicon carbide technology and materials. It produces and sells single-crystal silicon carbide (SiC) substrates and epitaxial thin films on SiC substrates. It is a child of Novecon Technologies which searched eastern Europe after the Cold War for technology to buy. It imported some Russian scientists with new ideas for silicon carbide and got two BMDO Fast Track SBIRs for $1M each in 1997. Uniroyal would use Sterling's technology for its high brightness LEDs. The market seemed to welcome Sterling by bidding up Uniroyal's stock 30% yesterday. If BMDO had taken an equity position proportional to all that money it invested, it would get Uniroyal stock worth something like $10M, a five-fold return in three years. Now, that's what SBIR ought to be doing! BMDO and by extension the rest of the government gets a leading edge SiC technology and a long-term commercial supplier, all for $2M. A smart investment at infancy, a co-investor for at least part of Phase 2, a readiness to invest more as the co-investment rises but tech risk remains, and in 3-4 years letting the company and its technology sink or swim. Compare that investment approach with the rest of DOD's approach in a company like CFD Research which has had over $20M of DOD SBIR over a decade for mostly combustion flow calculations. Nice solid research and a lot of knowledge gained (if you believe that simulations advance knowledge by much). Want to bet whether CFD has a market-pull high-volume product at the leading edge of the next decade in any market!
What's a good SBIR? High-risk (big chance that it won't work) with high market potential AND a market-driven company. A model: Sterling Semiconductor (Reston, VA), a start-up subsidiary of Novecon Technologies raised capital to manufacture Russian technology SiC. Its ideas were pristine SiC wafers, and improving SiC other ways. SiC without defects and micropipes of current SiC (such as from SiC trailblazer Cree Research helped at infancy by SBIR) will revolutionize power electronics and underlay GaN for blue lasers. Cree sells about $20M per year with a defective material (although currently the best game played) that works for low power LEDs. No one really knows how many multiples of $20M a perfect material would fetch. (Nor does the industry seem to know whether it will emerge from the laboratory says K Derbyshire, Wired, May97, despite BU's Moustakas's optimistic The potential is much more than we can envision.) The SBIR funds not the infant production line, that's for private ROI capital, but high-risk advances such as perfect SiC from the Russian-now-Virginian scientists. Business sense? The chairman is a semi-retired experienced business executive with the contacts that start-ups need in the big bad world. Where did Sterling take its story? To the most open SBIR program for marketable technology - 3 BMDO proposals. . BMDO's Answer: we love the idea and the company concept, but we don't need three big Phase 1s to find out if you're worth Phase 2(s). Two small awards will tell us enough while giving you time to assemble a convincing story of becoming a market competitor. Our likely Phase 2 approach? Here's some money for the really hard technical question(s), and if that works out, we'll match your private capital at a growing rate. No, we don't have a money limit but each new piece will be harder to get than the last. Or since you're so tiny and already know privateers, why not Fast Track? We'll almost surely do the 4:1 match, and from there an escalating rate starting at, say, 1:1. We're flexible as long as it's working, but we abandon sick projects. No mercy. And, oh watch out, we'll also fund most of your serious competitors because we don't pick technology winners, we back aggressive competitors.

Novella Clinical

Scioderm  [Durham, NC; no SBIR), a tiny startup drug developer headquartered in Durham, became the first biotech to secure "Breakthrough Therapy" designation by the U.S. Food and Drug Administration. ....  with a recent $16 million dollar fundraise .....  has teamed up with Novella Clinical  (no SBIR) which was recently acquired by Durham-based contract research giant Quintiles  to manage a Phase 2B trial for its lead candidate. [Lauren Ohnesorge, Triangle Business Journal, Oct 15, 13]

Novel Microdevices (Baltimore, MD)

Novel Microdevices (Baltimore, MD; $1.3M SBIR) a developer of an innovative molecular diagnostics platform, announced today that CARB-X has awarded it up to $13.8 million in non-dilutive funding to develop its next-generation rapid molecular test for the diagnosis of sexually transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae. [company press release, Apr 6, 21]

Novelos Pharmaceuticals

Novelos Pharmaceuticals  could have a blockbuster drug on its hands. The company will soon release data from a Phase 3 clinical trial for its drug target to treat non-small-cell lung cancer. [Mass High Tech, Jan 15, 10]

Novelos Therapeutics (Newton, MA) now Cellectar Biosciences (Madison, WI)

Novelos Therapuetics (Madison, WI; no SBIR) publicly-traded developer of drugs for the treatment and diagnosis of cancer, said  it has changed its name to Cellectar Biosciences  [Milwaukee Journal Sentinel, Feb 11, 14]

Novelos Therapeutics (Madison, WI; one SBIR in Mass) developing drugs to diagnose and treat cancer, said Friday it is pricing a public offering of 5,420,800 units at $1 each.  The units are a blend of securities. ... working to commercialize the research of University of Wisconsin-Madison radiology professor Jamey Weichert, who is also the firm's chief scientific officer. ....  based on work Weichert began at the University of Michigan in 1994 and continued after moving to Wisconsin and, in 2002, starting a company in Madison called Cellectar. But Novelos Therapeutics dates to the late 1990s in suburban Boston, where the company initially sought to commercialize drug technology developed in Russia. In February 2010, Novelos suffered a significant setback when its then-lead product, designed to help fight lung cancer, failed a pivotal clinical trial. With the announcement, the company's stock fell about 80% in one day. Wisconsin entered the picture in April 2011, when Novelos merged with Cellectar and switched its focus to Weichert's technology  .... has no product revenue  [ Milwaukee Journal Sentinel, Jun 8, 12]

Cellectar (Madison WI; no SBIR) working on cancer-fighting drugs, has merged with a publicly traded firm, Novelos Therapeutics (Newton MA; one SBIR) The transaction essentially grafts Cellectar's research onto the upper management of Novelos. With the merger, Novelos will shift its official headquarters to Madison. ... In February 2010 - well before the transaction with Cellectar - Novelos announced that a cancer-treating drug it was working on had failed clinical trials. [Rick Romell, Milwaukee Journal Sentinel, Apr 11, 11]

Novelos Therapeutics reports it has raised $1.5 million through a private placement of stock and warrants to fund the company through the second quarter of 2011, and move its breast cancer and hepatitis drug candidates forward.  [Rodney Brown, Mass High Tech, Jul 22, 10]

Novelos Therapeutics is offering 60 million shares of common stock, according to a filing .. $11.4 million .. [says it] has enough cash on hand to continue operating until the first quarter of 2011 but would require additional funds beyond that point.  [Mass High Tech, May 13, 10].

Novelos Therapeutics said it is discontinuing a development program for a potential treatment of advanced non-small cell lung cancer after disappointing test results. [Boston Globe, Mar 18, 10]

Novelos Therapeutics (Newton, MA; one SBIR) said in a press release today that "the primary endpoint of improvement in overall survival was not met" in a Phase 3 trial of its lead drug when it was used in combination with first-line chemotherapy. [Boston Globe, Feb 25]

Novelos Therapeutics with a late-stage drug target for lung cancer, has closed a $9 million private placement of shares [Mass High Tech, Nov 13]

NIH awarded Novelos Therapeutics (Newton, MA; one SBIR) and Massachusetts General Hospital a $950,371 grant to study the company’s treatment for radiation-induced lung injuries. The grant, intended for 17 months of study, will cover animal model studies on Novelos’ two compounds, NOV-002 and Nov-205. According to Novelos officials, the study will give a glimpse of pulmonary injuries stemming from potential dirty bombs, nuclear events, terrorist incidents or radiation accidents. [Mass High Tech, Sep 29, 09]

Novelos Therapeutics (Newton, MA; one SBIR) raised $9M in a private placement [Mass High Tech, Aug 26, 09]

Noveome Biotherapeutic (Pittsburgh, PA)

Noveome Biotherapeutics (Pittsburgh, PA; no SBIR) has been awarded [$500K] grant from the Commonwealth of Pennsylvania to begin clinical trials for eye and brain diseases. ... has received $109M in research funding from [USDOD]. [company press release, Apr 5, 18]

Noveome Biotherapeutic  (Pittsburgh, PA; no SBIR) a clinical-stage company and leader in the field of paracrine signaling, announced the initiation of a Phase 2 clinical trial of ST266, the company’s novel secretome, to treat patients with allergic conjunctivitis, an ocular inflammation condition caused by exposure to an allergen.  [company press release, Dec 5, 16]

Novian Health (Chicago, IL)

iNetworks  said it has invested $1 million in Novian Health (Chicago, IL; no SBIR) developer of laser technology to treat breast tumors. ....part of a $4 million bridge financing round by Novian that will be used for clinical trials currently underway, seeking European certification and acquiring hardware and software.  [Patty Tascarella, Pittsburgh Business Times, Jan 16, 15]

Novira Therapeutics (Radnor, PA)

Johnson & Johnson entered into a definitive agreement to acquire Novira Therapeutics (Doylestown, PA; no SBIR, founded 2009) biopharmaceutical company working on a potential cure for patients with chronic hepatitis B virus infection. ... Its lead new drug candidate, NVR 3-778 is a small-molecule antiviral medicine, taken orally, that is designed to inhibit the HBV core or capsid protein involved in multiple activities required for the virus to replicate and persist. ...  Financial terms not disclosed  [John George, Philadelphia Business Journal, Nov 4, 15]

The Pennsylvania Biotechnology Center of Bucks County is getting some federal government money to expand yet again.  ... serves as an incubator for early-stage life sciences companies. The grant will support the addition of 15 laboratories at the site, which is expected to result in the creation of 90 new jobs.  ...  Nearly 300 people currently work at biotech center.  ...   Five for-profit life sciences companies — Flow Metric,  Novira Therapeutics, Fox Chase Chemical Diversity Center  ($600K SBIR), Synergy Pharmaceuticals ($900K SBIR) , and Cross Currenthave committed to leasing the new space being created at the center.   [John George, Philadelphia Business Journal, Oct 10, 14] 

Novira Therapeutics (Radnor, PA ; no SBIR)raised $2.5 million in a second round of seed financing. ... developing treatments for viral diseases including hepatitis B and HIV.  [John George, Philadelphia Business Journal, Jul 26, 11]

Novocell (San Diego,CA)

ViaCyte (formerly Novocell; San Diego, CA), which is developing the implant as a treatment for type 1 diabetes, is now beginning the safety testing required for approval from the U.S. Food and Drug Administration before human testing can start.  [Emily Singer, MIT Tech review, Jun 28, 10]

Novocell   (San Diego, CA; no SBIR) a preclinical stem cell engineering company focused on diabetes, has changed its name to ViaCyte, ... the company says it also recently obtained three additional U.S. patents. The new patents cover methods for increasing definitive endoderm production, methods of producing pancreatic hormones, and a method of producing definitive endoderm that the company says has been widely adopted in the field. [Bruce Bigelow, signonsandiego,com, May 14, 10]

Novocell (San Diego, CA; no SBIR) raised $304K  ..... attracted a $20 million award from the California Institute for Regenerative Medicine in 2009 to fund its developing of cell therapy for type 2 diabetes. [Erin Kutz,]

Big pharma move stem cell research is starting to inject cash into little biotechnology companies, including San Diego's Novocell (no SBIR) at a crucial time.  Novocell is expected to announce this morning that it has signed a two-year collaboration with Pfizer giving the drug-making giant access to the tiny biotech's expertise at turning human embryonic stem cells into insulin-producing pancreas cells. [Terri Somers, San Diego Union Tribune, Dec 19, 08]

Two San Diego-area biotechnology companies yesterday were among six commercial operations to receive grants from the state's taxpayer-funded stem cell institute.  The funding included 23 grants ranging from $700,000 to $1.1 million. ...  Life Technologies, formerly known as Invitrogen, which makes tools for drug discovery, and Novocell(San Diego, CA; no SBIR) $827,000, which is using human embryonic stem cells to develop a therapy for diabetes. [Terri Somers, San Diego Union Tribune, Dec 11]

Human embryonic stem cells may provide the source of insulin-producing islet cells that diabetics need, new research suggests. Novocell (San Diego, CA; no SBIR), a privately held company with 37 employees, coaxed human embryonic stem cells to evolve into cells that produce insulin to control blood sugar when injected into mice with diabetes, according to an article published online yesterday by the journal Nature Biotechnology. [Terri Somers, San Diego Union-Tribune, Feb 21, 08]

Novogy (Cambridge, MA)

Novogy (Cambridge, MA; no SBIR)cleantech startup, has raised $4 million of a planned $7.5 million fundraise, federal documents show.  ...  developing cellulosic biofuels, but in Novogy's case, specifically made from waste paper sludge.  [Rodney Brown, Mass High Tech, Jan 6, 12]

Stealthy cleantech startup Novogy (Cambridge, MA; SBIR) has raised $750,000 more from venture backers .... made comments suggesting the company is working on cellulosic biofuels, made from waste paper sludge, to be used in transportation. [Mass High Tech, Mar 1, 11]

Novome Biotechnologies (South San Francisco, CA)

Novome Biotechnologies  (South San Francisco, CA; $1M SBIR, founded 2016) engineering first-in-class, living medicines for chronic diseases, today announced that it has secured $33 million in a Series A financing [to] advance the Company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its Genetically Engineered Microbial Medicines (GEMMs) platform to address additional indications. [company press release, Jan 7, 20] total funding $38M]

Novomer (Boston, MA)

Novomer (Waltham, MA; $1.1M SBIR), which aims to pioneer a new breed of environmentally responsible polymers and chemical intermediates, said it has raised new funding led by Saudi Aramco Energy Ventures. The amount wasn't disclosed in a news release, but an SEC filing shows a new $15 million fundraise.  ....  company last disclosed raising $10 million in October 2011.  [Kyle Alspach, Boston Business Journal, Dec 11, 13]

Plastics developer Novomer (Waltham, MA and Ithaca, NY; $1.1M SBIR) raised $10 million in an equity round as it works to commercialize technology that would use feedstocks to produce plastic-like materials, according to [SEC] filing  [James Connolly, Mass High Tech, Oct 28, 11]

Novomer ($1.1M SBIR) received $18.4 million from the U.S. Department of Energy for a project that seeks to convert waste carbon dioxide into plastics for use in bottles, laminates and other applications, the company announced.  [Mass High Tech, Jul 23, 10]

The US DEnergy has awarded $2.1 million in stimulus funds to Novomer (Waltham, MA and Ithaca, NY; $1M SBIR) that makes plastics and coating materials out of carbon dioxide, ... The project already has received financial support from the New York State Energy Research and Development Authority. [Boston Globe, Mar 29, 10]

Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon.  Among the fifty most innovative:  A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences. [MIT Tech Review, M/A10]

Novomer (Waltham, MA and Ithaca, NY; $800K SBIR) is getting $400,000 from the New York State Energy Research and Development Authority, and help from Kodak Specialty Chemicals to commercialize a process that uses carbon dioxide to make plastics and coating materials like those used in soda bottles and film. [Erin Ailworth, Boston Globe, Dec 14, 09]

Novomer (Boston, MA; $1M SBIR in New York) specializing in plastics, polymers, and other chemicals made from renewable feedstocks such as carbon dioxide, said that it has raised $14 million in a Series B funding round. [Chris Reidy, Boston Globe, Aug 17, 09]

Affordable, biodegradable plastics made from carbon dioxide are moving closer to market. Novomer, (Ithaca, NY; $200K SBIR by 2005), which is developing the plastics, has received $6.6M in venture-capital [MIT Tech Review, Nov 14]

Novophage (Boston, MA)

A small Boston University and MIT spin-out company, Novophage, wrapped up its first round of funding late last month, raising $5.75 million [Boston Globe, Jun 7, 11]

Novophage (Boston,MA; no SBIR), a startup that was known until March as Novophage Therapeutics Inc., has taken in $5.75 million in its first institutional funding round, the company confirmed ...  working on antimicrobial treatment for bacterial infections, intended for the oil and gas, pulp and paper, and HVAC system industries.  [Rodney Brown, Boston Business Journal, Jun 1, 11]

Novo Sol-u-tions MD (Scottsdale, AZ)

Novo Sol-u-tions MD (Scottsdale, AZ; no SBIR) is launching NovoScarMD, which is designed to reverse scar damage and stretch marks. The key ingredient is NovoSerum, which contains purified human umbilical cord serum.  [Angela Gonzales, Phoenix Business Journal, Aug 5, 13]

NovoSource (Dayton,OH)

NovoSource (Dayton, OH; no SBIR, )   received [FDA] clearance for a new knee replacement system. ... intended to be a more cost-effective alternative ...founded in 2012 with $1.12 million in support from the Dayton Development Coalition  [Tristan Navara, Dayton Business Journal, Apr 30, 13]

NovoSource (Dayton, OH; no SBIR) startup  is on a mission to cut down health care costs one hip or knee implant at a time, ... housed in the Entrepreneurs Center, is trying to raise $4 million through a securities offering  .... working on developing and selling a knee implant and a hip implant, both of which should soon get [FDA] approval. [Olivia Barrow, Dayton Business Journal, Nov 16, 12]

Novozymes (Franklinton, NC)

New secret Italian sauce. An Italian technology company has secured $99 million in federal loan guarantees, providing a government safety net that removes a major obstacle toward building an ethanol refinery in rural Sampson County in the eastern part of the [NC] state.  .... The planned Chemtex International ethanol plant, which would employ 65 people, is part of a multi-year national race to make transportation fuel economically from plants other than corn. Grasses and stems – which have near-impenetrable defenses against insects and fungi – are much harder to break down and convert into liquid fuels than corn.  ....Chemtex and the USDA say they have the secret sauce...Novozymes  (Franklinton, NC; no SBIR) , employing more than 500, is providing the enzyme cocktail to extract the carbohydrates that can be fermented into a fuel.  [John Murawski, Raleigh News & Observer, Aug 22, 12]

Novus Biologicals (Littleton,CO)

Novus Thera (Irvine, CA; no SBIR) announced results from two OP0201 single-dose phase 1 clinical trials. The primary objective of establishing safety and tolerability was achieved in both healthy adults (study C-001) and in adults with acute otitis media (study C-004). [company press release, Apr 22, 19]

Techne will pay $60 million for Novus Biologicals (Littleton,CO; one SBIR),a Colorado-based maker of antibodies and other medical-research products. It's the company's third acquisition in four months   [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jul 3, 14]

Noxilizer (Bethesda, MD)

Noxilizer (Baltimore, MD; no SBIR, 35 employees) is expanding its footprint at the University of Maryland BioPark to meet growing demand from clients.  ... developed a medical sterilization system that uses nitrogen dioxide, a faster alternative to traditional methods.  ...  a surface sterilization process that can be used for medical devices and tools, such as pre-filled syringes. The technique is becoming popular in part because it can be done at room temperature  [Sarah Gantz,  Baltimore Business Journal, Nov  20, 14]

Clarian Health Ventures said it has invested $5 million in Series C2 financing for Noxilizer (Bethesda, MD; no SBIR) that specializes in low-temperature sterilization techniques for use in hospitals and in biotherapeutics manufacturing.  [Indianapolis Star, Jul 8, 09] employs oxides of nitrogen to produce a sterilizing environment. .... selected as one of 48 Top Innovators at the 2008 New England Venture Summit. ... in 2008 joined the Incubator program at the University of Maryland, Baltimore County Technology Center  [company website]

Nox Technologies (Malvern, PA)

NuSkin announced it has signed an agreement to acquireNox Technologies  (Malvern, PA; no SBIR), a biotechnology and biodiagnostic company focused on the identification, characterization and detection of cell surface proteins relating to aging, for $12.5 million. [, Nov 14, 12]

NP Photonics (Tucson, AZ)

Perhaps the most surprising news to emerge from NFOEC came at the end when we met with a company called NP Photonics, a stealth spinout from the University of Arizona. They have achieved the first major advance in EDFA (erbium-doped fiber amplifier) technology since its inception 30 years ago. Nasser Peyghambarian having overthrown the formidable EDFA paradigm which demands ever-longer doped strands and ever-more powerful pump lasers in return for more amplification, NP Photonics will soon enable tiny EDFAs of far superior functionality and radically lower cost than possible today. Facilitating reductions in the cost of WDM undreamt in Nortel’s worst nightmares, their impact will reverberate through the net-work and among many of our favorite companies such as Corning and JDSU. [Gilder Tech Report]

NPS Pharma (Salt Lake City, UT)

Shire Plc (Ireland)has agreed to buy NPS Pharmaceuticals (Bedminster, NJ;  $250K SBIR in Utah in 1990s)for $5.2 billion [cash] in its biggest acquisition yet, as the Dublin-based drugmaker strengthens its position in the lucrative field of medicines for rare diseases.    NPS Pharma founded by Drs. Hunter Jackson and Thomas Parks in 1986, two dedicated research scientists from the University of Utah School of Medicine studying the medicinal effects of spider venom. ...  in 2006 osteoporosis treatment approved in Europe (and marketed by Nycomed) is not approved in the U.S., leading to significant company restructuring [leading to] 2007 re-invents itself as a rare disease company with a new strategic outsourcing business model. ...  2012 First NPS Pharma product approved in the U.S. and Europe to treat the rare disease Short Bowel Syndrome.   [NPS website]

NPS Pharma up 18% [Dec 17, 14]

NPS Pharma down 17% [Sep 15, 14]

NPS Pharmaceuticals up 25% [Sep 10, 14]

NPS Pharmaceuticals down 10% [Sep 9, 14]

NPS Pharma (Salt Lake City, UT; $200K SBIR)up 13% [May 30, 14]

NPS Pharma up 14% [May 9, 14]

NPS Pharma(Salt Lake City, UT; $250K SBIR) down 11% [May 8, 14]

NPS Pharma dowm 11% [Oct 11, 13]

NPS Pharma (Salt Lake City, UT; $200K SBIR) down 11% [Oct 8, 13]

NPS Pharmaceuticals (Bedminster, NJ; $250K SBIR in Salt Lake City, UT, founded 1968, 150 employees, IPO 1994) up 25% [Aug 9, 13]

NPS Pharma(Salt Lake City, UT; 3 SBIRs) up 19% [Oct 12, 12]

NRGindependence (Corvallis, OR)

NRGindependence (Corvallis, OR;  SBIR)  cleantech firm will team with researchers at Oregon State University on technology that could extend the life of certain battery cores to 20 years.    ...  secured $150,000 in commercialization funding from Oregon BEST to collaborate with Alex Yokochi, an OSU assistant professor of chemical engineering, to advance the technology of rechargeable "reduction-oxidation" or redox batteries.   [Wendy Culverwell, Portland Business Journal, Dec 15, 14]

NSS Labs (Austin, TX)

NSS Labs (Austin, TX; no SBIR, founded 1991, 50 employees)  announced that it has completed a $4 million Series A round of funding. ....  to fund an expansion and continued technology innovation as well as help the company further scale operations and support its customer base.  [Christopher Calnan, Austin Business Journal, Dec 5, 13]

Nucelis (San Diego, CA)

Cibus (San Diego, CA; one SBIR) spins off  biotech offshoot Nucelis to make specialty chemicals with non-transgenic technology  [, May 28, 13]

Nuclea Bioechnologies (Pittsfield,MA)

 Two nanotechnology companies affiliated with the SUNY Polytechnic Institute in Albany have joined the state's Start-Up New York program [which] allows businesses to operate tax free for a decade.  .... Glauconix (Albany, NY; no SBIR), co-founded by Ph.D student Karen Torrejon, develops a more effective drug screening to prevent glaucoma. It won $100,000 in the state's business competition in 2014. That company will create 14 new jobs and invest $1,272,500. ...  Nano DX is a new biotechnology company that is a spinoff of Nuclea Biotechnologies (Pittsfield, MA; no SBIR). That company develops, produces and markets nanoscale diagnostics to provide patients and physicians with better ways to manage and care for chronic disease like cancer. NANO DX will create 15 new jobs and invest $265,000.  [Chelsea Diana, Albany Business Review, Jul 23, 15]

Nuclea Biotechnologies (Pittsfield, MA; no SBIR) developer of diagnostic tests, announced a research partnership with the Stratton VA Medical Center in Albany in which the two will analyze samples from patients diagnosed with prostate cancer or a precancerous or benign prostate condition to determine potential characteristics that could provide information to clinicians for diagnosis or prognosis of these conditions in other patients.  [Eric Anderson, Albany Times Union, Mar 12, 12]

Nuclea (Pittsfield, MA;  no SBIR) took $3.4M to boost a Series B round for cancer diagnostics [company press release]

cancer diagnostics firm Nuclea Biotechnologies(Pittsfield, MA; no SBIR) has boosted its recent funding round from $3 million to $6.4 million. The round includes $4 million in new capital and $2.4 million in outstanding notes exchanged to preferred stock, according to a release from the company.  [Rodney Brown, Mass High Tech, Oct 13, 11]

Nuclea Biotechnologies (Pittsfield, MA; no SBIR) a cancer diagnostics firm in Pittsfield, has rounded up $3 million in an equity offering ... has developed its DecisionDX platform for diagnostic developments in cancer, including colon, stomach, leukemia, lung and prostate cancer, as well as cardiovascular, neurological, inflammation and metabolic disorders. [Michelle Lang, Mass High Tech, Apr 19, 11]

Nuclea Bioechnologies (Pittsfield,MA; SBIR) closed out a $3.4 million equity deal ... involved in biomarker research focused on cancer. [Mass High Tech, Oct 23, 09]

Nufern (East Granby, CT)

Six years ago, when Nufern (East Granby, CT; one SBIR in 2006) had 71 employees, the fiber optic and laser machine manufacturer's president was selling a vision of expansive growth to venture capitalists and to the state's own venture capital arm, Connecticut Innovations. ...   in 2008, when Rofin-Sinar Technologies Inc. bought the firm.  Rofin, which has dual headquarters in Germany and Michigan, .... Rofin added 40,000 square feet to Nufern's 60,000-square-foot building, and that addition opened a year ago. Rofin paid for $8 million of the expansion, and the state loaned the company $4 million at 1 percent — $3 million of which will be converted to a grant from the state if Nufern reaches 329 employees by 2017. ....    CI profited handsomely from its investment, making more than $2 million between interest payments and the value of its shares at the time of Rofin's purchase.  ....    Nufern recently bought a small Maryland company that made tiny coils of intricately wound fibers that are used to make replacement gyroscopes for intercontinental ballistic missiles.   [Mara Lee, Hartford Courant, May 30, 13]

NuGEN Technologies (San Carlos,CA)

NuGEN Technologies (San Carlos CA; $200K SBIR, founded 2000) is a big provider of genomics sample preparation solutions enabling scientists to get very accurate test results. .... it announced it was launching a sample preparation product that allows next-generation sequencing detection of multiple changes in more than 500 individual genes implicated in cancer.   [Angela Swartz, Silicon Valley Business Journal, Aug 28, 15]

NuMat Technologies (Skokie, IL)

NuMat Technologies (Skokie, IL; no SBIR) advanced materials startup, raised [$12M] to expand its product offerings to Europe and East Asia. .... use high-performance computing with technology in chemistry and hardware development to design metal-organic frameworks that address a wide range of challenges in industrial and engineering industries. [Katherine Davis, Chicago Inno, Apr 26, 18]

NuMedii (Palo Alto, CA)

NuMedii (Palo Alto, CA; no SBIR) startup looking to convert pages of drug safety data into faster drug-development times, lined up $3.5 million in a Series A [overscribed] round.... data-into-gold approach rolls a wide range of data — from public scientific journal data bases and other sources — into an algorithm to predict if a compound will translate into a drug. The company already has won converts, namely Aptalis Pharma (Alabama and Montreal; no SBIR)., which is trying to find new treatments for gastrointestinal disorders and cystic fibrosis. NuMedii and Aptalis signed their deal in October 2012. [Ron Leuty, San Francisco Business Times, Jun 26, 13]

NumereX (Albuquerque,NM)

NumereX (Albuquerque, NM; $ 4.2M SBIR) up 10% [May 8, 14]

NUMiX Materials (Evanston, IL)

NUMiX Materials (Evanston, IL, founded 2018) leverages Northwestern U-patented ion exchange technology from the lab of Mercouri Kanatzidis to remove toxic metals from water more efficiently than current technology ... won $100,000 in non-dilutive prize money.  [, May 30, 18]

NuPathe (Conshohocken, PA)

NuPathe (Malvern, PA; no SBIR, founded in 205 and IPO 2010) stock price climbed 47 percent after Endo Health Solutions (Malvern, PA; no SBIR) announced its plans to buy the company for $105 million.  [John George, Philadelphia Business Journal, Dec 16, 13]

NuPathe (Conshohocken, PA; no SBIR) went public. It focuses on developing treatments for diseases of the central nervous system, including psychiatric and neurological disorders. ...  completed a pivotal Phase III clinical trial for Zelrix in July 2009 and expects to submit a New Drug Application to the United States Food and Drug Administration in the fourth quarter of 2010. If approved, NuPathe would have to build a specialty sales force in the U.S. to launch Zelrix in the first half of 2012. Like many early-stage pharmaceutical companies, NuPathe has a history of operating losses, which has led its auditor to raised substantial doubt about its ability to continue operating as a business.    [Lynn Cowan, Wall Street Journal, Aug 6, 10]

Nurel (now PeriphaGen) (Pittsburgh, PA)

PeriphaGen (Pittsburgh, PA; no SBIR) a life sciences company has closed on $6.5 million [capital raise]  ...  for product development and hiring ... originally Nurel, a University of Pittsburgh spinout that was acquired by a Stockholm-based medical company, Diamyd Medical AB, in 2006. In October 2012, a management group bought the business from Diamyd. [Patty Tascarella, Pittsburgh Business Times, Apr 1, 14]

Nurix Therapeutics (San Francisco, CA)

Nurix Thera (San Francisco, CA; no SBIR, founded 2012) up 32% [Aug 13, 20] raised $209M in IPO July 2020; total funding $170M []

Nurix Therapeutics (San Francisco, CA; no SBIR, founded 2009) landed $55 million up front from Sanofi to kick off an alliance aiming to develop protein degradation drugs for multiple therapeutic areas. Nurix could earn up to $2.5 billion in milestone payments. [, Jan 10, 20] total funding $38M []

Gilead Sciences and Nurix Therapeutics (San Francisco, CA; one SBIR) discovering drugs that harness the body’s natural process to control protein levels, announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. [joint companies press release, Jun 19, 19] Nurix's NIH SBIR was College Alcohol Assessment and Intervention Training Simulation, a redux of NIH's famous early SBIR for a Smoke-enders Video. Ah well, Congress gave them unliateral authority to decide what constitutes investment quality innovation.

Nuron Biotech (Exton,PA)

Nuron Biotech (Exton, PA; no SBIR) in one of the largest private investment deals of the year for a local life sciences company, raised $80 million [John George Philadelphia Business Journal, Dec 20, 12]

Nutrient Recovery and Upcycling (Madison, WI)

Seven [Wisconsin] companies each will receive a $75,000 grant under a new program aimed at helping them commercialize their products. The first-ever grants are being distributed by a program called SBIR Advance. ... with $1 million from the Wisconsin Economic Development Corp. and administered by the UW-Extension Center for Technology Commercialization.   All of the companies have already received [SBIR or STTR]. But they aren't able to use those funds for activities like patent work and customer development and validation. receiving the grants are: C-Motive Technologies (Madison, WI; one SBIR)  Isthmus Biosciences (Madison, WI; one SBIR); Nutrient Recovery and Upcycling LLC (Madison, WI; one SBIR);  Pan Genome Systems (Madison, WI; one SBIR);  V-Glass LLC  (Milwaukee, WI; one SBIR); Fiberstar Bio-Ingredient Technologies (Eau Claire,WI; one SBIR);  Medical Cyberworlds (Verona, WI; $600K SBIR).  [Kathleen Gallagher, Milwaukee Journal Sentinel. Sep 25, 14]

Nuvaira (Minneapolis, MN)

Nuvaira (Minneapolis, MN; no SBIR),  developer of therapeutic medical devices for treating certain lung diseases, announced it had closed a $79 million financing round. The capital will be used to support a clinical trial for Nuvaira’s Lung Denervation System, a catheter-based treatment meant as an alternative to drug therapy. [Amanda Ostuni, MinnieInno, Feb 11, 19]

Nuvaira (Minneapolis, MN; no SBIR, founded 2008), a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced it has closed a $79 million equity financing. ... the first interventional pulmonary company to pursue and report one-year randomized, double-blinded and sham-controlled clinical evidence in COPD patients from a Phase 2b trial. [company press release, Feb 11, 19] prior funding $69M []


NuVant says it got an $870K extension to a $1.74M DOD contract.  It had an Army Phase 1 SBIR back in 2002 and a DOE Phase 2 in 2004.

NuVascular Technologies (Ashland, MA)

NuVascular that specializes in medical devices that use a fibrous material that can be infused with stem cells has spun out a separate firm called NuVascular Technologies (Ashland, MA; no SBIR) to commercialize its first two products....   has the same four core employees as Biosurfaces, ($2.7M SBIR)  hold the exclusive license to develop and sell a minimally-invasive treatment for heart disease developed by Biosurfaces and Worcester Polytechnic Institute.  ...  Another device currently in development is a biological pacemaker. Instead of using a battery-powered mechanical device to control electrical impulses in the heart to beat the correct way, the device would use modified stem cells, overcoming some of the limitations of mechanical devices, including the need to change batteries and infection.   [Don Seiffert,  Boston Business Journal, Jan 23, 15]

Nuve (Austin,TX)

Security tech maker Nuve (Austin, TX; no SBIR) increased its latest round of funding to $6.2 million. [Chris Calnan, Austin Business Journal, Apr 20, 15]  an international technology company focused on the emerging field of asset management and fraud prevention, providing organizations with fuel and cargo security, transparency and supply chain integrity from origin to destination. Using our patent-pending, tamper-proof sensors and physical security solutions   [company website]

Nuvation Bio (New York and San Francisco, CA)

Nuvation Bio (New York and San Francisco, CA; no SBIR) a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A financing. [company press release, Oct 28, 19]

Avid Thermalloy (Laconia, NH; no SBIR, founded 1964) announced it has acquired Nuventix (Austin, Texas, no SBIR, founded 2004) Nuventix designs, manufactures and distributes fanless thermal management solutions, including its patented Synjet technology, for LED lighting applications. ... Aavid designs, manufactures, and distributes thermal management solutions, including heat sinks, heat pipe assemblies, and cold plates for telecommunications, server, consumer electronics, transportation, and industrial applications.  ....  Avid also announced  has acquired Allcast, LLC  (Allenton, WI; no SBIR)  Allcast designs, manufactures and distributes aluminum die casting products for LED lighting, recreational vehicle, consumer, and industrial applications.   [Avid press releases Jul 1, 14]   Nuventix was founded by  researchers at the Georgia Institute of Technology, including Dr. Raghav Mahalingam who is currently Chief Scientist at Nuventix, with the simple goal of removing more heat with less air.  Much of the development was supported by  [federal government R&D funding] [company website]

GE Lighting is touting what it calls a breakthrough in light-emitting diode bulbs, thanks to a development accomplished with the help of Nuventix (Austin, TX; no SBIR). ....  will use just 27 watts of power and will be able to replace 100-watt incandescent bulbs ....  It makes an oscillating membrane called a synthetic jet that fits within the bulb and provides cooling [without making it bigger].  [Austin American Statesman, May 7, 12]  The company website says that much of the development was supported by DARPA, the U.S. Navy, and NSF.

Nuventix (Austin, TX;  two 2003 SBIRs as Innovative Fluidics, Atlanta, GA) said that it has raised an additional $10 million in investment funds to accelerate the company's global marketing program and to support development of a new generation of its SynJet cooling systems for LED lighting and electronics.  ....  total investment capital raised to $52 million since it was founded in 2004 [Kirk Ladendorf, Austin American Statesman, Mar 23, 12]

Nuventix (Austin, TX; no SBIR) has completed a $10 million investment round with the participation of General Electric Co. and the Bergquist Co., an investment firm.  Nuventix makes cooling systems that manage heat released from light-emitting diode fixtures and other devices. The company, which employs more than 30 people, received its first round of venture investment in 2005. The latest round brings its total investment to just more than $40 million. [Kirk Ladendorf, Austin American Statesman, Jul 19, 11]

Nuventix (Austin, TX; no SBIR) is among 10 companies nationwide that will receive a total of $63 million as part of a General Electric Co. program to invest in new energy-efficient technologies, GE said Thursday. Nuventix makes cooling systems that manage heat released from light-emitting diode fixtures and other devices. The company, which employs more than 30 people in Austin, received its first round of venture investment in 2005. ... So far, GE has invested in 20 startups and acquired one  [Austin American Statesman, Jun 23, 11]

Nuventix (formerly Innovative Fluids, Austin, TX; no SBIR) said it has raised $4.8 million of a planned $10 million offering. founded as  in 2005, develops a cooling device for electronics. ...  founded 2005..  has raised about $37 million in total  [Lori Hawkins, Austin American Statesman, Feb 10, 11]

Nuventix  (Austin, TX; no SBIR) closed an $8 million tranche on a Series C round of funding through a combination debt and equity financing. ... developer of a cooling device for electronics, reports that the capital will be used to cover further development costs combined with support for new Asian distributors. ....  founded in 2005, employs 30 workers. [Austin Business Journal, Apr 13]

Nuventix (Austin, TX, 30 employees; two 2003 SBIRs as Innovative Fluidics, Atlanta, GA)) which sells cooling technology for LED lighting systems, has raised $4 million in venture capital to speed product development and expand its push into Asia. Spun out of the Georgia Institute of Technology in 2005, Nuventix sells devices that use quick pulses of air to dissipate heat from lighting, consumer electronics, telecommunications devices and medical equipment. ... has raised $32.5 million since its inception  [Lori Hawkins, Austin American-Statesman, Apr 13]

Nuventix ((formerly Innovative Fluidics of Atlanta GA), Austin, TX; $100K SBIR) whose products cool lighting, electronics and other high-tech equipment, has raised $8.5M in VC investment ... manufactures its products at a Flextronics plant in China  [Austin American-Statesman, Jan 8, 08]

Nuvera Biosciences (Woburn, MA)

molecular diagnostics companyNuvera Biosciences (Woburn, MA; $1M SBIR) is licensing testing technology to Veridex LLC to help predict patient response to different types of breast cancer chemotherapy. ... Veridex will develop and sell Nuvera assays to evaluate patient response to tamoxifen and taxane chemotherapy treatment. [Mass High Tech, Apr 6, 09]

Nuvera Fuel Cells (Cambridge, MA)

Nuvera Fuel Cells (Billerica, MA; no SBIR), a provider of fuel cell power solutions for motive applications, announce construction of a fuel cell stack production line in the Hangzhou district government of Fuyang, China. [company press release, Dec 19, 19]

Nuvera Fuel Cells (Billerica, MA; no SBIR) is getting $8.4 million from the federal energy department. The money will help fund two projects - valued at $11.1 million total - that the  company says will help it increase the "durability and performance" of its fuel cells, which use hydrogen and oxygen to produce energy. The US DOE has said that by 2015 it wants fuel cells to cost about $15 per kilowatt of electricity produced and last for 5,000 hours. [Erin Ailworth, Boston Globe, Apr 12, 10]

Nuvera Fuel Cells (Cambridge, MA: $800K SBIR) struck a deal with landscape equipment giant The Toro Co. to provide its PowerFlow fuel cell systems for integration into Minnesota company's Workman utility vehicle [Mass High Tech, Apr 4]


Purdue University says it helped launch 10 startup companies from July 2007 to June 2008, including GreenTech America, Intelliphage and Nutrabiotix. All use Purdue-licensed technologies. Purdue Research Foundation's Office of Technology Commercialization also reported more than $4.1 million in royalties for that time frame.  [Indianapolis Star, Jul 29]

Nuvotronics (Durham,NC)

Cubic announced the acquisition of Nuvotronics [Duham, NC and Radford,VA; $27M SBIR, founded 2008), a disruptive technology provider of microfabricated radio frequency (RF) products, for approximately $64 million in cash .... The cornerstone of Nuvotronics’ innovation platform is their patented PolyStrata® technology, which was developed under DARPA and enables the company to design and produce uniquely packaged RF devices, such as antennas, filters and combiners [Cubic press release, Mar 14, 19]

IN THE Nuvotronics (Durham, NC; $5M NASA SBIR, founded 2008) factory, small is beautiful. ...  a process resembling 3D printing to make miniaturised radio chips for jets and satellites. Typically, such chips are the size of a chocolate bar; Nuvotronics’s widgets are smaller than a breath-mint. Such innovation is lucrative; every kilogram saved makes a satellite $15,000 cheaper to launch.  Nuvotronics is part of a cluster of high-tech firms that have increased Durham’s GDP per person by 28% since 2001. By the same measure, North Carolina as a whole grew by just 3% over the same period. Durham’s success reflects an emerging trend: high-flying cities, and the successful firms they contain, are detaching from the rest of the economy.  ....   In 2001 the richest 50 cities and their surroundings produced 27% more per head than America as a whole. Today’s richest cities make 34% more.   [The Economist, Mar 11, 16]

Nuvotronics  (Durham, NC; $2M SBIR in VA, founded 2008) defense contractor raised $15 million in equity financing, according to [SEC] filing. ... new workers are being hired to create 8-inch wafers intended to hold networks of coaxials     [Lauren K. Ohnesorge, Triangle Business Journal, Jul 10, 15]

Nuvox Pharma (Tucson, AZ)

Nuvox Pharma (Tucson, AZ; $200K SBIR, founded 2008) raised early stage $500,000 in first quarter  [Eric Jay Toll, Phoenix Business Journal, Apr 17, 15]  with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. ... chosen (for $250K) as one of six winners in the Fall 2014 Arizona Innovation Challenge, sponsored by the Arizona Commerce Authority. ...   received a $1M grant from the National Cancer Institute (NCI) in Oct 2014  [company website]

Nu Waves (Middletown, OH)

Dayton celebrates NASA Phase II SBIR awards:   Spectral Energies (Dayton, OH; $8M SBIR) two awards;  Cornerstone Research Group (Beavercreek OH; $35M SBIR) two awards;   Nu Waves (Middletown, OH; no SBIR);  Applied Optimization (Dayton, OH; $4M SBIR); Mound Laser & Photonics Center  (Miamisburg, OH; $4.6M SBIR). [Joe Cogliano, Dayton Business Journal, Apr 20, 15]  So NASA handed $5M to a group of firms that have already had $50M of the nursery money.   Dayton and the Dayton CODEL love it, but the American economy will see no growth spurt.   

NVE   (born NonVolatile Electronics, Eden Prairie, MN)

NVE (Originally Non Volatile Electronics) (Eden Prairie, MN; $40M SBIR) up 18% [Oct 20, 2022] no press release

NVE Corp (Eden Prairie, MN; $40+M SBIR) called A Rare Investment Opportunity Offering Growth And Stable Income ... revenue was the greatest in the past nine quarters as a result of its greatest product sales in the same period. It also generated the greatest profit margin in history. .. a leader in spintronics technology ... generaates the largest margins in the industry, etc, , etc. [Jenks Jumps, Seeking Alpha, Jan 21, 21] Note: Carl Nelson Consuting does not offer investment advice.

NVE (originally NonVolatile Electronics, Eden Prairie MN; early SBIR, 45 employees) declared its regular dividend [Oct 16, 18] development and sale of devices that use spintronics

NVE (formerly Nonvolatile Electronics, Eden Prairie, MN; $36M SBIR 1990-2009, market cap $400M, dividend 4.6%) offers the allure of revenue and earnings growth, bundled with a generous distribution. But it will not likely offer the possibility of dividend growth in the near future. ... When NVE began dividend payments [in 2015], its cash hoard totaled $106 million in cash and marketable securities. [Jenks Jumps,, Nov 29, 17] first SBIRs were for Giant Magnetoresistance Materials.

NVE (Eden Prairie MN; $17M SBIR) down 24% [Jul 23, 15] top percentage loser  a 7% decrease in product sales, partially offset by a 457% increase in contract research and development revenue. Net income for the first quarter of fiscal 2016 decreased 6% ... also announced a quarterly cash dividend to shareholders of $1.00 per share [company press release, Jul 23, 15]

NVE up 13%  [Jul 19, 12]

Real efficiency. NVE is the 4th most efficient company in [Technology stocks]. .. earnings per employee was $230,210 for the last 12 months. That's profits! Hittite Microwave  the 9th most efficient [with] earnings per employee was $140,570 for the last 12 months. [China Analyst, Feb 19 10]  Thanks to Jeff Bond for the info.

Forbes's 2009 list of best 200 small companies includes Aerovironment, American Science and Engineering (paying a dividend and with nearly $600M market cap), Argon ST, Hittite Microwave, II-IV, Meridian Bioscience, Neogen, NVE, and Synaptics

NVE up 15% [Jul 23, 09]


NVE up 10% [Mar 23, 09]

NVE up 12% [Mar 12, 09]

NVE up 21% [Jan 22, 09]

NVE down 11% [Nov 6, 08]

NVE up 11% [Oct 16, 08]

Forbes 200 Best Small Companies list for 2008 had several "SBIR involved" companies: Hittite Microwave 12, II-IV 23, Synaptics 33, NVE 39, ATMI 114, Cymer 166. 

NVE down 11% [Oct 6, 08]

NVE down 13% [Jul 24, 08]  earnings fail to inspire []

NVE up 34% [Jan 24, 08]

NVE up=14% [Nov 29, 07]

NVE down 14% [Jul 19, 07] after news of a 78% increase in profit. happiness is what you got minus what you expected.

NVE was up 11% [Jul 2, 07] and up 170% over 52 weeks.

NVE up another 20%  [Feb 26, 07]

NVE led the NASDAQ diving competition with a 24 percenter.  [Jan 17, 06]

NVE rose 11% despite Motley Fool's continued scoffing. [Jan 8, 07]

NVE, another volatile stock, up 11% [Oct 30,06]

NVE up 10% to 86 times earnings despite Motely Fool's Jack Ulrich's intransigence that I have seen nothing to convince me that Freescale Semiconductor or any other company intends to license NVE's Spintronic technology, and Tim Beyers's that the breadth of Big Blue's [patent] claim [against Amazon] could separate it from the typical bloviating that accompanies most patent cases, such as the on-again, off-again saber-rattling that characterizes NVE claims of intellectual ownership of magnetic random access memory (MRAM) technology.

NVE jumped 20% when it reported 25% higher profit for the quarter. [Oct 19, 06] Motley Fool contributor Stephen Ellis is less than thrilled with the story behind these numbers.

Volatile. The ups and downs of NVE continued with an 12% up day. It has gone from $60+ two years ago down to $12 and is now oscillating in the $30s. Two weeks ago Motley Fool contributor Tim Beyers called NVE a wonderful short candidate. Three weeks ago Fool columnist Seth Jayson called it an overhyped non-player in the non-existent MRAM market . Where lies the truth about NVE future profit prospects (what drives stock prices)?  That's why we have an auction market of buyers and sellers. [Oct 06]

NVE is approaching tripling in value since mid-June. Up 18% yesterday. [Sep 06]

NVE jumped 18% on the news of a patent award for "antiparallel magnetoresistive memory cells". [Aug 04]

NVE stock jumped 42% after it announced a nano-patent  for "spin-momentum magnetic memory cells" and "thermally assisted spin-momentum writing.". NVE has partnerships with Cypress Semiconductor and Motorola to license the company's MRAM technology. [Minneapolis Star Tribune, Jun 24] NVE started life when Jim Daughton left Honeywell and got SBIR from SDIO. That was back when SDIO (now MDA) favored entrepreneurs with new technology instead of service companies with a need for a government-paid salary. 

invest in this coming tidal wave? asked Josh White (Forbes, Nov 10,03)  Of the few nano-plays, White started with NonVolatile Electronics which has had a spectacular year rising from single digits to $40 a share after some visits to the penalty box of the pink sheets.  In the usual optimism of the marketers, Investors should look beyond today's meager revenue and earnings  because the real gold lies in MRAM. Ex Honeywell'er and founder Jim Daughton (who is still a major officer) started NVE life with SBIRs from SDIO in 1992 and has at least 24 Phase 2s over the decade from DOD and NSF.

Cypress Semiconductor Corp., which makes computer chips for video-game consoles and mobile phones, has sold a portion of its investment in NVE Corp. for $23M . NVE shares have nearly quadrupled this year....  Cypress, based in San Jose, Calif., said development of its magnetic random access memory chip is taking longer than expected. The company is developing the chip based on NVE's spintronics technology, a technique that uses magnetic spin to create circuits.  [Bloomberg News, Sep 6, 03]

NVE  reverse-split  its common shares, changed its symbol (NVCR.OB) and says it plans to  the repurchase  50,000 post-split shares in the next six months. [Nov 25, 02]

In the news from near Lake Wobegon (Eden Prairie, MN) NVE got a DARPA contract for an initial $365K for advanced "BioMagnetICs." in DARPA's program seeking nanoscale magnetics for "laboratory on a chip" diagnostics to detect and manipulate single bio-molecules and cells. The basis is NVE's GMR "spintronics" materials of exotic metals a few atoms thick. In typical hype, NVE claims a commercial potential of spintronics of $100B a year. The award feels like a Phase 2 SBIR for NVE's Phase 1 Spin Dependent Tunneling Magnetic Field Sensors for Clutter-Limited Detection. Spintronics got a cover story in June's Scientific American . This spring Cypress Semiconductor invested $6.2M in NVE for a 17% stake in the company, NVE was the child of Arthur Pohm and James Daughton, two Honeywell employees the late 1980s with technology that stored data in the magnetism created between thin films of iron, nickel, and cobalt alloys.

NVE reported a quarterly trickle of revenue, $2.3M, which was 60% larger than the previous trickle. NVE (nee Nonvolatile Electronics) now claims to be the leader in practical commercialization of spintronics, which many experts believe represents the next generation of microelectronics. Whether practical and spintronics and commercialization can be uttered together is still highly speculative. A decade ago NVE was making those kind of noises over GIANT MAGNETORESISTANCE for which it is still getting an occasional SBIR raising its SBIR total over $16M. The ever hopeful government actually doesn't care whether NVE lives or dies or commercializes as long as the government gets the technology rights from whatever NVE learns while spending the SBIR money.

NVE (ne Nonvolatile Electronics) signed an deal with Agilent Technologies whereby Agilent gains non-exclusive rights to certain NVE technology. NVE gets $1Min the first year and future payments based on sales of the Agilent products.

Nonvolatile Electronics which went public through the back door last fall is still losing in the range of $100K per quarter and the stock price muddles along at a market cap around $20M. NVE "merged" with a defunct software company and slipped into its public spot in stock trading markets. NVE has had 19 Phase 2 SBIRs going back to its first from NSF in 1991 to its most recent from BMDO.

The Economist Mar 18 reports that the NRL intends to commercialize its design of a magnetic nonvolatile memory in a GMR material through NonVolatile Electronics (Eden Prairie, MN) which recently began work on the necessary processing and fabrication techniques. But it will be some years before the first chips roll off the production line.. What is the government doing "commercializing its in-house developed technology"? The Economist didn't discuss the details or the ramifications of such government action, and may have misinterpreted an SBIR award to NVE. NVE had three BMDO Phase 2 SBIRs in the early 90s for its GMR based nonvolatile memory work and grew from 10 to 50 employees, but has neither gone public nor expanded its SBIR award rate. It did get a $1.8M ATP award recently. It did make the Minnesota Technology FAST 50 in 199 for the second year for the top 50 fastest growing technology companies in Minnesota. It bills itself as a semi-fabless manufacturer of giant magnetoresistance (GMR) based semiconductor devices.

Nucleus Biologics (San Diego, CA)

Nucleus Biologics (San Diego, CA; no SBIR), a leader in precision cell culture, announces the acquisition of Primorigen Biosciences (Madison, WI; $5.4M SBIR, founded 2005). The addition of Primorigen’s Vitronectin XFTM and platform recombinant protein production technology will play a huge role in Nucleus’ strategy of offering traceable, reproducible and xeno-free (XF) cell culture ecosystems for the cell and gene therapy space. [Nucleus press release, Aug 5, 19] [prior funding $2.5M []

Nvision Biomedical Technologies (San Antonio, TX)

Nvision Biomedical Technologies LLC, (San Antonio, TX, no SBIR) a medical device and biologics developer and manufacturer that has quietly been in product development stage since 2013, is finally pulling back the curtain on the company's plans. ...  focused on spinal implants, is officially launching with the commercialization and distribution of its initial proprietary products.  The first four products offered by Nvision received FDA approval in late 2014. They include nvc, an anterior cervical interbody fusion system; and nvt, a transforaminal lumbar interbody fusion system. The first four products offered by Nvision received FDA approval in late 2014. They include nvc, an anterior cervical interbody fusion system; and nvt, a transforaminal lumbar interbody fusion system. [W. Scott Bailey, San Antonio Business Journal, Nov 18, 15]

NxThera (St. Paul, MN)

Med-tech startup NxThera (Maple Grove, MN; no SBIR) closed on a $40 million round of funding led by Boston Scientific Corp. ... will use the capital to ramp up sales and marketing of its Rezūm System product for treating enlarged prostates  [Katharine Grayson,Minneapolis / St. Paul Business Journal, Dec 3, 15]

NxThera (Maple Grove, MN; no SBIR) developing technology to treat enlarged prostates, raised $3.5 million, according to a regulatory filing. [Katherine Grayson, Minneapolis / St Paul Business Journal, May 1, 13]

NxThera (St Paul, MN; no SBIR). this week it secured $21.6 million in funding from a group of venture capitalists and other investors.... specializes in using vapor technology to treat BPH, an enlarged prostate condition that ails 743,000 new patients annually.The company said the money would go toward its pivotal clinical study in Europe ....Earlier this year, NxThera raised $11.5 million in financing. [Wendy Lee, Minneapolis Star Tribune, Oct 12, 11]

NxThera (St. Paul, MN; no SBIR) medical device company, announced it raised $12.6 million in Series B equity financing. ... to launch a clinical study and toward gaining regulatory approval for its product in Europe. NxThera is developing therapy to treat an enlarged prostate condition known as benign prostatic hyperplasia (BPH).  [Wendy Lee, Minneapolis Star Tribune, Mar 16, 11]

NZ Applied Technologies (Woburn, MA))

OK, We'll Buy It All (Apr 28) Big fiber-optics company Corning agreed to buy the remaining 80% of NZ Applied Technologies (Woburn, MA) for $150M in Corning stock. NZ started life in 1993 when Peter Norris and Jing Zhao left now high-flying Emcore to strike out on their own in III-V materials like GaN. They got a slew of DOD Phase 1 SBIRs in 1993 and two Phase 2s in 1994 (first from, you guessed it, BMDO) with their SBIR-writing skill learned at Emcore. Now at least $17M in SBIR money later, the company sold for $200M valuation. With an average of about 15 employees for six years, the $17M would have bought a huge chunk of the company if the government took equity in return for the SBIR money. No, it it means nothing that the owners might protest that they would never have given equity, because without the SBIR money they would have still have been working as bench scientists with no equity at all. That technology was not attracting private capital at the stage of technological immaturity it had in the mid 90s. GaN scientists were coming out the woodwork to apply to SBIR. The government, then, can claim at least a hypothetical 50% equity in the $200M purchase price (if Corning's stock doesn't collapse) and a Treasury deposit of $100M. So, SBIR can claim, and the DOD agencies need the good press, a smart investment in Norris and Zhao. Now, if the DOD would do the same for the other SBIR awards instead of funding ten zillion hobby shops. For a while, though, NZ had the look of another Spire that absorbed as much II-V SBIR money as the government would pour in with a repeated story of a great future someday. Spire still has the market cap it started SBIR with $30M ago - about $12M.

A Glass Investment. If you make the equipment to send signals down a wire, what better partner could you have but the wire maker. Glass giant Corning has made an equity investment in SBIR-powered photonics materials house NZ Applied Technologies (Woburn, MA). The money will speed the development of photonic products with NZAT's proprietary OptoCeramic device technology and packaging architecture. NZ's co-founder Peter Norris thinks the market will be several billion dollars. The good news is that money like Corning's can be compounded by SBIR agencies who like commercial development of products, like BMDO, and without the pressure from such agencies, companies like NZAT have an incentive to promise commercial while doing essentially government R&D with mutual self-deception by company and government.

NZ Applied Technologies Inc. (Woburn, MA) was #24 in New England High Technology Fast 50 awards last week of companies whose growth over the last five years has been of astronomical proportions. Sponsored by Deloitte & Touche, a nationwide accounting firm, and the Boston-based law firm Hale & Doerr. [Mass High Tech] NZ's problem is that all that growth was SBIR awards that the government may suddenly stop for any kind of government reasons, one of which may be too much SBIR.

NZ-Corning Deal (Aug 10) Says the news release, NZ Applied Technologies (Woburn, MA) said it has entered into a collaborative business agreement with Corning under which NZAT will develop and supply Corning with evaluation quantities of certain photonic components. These components are targeted for use in Corning's growing optical communications business. The products utilize NZAT's proprietary photonic device technology and packaging architecture. The release gave no details and left the reader to infer a great future for NZ Applied. It did tout NZ's history, Founded in 1993, the Company was recently named one of the 50 fastest growing technology companies in New England by Deloitte & Touche , which should be qualified by adding that all that growth came from SBIR awards. BMDO will surely want details that convince it that NZ has made a leap forward in commercializing all that SBIR. Note: no stigma attaches to a lot of SBIR; the stigma comes if the ROI from it does not meet any reasonable investment standards (which are already pretty low for SBIR).



Oak-Mitsui (Hoosick Falls, NY)

New York State Energy Research and Development Authority awarded $250K to  DNV GL (Rochester, NY; no SBIR) –  will develop a novel separator for lithium-ion batteries. ... to decrease the risk of fires due to Lithium-ion batteries, which – while rare – have occurred in the past. Ultralife (Newark, N.Y.) and Oak-Mitsui (Hoosick Falls, N.Y.) will participate in project reviews. The company will also investigate methods for automatically extinguishing a Lithium-ion fire should it occur. [NYSERDA, Oct 27, 14]

Oasys (New Haven,CT)

Midori Renewables (no SBIR) launched last week as the latest sustainable-minded businesses Flagship supports, joining LS9 (no SBIR), Oasys Water (no SBIR) and Joule Unlimited (no SBIR). Brian Baynes, founder and chairman of Midori, [said] that the company is just now starting to market their technology: a solid material that can be heated up to break down the tough cellulose in plant matter, turning it into a simple sugar.  [Don Seiffert, Boston Business Journal, Sep 9, 12]

A Yale University spinoff Oasys (New Haven, CT; no SBIR) is developing  a novel desalination device that reduces the energy needed to purify water to one-tenth of that required by conventional systems. .... using what it calls engineered osmosis. Unlike conventional desalination systems, the Oasys system establishes an osmotic pressure gradient instead of using pressure or heat to force water through a purifying membrane. The approach exploits the fact that water naturally flows from a dilute region to one that's more concentrated when the two solutions are separated by a semipermeable material, thereby saving the energy normally needed to drive the process. [Lee Bruno, MIT Tech Review, Jan 8]

ObjectVideo (Reston, VA)

British start-up Ipsotek is a shrimp. .. expects losses in 2007 on estimated revenue of $3M. That puts him well behind ObjectVideo (projected 2007 sales: $30M) of Reston, VA. (nearly $2M SBIR), founded by scientists and managers from DARPA, which is monitoring platforms for the New York City subway system. [Stephanie Fitch, Forbes, Aug 13, 07]

Obsidian Therapeutics (Cambridge, MA)

Obsidian Therapeutics (Cambridge, MA; no SBIR, founded 2015), a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.  ... has developed a suite of platform technologies that allow for exquisite control of protein activity in cells, thereby enabling tunable cell and gene therapies.   [company press release, Dec 6, 17]

OBS Medical (English)

OBS Medical (Carmel, IN) will receive $2M from the Indiana 21st Century Fund to speed the development of its BioQT technology, designed to improve pharmaceutical cardiac safety.  ... a subsidiary of Oxford BioSignals Ltd., based in the United Kingdom. [Indianapolis Star, Jun 25]

Subsidising Foreign Companies. OBS Medical (Carmel, IN) will receive $2M from the Indiana 21st Century Fund to speed the development of its BioQT technology, designed to improve pharmaceutical cardiac safety. ...a subsidiary of Oxford BioSignals Ltd., based in the United Kingdom.  [Indianapolis Star, Jun 21]

Ocarina Networks (San Jose, CA)

Dell is buying Ocarina Networks (San Jose, CA; no SBIR) a 3-year-old company that compresses computer data in order to reduce storage costs. ... for an undisclosed price before the end of July.  .....  Ocarina, Dell said, has groundbreaking technology that helps companies cut their data storage spending by minimizing redundant data. [Austin American Statesman, Jul 19, 10]

Ocata Thera

Astellas Pharma finally completed its buyout of -based stem cell drugmaker Ocata Therapeutics (Marlborough, MA; some SBIR) after some initial resistance from shareholders over the price of the deal .... paid $8.50 a share, or about $380 million [Ben Fidler,, Feb 11, 16]

Ocata Thera up 10% [Aug 31, 15]

Occipital (Boulder, CO)

3-D scanning and modeling company Occipital (Boulder, CO; no SBIR) raised $13 million  ... Occipital’s main product is its Structure Sensor, a product that attaches to iPads and scans real-world items and then renders a 3-D map of it that can be sent to a 3-D printer or used in virtual reality technologies.  [Greg Avery, Denver Business Journal, Jul 29, 15]

Occipital (Boulder, CO; no SBIR, 14 employees) is building an ambitious and futuristic iPad sensor [that] lets people use their Apple mobile devices to scan an area, object or room and capture a precise three-dimensional representation of it for use in 3-D printing, gaming or in design.  .... About 18 months ago, the small company began hiring and quietly morphing into a hardware company as well as a maker of apps.  ...... had already built the RedLaser iPhone app — bought by eBay for an undisclosed sum in 2010 — and the 360 Panorama app, which has been downloaded 7.5 million times.  [Greg Avery, Denver Business Journal, Sep 27, 13]

Ocean Bio-Chem (Fort Lauderdale, FL)

Ocean Bio-Chem (Fort Lauderdale, FL; no SBIR) announced that its' subsidiary Star brite, Inc product PERFORMACIDE(R) is registered with the U.S. Environmental Protection Agency (EPA) as a virucide effective against coronavirus, when used as directed. [company press relase, Jan 28, 20]

Ocean Power Technologies

Ocean Power Tech up 34% [Jan 22, 21]

Ocean Power Tech down 59% [Apr 4, 19] announced the pricing of an underwritten public offering with gross proceeds of approximately $15,000,000 [company press release, Apr 4, 19]

Ocean Power Tech up 55% [Apr 3, 19] signed a contract with a leading oil and gas exploration and production company to complete a 12-week paid feasibility study that will examine the use of OPT's products and services in monitoring subsea wells during decommissioning activities. [company press release, Apr 3. 19]

Ocean Power Tech down 23% [Mar 13, 19]

Ocean Power Tech up 13% [Dec 5, 16]

Ocean Power Tech up 61% [Nov 15, 16] in shipping companies new enthusiasm

Ocean Power Tech  down 19% [Oct 31, 16]

Ocean Power Tech up 21% [Oct 17, 16] 

Ocean Power Tech down 30% [Oct 14, 16] announced the pricing of an underwritten public offering of 2,400,000 shares of its common stock [company press release]

Ocean Power Tech down 14% [Oct 13, 16]

Ocean PowerTech up 12% [Sep 27, 16]

Ocean Power Tech up 22% [Aug 3,16]

Ocean Power Tech down 11% [Aug 1, 16]

Ocean Power Tech up 76% [Jul 20, 16]

Ocean Power Tech up 24% [Jul 19, 16]

Ocean Power Tech up 75% [Jul 15, 16]

Ocean Power Tech up 61% [Jul 14, 16] announced the deployment of its commercial design of the PB3 PowerBuoy(R) approximately four miles off of the coast of New Jersey. The commercial PB3 incorporates multiple enhancements over early prototypes  [company press release]

Ocean Power Tech  down 18% [Jun 7, 16]

Ocean Power Tech  up 14% [Jun 6, 16]

Ocean Power Tech down 31% [Jun 2, 16] after announcing a secondary offering to raise $1.6M [company press release]

Ocean Power Tech up 24% [Nov 23, 15]

Ocean Power Tech  down 14% [Oct 29, 15]

 Despite receiving at least $8.7 million in federal and state grants, Ocean Power told regulators that it could not raise enough money to cover higher-than-expected costs and would instead pursue a similar project in Australia, backed by a $62 million commitment from that country’s government.  The shuttering of the ambitious project — which, as the nation’s first grid-connected commercial-scale wave park, was to have 10 buoys supplying power to about 1,000 homes — is the latest setback for the nascent wave energy sector in the United States.  [JOSHUA HUNT and DIANE CARDWELL, New York Times, APRIL 27,14]

Ocean Power Tech  down 20% [Apr 4, 14] after it priced an underwritten public offering of 3.8 mln shares of its common stock at a price of $3.10/share []

Ocean Power Tech   down 15% [Mar 14, 14]

Ocean Power Tech   down 15% [Mar 12, 14]

Ocean Power Tech up 20%  [Mar 11, 14]

Ocean Power Tech up 13%  [Mar 5, 14]

Ocean Power Tech up 32% [Feb 12, 14]

Ocean Power Tech up 54% [Feb 11, 14] Lockheed Martin said it had signed an agreement with a unit of Ocean Power Technologies Inc to harness the motion of ocean waves to generate electricity off the coast of Victoria, Australia. The A$230 million ($205.68 million) deal will produce the world's largest wave energy project using power buoys designed by Ocean Power Technologies that tap energy from the surface motion of waves.    [Andrea Shalal-Esa, Reuters, Feb 12, 14]

Ocean Power Tech  up 12%  [Sep 11, 12]

Federal regulators have approved deploying up to 10 wave energy buoys near Reedsport, 2  1/2 miles off the central-Oregon coast. Ocean Power Technologies announced the U.S. Federal Energy Regulatory Commission decision today. The 35-year license is FERC's first for a wave power station in the United States, the New Jersey-based company said.  [Scott Learn, The Oregonian, Aug 20, 12]

Ocean Power Tech down 16%  [Jul 12, 12]

Ocean Power Tech up 72%  [Jul 11, 12]The company and Lockheed Martin have entered into a teaming agreement with the goal of developing a 19 megawatt wave-energy project in Victoria, Australia. This is one of the largest wave-energy projects announced to date, and leverages a grant from the Commonwealth of Australia. [PR Newswire, Jul 11]

Ocean Power Tech  up 15% [Feb 3, 12]

Ocean Power Tech  down 15% [Dec 7, 11]

Ocean Power Tech up 15% [Nov 28, 11]

Ocean Power Tech/span> down 11% [Oct 25, 11]

Ocean Power Tech  down 12% [Oct 20, 11]

Ocean Power up 12% [Oct 19, 11]

Ocean Power Tech  up 11% [Oct 14, 11]

Oregon environmental regulators today proposed approving [Ocean Power Tech] a New Jersey company's plan to put 10 wave energy buoys off the central Oregon coast [Scott Learn The Oregonian, Oct 12, 11]

Ocean Power Tech up 18% [Oct 6, 11]

Ocean Power up 26% [Oct 4, 11]

Ocean Power Tech up 11% [Aug 10, 11]

Ocean Power Tech up 10% [May 17,11]

Ocean Power Tech  down 10% [Jul 27, 10]

Ocean Power Tech down 10% [Jun 8, 10]

Ocean Power Technologies Inc. (Pennington, N.J; $1M SBIR) said it has won a $1.5 million federal [DOE] grant to develop the next generation of wave energy buoy. ...  to increase the power output of its PowerBuoy device from 150 kilowatts to 500 kilowatts. The effort will also focusing on increasing efficiency while achieving lower installed capital and energy costs to keep the technology competitive with fossil fuels. It’s the second DOE grant awarded to Ocean Power. The first, a $2 million award, came in 2008 to build a PowerBuoy for the company’s wave energy project in Reedsport, where it plans to develop a 10-buoy, 1.5 megawatt wave energy system off the Oregon Coast.  [Portland Business Journal, Apr 12, 10]

Ocean Power Tech up 13% [Nov 9, 09]

Ocean Power Tech up 25% [Nov 6, 09] received a A$66.46 ($60.6 US) million grant from the Federal Government of Australia to build a 19 MW wave power project off the coast of Victoria,  Australia. [DJ Business Wire, Nov 6]

Ocean Power Tech down 11% [Oct 28, 09]/p>

Ocean Power Tech  down 11% [Oct 20, 09]

Ocean Power Tech up 13% [Sep 10, 09]

Ocean Power Tech up 16% [May 27, 09]

Ocean Power  up 13% [Apr 30, 09]

Ocean Power  up 12% [Apr 22, 09]

Ocean Powerdown 10% [Apr 6, 09]

Ocean Power Tech  up 10%% [Apr 2, 09]

Ocean Power Tech  up 14% [Mar 26, 09]

Ocean Power Tech up 11% [Mar 17, 09]

Ocean Power down 10% [Mar 2, 09]

Ocean Power Tech    down 10% [Feb 19, 09]

Ocean Power Tech  up 12% [Jan 26, 09]

Ocean Power Tech down 13% [Jan 7, 09]

Ocean Power Tech up 17% [Jan 2, 09]

Ocean Power up 12% [Dec 31, 08]

Ocean Power down 12% [Dec 30, 08]

Ocean Power  down 25% [Dec 29, 08]

Ocean Power Tech down 19% [Dec 10, 08]

Ocean Power Tech up 13% [Dec 8, 08]

Ocean Power Tech up 10% [Dec 3, 08]

Ocean Power Tech up 17% [Dec 2, 08]

Ocean Power Tech up 13% [Nov 24, 08]

Ocean Power Tech up 11% [Nov 4, 08]

Ocean Power Tech down 10% [Oct 23, 08]

Ocean Power down 14% [Oct 8, 08]

Ocean Power Tech down 18% [Oct 6, 08]

Ocean PowerTech up 14% [Sep 29, 08]

Ocean Power Tech up 10% [May 15, 08]

Ocean Power Tech down 12%  [Jan 4,08]

Ocean Power Tech up another 23% [Dec 27, 07]

Ocean Power Tech up 17% [Dec 26, 07]

Ocean Power Technologies up 11% [Oct 1, 07]

Revenue up, loss up, shares up 11% for Ocean Power Technologies. [Sep 14, 07]

Ocean Power Technologies down 12%. [Aug 6, 07]

Ocean Power Technologies which IPO'd Apr 25,07 is trading about 10% below the IPO price. About $1.4M SBIR.

Ocean Renewable Power (Portland, ME)

 States lean in on R&D. At the mouth of the Bay of Fundy, just off the coast of Maine, a tidal power system built and operated by Ocean Renewable Power (Portland, ME; $900K SBIR) draws energy from currents created as 100 billion tons of water flow into and out of the bay. The system was the first commercial, grid-connected tidal power system in the United States, and ORPC expects to expand in the coming years to provide electricity to roughly 2000 homes and businesses.  ...  The company, which estimates that it has pumped more than $25 million into the Maine economy, attributes much of its early success to the $1.75 million in loans and grants it received from the Maine Technology Institute (MTI)  [which] offers early-stage capital and commercialization assistance for the development of technologies that create new products, services, and jobs in Maine. ...   Similar home cooked state R&D in Connecticut Bioscience Innovation Fund and UNorth Carolina Research Opportunities Initiative.  [Kathy Wren, Science, 30 January 2015] 

Ocera Thera (formerly Tranzyme (Palo Alto, CA)

Mallinckrodt Pharmaceuticals  (England), a leading global specialty pharmaceutical company, and Ocera Therapeutics (Redwood City, CA; no SBIR), announced that they have entered into an agreement under which Mallinckrodt will acquire Ocera, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan and other serious liver diseases with high unmet medical need. Ocera's developmental product OCR-002, an ammonia scavenger, is being studied for treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia, a complication of acute or chronic liver disease. ... [priced at] approximately $42 million, plus one Contingent Value Right to receive one or more payments in cash of up to approximately $75 million based on the successful completion of certain development and sales milestones.  [joint companies press release, Nov 2, 17]

Drug developer Ocera Therapeutics (Palo Alto, CA, formerly Tranzyme; $400K SBIR in Alabama, 11 employees) could borrow up to $20 million, extending the company’s cash runway into at least mid-2017. ... In 2003, Tranzyme Pharma received $150,000 from the N.C. Biotechnology Center and had raised $146 million, including $54 through an IPO, before this loan.  [Jason deBruyn, Triangle Business Journal, Jul 31, 15]

Ocera Thera down 16% [Jul 10,14]

Ocera Thera up 11% [Dec 4,13]

OCI (St Louis, MO)

The Army FCS Program awarded its Small Business of the Year award to OCI (St Louis, MO; no SBIR). [St Louis Post Dispatch, Feb 22]

Ocugen (Aurora, CO and Malvern, PA)

Histogenics (Waltham, MA; no SBIR), and Ocugen (Malvern, PA, no SBIR) clinical-stage biopharmaceutical focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, jointly announced that they have entered into a definitive merger agreement under which the stockholders of Ocugen will become the majority owners of Histogenics’ outstanding common stock [joint companies press release,  Apr 8, 19]

Ocugen (Aurora, CO and Malvern, PA; no SBIR) biopharmaceutical company developing treatments for sight-threatening diseases, announced that it has closed a $6 million round of Series A funding. ... OCU300 is a repurposed drug with an established safety track record in ocular applications that is being developed for the treatment of ocular graft versus host disease (oGVHD) under the U.S. Food and Drug Agency’s 505(b)(2) regulatory pathway. Ocular GVHD is a common complication that occurs in patients who have undergone allogenic hematological stem cell transplantation (allo-SCT), or bone marrow transplants. There is currently no therapy indicated for the treatment of this condition.  [company press release, Dec 15, 16]

Ocular Therapeutix (Bedford, MA)

Ocular Therapeutix up 29% [Oct 7, 20]

Ocular Therapeutix up 18% [Jun 13, 19]

Ocular Therapeutix up 20% [Jun 11, 19]

Ocular Thera up 10% [Mar 16, 18]

Ocular Thera down 14% [Jan 25,18] announced the pricing of an underwritten public offering.

Ocular Thera up 12% [Jan 19, 18]

Ocular Thera up 14% [Jan 12, 18]

Ocular Thera up 10% [Dec 13, 17]

Ocular Thera down 10% [Nov 27, 17]

Ocular Therapeutix down 14% [Aug 3, 17]

Ocular Therapeutix down 12% [Jul 12, 17]

Ocular Thera (Bedford MA; no SBIR) down 25% [Jul 7, 17]  Law firms scrambled to sue the company; one cited On July 6, 2017, Seeking Alpha published an article alleging that Ocular's management has been misleading investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by the Company contain bad product, and that these issues could imperil the approval of DEXTENZA by the FDA. Following this news, Ocular's stock price dropped materially, which caused investors harm.  [Goldberg Law PC press release, Jul 8, 17]

Ocular Thera down 12% [Jun 22,17]

Ocular Thera up 15% [May 12,17]

Ocular Therapeutics up 12% [Mar 16, 17]

Ocular Thera down 10% [Feb 21,17]

Ocular Thera up 18% [Feb 10, 17]

Ocular Thera up 10% [Dec 19, 16]

Ocular Thera up 13% [Nov 18, 16]

Ocular Thera up 12% [Nov 16, 16]

Ocular Therapeutix (Bedford, MA;  no SBIR) up 14% [Oct 13, 16], a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals [to]collaborate on the development of a sustained release formulation of the vascular endothelial growth factor (VEGF) trap aflibercept for the treatment of wet age-related macular degeneration (wet AMD) and other serious retinal diseases....  Upon exercising of the option, Ocular Therapeutix would receive a payment of $10 million from Regeneron and Ocular Therapeutix would be responsible for funding development through Phase 1. Regeneron would be responsible for any subsequent development and commercialization costs. Ocular Therapeutix would be eligible to receive up to $305 million in milestone payments from Regeneron for a sustained release version of aflibercept containing Ocular Therapeutix’s sustained release hydrogel depot, comprised of up to $155 million in development and regulatory milestone payments, $100 million for the first commercial sale and up to $50 million in commercial milestone payments. In addition, Ocular Therapeutix is eligible to receive tiered high single-digit to low-to-mid teen-digit royalties on potential future net sales.   [Ocular press release, Oct 13, 16]

Ocular Therapeutics up 21% [Aug 15, 16]

Ocular Therapeutix  down 15% [Jul 25, 16]

Ocular Thera down 10% [Jul 13, 16]

Ocular Therapeutix  (Bedford, MA; no SBIR, founded 2006, IPO 2014) down 43% [Jun 6, 16] said that OTX-DP, an implantable device that delivers the steroid dexamethasone into the eye over about 30 days, failed the second of two Phase 3 trials in allergic conjunctivitis, a chronic condition that causes itchy and watery eyes. Though measures of eye itching among patients on Ocular’s drug-device was “numerically lower,” the results weren’t statistically significant.  [Ben Fidler,, Jun 6, 16]

Ocular Therapeutix  (Bedford, MA; no SBIR) up 39% [Feb 17, 16] announced the Phase 3 clinical development strategy for its OTX-TP (sustained release travoprost) drug product candidate for the treatment of glaucoma and ocular hypertension. Based on feedback from a recent meeting with the US Food and Drug Administration (FDA), Ocular Therapeutix intends to commence the first of two planned Phase 3 clinical trials in the third quarter of 2016.  [company press release]

Ocular Therapeutix  (Bedford, MA; no SBIR) looking to use is proprietary hydrogel technology to commercialize treatments for eye ailments, said that it recently closed a Series D extension round of financing totaling $23.8 million. [Chris Reidy, Boston Globe, Jan 29, 13]

Less than a month after it bumped a financing round from $15 million to $21 million, Ocular Therapeutix (Bedford, MA) has raised a Series D round worth $14 million, according to a federal document and company officials. [Rodney Brown, Mass High Tech, Feb 8, 11]

Ocular Therapeutix (Bedford, MA; no SBIR), another eye therapy company launched by Amar Sawhney, has boosted its most recent funding round to $21 million, just days after Sawhney’s Eyegate Pharmaceuticals (Bedford, MA; no SBIR) itself announced a funding bump.  [Mass High Tech, Jan 12, 11]

Oculeve (San Diego, CA)

a trio of nascent biotechnology firms with San Diego ties from trying. Each of the companies in recent weeks has won fans and thousands of dollars in prize money as they’ve moved through the annual circuit of business-plan competitions ... NeuroMap is working on a way to test the effectiveness of antidepressant medications in a patient. ... NeuroVigil, the San Diego-based winner of the second UCSD business-plan contest, announced last month that it had completed its first round of outside investment fundraising, which was led by an unnamed “American industrialist” and included investors from both U.S. coasts. ... Oculeve’s experimental device is designed to treat dry eye disease, a painful and debilitating condition that affects tens of millions of people in the United States and Europe. As many as 1.5 million Americans have the most severe form of the disease, Smith said. Most patients are treated with the tear production drug Restasis, but the therapy doesn’t work well in many patients, Smith said. In an initial test of the Oculeve device on a patient, its effectiveness was 10 times better than Restasis, he said.   [Keith Darce,, Jun 24]

Oculogica (New York NY)

Oculogica (New York NY; no SBIR, founded 2013), a pioneer in algorithm-based neuro-diagnostics, announced that [FDA] granted their De Novo request for the commercialization of EyeBOX®, the first non-invasive, baseline-free tool to aid in the diagnosis of concussion. Oculogica plans to market the device for use in pediatrics ages 5 and older and adults up to 67 years of age, starting with a pilot launch for select, qualified sites. [company press release, Jan 3, 19] total funding $7M []


Facebook will acquire two-year-old Oculus VR (Irvine, CA, no SBIR, employs more than 100  ), a maker of virtual-reality glasses for gaming, for $2 billion, buying its way into the fast-growing wearable devices arena with its first-ever hardware deal.  .... "We're making a long-term bet that immersive, virtual and augmented reality will become a part of people's daily life," the 29-year-old Zuckerberg said, noting that wearing the Oculus goggles was "different than anything I've ever experienced in my life." .... founded by Palmer Luckey, a self-described virtual-reality enthusiast and hardware geek, got its start as a Kickstarter-funded program, drawing small investments from thousands of people on the popular fund-raising platform.  .... raised $75 million in December  [Alexei Oreskovic and Malathi Nayak, Reuters, Mar 25, 14]

Oculus fell 2.5% from its IPO price. [Jan 25, 07] No SBIR for the wound-care products like Dermacyn.


Oddpost is part of an emerging breed of here-today, bought-tomorrow startups that are sprouting with minimal funding, flowering briefly, and being gobbled up by far bigger companies. In many instances, these built-to-flip outfits forgo -- or sometimes can't get -- money from venture capitalists. They instead create shoestring operations focused on the rapid development of narrow technologies to plug gaps in existing product lines or add useful features to existing products. Then they look to a deep-pocketed patron to scoop them up. .... By the end of September, there will have been more than 5,300 tech acquisitions in 2004, based on research from Mergerstat. The average reported selling price was $12 million. Microsoft alone has bought 46 companies in the past four years; ... large companies increasingly recognize that, with stock options no longer the lure they once were, the most cost-effective way to bring in new talent and to fund R&D is simply to buy up innovators and their ideas. "Big companies stink at innovation, and they know it," says Vivek Mehra, general partner at venture fund August Capital.  [Om Malik, Business 2.0, Oct 04]

Odyssey Systems Consulting Group (Wakefield, MA)

A massive U.S. Air Force contract has been awarded to a group of five small businesses that will share in the $851 million worth of work, according to Washington Technology ...  sharing the contract: Abacus Technology (Chevy Chase, MD); EIS (Vienna, VA); Odyssey Systems Consulting Group(Wakefield, MA); P3I (Hopkinton, MA); and SpectrumS4 (Burlington, MA). [Dayton Business Journal, Nov 1, 12]  No SBIR to any.

Oil Chem Technologies (SugarLand, TX)

"The first time we used the product in the field was for a Chinese well," said Christie Lee, president of Oil Chem Technologies  (SugarLand, TX; no SBIR). "In the meetings, there would be six of us and a dozen of them. They tried to duplicate our product by breaking it down and analyzing it, but they were not able to totally replicate it." ..."We were a small fish swimming with sharks," Lee said. "But it established credibility for us because we could say our product had been tested in the field."  [Sandra Bretting, Houston Chronicle, Sep 30]

OLEDWorks (Rochester, NY)

nanocrystal-maker Pixelligent Technologies (Baltimore, MD; $900K SBIR) is working on a new type of lighting that would be more energy efficient and cast a higher quality light. The work, a partnership with OLEDWorks  (Rochester, NY; no SBIR), is backed by a $1.25 million grant from the DOEenrgy.   ...  OLED lights are sheets of glass that emit light when plugged in, ... so efficient they could last the lifetime of a building, but thousands of dollars per light  ...  expects this type of light to begin gaining traction in the commercial market by 2020.   [Sarah Gantz, Baltimore Business Journal, Sep 22, 14]

Olema Oncology (San Francisco, CA)

Olema Pharmaceuticals (San Francisco, CA; no SBIR) up 157% after IPO raises $290M [company presss release, Nov 18, 20]

Olema Oncology (San Francisco, CA; no SBIR) biopharmaceutical company developing innovative targeted therapies for women's cancers, announced the closing of an oversubscribed $54 million Series B financing [to] advance OP-1250, the Company's lead program in breast cancer, into Phase 1/2 clinical development and expand ongoing research and development activities. [company press release, Jul 22. 20]


Omega Therapeutics (Cambridge, MA)

Omega Therapeutics (Cambridge, MA; no SBIR founded 2017) pioneering a new category of genomic medicine through epigenomic programming, announced the completion of an $85 million financing [to] support progression to first-in-human clinicaltrialsofthe company’s Epigenomic Controllersfor programsin oncology, inflammation, autoimmune, metabolic,and rare genetic diseases. [company press release, Jul 29, 20]

Omeros  (Seattle, WA)

Omeros down 26% [Sep 15, 22]

Omeros (Seattle, WA; $5M SBIR) up 20% [Aug 10, 22] reported quarterly financial results

Omeros (Seattle, WA) up 69%  [Jul 1, 22]

Omeros (Seattle, WA; $5.4 M SBIR) announced is selling its Omidria franchise to the British eye care company Rayner Surgical Group Ltd. The deal includes a $125 million upfront payment and a commercial milestone payment of $200 million for Omidria, a drug that prevents excessive pupil constriction in cataract surgery. Omeros will also receive royalty payments for sales made both within and outside of the U.S. According to Omeros, the deal is valued at more than $1 billion. [company press release, Dec 6, 21]

Omeros down 26%, [Oct 18, 21] announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). [company press release, Oct 18, 21]

Omeros (Seattle, WA; $5M SBIR) down 38% [Oct 1, 21] announced that [FDA] notified the company that, as part of FDA's ongoing review of the company's Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA), FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. FDA stated that the notification does not reflect a final decision on the information under review. [company press release, Oct 1, 21]

Omeros Therapeutics up 51% [Aug 10, 20] reported the results of a compassionate-use study evaluating narsoplimab, Omeros' investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19. [company press release, Aug 10, 20]

Omeros up 17% [Mar 31, 20]

Omeros down 26% [Mar 16, 20]

Omeros up 55% [Mar 3, 20]

A pivotal trial of Omeros’ narsoplimab in hematopoietic stem cell transplant (HSCT) patients has hit its primary endpoint. Omeros expects to use the data to win FDA approval, although secrecy around the design of the trial means there remains scope for skepticism about the results. [Nick Paul Taylor, Fierce Biotech, Dec 4, 19]

Omeros down 19% [Nov 9, 18]

Omeros up 10% [Oct 2, 18]

Omeros down 43% [Oct 1, 18] announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company's cataract surgery drug OMIDRIA(R) (phenylephrine and ketorolac intraocular solution) 1% / 0.3% [company press release, Oct 1, 18]

Omeros down 18%  [May 16, 18]

Omeros up 14%  [May 14, 18]

Omeros up 23%  [May 11, 18] reported a net [quarterly] loss of $30.1 million [company press release, May 10, 18]

Omeros  up 11% [Apr 4, 18]

Omeros  up 13% [Apr 3, 18]

Omeros down 13% [Mar 26, 18]

Omeros down 11% [Mar 23, 18]

Omeros up 35% [Mar 22, 18]

Omeros up 11% [Feb 26, 18]

Omeros up 11% [Feb 23, 18]

Omeros down 15% [Feb 22, 18]   Investment adviser FourWorld Capital Management, which recently issued a research report analyzing the potential financial deterioration of biopharmaceutical company Omeros, has uncovered new data showing that sales of the company's principal commercial product have fallen dramatically in the past two months. FourWorld believes this casts serious doubt about Omeros' future viability.  [Four World press release, Feb 22, 18]

Omeros up 29% [Nov 10, 17] reported lower quarterly loss and patent dispute settlement [company press release, Nov 9, 17]

Omeros up 13% [Nov 3, 17]

Omeros down 14% [Nov 2,17]

Omeros up 12% [Oct 27, 17]

Omeros down 11% [Oct 24, 17]

Omeros said it wrapped up an underwritten [net]public offering of about $63.6 million [Armie Margaret Lee,, Aug 22, 17]

Omeros up15% [Aug 9, 17]

Omeros up 12% [Jun 14,17]

Omeros up 15% [Jun 13,17]

Omeros up 12% [Jun 12,17]

Omeros up 11% [Mar 28, 17]

Omeros up 10% [Mar 27, 17]

Omeros up 11% [Mar 20, 17]

Omeros up 17% [Nov 10,16]

biotech Omeros announced the results of a mid-stage drug trial for the treatment of kidney disorders and reported that the company will pursue special FDA status to fast-track approval. The company’s Phase II trial of OMS721 drug showed improvements in kidney functions in patients with progressive renal diseases which currently have no approved treatments.   [Casey Coombs, Puget Sound Business Journal, Oct 18, 16]

Omeros announced a public offering of common stock to raise $40 million.  ...  Over the last 6 months the company burned through $29 millionin cash as it continues research and development for a new drug program and costs associated with a pediatric trial for Omidria.  The bulk of the company's growth is tied to the April 2015 launch of Omidria, its first commercial product. [Casey Coombs, Puget Sound Business Journal, Aug 11, 16]

Omeros down 12%[Aug 11, 16]

Omeros has racked up more than half as much in sales of its cataract surgery drug in the first quarter as it did for the whole of last year, the biotech said. ...  Omidria, which is the company’s first drug, launched broadly in the U.S. in April 2015. Since then, interest in the drug has grown. That's prompted the company to bulk up its sales department. The company hired 26 field sales representatives and 11 other sales reps in the first quarter.  [Rachel Nielsen Puget Sound Business Journal, May 10, 16]

Omeros down 16% [May 10,16]

Omeros closed 2015 with $13.5 million in revenue, $13.3 million of which came from sales of its first drug, Omidria, [used during cataract surgery to maintain pupil size and reduce post-surgery pain] the company reported. ...   [CEO] Demopulos said Omeros now has a fully staffed team of sales representatives and it is promoting OmidriAssure, the company's program that reimburses patients whose surgeons administer the drug.  [Rachel Nielsen, Puget Sound Business Journal, Mar 7, 16]

Omeros down 14% [Mar 15,16]

Omeros up 16%[Mar 8,16]

Omeros is getting a boost from the sales ofitsfirst commercial product [Omidria, launched in April].... posted a $19.9 million loss on a revenue of $3.3 million for the third quarter ...  That's a 1,423 percent jump in revenue. ...  develops treatments for eye surgery, inflammation, disorders of the central nervous system and more, and went public in 2009. ...      [Annie Zak,Puget Sound Business Journal, Nov 10, 15]

Omeros up 10% [Nov 2, 15]

Omerosdown 14% [Aug 24, 15]

Omeros said it plans to file a patent infringement lawsuit against Par Pharmaceutical because of Par's plans to market a generic version of Omeros' eye-surgery drug Omidria.  Par recently sought [FDA] approval for the generic version.  [Annie Zak, Puget Sound Business Journal, Aug 17, 15]

Omerosdown 10% [Aug 19, 15]

Omerosup 72% [Aug 18,15] announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) -- aggregations of platelets -- in the microcirculation of the body's organs, most commonly the kidney and brain.  {company press release]

Omeros up12% [Aug 17, 15]

Omeros is seeing the benefits of its first commercial product launch earlier this year.  The company reported$3.2 million revenue for the second quarter of 2015 — nearly all for its new cataract-surgery drug — compared to about $45,000 for the same percent last year.  [Annie Zak, Puget Sound BusinessJournal, Aug 10, 15]   Omeros received approval for use of itsfirst drug in Europe.  The European Commission has granted marketing authorization for Omidria, which is used in cataract surgery and lens replacement procedures.  [Becky Monk, Puget SoundBusiness Journal, Aug 3, 15]

Omeros  announcing a major licensing dealwithinternational pharmaceutical company Fagron.... launched its first commercial product called Omidria in April, went public in 2009 and has 12 drugs in its pipeline including those in preclinical stages. The company's OMS103, which was involved in the licensing deal with Fagron, is used during arthroscopic surgery. The deal will take OMS103 to market.   [Emily Parkhurst, Puget Sound Business Journal, Jun 18, 15]

Omeros reported an $18.7 million firstquarterloss after the launch of its first commercial product, Omidria, in April. ... develops treatments for eye and other diseases and went public in 2009.  [Annie Zak, Puget Sound Business Journal,May 11, 15]

Omeros made a big step forward yesterday with the commercial launch of Omidria, a product developed for use during cataract surgery.  It's the first product to make it to market for Omeros.   [Annie Zak, Puget Sound Business Journal, Apr 3, 15]

Omeros  up 27% [Mar 2, 15]

Omeros up 17% [Jan 29, 15] said it plans a stock offering that could raise as much as $80 million.  [Ben Miller, Puget Sound Business Journal, Jan 29, 15]

Shares in Omeros  shot up more than 43 percent after the biotech got good news about its Omidria drug used in cataract surgery. ....   said Omidria received " transitional pass-through status from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program."  [Ben Miller, Puget Sound Business Journal, Oct 31, 14]  

Omeros said it's suspended a drug trial of its OMS824 drug being developed for treatment of schizophrenia and Huntington's disease "as it further evaluates an observation from a nonclinical study in rats." Shares dropped more than 14 percent in early  trading [Ben Miller, Puget Sound Business Journal, Oct 21, 14]  

Omerosup 43% [Oct 30, 14] announced today that it has received transitional pass-through status for its lead product Omidria(TM) (phenylephrine and ketorolac injection) 1%/0.3% from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program.  [company press release, Oct 30, 14]

Omeros down 12% [Oct 21, 14]

Omeros down 10% [Jul 8,14]

Omeros down 10% [Jun 12, 14]

Omerosup 11% [Jun 10, 14]

Omeros said it's received [FDA] approval for its drug used during cataract surgery or intraocular lens replacement.  ... said its Omidria drug, now can be used in the most common surgical procedures performed in the U.S. at nearly four million annually. [Ben Miller,  Puget Sound Business Journal, Jun 2, 14]

Omerosup 12% [May 23, 14]

Omerossaid it's getting ready for a launch this year of its eye-surgery drug Omidria. ... in intraocular lens replacement surgery, including cataract and other lens replacement surgery, to reduce postoperative pain and irritation. [Ben Miller, Puget Sound Business Journal, May 13, 14]

Omeros  said it raised $37.8 million in its recent stock offering  [Ben Miller, Puget Sound Business Journal, Mar 20, 14]

Omeros said the [FDA] has granted fast track status for one of its OMS824 for the treatment of cognitive impairment in patients with Huntington's disease. [Ben Miller, Puget Sound Business Journal, Feb 5, 14]

Omeros up 11% [Feb 18, 14]

Omerosup 18% [Dec 18, 13]

Omeros  up 12% [Dec 16, 13]

Omeros up 12% [Nov 5, 13]

Omeros up 18% [Oct 3, 13]

Omeros up 14% [Oct 2, 13]

Omeros up 28% [Sep 23, 13]

Omeros down 11% [Sep 17, 13]

Omeros up 68% [Sep 16, 13] said its investigational new drug application (IND) to evaluate its treatment for Huntington's disease has been cleared by the U.S. Food and Drug Administration. The treatment, OMS824, selectively inhibits phosphodiesterase 10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia. [Dow Jones Newswire, Sep 16]

Omeros will be 20 years old as a company next year, and it hopes to celebrate that milestone by getting the go-ahead to start selling its first new drug. ...  filed an application to the FDA for clearance to start selling OMS302, an experimental drug to help people undergoing eye surgery to correct cataracts or getting a procedure called refractive lens exchange.  [Luke Timmerman,, Aug 1, 13]

Omerosup 14% [May 10, 13]

Omeros down 15% [Nov 12, 12]

notified the FDA that the biotech company intends to submit an investigational new drug (IND) application this quarter for a medication expected to treat schizophrenia. [Valerie Bauman, Puget Sound Business Journal, Jul 18, 12]

Omeros down 20%  [Jun 27, 12]

Omeros up 12%  [Jun 8, 12]

Omeros up 34% [Mar 13, 12]  reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. [company press release]

Omeros up 16% [Nov 30, 11]

Omeros up 11% [Sep 17, 11]

Omerosup 10% [Jun 23, 11]

Omeros down 37% [Apr 1, 11] after late stage drug trial failure [AP]

Omeros up 10% [Mar 25, 11]

Omeros up 11% [Mar 23, 11]

Omeros said a test of its drug for patients undergoing ureteroscopies for removal of ureteral or renal stones was “safe and well tolerated.”  [Puget Sound Business Journal, Dec 29, 10]

In Washington state’s biotech cluster, 83 local biotech companies were awarded grants worth a combined $34 million,   Adaptive TCR, AVI Biopharma, Omeros, Proteotech, and Trubion Pharmaceuticals and 78 others. [Luke Timmerman, Seattle Times, Nov 3] Most were $245K, a little money for almost everyone. Too little money to make a big swing in effect. Just politics.

Omeros plans to announce Monday a $20 million investment from Paul Allen's Vulcan Capital and a $5 million grant from a state biotechnology-research fund.  The financing will help Omeros advance its research on what are known as G protein-coupled receptors (GPCRs) — a key family of proteins that guides cells' responses to nearby molecules and forms the basis for many modern pharmaceuticals.  [Seattle Times, Oct 22, 10]

Omeros up 10% [Aug 27, 10]

Omeros  up 11% [Jul 13, 10]

Omeros up 17% [Jun 25, 10]

Omeros up 10% [May 27, 10]

Omeros  up 17% [Mar 31, 10

Omeros  up 12% [Jan 29, 10]

Omeros up 11% [Nov 13, 09]

Omeros up 12% [Nov 3, 09]

Soggy IPO.  Shares of Omeros (Seattle, WA; $1.4M SBIR)-- which sold last night at $10 at the bottom end of the anticipated range -- sank even further in the opening day on Nasdaq. ... raised $68.2 million in the offering, saw the stock [fall 13% in first day trading] ...  developing treatments to reduce pain and improve joint function after arthroscopic surgery, has accumulated a deficit of $108 million over the years. It currently has no products on the market .. the first Washington technology company to go public since March 2007. [Puget Sound Business Journal, Oct 8, 09]  trades as OMER

Omeros, (Seattle, WA; $1.4M SBIR) biopharmaceutical company, expects to price its initial public offering of stock at $10 to $12 a share, yielding $62 million or more in net proceeds, it said Wednesday in a regulatory filing. [Seattle Times, Sep 16, 09]

Omeros (Seattle, WA; $1M SBIR) said it’s received $3.1 million in funding from the Stanley Medical Research Institute for development of its schizophrenia treatment drugs.  [Puget Sound Business Journal, Jan 28, 08]

Biopharma Omeros (Seattle, WA; $1M SBIR) filed for an IPO, aiming to raise as much as $115M ... founded in 1994, has no product revenue and no products approved for marketing. It is developing compounds for inflammation and disorders of the central nervous system [Seattle Times, Jan 10, 08]  In Feb 07 it raised $63M.

OmniGene Bioproducts (Cambridge, MA)

BioEnergy International LLC, a developer and manufacturer of next-generation, renewable biochemicals and biofuels acquired the assets of OmniGene Bioproducts (Cambridge, MA; $700K SBIR).

OmniGuide (Cambridge, MA)

OmniGuide Surgical (Cambridge, MA; no SBIR, founded 2000) medical device company, announced the closing of a $15 million financing  .....  to accelerate OmniGuide’s growth in the field of gynecology, the company said in a press release. ... Since its launch, the BeamPath Laser System has been used in nearly 100,000 surgical procedures, OmniGuide added.   [Chris Reidy, Boston Globe, Sep 26, 13]

OmniGuide  (Cambridge, MA; $1.6M SBIR)  maker of “advanced energy surgical products” for improving accuracy and control in minimally invasive surgeries, said that it brought in $35 million in non-dilutive funding [Erin Kutz,, Aug 29, 12]

OmniGuide (Cambridge, MA; $1.8M SBIR mostly as Omniguide Communications), a developer of laser scalpels used in minimally invasive surgeries, has pulled in $1.8 million in an equity round, according to a regulatory filing .. A prior Series E private equity financing, announced last May, brought in $25 million  ... backed by Analog Devices Inc. founder and chairman Ray Stata, who serves as chairman of the board   [Mass High Tech, May 15, 09]

OmniGuide (Cambridge, MA; $1.6M SBIR), a developer of laser scalpels used in minimally invasive surgeries, reports it has closed a $25 million Series E round of private equity financing. [Mass High Tech, May 15]

OmniLytics (Salt Lake City, UT)

Eli Lilly announced an agreement with OmniLytics (Salt Lake City, UT; no SBIR) to collaborate to research and license products to treat food-borne bacteria. [Indianapolis Star, Mar 12, 08]

Omniox (San Carlos, CA)

Biotech firm Omniox (San Carlos, CA; $3.8M SBIR) has raised slightly more than $3 million in its latest funding round, according to an SEC filing.  ....   known for its work on cancer therapy treatments. [Vincent Lara-Cinisomo,Silicon Valley Business Journal, Aug 7, 13

OmniSonics Medical Technologies (Wilmington, MA)

OmniSonics Medical Technologies (Wilmington, MA; no SBIR)  ceased operations in January. The end came without warning to doctors who were conducting studies on new applications of its federally approved device to break up blood clots with ultrasound pulses. [Barnaby Feder, NY Times, Apr 5, 09]

Omnis PharmaRebiotix (Roseville, MN)

Omnis Pharmaceuticals (Rochester, MN; no SBIR, founded by several researchers from Mayo Clinic) biotech start-up with ties to the Mayo Clinic has signed a licensing deal with an international drugmaker to study how to improve genetically engineered viruses that kill cancer cells. ... signed an agreement to allow biologics maker MedImmune to study and potentially commercialize the cancer-killing virus that Omnis has been designing. MedImmune plans to pair Omnis’ vesicular stomatitis virus (VSV) with its own “immunotherapeutic” drugs that use the body’s immune system to attack tumor cells.  ....  Its founders include Shruthi Naik, a Mayo scientist who has designed and developed VSV technologies in clinical development, and Russell, who is Mayo’s former dean of discovery and experimental research.   ...  This week AstraZeneca said it would speed up development of the VSV virus, with the goal of pairing it with MedImmune investigational drugs that stimulate the body’s immune response to cancer.   [Joe Carlson, Minneapolis Star Tribune, Jan 13, 15]

LifeScience Alley, the regional trade association that represents life science and health technology companies, announced that 10 organizations will be exhibiting cutting-edge products as part of the association’s New Technology Showcase at the 2013 LifeScience Alley Conference, Nov. 20 at the Minneapolis Convention Center.   Featured will be:  (Rochester, MN;  no SBIR), developing a cancer-selective virus particularly suited to destroy relapsed or metastatic cancer cells; Omnis PharmaRebiotix (Roseville, MN; no SBIR), which will present something called Microbiota Restoration Therapy, which delivers live, human-derived microbes to patients’ intestinal tracts to restore balance and treat certain diseases; and (Naperville, IL; no SBIR) will demonstrate its remote patient monitoring and predictive analytics system, which converts patient vital signs into information to aid in care.    VGBioCogCubed (Minneapolis, MN;  no SBIR) will exhibit an approach to diagnosing and treating cognitive health by analyzing game play data; Datuit (Roseville, MN; no SBIR) will display a platform allowing patients, family and clinicians to confidentially share medical information; Imanis Life Sciences   (Rochester, MN; no SBIR) will show a gene-based platform for promoting non-invasive, long-term imaging technologies in living beings; Mednology Solutions (Excelsior, MN;  no SBIR) will exhibit a system designed to improve efficiency in the management of medical emergencies; NanoVault Medical (St. Paul, MN; no SBIR) will show a cellular and biotherapeutic delivery technology to treat autoimmune diseases. ReMind Technologies of Houston, Tex., will exhibit a smartphone-based medication dispensing device and Skyline Medical, Inc. of Eagan will show an automated surgical fluid disposal device with unlimited capacity and real-time fluid volume data. For more information.  [James Walsh, Minneapolis Star Tribune, Sep 25]

Omni Water Solutions (Austin, TX)

Dow Chemical’s water treatment business unit and Omni Water Solutions (Austin, TX; no SBIR, founded 2010) together have treated more than 245,000 barrels of wastewater used in Eagle Ford Shale hydraulic fracturing operations.  [Sanford Nowlin, San Antonio Business Journal, Nov 22, 13]

Omni Water Solutions  (Austin, TX; no SBIR), which sells water treatment technology for use in fracking operations, has raised $4 million to accelerate product development. ... A single fracking process uses an average of 4 million gallons of water per well. The water is trucked in, becomes contaminated in the fracking process and is then trucked back out for disposal..  ... Omni’s system uses built-in intelligence that automatically adjusts to changing conditions. It removes contaminants from the water, allowing it to be reused many times. [Lori Hawkins, Austin American Statesman, Apr 22, 13]

startup Omni Water Solutions(Austin, TX; no SBIR) that has developed water treatment technology for use in fracking operations has raised $7.9 million from Austin Ventures and other investors.  ....    said it will use the money to commercialize its product, which lets oil companies recycle millions of gallons of water used in hydraulic fracturing, or fracking.  [Lori Hawkins, Austin American Statesman, Feb 28, 12]

Onboard Dynamics (Bend, OR)

Onboard Dynamics (Bend, OR; no SBIR) an innovator in compressed natural gas (CNG) refueling, received $3 million from ARPA-E, Portland Seed Fund, NW Natural and other utilities, and private investors. ... currently pursuing two compressed natural gas refueling solutions, based on novel technology for both on and off vehicle applications.  [company press release, Apr 26, 16]

OnChip Power (South Boston, MA)

OnChip Power (South Boston, MA; no SBIR) boosted its Series A fundraise by an additional $1 million, bringing the company’s first round to $2.8 million. ...  developing technology that would allow for a smaller, less costly power supply for LED bulbs, in an effort to help drive greater adoption of the energy-saving lighting option.   [Rodney Brown, Mass High Tech, Dec 27, 11]

ONCE Innovations (Plymouth, MN)

Once (Plymouth, MN; no SBIR) received a notice of allowance on its application from the patent office to influence the sex of oviparous embryos naturally through the application of light.  Prior to this technology, controlling the sex of embryos in eggs could only be achieved by either genetically modifying the organism (GMO) or injecting it with potentially harmful hormones. [company press release, Apr 26, 16]

ONCE Innovations  (Plymouth, MN; no SBIR), a developer of animal-specific light-emitting diode (LED) lighting systems announced the successful completion of a $5.3 million Series A Equity Capital Round.  The round was led by New Fashion Pork (NFP) of Jackson, MN, the Ag Ventures Alliance of Mason City, IA, Lateral Capital of Minneapolis, MN, and ONCE founder and chief executive officer Zdenko Grajcar. [and] a number of angel investors. ...  also announced that it reached an additional agreement with leading investors that gives ONCE access to future growth capital in excess of $14 million. [Feedstuffs, Nov 23, 13]

Oncobiologics (Cranbury, NJ)

Oncobiologics (Cranbury, NJ; no SBIR) up 18% [Aug 31, 16]

Oncobiologics (Cranbury, NJ; no SBIR) raised $35 million in what was a rough [IPO] public debut.  Shares closed its first day of trading down 20%. [Anthony Noto, New York Business Journal, May 16, 16]

Oncobiologics (Cranbury, NJ; no SBIR) a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mAbs),  received 38M in VC in 3Q 2015.  [Philadelphia Business Journal and company website, Nov 20, 15]

Sans moi, le deluge. A presidential candidate offers himself as a candidate for dictator if his declared party declines to nominate him, desspite his obvious lack of knowledge of how our government structure has worked since the founding.

Oncoceutics (Philadelphia, PA)

Chimerix up 69% [Jan 8, 21] announced that the Company has acquired Oncoceutics, (Philadelphia, PA; $4M SBIR), clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics' lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. [company press release, Jan 8, 21]


OncoCyte down 37% [Jun 26, 19]

OncoCyte up 19% [Jun 21, 19]

OncoCyte up 18% [May 15, 19]

OncoCyte (once a subsidiary of BioTime, Alameda, CA; no SBIR, founded 2009), a developer of novel, non-invasive tests for the early detection of cancer, announced positive results from its key R&D Validation study demonstrating the accuracy of the Company’s DetermaVu™ liquid biopsy test for lung cancer. The R&D Validation study demonstrated a sensitivity of 90% (95% CI 82%-95%) and specificity of 75% (95% CI 68%-81%) of DetermaVu™ on a prospectively collected cohort of 250 patient blood samples that were blinded to laboratory operators. [company press release, Jan 30, 19]

Oncogenex Pharmaceuticals (Bothell,WA)

Trials of OncoGenex Pharmaceuticals (Bothell, WA; no SBIR) experimental prostate cancer drug has failed to increase survival rates of late-stage prostate cancer of patients.  ....   company is exploring strategic alternatives   [Casey Coombs, Puget Sound Business Journal, Aug 16, 16]

OncoGenex Pharmaceuticals (Bothell, WA; no SBIR) is cutting a quarter of its staff to help preserve the $55 million cash it had on hand at the end of 2015. [Alex Lash,, Feb 5, 16]

OncoGenex Pharmaceuticals (Bothell, WA, no SBIR) said it's retained the rights to prostate and lung cancer drug custirsen from Teva Pharmaceutical Industries , and will receive a $27 million payment from Teva.  [Puget Sound Business Journal, Dec 30, 14]

There are several harsh lessons to be learned in drug development, and OncoGenex (Bothell, WA; no SBIR, founded 2000) learned perhaps the most brutal one of all: a knockout Phase 2 trial doesn’t guarantee a thing in Phase 3.   ....  To the stunned disbelief of OncoGenex, however, the trial the company ran ...there was barely any difference between the two groups of patients. Droves of investors immediately jumped ship, sending shares down more than 50 percent. [Ben Fidler,, May 22, 14]

OncoGenex Pharmaceuticals (Bothell, WA; no SBIR) has clinched $60 million in upfront payments from Israel-based Teva Pharmaceutical for the right to co-develop an experimental prostate cancer drug, as Luke reported. ... But OncoGenex’s stock took a dive as investors saw how much of the future royalties will end up going to Isis Pharmaceuticals.  [Gregory Huang, xconomy Seattle Times, Dec 22, 09]

Some 60% of new cancer drugs are developed in the labs of biotech firms, many of them startups. But this has been a year of living miserably for the biotech industry, and hundreds of these cancer-focused companies are close to folding as investors flee, stock prices sink to near-nothing, and operating cash dwindles. ...  Cougar Biotechnology  (no SBIR) no longer needs to worry—Johnson & Johnson announced on May 21 that it would pay close to $1 billion for the six-year-old Los Angeles company. The biotech is in the final stages of testing a drug, Abiraterone, that has shown promise against late-stage prostate cancer.  OncoGenex Pharmaceuticals (no SBIR) stock hit new highs five days in a row in late May, going from $4 a share in April to $14, in anticipation of the ASCO presentation on its own prostate cancer drug, OGX-11. In early trials the drug appeared to help patients live longer, but OncoGenex had only $9.4 million in cash at the end of March, not enough to fund the next round of clinical trials. Biotech analysts say ASCO gives the company a good chance to find a financing deal. [Business Week, Jun 8]

Canadian firm Oncogenex going public this week. Not to be confused with Oncogene Science of lower NY which had a ton of HHS SBIR and was once a public firm before being bought by Bayer in 1999.

Oncolmmune (Rockville, MD)

As Merck announced scrapping its Covid-19 vaccine candidate, it announced that One of the experimental [therapeutic] drugs Merck is working on would treat severe and critical Covid-19 patients. Merck acquired the drug via a $425 million acquisition of OncoImmune (Rockville, MD; $4.3M SBIR). Merck expects results from a late-stage study by the end of March. [Jared Hopkins, Wall Street Journal, Jan 25, 21]

Merck and OncoImmune (Rockville, MD; $4.3M SBIR) [which has reported positive results from a late-stage study of a coronavirus therapeutic candidate],announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19. [joint companies press release, Nov 23, 20]

OncoImmune (Rockville, MD; $4.3M SBIR) announced the completion of a $56 million financing in Series B [to] support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline. [company press release, Sep 9, 20]

OncoImmmune (Rockville, MD ; no SBIR) closed $5.5 million in fundraising toward beginning clinical trials for its inflammation drug, nearly $10 million short of its goal. China-based Bioventures Capital – a venture investment fund focused on health care – led the Series A funding round. A Securities and Exchange Commission filing shows the company was trying to raise $15 million. [Washington Business Journal, Feb 11, 17]

biopharmaceutical Oncolmmune (Rockville, MD; no SBIR, founded 2000) raised $15 million in Series A funding. ....  is actively engaged in the discovery and development of novel immunotherapies [the use of CD24 proteins] for cancer, inflammation and autoimmune diseases.  [, Jan 17, 17]

Oncolinx (Boston, MA)

Oncolinx (Boston, MA; no SBIR) had the $1 million plan. 43North [selected the] company that develops cancer immunotherapies, known as antibody-drug conjugates, as the top prize winner. ....  has worked with the National Cancer Institute on efforts to target cancer cells without harming healthy cells and without the side effects of chemotherapy -- a concept that seems like it would be right at home on the Buffalo Niagara Medical Campus -- took home the cash after a competition that built in tension and excitement.  [Stephen Watson, Buffalo News, Oct 27, 16]

Oncolytics Biotech

Oncolytics Biotech (Calgary, AB; 11 employees) has tinkered with the structure of the reovirus [carried in water supplies and found in the intestines of most adult humans appears to be lethal to cancer cells] to create a drug candidate called Reolysin. Encouraged by promising animal trials, the National Cancer Institute in Bethesda, Md., is about to start testing Reolysin in human patients with ovarian cancer, the fifth-leading cause of cancer death for women. [Business Week, Feb 4, 08]

Oncolix (Houston, TX)

Oncolix (Houston, TX; no SBIR), which is developing a treatment for ovarian cancer, announced it has completed a reverse merger with Advanced Environmental Petroleum Producers, making it a public company. With the merger and recapitalization, Oncolix is now a wholly-owned subsidiary of AEPP.  ....  Prior to the merger, Oncolix had raised more than $15 million in venture funding.  [Angela Shah,, Aug 8, 17]

OncoMed Pharmaceuticals (Redwood City, CA)

OncoMed Pharmaceuticals (Redwood City, CA; no SBIR) announced a [50%] reduction in its workforce to focus internal efforts on the advancement of three clinical-stage programs to key milestones and continued immuno-oncology drug discovery and development, while seeking to partner select pipeline assets. ... resulting in 64 remaining full-time employees.  [company press releasem Apr 24, 17] earlier,  reported top-line results from the company's randomized 145-patient Phase 2 PINNACLE clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) in combination with etoposide plus either cisplatin or carboplatin chemotherapy ("chemotherapy") in previously untreated patients with extensive-stage small cell lung cancer.  Results for the combination of tarextumab plus chemotherapy were undifferentiated from those of chemotherapy plus placebo, and therefore the trial did not meet its primary endpoint of progression-free survival or secondary endpoints of overall survival and biomarkers reflective of Notch pathway gene activation.  [company press release, Apr 13, 17]

OncoMed Pharmaceuticals (Redwood City, CA; no SBIR) said it stopped enrolling new patients in two early stage clinical trials of cancer treatments after some people suffered "bone-related adverse events."   [Steven E.F. Brown, San Francisco Business Times, Jun 13, 14]

OncoMed Pharmaceuticals (Redwood City, CA;  no SBIR) will get $177.25 million upfront and Celgene Corp. will take an equity stake in the Redwood City company as part of a deal around an experimental cancer treatment and up to five other potential drugs.  ....  the deal eventually could be worth more than $2.7 billion with milestone payments, royalties and more.  ....  [the stock  doubled] to a level unseen since its first week of trading in July. [Ron Leuty, San Francisco Business Times, Dec 3, 13] fewer than 90 employees [company press release]

OncoMed Pharmaceuticals soared 60 percent after the company raised $82 million in an [IPO] ...  develops monoclonal antibody therapeutics that target cancer stem cells ...  has collaboration agreements with GlaxoSmithKline for the development of two of its drug candidates, each with possible payments of up to about $350 million.  [Silicon Valley Business Journal, Jul 18, 13]

OncoMed Pharmaceuticals (Redwood City, CA; no SBIR) priced its initial public offering to raise as much as $73.6 million. ....  developing monoclonal antibody drugs that target cancer stem cells, a relatively small subpopulation of stem cells in a tumor that drive the cancer to grow and spread  [Ron Leuty, San Francisco Business Times, Jul 8, 13]

OncoMed Pharmaceuticals (Redwood City, CA; no SBIR). will work with Germany’s Bayer Schering Pharma AG on stem cell drugs to fight cancer.... gets a $40 million upfront payment  [Stephen EF Brown, San Francisco Business Times, Jun 17,10]  founded 2004, by Drs. Michael F. Clarke and Max Wicha who led the discovery of cancer stem cells, in solid tumors ... has attracted significant funding from a prominent group of investors [company website]  raised $93 million in a Series B funding extension, bringing the round total to $154 million.[SF Business Times, Nov 4, 08]

OncoNano Medicine (Dallas, TX)

OncoNano Medicine  (Dallas, TX, spinout company from the University of Texas Southwestern Medical Center, one SBIR) which is developing an imaging agent to help surgeons better remove tumors, has raised $11.7 million in Series A funding. ...  follows a $6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT)  [Angela Shah,, May 18, 18]

biotech company OncoNano Medicine (Dallas, TX; no SBIR) was one of the big winners in a $107 million round of funding (101 grants) awarded by the state’s cancer-fighting agency today. ...  awarded $6 million to OncoNano for a project that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. ...  [funding agency CPRIT] is a state agency created with $3 billion in bond money ... The largest single grant given this round by the state anti-cancer agency will go to Curtana Pharmaceuticals (San Diego, CA; no SBIR), relocating to Austin. It will receive $7.5 million over three years to develop treatments for adult and pediatric brain cancer tumors.  ...  Get the full list of 101 grant recipients here .   [Bill Hethcock, Dallas Business Journal, Aug 21, 14]

Onconova Therapeutics (Newtown, PA)

Onconova Therapeutics (Newtown, PA; $2.2M SBIR), a biopharmaceutical focused on discovering and developing novel products to treat cancer, announced that INSPIRE, the company’s pivotal Phase 3 study assessing the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients, did not meet its primary endpoint of improved survival. [company press release, Aug 24, 20]

Onconova Therapeutics  down 12% [Jan 11, 17]

Onconova Therapeutics  up 32% [Jan 10, 17]

Onconova Thera down 14% [Jul 25, 16]

Onconova Thera down 15% [Jul 1, 16]

Onconova down 11% [Jun 14, 16]

Onconova Thera  up 33% [Jun 9, 16]

Onconova Thera  up 11% [Jun 6, 16]

Onconova Therapeutics (Newtown, PA; $1.7M SBIR) said it has received a notice that Baxalta was terminating their multimillion-dollar development and licensing agreement for rigosertib, Onconova’s lead new drug candidate. ... [the original deal] included an upfront payment of $50 million and the chance for Onconova to earn another $515 million milestone payments  [John George, Philadelphia Business Journal, Mar 4, 16]

Onconova Thera up 10% [Jul 1, 15]

Onconova Thera down 36% [Feb 3, 15] announced that [it] has solidified its plans for a Phase 3 clinical trial for rigosertib in HR-MDS patients after failure of treatment with HMAs. [company press release, Feb 2, 15]

Onconova Thera  down 10% [Dec 10, 14]

Onconova Therapeutics  ($2M SBIR) up 14% [Jun 12, 14]

down 37% [Feb 20, 14] after the cancer-focused biopharmaceutical company said a late-stage clinical trial of its drug rigosertib failed to meet its primary objective. [Wall Street Journal, Feb 20, 14]

Onconova Pharma up 11%   [Jan 30, 14]

Onconova Thera up 13% [Jan 28, 14] 

Onconova Therapeutics said it is discontinuing a phase-III study of its lead experimental anti-cancer drug ...   after a data safety monitoring board determined that the combination of rigosertib and gemcitabine is unlikely to demonstrate a statistically significant improvement in overall survival when compared to gemcitabine alone. There were no safety concerns raised by the board in its review of the study.  [John George, Philadelphia Business Journal, Dec 17, 13]

Onconova Thera down 19% [Dec 18, 13]

Onconova Thera  up 10% [Dec 16, 13]

Onconova Thera up 17% [Nov 20, 13]

Onconova Thera ($2M SBIR) up 10% [Nov 19, 13]

Oncanova Thera down 14% [Nov 7, 13]

Onconova Therapeutics (Newtown, PA; $2M SBIR) up 10% [Nov 5, 13]

Onconova Therapeutics (Newtown, PA; $1.4M SBIR) up 24% [Aug 5, 13] after raising $79M in an IPO Jul 30.

Onconova Therapeutics (Newtown, PA;  $2M SBIR)  filed for IPO  .... focused on cancer treatment and diagnostic products.  [John George, Philadelphia Business Journal,  Jun 21, 13]

Onconova Therapeutics (Newtown, PA; $2M SBIR) entered into a partnership Wednesday with GVK BIO, a contract research-and development organization based in India, to develop new drugs to treat cancer. [John George, Philadelphia Business Journal, Jan 9, 13]

Onconova Therapeutics (Newtown, PA; $2M SBIR) raised $50 million in a private-equity sale, according to a [SEC] filing ....  developing new drugs for treatment of cancer and radiation injury.  [Peter Key, Philadelphia Business Journal, Aug 13, 12]

Onconova Therapeutics (Newtown, PA; $2M SBIR) raised $7.05 million in a private equity financing, according to [SEC] documents ...  seeking to raise a total of $30 million.  ...  developing new therapies to treat cancer and related disorders.    [John George, Philadelphia Business Journal, May 11, 12]

OnCore Biopharma (Doylestown, PA)

OnCore Biopharma (Doylestown, PA; no SBIR) biopharmaceutical company seeking to develop a cure for hepatitis B, is merging with Tekmira Pharmaceuticals (Canada) ....  founded in 2012 by the group at Pharmasset (led by Mike Sofia) that developed Sovaldi, a drug now used as part of a combination therapy to cure hepatitis C. Pharmasset was acquired by Gilead Sciences (NASDAQ: GILD) for $11.5 billion in early 2012. ...  will focus on developing a "curative regimen" for hepatitis B patients by combining multiple therapeutic approaches.   [John George, Philadelphia Business Journal, Jan 12, 15]

OncoResponse (Houston, TX)

OncoResponse (Seattle, WA; no SBIR, founded 2015) an immunotherapy company developing a portfolio of novel antibodies to high-value targets for the treatment of cancer, today announced the completion of a $40 million series B equity financing. [company press release, Sep 11, 18] total funding $62M []

OncoResponse (Houston, TX; no SBIR), an immuno-oncology antibody discovery company,` announced that it has closed its ongoing $22.5 million Series A financing round ... utilizes a clinically validated platform technology to rapidly screen antibodies made by the human immune system and identify those with exceptional reactivity to cancer. The Company has a strategic alliance with MD Anderson Cancer Center. [company press release, Mar 9, 17]

OncoResponse  (Houston, TX; no SBIR), an immuno-oncology antibody discovery company,  announced $7 million in a supplemental Series A financing ....In October 2015, secured $9.5 million as part of an initial closing of its Series A ....   utilizes a clinically validated platform technology to rapidly screen antibodies made by the human immune system and identify those with exceptional reactivity to cancer immunotherapy.   [company press release, Oct 10, 16]

OncoResponse is a new cancer immunotherapy company formed by the University of Texas M.D. Anderson Cancer Center and Seattle-based Theraclone. With its public launch, the company also announced it has raised $9.5 million in a Series A round  [Angela Shah,, Oct 6, 15]

Theraclone Sciences (Seattle, WA; no SBIR) and the University of Texas MD Anderson Cancer Center have launched OncoResponse (Houston, TX), [after raising $9.5 million in Series A funding] dedicated to discovering new immunotherapy treatments for cancer by examining blood samples from cancer patients who have responded well to immunotherapy. ... Ultimately, clinical trials for treatments developed at OncoResponse also will be conducted at MD Anderson.  Immunotherapy involves engineering a patient's blood cells and then infusing them back into the body to boost the immune system and battle cancer, or other diseases. This is a booming sector of the Puget Sound region's biotech industry right now.   [Annie Zak, Puget Sound Business Journal, Oct 6, 15]

Oncorus (Cambridge, MA)

Oncorus ($300K SBIR) down 45% [Nov 12, 21] presented initial safety, tolerability and immune activation and clinical response data from its ongoing Phase 1 open-label, multi-center, dose escalation and expansion clinical trial of ONCR-177 and that it has signed an exclusive licensing agreement with Gaeta Therapeutics Ltd., related to the use of locally delivered Interleukin-12 (IL-12) via oncolytic viral expression in combination with immune checkpoint inhibitors, [company press releases, Nov 11, 21]

Oncorus (Cambridge, MA; $300K SBIR, IPO Oct 1, 20) up 24% [Oct 14, 20]

Oncorus (Cambridge, MA; no SBIR, founded 2015), an oncolytic virus company focused to transform outcomes for cancer patients, announced the completion of an oversubscribed $79.5 million Series B financing. [company press release, Aug 21, 19] prior funding $60M []

Oncorus  (Cambridge, MA; no SBIR) a new immuno-oncology company developing a next-generation immunotherapy platform of oncolytic viruses for the treatment of several tumor types including highly malignant and aggressive cancers such as glioblastoma multiforme (GBM), announced the successful completion of a $57 million Series A financing. ... licensed certain patent rights from the University of Pittsburgh based upon the work of renowned scientists Joseph Glorioso III, Ph.D., and Paola Grandi, Ph.D., who will join Oncorus's Scientific Advisory Board.  [company press release, Jul 19, 16]

Oncorus, (Cambridge, MA; no SBIR) startup closed a $57 million from a large group of investors. ... founded by Mitchell Finer, a biotech veteran who most recently served as the chief scientific officer of gene therapy developer Bluebird Bio for five years before leaving in 2015 to join MPM Capital  ... plan, meanwhile, is to develop what it calls, of course, a next-generation platform of oncolytic viruses—viruses engineered to get into tumor cells, replicate, and cause them to explode, in the process activating the immune system to destroy any remaining cancer.  ...  developing an oncolytic herpes simplex virus, and is targeting deadly, aggressive cancers like the brain cancer glioblastoma.  [Ben Fidler,, Jul 20, 16]

Oncoscope (Durham, NC)

Oncoscope (Durham, NC; $300K SBIR) says it has raised $890,000 in stock and warrant offering. The five-year-old start up, develops imaging equipment to detect cancer ... The company’s optical imaging technology stems from work done by Dr. Adam Wax who sits on the company’s board and who works in the Department of Biomedical Engineering at Duke University.  [Lee Weisbecker, Triangle Business Journal, Jul 20, 11]

OncoSec Medical (San Diego, CA)

San Diego’s newest biotechnology company has been launched under the name OncoSec Medical. The company said Monday that it launched operations with the purchase and licensing of a drug delivery technology from vaccine developer Inovio Pharmaceuticals, which operates a facility in San Diego.   OncoSec’s corporate identity was created March 1 through a so-called reverse merger with NetVentory Solutions, a Reno-based public company that provided online inventory services to business clients.  [Keith Darce,, Mar 21, 11]

OncoTartis (Buffalo, NY)

OncoTartis (Buffalo, NY; no SBIR, founded 2011), a biotechnology company developing a novel category of anti-cancer drugs, has concluded a $6 million financing round to support the Phase 1 clinical trial of its lead drug candidate, OT-82. [company press release, Dec 11, 17]

Oncothyreon (now Cascadian Therapeutics) (Seattle, WA)

Cascadian Thera (formerly Oncothyreon, no SBIR) up 18% [Jun 28,17]

Alder Biopharma down 10% [Jun 28,17]

biopharmaceutical company Oncothyreon (Seattle, WA; no SBIR) said it is changing it name to Cascadian Therapeutics and will trade on Nasdaq under the new ticker symbol CASC starting Thursday.  CEO Scott Myers said in a statement that the company is changing its name “to underscore our transition away from therapeutic vaccines to developing innovative targeted therapies for cancers.”   [Seattle Times, Jun 8, 16]

Oncothyreon down 32% [Dec 9, 15]  after announcing updated data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer.  [company press release]

Oncothyreon up 10% [Nov 2, 15]

Oncotyreon down 12% [Sep 25, 15]

Oncothyreon up 16% [Jun 1, 15]

Oncothyreon up 20% [May 22,15]

Oncothyreon down 17% [Apr 19, 14] said a test of its lung cancer drug in Japan "did not meet its primary endpoint of an improvement in overall survival, and no treatment effect was seen."  The study of 178 patients in Japan of patients with Stage III non-small cell lung cancer by Merck of Germany of tecemotide, compared with a placebo    [Ben Miller, Puget Sound Business Journal, Aug 19, 14]   also has acquired Alpine Biosciences  (Seattle, WA; no SBIR) [for about $27 million in stock] developing protocells, a technology platform designed to deliver therapeutic agents.  [Ashley Stewart, Puget Sound Business Journal, Aug 11, 14]

Oncothyreon has acquired another local firm, Alpine Biosciences  (Seattle, WA; no SBIR) for about $27 million in stock.  Alpine Biosciences, an early stage company that has not advanced any drugs into clinical trials  [Seattle Times, Aug 11, 14]

Oncothyreon up 13% [Apr 22, 14]

Oncothyreon up 10%  [Mar 5, 14]

Oncothyreon up 12% [Feb 7, 14]

Oncothyreon  (Seattle, WA; no SBIR) biotechnology company said it has agreed to a private placement deal that will raise about $14.9 million before expenses.  [Seattle Times, Sep 24, 10]

Oncothyreon (Seattle, WA; no SBIR) slid 27% after temporarily suspending a program with German drug maker Merck KGaA on developing a cancer vaccine following an “unexpected serious adverse reaction” in a patient who experienced brain swelling. The Food and Drug Administration has placed a clinical hold on the investigational new-drug application for the drug, Stimuvax.  [Wall Street Journal, Mar 24, 10]

Oncovista Innovative Therapies (San Antonio, TX)

Oncovista Innovative Therapies (San Antonio, TX; no SBIR, founded in 2004) favorably settled its three-year litigation in New York Supreme Court, the company said ... has two cancer-fighting drugs in the development pipeline, one in Phase I for the treatment of colon cancer and one in Phase I/II for the treatment of leukemias.   [James Aldridge, San Antonio Business Journal, Jun 19, 15]

Oncternal Therapeutics (San Diego, CA)

Oncternal Therapeutics up 31% [Oct 14, 19]

Oncternal Thera up 18% [Aug 19, 19]

Oncternal Therapeutics up 24% [Jun 18, 19]

Viela Bio (Gaithersburg, MD; SBIR) closed on $75M of funding, for a total haul of $350M since launching 16 months ago. ... in late May, Viela sealed a deal worth up to $220M with Chinese company Hansoh Pharmaceutical Group to commercialize inebilizumab in China. [DCInno, Jun 18, 19]

Oncternal Therapeutics (San Diego, CA, no SBIR, founded 2013) down 17% [Jun 12, 19] Goes Public After Reverse Merger With GTx. Oncternal is in the midst of early-stage testing of its lead drug candidate, cirmtuzumab, which is being studied in combination with AbbVie’s (NYSE: ABBV) cancer drug ibrutinib (Imbruvica) for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. [Sarah de Crescenzo,, Jun 12, 19) total funding $53M []

GTx (Memphis, TN; $300K SBIR) and Oncternal Therapeutics (San Diego, CA; no SBIR) biotechnology company developing potential first-in-class therapeutic candidates for cancers, jointly announced that they have entered into a definitive merger agreement under which the stockholders of Oncternal would become the majority owners of GTx’s outstanding common stock. The proposed merger will create a publicly-traded, clinical-stage oncology company, Oncternal Therapeutics. [joint companies press release, Mar 7, 19]

One Resonance Sensors (San Diego, CA)

Raytheon has been working to develop a sensor that could identify those explosive materials shielded in a car, packed into a case, or hidden on a person. The result of that decade of work: a new radio-frequency sensor that identifies explosives by their chemical composition. The system is called REDS, or Raytheon’s Explosive Detection System, and it’s scalable — from a handheld sensor the size of a laptop to a full-size checkpoint that can scan pedestrians and vehicles as they pass. It’s still experimental.  ... In competition  One Resonance Sensors  (San Diego, CA;  SBIR, 10 employees) startup has developed an RF scanner that identifies explosives in liquids and electronic devices — the two threat scenarios that most concern airport security.  [Caroline Houck, DefenseOne, Oct 20, 17]    [ORS has] four federal contracts: $3 million from DHS’ Science and Technology Directorate to evaluate the device scanner, $1 million from TSA to modify the bottle scanner already certified for use at airports in Europe, and smaller research contracts from the Agriculture Department and the U.S. Army to scan soil for moisture levels.   [Mohana Ravindranath,, July 11, 2017]

Onduo (Cambridge MA)

Rich startup.  A new Cambridge [MA] startup with half a billion dollars in funding from Verily, the life sciences effort launched by Google's parent, Alphabet, and French drug giant Sanofi aims to address one of the biggest problems in health care — diabetes. And it aims to do so through “the marriage of technology and medicine.” ...  Onduo will be headed by Joshua Riff, a Tufts Medical School graduate and former emergency room doctor. [ Don Seiffert, Boston Business Journal, Sep 12, 16]

Onexio Biosystems (Madison, WI)

Six Madison [WI]-area tech startups are receiving grants from the SBIR Advance program, a collaboration between the Wisconsin Economic Development Corp. and the UW System Administration's Center for Technology Commercialization, to grow their businesses.  Onexio Biosystems, Madison $75K, Equipment used to quickly screen potential drug compounds during the drug development process. Pyran, Madison $75K: Using wood and crop waste to make a key chemical used to manufacture paints and plastics; Stem Pharm, Fitchburg, $75K: Biomaterials for cell and tissue manufacturing; NCD Technologies, Madison $100K: Diamond and diamond-like coatings for medical devices and other industries. PhylloTech, Middleton $100K: A process to engineer plants to produce proteins that will help them resist agricultural diseases. [Judy Newman, Wisconsin State Journal, Mar 27, 19]

Onko Solutions (Austin,TX and  Mexico)

Onko Solutions LLC (Austin, TX and  Mexico) announced it has closed its Series A financing round, raising a total of $1.6 million USD for the commercialization of a cervical cancer screening [VitaScreen] device that aims to replace the Pap smear as the worldwide standard. Onko's medical device offers accurate, instantaneous, and accessible cervical cancer screening for marginalized communities and women in general. ....   does not require laboratory analysis or a tissue sample. ... Our device combines multiple technologies leveraging Intelligent systems based on neural networks and support vector machines, including biophotonics, bioimpedance and biophysics, an increasingly important field in the area of cancer prevention and diagnosis  [company website, Feb 10, 16]

OOnKure Therapeutics (Boulder, CO)

OnKure Therapeutics (Boulder, CO; no SBIR), developing small molecule drugs for cancer treatment, raised $3.2 million in equity funding as part of a $5.2 million round, according to a Form D filing. The company spun out of research performed in a CU Boulder biochemistry lab and enrolled its first cancer patient in clinical trials last year. [Colorado Inno]

ONL Therapeutics (Ann Arbor, MI)

ONL Therapeutics (Ann Arbor, MI; $2M SBIR) [University of Michigan spin-out] received an orphan drug designation from the FDA for ONL1204, an experimental treatment for retinal detachment. In a press release, ONL said it’s the only company that has secured orphan status for a retinal detachment drug. Clinical trials for ONL1204 are expected to get underway some time this year. [Sarah Schmid,, Feb 19, 16]

OnLume (Madison, WI)

OnLume (Madison,WI; $3.4M SBIR, founded 2015) announced the completion of its [$7M] Series A funding to assist its plans for commercial launch. [company press release, Apr 30, 21]

medical imaging device startup OnLume (Madison, WI; $300K SBIR) received FDA clearance to bring its fluorescence-guided surgery system to market. OnLume's cart-based imaging technology uses fluorescence imaging to monitor blood flow and tissue perfusion before, during and after vascular, gastrointestinal, organ transplant, plastic, reconstructive and micro-surgeries. [WiscInno, Feb 18,20]

On-Q-ity (Waltham, MA)

cancer diagnostics firm On-Q-ity (Waltham, MA; founded 2009) pulled in $5 million in funding ... amassing a total of $26 million in its Series A round .... identifies cancer characteristics of individual patients in order to determine the best treatment to follow. The company’s technology combines DNA repair biomarkers with circulating tumor cell analysis in determining potential treatments.  [Mass High Tech, Dec 14, 09]

cancer diagnostics firm On-Q-ity (Waltham, MA; no SBIR) is taking in $21 million in venture capital funds  [Mass High Tech, Nov 3, 09]

Onspira Therapeutics (Malvern. PA)

Onspira Therapeutics (Malvern. PA; no SBIR) biopharm firm targeting rare pulmonary disorders raises $1M ...  the latest to be launched by Malvern-based NeXeption  [John George, Philadelphia Business Journal,  Jul 5, 17]

On Target Laboratories (West Lafayette, IN)

On Target Laboratories (West Lafayette, IN; no SBIR, founded 2010 spinout from Purdue U) developing tumor-targeted fluorescent dyes to improve cancer surgery, has secured $40 million in a combination of equity and convertible debt financing led by new investor Johnson& Johnson Innovation ...  to further advance the development of its lead imaging compound, OTL38, for use in detecting multiple cancers, including ovarian and lung, and also development of a second imaging compound for additional cancers.  [company press release, Nov 1, 17]

Ontela (Seattle, WA)

Glowforge  (Seattle, WA; no SBIR)  startup announced a $9 million series A financing round  from big name venture firms ... created a [3D] printer that is simpler to use  ... The technology works by letting people upload sketches to the cloud and minutes later, the machine can create a 3D version of that sketch by carving it into a block of wood, leather or other materials. [Founder Dan] Shapiro has an impressive history in the business world — he was CEO of Google Comparison, and founded Ontela (Seattle, WA; no SBIR) and Sparkbuy (Seattle, WA; no SBIR).  [Rachel Lerman, Puget Sound Business Journal, May 20, 15]

On-X Life Technologies (Austin, TX)

CryoLife (Atlanta, GA; $2M SBIR) entered into an agreement to acquire On-X Life Technologies Holdings (Austin, TX; no SBIR)  mechanical heart valve company ...  On-X valves have been implanted in over 200,000 patients ... for an upfront payment of $130 million. [Carla Caldwell, Atlanta Business Chronicle, Dec 2, 15]

On-X Life Technologies (Austin, TX; no SBIR, founded 1994) can market its prosthetic heart valve that helps prevent flattening and distortion after receiving [FDA] approval ... easier to implant in small patients which is common in southern Europe, Latin America and Asia, company officials said in a news release. ... employed more than 100 workers in 2010   [Sarah Drake, Austin Business Journal, Feb 26, 13]

Onyx Pharmaceuticals (Emeryville, CA)

Onyx Pharmaceuticals ($800K SBIR),  [now] a division of Amgen, has asked the FDA to expand its approval of carfilzomib (Kyprolis) to multiple myeloma patients whose disease has relapsed after at least one other therapy. Onyx also asked European regulators for approval to treat the same patient group. [Alex Lash,, Jan 29, 15]

When Amgen bought Onyx Pharmaceuticals (South San Francisco, CA; $800K SBIR) last year for $10.4 billion, it expected great things from Onyx’s multiple myeloma treatment carfilzomib (Kyprolis), which won its first approval in 2012 in a limited patient population.   Those expectations went a bit sideways this week, as Amgen said late Wednesday that carfilzomib did not meaningfully extend the lives of patients whose multiple myeloma was in advanced stages and not responsive to other treatments. It was a Phase 3 trial with 315 patients that Amgen hoped would pave the way for the use of carfilzomib as a single agent outside the U.S. It has not been approved outside the U.S.   [Alex Lash,, Aug 14, 14]

How Onyx morphed from a one-hit wonder to the most-wanted list. Story by Ron Leuty: []

Amgen reached a deal to buy fellow biotech Onyx Pharmaceuticals ($700K SBIR in the late 1990s) for roughly $10.4 billion, the latest proposed takeover aimed at tapping into growth expected from the cancer-drug industry. [Dana Cimilluca and Jonathan D. Rockoff, Wall Street Journal, Aug 25, 13]

Onyx Pharma ($700K SBIR in late 1990s) shares rocket 51% after the company says it's seeking buyers after receiving inquiries. No shortage of speculation about who could acquire Onyx: Bayer, Celgene , Novartis , Bristol-Myers , AstraZeneca , Eli Lilly , Gilead and Pfizer. [, Jul 1, 13]  has been transformed from a struggling biotech company to a $10 billion acquisition target in just a few years, the result of gambles made by its hard-charging chief executive, N. Anthony Coles, who sued his company's partner and agreed to pay more than $800 million for an unproven drug startup.  [Joseph Walker, Wall Street Journal, Jul 2]    Market cap now $6B and rising.  How many SBIR awardees from DOD and NASA have that kind of ROI which happens often from NIH SBIR?

Onyx Pharmaceuticals said it rejected a roughly $10 billion takeover offer from larger rival Amgen Inc as too low but is still considering a sale of the company. [Ryan Vlastelica and Olivia Oran, Reuters, Jun 30, 13]

Bayer AG and Onyx Pharmaceuticals said their drug Nexavar helped to nearly double the number of months that patients with a rare type of advanced thyroid cancer lived without their diseases worsening—but that the drug made no difference in patients' overall survival. [Joseph Walker, Wall Street Journal, Jun 3, 13]

Onyx Pharma 12% [Feb 22,13]

Tony Coles, the CEO of  Onyx Pharmaceuticals(South San Francisco, CA; $700K SBIR), along with BayBio and Deloitte, has convened a working group of top CEOs, venture capitalists and university officials to brainstorm about actions the region can take to stimulate more biotech activity. [Luke Timmerman,, Jan 21,13] [Onyx] will raise more than $358 million by selling 4.4 million shares of its common stock. [Ron Leuty, San Francisco Business Times, Jan 16, 13] 

(South San Francisco, CA) up 12%  [Jul 20, 12] just went from being a one-drug company, to a two-drug company. won clearance from the FDA to start selling carfilzomib (Kyprolis) as a new treatment for patients with multiple myeloma, who have gotten at least two prior treatments. [Luke Timmerman, Jul 20, 12]

[La Jolla venture capitalist Kevin Kinsella] feels the salad days of biotech — when you could take a promising therapeutic protein, and then build a company around it, and IPO that company, or hold on to it all the way to the bank — those days may be over. And Kinsella has an informed opinion on the matter because over the past 34 years he’s helped to bring 100-plus biotech and pharma companies to market, including Vertex and Onyx Pharmaceuticals along with several billion-dollar drugs for cancer and hepatitis [Steve Chapple,, Jun 23]

ONYX Pharma up 43% [Jun 21, 12]

Onyx Pharma up 14% [Nov 28, 11]

Onyx Pharma up 10% [Oct 26, 11]

Onyx Pharmaceuticals (Emeryville, CA; $900K SBIR) jumped 21% after reporting that its experimental drug, called carfilzomib, was effective in treating advanced multiple myeloma, a fatal blood cancer, in patients that had no remaining treatment options. ... now expects to file for Food and Drug Administration approval for its lead development candidate by year-end.  [Wall Street Journal, Jul 27, 10]

Onyx Pharmaceuticals ($800K SBIR in the 1990s) said it will buy cancer drug developer Proteolix (South San Francisco, CA; no SBIR) in a deal that could be worth as much as $851 million. [Seattle Times, Oct 13, 09]

ONYX Pharma down 15% [Aug 5, 09]

Onyx Pharmaceuticals' ($800K SBIR) kidney and liver cancer drug Nexavar, sold with large-cap Bayer, proved effective in a mid-stage trial in delaying the progression of advanced breast cancer. Emeryville, Calif., biopharmaceutical company Onyx closed up 21%.  [Wall Street Journal, Jul 23]

Onyx Pharmaceuticals (Emeryville, CA; $800K SBIR) and its partner, Bayer HealthCare Pharmaceuticals, said Monday that a test of their cancer drug Nexavar failed a Phase III trial to treat a form of melanoma. [San Francisco Business Times, Apr 27, 09]

Onyx Pharmaceuticals (Emeryville, CA; $600K SBIR) said a lung cancer trial its flagship drug nexavar was halted because of increased death in patients taking the drug.  [Wall Street Journal, Feb 20]

Onyx Pharmaceuticals (Emeryville, CA; $800K SBIR a decade ago) up 18%, now up 11 of the last 12 sessions as part of its 448% gain so far this year. Yesterday's move came after the pharmaceutical company swung to a third-quarter profit of $555,000, or 1 cent a share, and noted a jump in revenue for Nexavar, a kidney- and liver-cancer therapy. [Wall Street Journal, Nov 8]

Oorja Protonics (Fremont, CA)

Oorja Protonics (Fremont, CA; no SBIR) has sold 15 methanol fuel cells to power materials handling vehicles at a Martin-Brower food distribution warehouse in Stockton. ... Sanjiv Malhotra founded Oorja Protonics in 2005. Since then it’s raised about $25 million from venture capitalists, plus seed funding from Toyota  [Lindsey Riddell, San Francisco Business Times, Jun 17,10]

Open Algae (Texas)

When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes.  Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund.....  Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital.  [Lori Hawkins, Austin American Statesman, Jan 26, 12]  Graduates: Agile Planet,  Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar,  Savara Pharmaceuticals, Spredfast, Terapio ($500K  SBIR), Unwired Nation, 

Open Monoclonal Technology (Palo Alto, CA)

Biotech company Ligand Pharmaceuticals (San Diego, CA; one SBIR) acquired genetic engineering company Open Monoclonal Technology (Palo Alto, CA; no SBIR) for $178 million.  ...  OMT brings with it license agreements with biotechnology partners such as Amgen, Celgene, Genmab, Janssen, Merck KGaA, Pfizer, Seattle Genetics, Five Prime and Symphogen....   to genetically engineer animals to develop antibody therapeutics. OMT’s antibody drug discovery technology is believed to make it the only company in the world offering three transgenic animal platforms for license.  [Gina Hall, Silicon Valley Business Journal, Dec 18, 15]

Open Silicon

Open Silicon's innovation was its strategy to outsource chip design to lower-cost workers in India. ...When Intel changed its mind and closed the [ASIC] business, he lured five co-workers to help start his company. Within nine months, he brought over another 20 former colleagues, both in the United States and India. ... The advantage Open Silicon offers is that it can negotiate pricing with chip factories and other vendors based on a volume of business that none of its customers could attain by themselves, [Mark Boslet, San Jose Mercury News, Jun 21]  SBIR? Get serious.

OpenWater Power (Somerville, MA)

OpenWater Power (Somerville, MA; no SBIR) an MIT spin-out   ...  set a record: the longest-ever trip for a battery-powered undersea craft. [315 miles Boston-NYC]  ...  being funded by a $450,000 grant from the US Navy  ... working on two different kinds of battery designs: an aluminum-seawater version that needs seawater to operate and must be vented; and an aluminum-permanganate version that is completely sealed.   ....   [co-founder] Milnes was involved with two previous startups, both in the 3D scanning and printing arena. Brontes Technologies (no SBIR) made scanning equipment for dentists, and was sold to 3M for $95 million. Viztu Technologies (no SBIR) was acquired for an undisclosed amount by 3D Systems; it developed software to let consumers turn pictures and videos into printable objects. [Scott Kirsner , Boston Globe, Jan 31, 14] Want an innovation that will travel, use an experiened innovator, not just a well credentialed scientist. Although the Navy won't care about private success.

Opertech Bio (Philadelphia, PA)

Opertech Bio (Philadelphia, PA; no SBIR) that has pioneered a new system for turning animals and humans into highly efficient taste testers, has raised $750,000 in private equity financing. ... Historically, [CEO Scott] Horvitz said, taste testing by companies in the food and flavor industries was an expensive process that required many subjects, large amounts of test samples, and days to weeks for evaluation of only a few samples. MOG, he said, accomplishes the task on hundreds of samples in an afternoon — using far fewer subjects and smaller sample amounts at a fraction of the cost and with greater accuracy and consistency.   [John George,Philadelphia  Business Journal, Dec 22, 14]

Opexa Therapeutics (Woodlands, TX)

Opexa Therapeutics (originally PharmaFrontrers;  no SBIR) is the target of a reverse merger with Acer Therapeutics (Cambridge, MA; no SBIR) and Acer would receive $15.7 million in a financing round   [Angela Shah,, July 5, 17]

Opexa Thera  down 21%  [Sep 14, 16]  leading percentage decliner

Opexa Therapeutics (Woodlands, TX; no SBIR) is looking to multiple sources for capital as it proceeds through Phase 2 trials of its fast-track drug, Tcelna.... has two purchasing agreements that would provide it access to $16.5 million.  [Bayan Raji, Houston Business Journal, Nov 21]

Opexa Therapeutics (Woodlands, TX; no SBIR) has agreed to sell $5.1million in shares to institutional investors. [Houston Business Journal,Dec 10, 09]

OpGen (Gaithersburg, MD, formerly Madison, WI)

OpGen down 21% [Mar 17, 20]

OpGen up 101% [Mar 16, 20] reported an update on the business of Curetis GmbH ("Curetis"), the other party to the planned business combination with OpGen. Today, Curetis announced that it started offering a CE-IVD certified real-time PCR test kit for SARS-CoV2 (also known as 2019-nCov), the causal pathogen of Corona Virus Disease 2019 (Covid-19). [company press release, Mar 16, 20]

OpGen up 15% [Mar 3, 20]

OpGen down 18% [Mar 4, 20]

Op Gen down 55% [Oct 24, 19]

Op Gen down 38% [Oct 23, 19] announced the pricing of an underwritten offering [to] raise $9.4M [company press release, Oct 23, 19]

OpGen is acquiring German molecular diagnostic company Curetis in a move that will create a combined firm worth $24M. OpGen, a precision medicine developer, will make Curetis a wholly owned subsidiary [DCInno, Sep 5, 19]

OpGen up 23% [Sep 4, 19]

OpGen (Gaithersburg, MD; no SBIR) up 18% [Aug 30, 19]

Sonavex (spun out of Johns Hopkins, Baltimore. MD; $1.2M prior SBIR) medical device company announced a $3 million [NIH] Phase II SBIR to use its EchoMark & EchoSure devices to support arteriovenous (AV) fistula maturation and long-term viability. ... for prospective clinical studies and continued [R&D]. [company press release, Aug 29, 19] prior funding $10M []

OpGen down 19% [Feb 2,18]

OpGen down 23% [Jan 31,18]

OpGen down 18% [Jan 29,18]

OpGen  down 10% [Jan 26, 18]

OpGen up 26% [Jan 25,18]

OpGen up 30% [Jan 24,18]

OpGen up 21% [Jan 22, 18] after a 1-for-25 reverse stock split of its common stock on Jan 17

molecular diagnostics company OpGen says it has come back into compliance with Nasdaq rules after facing the threat of delisting in May. OpGen was informed of a possible delisting after stockholders' equity fell below the required $2.5 million minimum. (Washington Business Journal, Jul 31, 17])

OpGen (Gaithersburg, MA; no SBIR) received a written notification from The Nasdaq that it fails to comply with Nasdaq’s Marketplace Rule because the Company’s stockholders’ equity as of March 31, 2017 fell below the required minimum of $2,500,000 [, May 15, 17]

OpGen (Gaitherburg, MD; no SBIR) announced it has entered into a research collaboration with Merck to develop new rapid diagnostics and information technology products to help combat the threat of antimicrobial resistance. The companies will collaborate to support OpGen’s development of rapid DNA tests and a genomic knowledgebase of antibiotic-resistant pathogens for predicting antibiotic susceptibility based on test results. [company press release, Nov 14, 16]

OpGen down 19%  [Jul 21, 16]

OpGen (Gaithersburg, MD; no SBIR), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the first closing of a private placement financing raising gross proceeds of $10.4 million.  ...  to support the sales and marketing and continued research and development of the Company’s rapid diagnostic and Acuitas Lighthouse™ bioinformatics products and services, and for general corporate purposes.  Lead investors in the financing included Merck Global Health Innovation Fund [subsidiary of giant pharma Merck[company press release, May 20, 16]

OpGen up 11% [Oct 16,15]

OpGen down 21% [Sep 21, 15]

OpGen up 50% [Sep 18, 15]

OpGen down 11% [Jul 21,15]

OpGen   up 10% [Jul 13,15]

OpGen down 19% [May 5,15] after raising $17M in an IPO

OpGen (Gaithersburg, MD; no SBIR) intends to raise about $18.7 million in its [IPO] expected sometime this week. ...  specializes in infectious disease screening and estimates it's targeting an $800 million U.S. market for preventing hospital-acquired infection outbreaks.   [Tina Reed, Washington Business Journal, Apr 28, 15]

OpGen (Gaithersburg, MD; no SBIR) filed to go public in hopes of raising as much as $37.4 million. ...  working to develop diagnostics to address the threat of antibiotic resistance.  ...  describes itself as an "early commercial-stage company using molecular testing and bioinformatics to assist health care providers to combat multidrug-resistant bacterial infections."  ...  led by CEO Evan Jones, who co-founded Digene  ($1.3M SBIR), a genomics company well known to local biotech watchers during Montgomery County's "DNA Alley" heyday of the late 1990s and early aughts. Digene was acquired by Qiagen NV in 2007 for $1.6 billion.   [Jeff Clabaugh, Washington Business Journal, Mar 3, 15]

OpGen (Madison, WI; no SBIR) The leader in microbial genome analysis today announced a strategic investment and development agreement with In-Q-Tel [company press release, Oct 29, 07]

OpGen (Madison, WI; no SBIR) raised $23.6M more a financing led by VC firms on both coasts for developing products that can rapidly identify bacteria and other organisms. FDA used Opgen's technology to determine whether all contaminated spinach in an outbreak earlier this year was related to the same organism[Kathleen Gallagher, Milwaukee Journal-Sentinel, Sep 13]

OPNET Technologies

Riverbed Technology (no SBIR) finished buying OPNET Technologies for $1 billion in cash and stock.  [Stephen EF Brown, San Francisco Business Times, Dec 18, 2012]

Opnet Tech  up 31% [Oct 31, 12]

Opnet  up 24% [May 15, 12]

Opnet Tech  down 15% [Feb 8, 12]

Opnet down 21% [Nov 10, 11]

OpNet Tech  down 13% [Aug 18, 11]

OpNet down 11 [Aug 8, 11]

OPNET Tech up 10% [Aug 3, 11]

OPNET up 12% [Sep 15, 10]

Opnet Technologies fell 12% after trimming its first-quarter revenue outlook. said seasonal customer patterns were more pronounced in the quarter than the company anticipated.  [Wall Street Journal, Jul 16, 10]

Opnet up 11% [May 29, 09]

Opnet declared an initial dividend. [May 14, 09] 

OpNet  down 10% [Apr 20, 09]

OPNET  up 12% [Mar 23, 09]

Opnet up 13% [Mar 12, 09]

OPNET up 11% [Dec 16, 08]

OPNET down 10% [Dec 15, 08]

Opnet  down 12% [Dec 1, 08]  On a stock bloodbath day

Opnet up 11% [Nov 21, 08]

Opnet Tech up 21% [Oct 28, 08]

Opnet Tech up 20% [Oct 16, 08]

Opnet Tech down 10% [Oct 14, 08]

Opnet Tech up 12% [Oct 13, 08]

Opnet Tech  up 11% [Oct 10, 08]

Opnet Tech down 11% [Oct 9, 08]

Opnet Tech up 17% [Sep 19, 08]

Opnet Tech up 15% [Jul 11,08]

OPNET Technologies down 24%  [Nov 2, 07]

Forbes's annual list of the best 200 small companies had several SBIR awardees: Ceradyne #12, Flir Systems 37, II-IV 58, ATMI 69, ViaSat 90, Surmodics 105,Micrel 149, OPNET Tech 167.

OPNET Technologies topped the list of Biggest Percentage Price Decliners on the Nasdaq after soggy profits results and forecast. [May 17, 07]

OPNET Technologies up 15% [Feb 1, 07] on better earnings.

Opsonix (Cambridge, MA)

Opsonix (Cambridge, MA; no SBIR), a startup spun out of the [Harvard University’s Wyss Institute] emerged from stealth with $8 million in Series A financing.  ... has a license from Harvard to use engineered opsonins in pathogen-extracting devices and as companion diagnostics.  [Ben Fidler,, Oct 8, 15]

OptTek Systems (Boulder, CO)

Companies contending with an aging looking new ways attract and retain diverse workforce may one day turn to a tiny software company for help.OptTek Systems (Boulder, CO) is a developer of software that helps optimize problem-solving software. Most of its work centers on software that can simulate a specific business or financial problem, such as how to staff a hospital with the right number of doctors and nurses or, as in the case of its customer Halliburton, which oil and gas fields to explore to optimize investment. However, with a [Phase 2] SBIR grant of $450,000, 14-person OptTek is building a complete software application that can be applied to workplace issues.  .... after working on a similar project for the Navy ....  Founded in 1992 by former University of Colorado at Boulder researchers, OptTek began using SBIR grants to help fund research and development a few years ago. Its new software, called OptForce, will be available for commercial sale by the end of the year. [Kimberly Johnson, Denver Post, May 30, 08]  If the work was done for the Navy and is ready for commercialization, why is NSF funding it with SBIR?  Because tech merit runs the show where peer review dominates since the academics don't care much whether a company has already had SBIR for essentially the same stuff.


Optelecom down 13% [May 7, 10]

Optelecom  up 11% [Feb 4, 10]

Optelecom  up 13% [Jan 29, 10]

Optelecom up 10% [Jan 4, 10]

Optelecom up 24% [Dec 31, 09]

Optelecom down 18% [Nov 9, 09]

Optelecom up 10% [Nov 6, 09]

Optelecom up 10% [Nov 3, 09]

Optelecom down 11% [Nov 3, 09]

Optelecom down 11% [Sep 17, 09]

Optelecom up 10% [Aug 5, 09]

Optelecom up 18% [Jul 22, 09]

Optelecom down 14% [Jul 21, 09]

Optelecom  down 17% [May 13, 09]

Optelecom  up 12% [Apr 20, 09]

Optelecom up 11%% [Apr 1, 09]

Optelecom down 10% [Mar 11, 09]

Optelecom  down 21% [Mar 9, 09]

Optelecom  up 12% [Mar 6, 09]

Optelecom  down 13% [Mar 5, 09]

Optelecom   down 12% [Feb 18, 09]

Optelecom   up 15% [Feb 17, 09]

Optelecom  down 15% [Feb 13, 09]

Optelecom up 17% [Feb 12, 09]

Optelecom  up 12% [Jan 29, 09]

Optelecom  down 10% [Jan 28, 09]

Optelecom up 13% [Jan 22, 09]

Optelecom up 12% [Dec 31, 08]

Opteelcom down 16% [Dec 30, 08]

Optelecom up 10% [Dec 16, 08]

Optelecom up 13% [Nov 17, 08]

Optelecom down 12% [Nov 10, 08]

Optelecom up 15% [Nov 7, 08]

Optelecom down 19% [Nov 6, 08]

Optelecom-NKF up 15% [Nov 5, 08]

Optelecom down 16% [Oct 24, 08]

Optelecom up 21% [Oct 21, 08]

Optelecom up 23% [Oct 14, 08]

Optelecom down 13% [Oct 9, 08]

Optelecom-NKF up 10%  [May 2, 08]

Optelecom-NKF up 17% [Nov 7, 07] on bright earnings.

Optelecom down 12% after reporting another loss. [Aug 1, 07]

Optelecom was down 11% on disappointing earnings. [Feb 28, 07]

Optherion (New Haven CT)

Optherion (New Haven CT; no SBIR) reports it has raised startup capital of $37m to advance products for age-related macular degeneration.[Mass High Tech, Oct 9] Labs in New Haven near its scientific founders at Yale and at the U of Iowa in Coralville.

Optical Concepts (Lompoc, CA)

Corning and WL Gore says they are testing a prototype fiber with Gore's 850nm VCSEL. That VCSEL probably came from SBIR awards 1992-1995 to a start-up in Lompoc, CA that was bought out by Gore. Optical Concepts founded by Kevin Kilcoyne got about $3M of BMDO Phase 2 money plus the co-investment that BMDO encourages, especially for any Phase 2 after the first, and developed products that are now serious candidates for big time commercial use.

Optigain (Peacedale, RI)

Optigain Joins Lucent. Optigain (Peacedale, RI) sold a majority equity share to FITEL Technologies, a joint venture company of Lucent Technologies and The Furukawa Electric Co. Optigain under founder Harish Sunak got much of its early R&D capital from BMDO SBIR awards in erbium-doped amplifiers.Six of the seven Phase 2s were from BMDO. The company's pre-Optigain name in 1992 was EDFA. Says the press release: The agreement positions FITEL to provide a broader suite of amplification products and Raman pump units for signal amplification in optical networks. The Rhode Island facility, to be named Optigain-FITEL, will be a center of excellence for Raman technologies as well as a North American design and manufacturing center for amplification products. The technology: Amplification products for the C and L-band have grown exponentially in demand over the past few years due to the increased reliance on fiber optic communications and transmission systems. Raman technologies have recently become an important factor in long-haul transmission systems due in part to their ability to increase the bandwidth per channel and optimizing signal to noise ratio for 10Gb to 40Gb systems by using the existing fiber as the gain medium. FITEL’s integrated Raman pump system uses a series of high-powered pump units to optimize the signal to noise ratio of an optical signal, allowing the signal to travel longer distances with less regeneration. FITEL develops and markets some of the most powerful and reliable pump modules available on the market. The Raman pump units are used in conjunction with Erbium Doped Fiber Amplifiers (EDFA) in long-haul and high-speed transmission systems. FITEL also manufactures some of the smallest single channel EDFAs available on the market.

Optimal Technologies

The formula is top secret, and some say the technological claims are mathematically impossible. But Raleigh NC politicians and state officials have been wowed by Optimal Technologies' (Canada) claims that its product can prevent electricity blackouts and lower utility costs. They lured the startup company to downtown Raleigh with the promise of $650,000 if it creates 325 local jobs. ... The eight-year-old company's product: a network management tool that can improve electricity flow over clogged utility transmission systems, many of which are aging and in need of expensive upgrades [John Murawski, Raleigh News&Observer, Jan 16]

OptiMedica (Sunnyvale, CA)

Abbott Laboratories said it has agreed to pay up to $400 million to acquire laser surgery device maker OptiMedica (Sunnyvale, CA;  no SBIR)  ... in the past year raised a $35 million Series E round  [Cromwell Schubarth, Silicon Valley Business Journal, Jul 15, 13]

OptiMedica (Sunnyvale, CA; no SBIR)  raised $35 million in a new round of funding ... to continue the commercialization of its Catalys cataract surgery product, develop "system enhancements" and work on additional products. ...  founded in 2004  [Lisa Ward, Silicon Valley / San Jose Business Journal, Nov 16, 12]

Optimer Pharmaceuticals

Cubist Pharmaceuticals has agreed to pay up to $1.6 billion for Trius Therapeutics and Optimer Pharmaceuticals, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise. The widely praised deals will give Cubist, one of the few big players in U.S. antibiotics in the United States, an additional $600 million to $1 billion in revenue on an annual basis from the companies' lead drugs. Antibiotics has often been shunned by many big pharma firms as a field of research due to poor returns.  [Vrinda Manocha and Zeba Siddiqui, Reuters, Jul 30, 13]

Optimer Pharma up 14% [May 15, 13]

Optimer Pharmaceuticals has attracted multiple bidders for a potential sale, including such big names as AstraZeneca, Astellas and Cubist, according to Bloomberg News.  [Bradley Fikes,, May 14, 13]

Optimer Pharma up 14% [May 13, 13]

Optimer Pharma up 13% [Feb 27, 13]

Optimer Pharma up 13% [Jan 7,13]  after it provided an update on its sales of a drug to treat the antibiotic-resistant bacterium Clostridium difficile. [Bradley Fikes,, Jan 7, 13]

Optimer Pharma up 11%  [Aug 2,12]

Optimer Pharma  down 13% [Nov 7, 11]

Optimer Pharma down 15% [Nov 4, 11] after a disappointingly large net loss

Optimer Pharma up 10% [Oct 20, 11]

Optimer Pharma  up 12% [Sep 16, 11]>

Optimer Pharma  up 13% [Aug 15, 11]

Optimer Pharma up 10% [Aug 11, 11]

Optimer Pharma

down 12% [Aug 8, 11]

Optimer Pharma down 10% [Aug 4, 11]

After more than 13 years of drug development work, Optimer Pharmaceuticals moved into the world of drug sales Monday with the launch of its first commercial product, a prescription antibiotic for treating a potentially deadly intestinal infection. [Keith Darce,, Jul 18, 11]

Federal regulators on Friday approved Optimer Pharmaceuticals new antibiotic for treating Clostridium difficile, a hard-to-kill and potentially deadly intestinal infection running rampant in hospitals. The clearance of Dificid, also known as fidaxomicin, marked the culmination of a decade of work and nearly $200 million in development spending by the San Diego company on its first prescription drug.  [Keith Darce,, May 28, 11]

Optimer Pharma up 12% [May 31, 11]

A day after a federal advisory panel endorsed Optimer Pharmaceuticalsnew antibiotic for approval, the San Diego company said Wednesday that it would co-market the drug with Cubist Pharmaceuticals, which already sells its own antibiotic in hundreds of hospitals across the country. ...  Optimer will pay Cubist $30 million in service fees over the two-year life of the agreement. [Keith Darce, signonsandiego,com, Apr 7, 11]

Optimer Pharmaceuticals (San Diego, CA; $5.3M SBIR) said Monday that it signed a licensing agreement potentially worth more than $224 million with a Japanese company to sell the San Diego drugmaker's new antibiotic, fidaxomicin, in Europe, Africa, the Middle East and former Soviet Union states. [Keith Darce,, Feb 7, 11]

Optimer Pharmaceuticals (San Diego, CA; $5.3M SBIR) working on a new treatment for respiratory infections, received a $500,000 payment from its partner Cempra Pharmaceuticals after the drug successfully completed a phase 1 clinical trial. [San Diego Union Tribune, Jul 8, 10]

top management of Optimer Pharmaceuticals has gone bullish on the stock in recent weeks.  Through option exercises and open-market purchases, Chief Executive Michael Chang and [his wife] Chief Operating Officer Tessie Che have raised their holdings by more than 16% as the drug developer awaits results from an important clinical trial.  [David Reynolds, Wall Street Journal, Jan 13, 10]

Optimer Pharmaceuticals  up 13% [May 20, 09]

Optimer Pharmaceuticals fell 6.3% as the firm said results from its recent study on an antibiotic treatment didn't differentiate its drug from a competitor's treatment as much as was previously hoped.  [Wall Street Journal, May 19, 09]

Optimer Pharmaceuticals said it has more good news for travelers. The San Diego company announced yesterday that its second Phase 3 clinical trial of its antibiotic Prulifloxacin successfully killed pathogens that cause traveler's diarrhea in people visiting India, Guatemala and regions of Mexico. [Terri Somers, San Diego Union Tribune, Feb 25, 09]

Optimer Pharma up 13% [Jan 21, 09]

Optimer Pharma down 12% [Jan 9, 09]

Optimer Pharma up  13% [Nov 14, 08]

Optimer Pharma up 22% [Nov 13, 08]

Optimer Pharma doubled [Nov 11, 08] ... reported positive top-line results from a late-stage study of its lead anti-infective drug candidate for the treatment of Clostridium difficile infection, an illness caused by infection of the inner lining of the colon by a certain kind of bacteria.  [Wall Street Journal, Nov 12]

Optimer Pharma down 35% [Nov 12, 08]

Optimer Pharma down 10% [Oct 23, 08]

Optimer up 12% [Oct 16, 08]

Optimer up 23% [Oct 13, 08]

Optimer Pharma  down 15% [Oct 10, 08]

Optimer Pharma down 12% [Oct 9, 08]

Optimer Pharma down 10% [Oct 8, 08]

Optimer Pharmaceuticals (San Diego, CA; $2.3M SBIR) developing an antibiotic for traveler's diarrhea said results from a late-stage clinical trial show that its product is faster and works on a broader range of gut-wrenching bacteria than those already on the market. The trial showed that one dose of 'once-daily Prulifloxacin started curing traveler's diarrhea within 24 hours, the company reported  [Terri Somers, San Diego Union Tribune, Jul 17, 08]

Optimer Pharmaceuticals (San Diego, CA, $2.3M in HHS SBIR) went public last week and is trading 20% above the IPO price.

Optimer Pharmaceuticals (San Diego, CA), which has two late-stage anti-infective product candidates, filed to go public. $2M+ SBIR from HHS.

Optimus Technologies (Pittsburgh, PA)

Optimus Technologies (Pittsburgh, PA; no SBIR) startup, announced it was launching a new biofuel conversion product aimed at reducing costs and emissions in medium- and heavy-duty truck fleets. ...  By converting biofuels so that they can be consumed by trucks that typically run on diesel fuel, the device, which is fitted onto the truck's engine, can help trucks reduce costs by up to 25 percent, because biofuels are on average priced that much lower than diesel fuels [as long as the big government subsidies last] ...  The company has used data collected from the five [city of] Pittsburgh trucks to improve the device for more widespread use.  [Stephanie Novak,  Pittsburgh Business Times, Mar 25, 14]

OptiNose (Yardley, PA)

Optinose down 22% [Aug 14, 20] Announces Pricing of Public Offering of Common Stock [company press release, Aug 14, 20]

OptiNose down 18% [Nov 21, 19]

OptiNose down 29% [Aug 14, 18] reported quarterly results and drew lawsuits

Xenetic Bio down 15% [Aug 14, 18]

OptiNose (Yardley, PA; no SBIR) announced the pricing a public stock offering for $52M to the company and $52M to some some stockholders [company press release, Jun 6, 18]

Optinose up 10%  [May 14, 18]

Optinose up 10% [Mar 16, 18]

Optinose up 12% [Feb 21, 18]

Optinose (Yardley, PA; no SBIR, founded Y2K), focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced that it has entered into a $100 million debt financing agreement [company press release, Jan 3, 18] devised a way to apply natural body mechanics to propel medications deep into the nasal cavity more efficiently and consistently than other approaches [company website]

Optinose up 10% [Dec 13, 17]

OptiNose Thera down 10% [Dec 12, 17]

Optinose up 10% [Nov 22, 17]

Optinose down 10% [Nov 14, 17]

Optinose (Yardley, PA; no SBIR), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists,  announced the closing of its [$138 million IPO] [company press release, Oct 17, 17]

Drug maker Optinose (Yardley, PA;  SBIR) seeks to raise up to $100 million [IPO], according to [SEC] filing .... specializes in allergy and ear, nose and throat treatments ... reported $47.5 million in licensing revenue and earnings of 94 cents a share in 2016  [MarketWatch, Sep 18, 17]

OptiNose (Yardley,PA; no SBIR) was awarded up to $1.8 million by the Research Council of Norway to study a narcolepsy treatment that uses the firm's unique nasal drug-delivery technology. ... founded in Norway 16 years ago, moved to UD six years ago ... uses the company’s patented bi-directional breath powered delivery technology that uses the natural functions of a patient’s breath to deliver medications beyond the nasal valve into deep, targeted areas of the nasal cavity.   [John George, Philadelphia Business Journal, Feb 2, 16]

OptiNose (Bucks County, PA; no SBIR) that has developed a breath-powered intranasal drug-delivery system — has completed its third venture capital round, securing up to $35 million in funding from its existing major investors. ....  to further develop an experimental treatment for serious chronic nasal inflammatory diseases such as chronic rhinosinusitis.  ... Last year, OptiNose signed a licensing deal, valued at up to $110 million, for its experimental migraine headache treatment with Avanir Pharmaceuticals  (San Diego, CA; $2M SBIR)   [John George, Philadelphia Business Journal, Aug 6, 14]

Optivision (Palo Alto, CA)

Optivision Makes Top 100 (Aug 13) At last, an SBIR company in a market-driven list of 100 best technology companies. Optivision (Palo Alto, CA) made The Red Herring list as the best of class for "bloodiest edge" private companies. After about $9M of SBIR, Optivision is profitable, employs 100 people (up from the six who got a Star Wars SBIR in 1987), and its photonic switching is seen to have a future in the next next generation of switching. The Red Herring story Sep 97 predicts that the present future (ATM and Gigabit Ethernet) will not handle the switching demands of everyone's, even government technologists', demanding instant information fast and perfect (the switching, not the info). Two barriers noted: cost (of course) and company secrecy. Optivision's success should induce the government technologists to invest in photonics startups who offer more than government-funded research with pure fancy for commercialization - companies like Templex, CoreTek, and Picolight.

A Piece for Optivision A piece of a $13.2M TRP consortium pie went to Optivision (Palo Alto, CA), [says Laser Focus World, Sep96] a 1980s three-professor Silicon Valley start-up. Optivision, which had two BMDO Phase 2 SBIRs and a piece of a Phase 2 to another optician, has grown from 6 to 100 in nine years. Much of the early growth came from $7.7M of SBIR (at $77K per staff year, for example, that's 100 staff years). The firm went from 25 to 100 in the past four years.

Optofluidics (Philadelphia, PA)

Optofluidics (Philadelphia, PA; no SBIR) life sciences company, launched its flagship device designed for nanoparticle analysis and manipulation.  The NanoTweezer — which attaches to standard microscopes — uses proprietary nanophotonic waveguide technology to measure key properties of nanoparticles including size, shape and coating quality.  .... received financial backing from BioAdvance, operators of the Biotechnology Greenhouse of Southeastern Pennsylvania [John George, Philadelphia Business Journal, Dec 12, 13] 

Optofluidics (Philadelphia, PA; no SBIR) graduated from the University City Science Center’s Port Incubator and moved into large space nearby. ....  licensed technology from Cornell University, is developing a “NanoTweezer” system designed to easily capture and analyze proteins, viruses and inorganic nanoparticles.  ... funding from BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency and Ben Franklin Technology Partners of Southeastern Pennsylvania. [John George, Philadelphia Business Journal, May 31, 13]

OptoLum (Tempe, AZ)

OptoLum (Tempe, AZ; no SBIR) a small LED lighting systems company, that is both a customer and competitor of Cree has sued it for patent infringement, contending [Cree] copied the technology that went into its groundbreaking LED light bulb that was launched in 2013.  ...    also has accused Cree of wrongfully touting that it invented the innovative technology that enabled it to create its own brand of LED bulbs that are sold exclusively at Home Depot.  ....   buys Cree-made LED chips that it uses in its own lighting products, filed its lawsuit seeking unspecified actual damages as well as punitive damages in federal district court in Arizona last week.   [David Ranii, Raleigh News & Observer, Nov 9, 16]

Optomec (Albuquerque, NM)

Optomec (Albuquerque, NM; $6M SBIR) will unveil the details of its newest 3D printing technology that will connect directly to existing metal machine tools. [Dan Mayfield,  Albuquerque Business First, Mar 12, 14]

Optomec(Albuquerque, NM; $5M SBIR)  announced a new 3-D printer designed to rapidly manufacture metal components....  using technology licensed from Sandia National Laboratories, has become very active in additive manufacturing. [Dan Mayfield, Albuquerque Business First, Jun 12, 13]  Optomec also says it can print antennas onto parts for smartphones. [Dan Mayfield, Albuquerque Business First, May 31, 13]

Optonicus (Dayton, OH)

The University of Dayton and a spin-off company Optonicus (Dayton, OH; no SBIR) are eyeing a $4 million project to boost the use of lasers in manufacturing  .....   that would transition high-energy laser weapon technology used by the military into a new generation of manufacturing technologies. The idea is to create a new class of intelligent optical systems that would improve 3D printing, laser cutting and welding.  [Joe Cogliano, Dayton Business Journal, Dec 4, 13]

Opto Technology

Perkin Elmersaid it has bought Opto Technology (no SBIR; annual revenues are under $15 million), a supplier of LED- based lighting components and subsystems  [Boston Globe, Feb 3, 09]

OPX Biotech

ARPA-E Awards. The administration announced $106M in ARPA-E stimulus awards. Small biz winners:  Ginkgo BioWorks (Boston, MA; one SBIR) $6M primary;  OPX Biotech (no SBIR) $6M primary; Logos Tech (Arlington, VA; $2M SBIR) secondary; Sion Power (Tucson, AZ; $250K SBIR) $5M primary; ReVolt Tech (no SBIR) $5M primary; PolyPlus Battery (Berkeley, CA; one SBIR) $5M; Pellion Tech (no SBIR) $3.2M primary; A123 Systems  secondary, twice;  Planar Energy Devices (no SBIR) $4M; Maxpower (Harleysville, PA; $9M SBIR) secondary; NanoLab (Newton, MA; $5M SBIR) secondary; Codexis (no SBIR) $4.6M; Nexant (no SBIR) secondary.

Oragenics (Tampa, FL )

Oragenics (Tampa, FL, $900K SBIR) following a further review of new data and other factors related to the Company’s international multicenter Phase 2 clinical trial of AG013 in oral mucositis, Oragenics has determined to cease further development of AG013 in this indication by discontinuing the trial and withdrawing the applicable Investigational New Drug application [company press relese, Jul 10, 20]

Oragenics (Tampa, FL; $900K SBIR) down 51% [Oct 3, 18]

Oragenics  (Tampa, FL; $900K SBIR) up 22% [Aug 3,15] announced positive data on multiple compounds from Oragenics' Mutacin 1140 ("MU1140") lantibiotic platform in a critical animal model study, as well as the selection of a lead clinical candidate.   [press release, FN Media Group, Aug 3]

OraMerix (Richardson, TX)

OraMerix (Richardson, TX; no SBIR) developer of technology that cuts the time and hassle of wearing braces has raised $8.1 million in equity funding ... Founded in 1998, has raised a total of around $128 million ... has about 135 employees, 30 of which work in Germany[Dallas Business Journal, Dec 10, 09]

Orasi Medical (St. Louis Park, MN

Orasi Medical (St. Louis Park, MN; no SBIR) opened an office in Tokyo, where it will help Japanese pharmaceutical companies develop treatments for diseases like Alzheimer's and Parkinson's disease. The St. Louis Park-based start-up, a spin-off from the University of Minnesota, has raised a total of $6 million from angel investors.  [Thomas Lee's Patent_pending blog, Minneapolis Star Tribune, Sep 14, 09]

OraSure Technologies (Bethlehem, PA)

OraSure Technologies (Betkhlehem, PA; one SBIR in 2012} is expanding operations to support manufacturing of its rapid at-home antigen test. The company aims to have it on the market by year-end, [Brianna Abbott and Thomas M. Burton, Wall Street Journal, Sep 8, 20]

Orasure Technologies (Bethlehem PA; one SBIR) down 33% [Aug 6, 20] announced its financial results to anticipate that sales of our existing and new products for COVID-19 testing will offset the negative impact of the pandemic on our non-COVID-19 business." [company press release, Aug 5, 20]

OraSure Technologies (Bethlehem, PA; one SBIR in 2012) has a $700 million federal contract to develop a saliva-based antigen test that could be performed at home. The company has antigen tests for other viruses — including HIV and Ebola — and those have accuracy rates of over 95%. Along with accuracy, the company is focused on speed, aiming to delivers results in 20 to 30 minutes. [AP, May 11. 20]

OraSure Technologies, (Bethlehem, PA; no SBIR) developer of point of care diagnostic tests and specimen collection devices, has a major investment and a large purchase order from [HHS], will provide the company with another $7.2 million to support the development of its OraQuick Ebola Rapid Antigen Test. ... In addition, the Centers for Disease Control and Prevention in Atlanta has committed to purchasing about $1.5 million of the company’s OraQuick Ebola Rapid Antigen Test, for field evaluations in West Africa. [John George, Philadelphia Business Journal, Sep 29, 15]

 A race to detect Ebola:

  • [FDA] authorized emergency use of BioFire (Salt Lake City, UT; no SBIR)’s FilmArray system to diagnose Ebola in U.S. hospitals and military labs.   ...  uses PCR [polymerase chain reaction] technology, but can deliver results in about one hour on the premises of any treatment facility that has one of the machines, which cost around $39,000 apiece.  ...  Many U.S. hospitals already have the machines, which were approved to diagnose pathogens including those causing gastrointestinal and respiratory diseases.   
  • Corgenix Medical (Denver, CO; $600K SBIR) is speeding up development of a portable Ebola test kit designed to deliver results from a drop of blood in about 10 minutes, said [CEO] Doug Simpson. It uses so-called “lateral-flow” technology, which is similar to that found in a home pregnancy test, and doesn’t require electricity or a machine to process the sample. A paper strip displays one blue line if no virus is detected, two blue lines if virus is detected, and no lines if the test didn’t work properly.  ...  Corgenix is working with Tulane University in New Orleans and other partners in the Viral Hemorrhagic Fever Consortium, with funding from the NIH. ..  Researchers are testing the Corgenix device, including in West Africa, but haven’t yet gathered enough data to apply for approval by either FDA or WHO, said Mr. Simpson.  
  • Chembio Diagnostics Systems(Medford, NY; no SBIR) maker of rapid diagnostics for HIV and syphilis, this week formed a partnership with another company, Integrated BioTherapeutics (Gaithersburg, MD;  $1.1M SBIR), to develop a point-of-care test for Ebola. Chembio plans to use substances known as “reagents,” developed by Integrated BioTherapeutics, for the test. Chembio hopes to begin testing the tool in Africa within months, said Chief Executive John Sperzel. 
  • Genalyte (San Diego, CA;  no SBIR) developing an Ebola diagnostic that uses a silicon chip to test a drop of blood drawn with a pinprick. The chip is processed through a 15-inch-wide machine that delivers results in about 10 minutes, said Genalyte Chief Executive Cary Gunn.  
  • OraSure Technologies(Bethlehem, PA; no SBIR), maker of an oral test for HIV, is exploring whether it can develop a rapid oral test for Ebola, said Chief Executive Douglas Michels. Chembio’s Mr. Sperzel said his company also would consider developing an oral Ebola test.     [Peter Loftus, Wall  Street Journal, Nov 5, 14]

Orbital Insight

The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20]  almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics,, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release

Orbital Sidekick

The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20]  almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics,, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release , Mar 13, 20]

Orbital Technologies (Madison, WI)

Orbital Technologies (Madison, WI; $36M SBIR) announced that it is seeking investors to embark on its next stage of expansion. .... which looks ahead to the privatization of space travel for commercial and even private purposes, is unfazed by the economic slowdown and credit crisis. ....  about 80 staff members, most of them engineers or scientists  ... In more recent years, its investments in research and development have yielded so many diverse spin-offs that it reorganized itself in October into five separate operating groups. Each of the five has applications that are ripe for commercialization, Crabb said.   [John Schmid, Milwaukee Journal Sentinel, Dec 2, 08]  Twenty years and $36M to get to the stage where the company is organizing for commercialization.  Of what for what realistic profitable markets? What did the government think it was doing for all those years and millions?

Orbotix (Boulder, CO)

Orbotix (Boulder, CO; no SBIR) behind the high-tech robotic ball known as Sphero, has raised $4 million out of a planned $9.9 million investment round, the Daily Camera reports. ... has raised more than $11.1 million since 2010.  [Denver Business Journal, May 10, 13]

Orca Bio (Menlo Park, CA)

Orca Bio (Menlo Park, CA; no SBIR) is coming out of stealth with a $192 million series D round that will propel a pipeline of “high precision” allogeneic cell therapies and the manufacturing technology behind those treatments. Founded in 2016, Orca Bio zeroed in on manufacturing to make bone marrow transplants safer and more effective. ... brings Orca’s total raised to nearly $300 million [Amirah Al Idrus, Fierce Biotech, Jun 17, 20]

Orchard Therapeutics

GlaxoSmithKline is bidding adieu to its stable of gene therapies—it is transferring the assets to Orchard Therapeutics (UK, founded 2016) for a 19.9% stake in Orchard and an undisclosed amount in potential milestones and royalties. ... Orchard launched in 2016 with $33 million, two GSK alums among its founders and a mission to develop a drug to rival Strimvelis. [Amirah Al Idrus, Fierce Biotech, Apr 12,18]

Avrobio (Cambridge, MA; no SBIR) raised $25 million. Along with Bluebird Bio and U.K. startup Orchard Therapeutics, Avrobio is one of the few companies advancing an “ex vivo” gene therapy approach, which involves harvesting a patient’s own stem cells outside the body.  [Ben Fidler,, Aug 5. 16]

Orchestra BioMed (New Hope, PA)

Orchestra BioMed (New Hope, PA; no SBIR), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, announced it has completed a $34 million Series B-1 Preferred Stock financing ... Orchestra BioMed’s June 2019 partnership with Terumo included a $30 million up-front payment as well as significant future milestone payments from Terumo and meaningful revenue sharing through sales royalties and exclusive drug formulation supply payments. [company press release, July 10, 19] prior funding $100M []

Orchestra BioMed (New Hope, PA; no SBIR), providing high-impact solutions for large unmet needs in procedure-based medicine, announced it has formed a global strategic partnership with Terumo Corporation (Japan), one of the world’s leading medical device manufacturers, for development and commercialization of Virtue® Sirolimus-Eluting Balloon (SEB), one of its lead assets, in the percutaneous coronary and peripheral interventions field.  ... Terumo will make a one-time, up-front payment of $30 million and an equity commitment of $5 million to Orchestra BioMed. Terumo will also make substantial future clinical and regulatory milestone payments to Orchestra BioMed.   [Orchestra press release, Jun 13, 19]

Orchid Cellmark

Orchid Cellmark up 10% [Aug 1, 08]

Orchid Cellmark up 18% [Jul 11,08]

Orchid Cellmark up 13% [Nov 23, 07]

Orchid Cellmark down 12% on soggy earnings [Nov 1, 07]

Oregon Iron Works (Clackamas, OR)

Oregon Iron Works (Clackamas, OR; $2.1M SBIR) has been awarded a contract to build watercraft for the [DOD] Combatant Craft Medium Mark One building program. ....  The previously announced contract ceiling is $400 million, with $17.5 million awarded in the first phase. The contract, including all options, will run through December 2021.  [Suzanne Stevens, Portland Business Journal, Feb 11, 14]

Orexigen Therapeutics (San Diego, CA)

Orexigen Therapeutics (La Jolla, CA; no SBIR) shares jumped 18% after the alif., biopharmaceutical company presented data on its lead experimental weight-loss drug, Contrave, that pleased investors. [Wall Street Journal, Jun 29, 10]

Orexigen Therapeutics (San Diego, CA; no SBIR) said it has filed an application with the Food and Drug Administration for approval of its obesity drug Contrave.  [Thomas Kupper,, Apr 1, 10]

Organic Research (Milwaukee, WI)

Five bioscience companies winners of [Wisconsin] BIOforward’s 2014 Emerging Company Showcase. ... chosen because they have transitioned successfully out of research and development, with good proof of concept for their products.  BioTechnique  (Madison, WI; no SBIR) will make cancer-fighting drugs and other types of drugs for other companies; Cellara (Madison, WI; no SBIR) working on a small-platform modular robotic system for use in stem cell production;
Gel Combs (Madison, WI; no SBIR) designs and makes improved combs for gel electrophoresis applications as well as custom plastic parts for the microscopy and microbiology industries; Kosmetikos (Marshfield, WI; no SBIR) a skin care company start-up; and Organic Research (Milwaukee, WI; no SBIR) develops digital pathology software tools to provide critical decision support to pathologists by automatically identifying disease markers.   The winning companies receive high-visibility exhibit space at the Oct. 8 Bioscience Vision Summit, recognition at one of the summit’s large plenary sessions, a free year of membership in BIOforward, and specialized one-on-one technical assistance ranging from business planning and investor introductions to collaborative partnerships.  ...   BioForward was founded in 1987, as the Wisconsin Biotechnology Association, a partnership among leaders in Wisconsin’s emerging biotechnology industry.   [Bob Van Enkenvoort, Wisconsin State Journal, Sep 26, 14]

Organogenesis (Canton, MA)

Organogenesis down 14% [Feb 4, 19]

Organogenesis down 29% [Jan 22, 19]

Organogenesis down 45% [Jan 18, 19]

Organogenesis down 60% [Jan 17, 19]

Organogenesis (Canton, MA; two SBIRs) up 513% [Jan 9, 19] re-cleared for market listing

[Irish] Pharmaceuticals  Shire has agreed to sell its Dermagraft treatment to U.S. group Organogenesis  (Cambridge, MA; $300K SBIR a decade ago), taking a $650 million hit on the loss-making bio-engineered skin substitute it bought less than three years ago. Shire had hoped that Dermagraft would be the foundation of a regenerative medicine franchise when its acquired owner Advanced BioHealing (Westport, CT; no SBIR) for $750 million, but it received a setback when the treatment for diabetic foot ulcers failed to be approved for leg ulcers months after the deal in June 2011. The company said on Friday that Dermagraft's prospects had also reduced significantly after changes in U.S. federal reimbursement payments for wound-care products. Shire said it will receive no upfront payment from Organogenesis but it would be entitled to up to $300 million cash in milestone payments if it meet sales targets up to 2018.   [Paul Sandle, Reuters, Jan 17, 14]

Organogenesis (Canton, MA; $300K SBIR)  biotechnology company that grows living skin cells, received FDA approval to market a product that will make it easier and less painful for patients to undergo dental gum surgery. The product, called Gintuit, is made up of donated skin cells sewn into bovine collagen, a natural substance derived from cows. Dental surgeons will use it in procedures to replace receding gum tissue.  [Robert Weisman, Boston Globe, Mar 10, 12]

Thirty Massachusetts life sciences companies have been awarded a total of $23.9 million in tax incentives by the state in an effort to spur job creation. The awards range from as much as $5.85 million to as little as $55,000.  The companies receiving the awards have committed to creating nearly 1,000 new jobs in the Commonwealth over the coming year.  ...  Last year, the program's first, the state awarded $24.5 million to 26 companies that pledged to create 800 jobs in the state. As of June 30th, those companies had created around 400 jobs, according to the state's Life Sciences Center.   [DC Dennison, Boston Globe, Dec 22]   That's $24000 per job created IFF the recipients create the 1000 jobs.  Last year's cost per actual job was about $70000.  What do you think should be the state's limit on amount spent per job created?  Or is it all sound-bite politics anyway and that real economics don't matter? And if so, how many federal programs do the same thing, only bigger?  SBIR firms taking the money are:  BIND Biosciences, Cytonome, Merrimack Pharmaceuticals, Organogenesis, Vertex Pharmaceuticals.

To see both the reality of the innovation shortfall and its potentially happy ending, look at Organogenesis (Canton, MA; $300K SBIR). Back in 1998, Organogenesis received approval from the Food & Drug Administration to sell the world's first living skin substitute - Appligraf ...  but Apligraf cost more to make than the company could sell it for ... couldn't figure out how to deliver Apligraf reliably, since it was shipping a product made out of living cells ...  By 2002 the early enthusiasm for Apligraf had vanished, along with the money. Novartis pulled out, Organogenesis declared bankruptcy ... enter new CEO Mackay By bringing down costs, "we now have margins that are pharmaceutical-like," says MacKay. Sales of Apligraf are growing at more than 20% per year, the company is taking over two more buildings on the same street in Canton, and it has FDA approval to install high-reliability robots from Japan's Denso, the same supplier Toyota uses, he says. Employment is expected to climb from 350 jobs to about 600, the company is introducing products ...  Organogenesis is fulfilling the promise of 1998—a decade later.  [Michael Malone, Business Week, Jun 15]

Organogenesis (Canton, MA; small SBIR), that makes artificial skin, said it is part of a large consortium that aims to develop regenerative medicine therapies to treat battlefield injuries. [Boston Globe, Apr 18, 08]

Organogenesis (Canton, MA; 3 Phase 1 SBIRs), a maker of regenerative-medicine products, reports it plans to expand into a third building in Canton intended for manufacturing -- part of a multimillion-dollar incentive package pledged by the state. ... the state provided the firm with an incentives package worth $12.9M  to expand and create jobs in the state, according to the company. In a statement, [Gov] Patrick said the expansion of Organogenesis in Massachusetts serves as proof of the state's commitment to spur long-term growth in life sciences. [Mass High Tech, Apr 3, 08]

Organogenesis (Canton, MA; $200K SBIR) a life sciences firm focused on regenerative medicine, has acquired NanoMatrix(Baton Rouge, LA; $300K SBIR), a maker of biologically compatible materials.[Mass High Tech,  Feb 27, 08]

Organovo (San Diego, CA )

Organovo Holdings (San Diego, CA; $2.4M SBIR) up 26% [Dec 22, 20]

Organovo Holdings (Solana Beach, CA; $2.4M SBIR) up 30% [Oct 21, 20]

Coapt (Chicago, IL; $2.4M SBIR), a startup creating technology that turns prosthetic arms and hands into fully-functioning body parts, announced Wednesday that it received $2.3 million from the DoD to develop virtual reality and hardware-based therapies that help war vets with pain related to the loss of their arms or legs. [Jim Dallke, Chicago Inno, Oct 21, 20]

Organovo (San Diego, CA; $1.6M SBIR) and Tarveda Therapeutics, (formerly Blend Thera, Watertown, MA; no SBIR) clinical stage biopharmaceutical developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction. [joint company press relese, Dec 16, 19]

Organovo Holdings (San Diego, CA; $1.6M SBIR) ) announced that it has engaged Roth Capital Partners (“Roth”) as its financial advisor to assist in the exploration of strategic alternatives [after] concluding that the Company had not generated decisive scientific data supporting the prolonged functionality and therapeutic benefit of its lead therapeutic liver tissue candidate, and that the necessary redevelopment of the tissue would require significant time, additional resources and development risks, and would likely not provide sufficient return on investment for the Company’s stockholders. [company press release, Aug 7, 19]

Organovo (San Diego, CA; $200K SBIR) up 12% [Dec 13, 16] is laying out its pre-clinical data for the first time today. And the company says the results are promising enough to warrant further development of the technology.  ... says it intends to submit an investigational new drug application to the FDA in three to five years for therapeutic use of its bio-printed liver tissue.  [Bruce Bigelow,, Dec 13, 16]

It’s been almost two years since Organovo (San Diego, CA; $300K SBIR) ) created a new business—using its bio-printing technology to create 3-D samples of living human liver tissue for use in testing the toxicity of pre-clinical drug candidates. ...  According to Organovo CEO Keith Murphy, the technology has been validated across a broad set of safety data, and seven of the top 25 global pharmaceuticals are now customers—including Merck, Roche, Astellas, and Bristol-Myers Squibb.  ....  The company announced this week that it has developed a similar testing service for screening pre-clinical drug candidates on living human kidney tissue. [Bruce Bigelow,, Sep 9, 16]

Organovo Holdings up 12% [Oct 8,15]

Organovo Holdings ($300K SBIR as Organovo) up 15% [Sep 15, 15] first 3D human tissues company [company website]

Organovo up 17% [Aug 10, 15]

One advisor recommends Organovo Holdings (San Diego, CA; $300K SBIR, founded 2007, 80 employees) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners.  []

Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive.  ....  Genome sequencers from Illumina took second and third place   [Bradley Fikes,, Dec 1, 14]  Other winners: BioNano Genomics, RainDance Technologies  (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo  (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape.    [The Scientist, Dec 1, 14]

Organovo Holdings (San Diego,CA; $300K SBIR) said that it has commercially launched its long-discussed human liver tissue model, which can be used to help drug development.  ...  The product, called exVive3D Human Liver Tissue, contains human hepatocytes, stellate and endothelial cells, which are found in natural human liver tissue. It's now being sold through Organovo's contract research program to help in late-stage preclinical drug discovery.  [Bradley Fikes,, Nov 18, 14]

Organovo (San Diego, CA; $270K SBIR) shares jumped more than 25 percent Tuesday after the "bioprinting" company said it is joining the NYSE MKT exchange. ....   assembles tissues resembling organs in living organisms, such as liver, by sending cells through its "bioprinter" that deposits them in layers.    [utsandiego, Jul 11, 13]

Organovo (San Diego, CA; $300K SBIR) regenerative medicine company developing bio-printing technology, says it has used its proprietary NovaGen bioprinter to produce 3D samples of human liver cells that show some of the same characteristics as a functional liver in the body. [Bruce Bigelow,, Apr 23, 13]

Fifty Nifty Techno-Innovators as judged by Technology Review magazine [Apr 12]. In the company of investment magnets like Facebook and Google are a few companies and ideas that would be fit for a realistic SBIR program intent on seeding technically uncertain innovation with a future if it can be shown to work.  
Alta Devices
(no SBIR) high-efficiency gallium arsenide–based solar cells provide a way to lower the cost of solar power.  Can economically produce robust cells that use only small amounts of the expensive semiconductor.
 Integrated Diagnostics
(Baltimore, MD; $1M SBIR)  By reducing the cost of diagnostic tests, it has allowed the monitoring of more disease markers. Its synthetic antibodies replace more expensive antibodies widely used in diagnostics.   
Suntech (no SBIR) Has developed a low-cost way of making better silicon solar cells. Its new panels are more efficient because they reflect less light and use thinner electrodes that block less light.   
(no SBIR) Its high-energy batteries, which will first appear in consumer devices, could make electric cars cheaper and improve their range.  Making batteries without the flammable liquid found in conventional electric-car batteries means they can store more energy. 
(no SBIR) Makes fuel and chemicals from the carbon monoxide produced by processes such as steelmaking.  Genetically engineered organisms turn the gas into ethanol and other useful chemicals. 
First Solar
  (Toledo, OH; $750K SBIR) It is reducing the cost of utility-­scale photovoltaic installations.  constrains costs with vertical integration of everything from plant construction to the manufacture of high-efficiency cadmium telluride cells. 
Wildcat Discovery (no SBIR) Has used high-speed methods to find materials that improve the performance of batteries. Identified a pair of materials that could increase energy density by 25 percent in batteries for cars and portable electronics. 
Siluria  (no SBIR) Its catalytic process is able to convert cheap and abundant natural gas into ethylene, a commodity chemical used to make plastic.  Developed a family of catalysts that selectively cause methane to react to form ethylene.
  (San Diego, CA; $260K SBIR) Its three-dimensional artificial tissue structures can be used for drug testing and are likely to find therapeutic applications. A printing process methodically deposits layers of cells and gel material to build up new tissues.    Cellular Dynamics International (Madison, WI; $500K SBIR) Using human iPS cells in drug screening could accelerate the development of new therapies.  Its new product derived from iPS cells is meant for use in vascular targeted drug discovery, tissue regeneration, and life science research.
Foundation Medicine 
(no SBIR)  Its new diagnostics exploit a growing understanding of the molecular basis of cancer.   It has developed a comprehensive cancer diagnostic test and is partnering with pharmaceutical companies to use the test in drug development.

Organovo (San Diego, CA; $260K SBIR) startup developing 3-dimensional “bio-printing” technology was listed on the Over the Counter market following a reverse merger with a public company and $6.5 million in private placement financing. Organovo CEO Keith Murphy describes the complex steps as an alternative public offering. [Bruce Bigelow,, Feb 16, 12]

ORIC Pharmaceuticals (South San Francisco, CA)

ORIC Pharmaceuticals announced the pricing of its initial public offering expected to be $120.0 million,... ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. [company press release, Apr 23, 20]

ORIC Pharma (South San Francisco, CA; no SBIR, founded 2014) plans an IPO [to raise $86M] to test therapies for drug-resistant cancers [Sarah de Crescenzo,, Mar 2, 20]

ORIC Pharmaceuticals (South San Francisco, CA; no SBIR), clinical-stage oncology company focused on developing cancer treatments that address mechanisms of therapeutic resistance, announced the closing of a $55 million Series D financing. [which] brings the total capital raised to over $175 million. [company press release, August 8, 19]

$53 million [Series B round] will help year-old ORIC Pharmaceuticals (South San Francisco, CA; no SBIR) take at least one drug into a human clinical trial in about two years. It also will allow the company to stock its shelves with other anti-cancer compounds, interim CEO Heyman said. [Ron Leuty, San Francisco Business Times, Dec 2, 15]

Oricula Therapeutics (Seattle, WA)

Oricula Therapeutics (Seattle, WA; $200K SBIR, founded 2013) will use the [NIH $2M] to get its new drug that it says will help prevent hearing loss ready to test on humans. [Becky Monk, Puget Sound Business Journal, Feb 2, 16]   to develop medicines that protect hearing and balance from the effects of ototoxic drugs and aging. Our first product will be the first medication to prevent hearing loss in patients undergoing treatment for serious infections with aminoglycoside antibiotics. ... grew from research conducted at the University of Washington   [company website]

Oricula Therapeutics (Seattle, WA; no SBIR), founded 2013) said it's obtained funding and licensed intellectual property from University of Washington to begin commercialization of products it has developed targeting hearing loss.   ....  said its first product will "protect the inner ear from the damaging effects of antibiotics that are known to cause permanent hearing loss."  [Ben Miller, Puget Sound Business Journal, Apr 9, 14]

Origin Medsystems

Stealthy startup Auris Surgical Robotics (San Carlos, CA; no SBIR) disclosed that it has raised $150 million ...  the fourth robotic surgery business co-founded by Dr. Frederic Moll. He previously co-founded Intuitive Surgical  ($2.5M SBIR) , Hansen Medical (no SBIR), Endotherapeutics (no SBIR), and Origin Medsystems (no SBIR) ....has now raised a total of $185 million.  [Cromwell Schubarth, Silicon Valley Business Journal, Sep 24, 15]

>OriginOil (Los Angeles, CA)

OriginOil (Los Angeles, CA; no SBIR), an algae biofuel company, has developed a simpler and more efficient way to extract oil from algae. The process combines ultrasound and an electromagnetic pulse to break the algal cell walls. Then the algae solution is force-fed carbon dioxide, which lowers its pH, separating the biomass from the oil.  [MIT Tech Review, May 1, 09]

Orion Energy Systems (Plymouth, WI)

Orion Energy Systems (Plymouth, WI; no SBIR) posted a glowing debut through its IPO, with the company's stock closing up 65%. ... high-intensity fluorescent lighting helps businesses save on energy costs associated with lighting large buildings such as factories, warehouses and distribution centers  [Tom Daykin,Milwaukee Journal-Sentinel, Dec 20]

Orion Genomics (St Louis, MO)

Orion Genomics (St Louis, MO; one SBIR), a biotechnology startup in the Center for Emerging Technologies, [St Louis Post Dispatch, Dec 20,07] announced today the discovery and validation of the most frequent DNA alterations detected in breast cancer to date. The results of a genome-wide analysis of DNA methylation appeared in PLoS ONE. The study entitled, "Identification of Novel High-Frequency DNA Methylation Changes in Breast Cancer" found more than 50 novel biomarkers, which were subsequently validated in up to 230 independent patient samples. [company press release]

Ormet Circuits (San Diego, CA)

Ormet Circuits, (San Diego, CA; $160K SBIR) with proprietary technology for printing circuit patterns on a variety of materials, has raised more than $1.7 million from equity investors ... says its technology can print circuits with high electrical and thermal conductivity and good solderability on cardboard, plastic, and paper. The ink is cured to become a fused metal network that alloys itself to conventional circuit materials. The company says it is currently concentrating on the creation of electrical and thermal vias in multi layer structures.  [Bruce Bigelow,, Jul 18,11]

Oroboros Bio (Cambridge, MA)

Oroboros Bio (Cambridge, MA; no SBIR) raised $5M in a $10M funding round, according to an SEC filing. [BostInno, Aug 8, 19]


Orologic wants to be "the Intel of networking eventually" with its 10 employees and no product, But this summer, it raised $500K seed money and hopes soon on $4-6M of VC. First prototype early next year. Orologic's founders believe they have discovered the Holy Grail of networking. - layer 4 switching which combines routing and switching into one box and allows a network to give priority to specified kinds of traffic. Orologic, which moved into RTP's First Flight Venture Center last December plans to use its next round of funding to finish work on its prototype and begin marketing and sales efforts. [CHRIS O'BRIEN, Raleigh News & Observer, Sep 8]

OrphoMed (Mill Valley, CA)

OrphoMed  (Mill Valley, CA; no SBIR), a clinical stage biopharmaceutical company developing first-in-class dimer therapies, announced the completion of a $39 million Series A financing [co-led by existing seed investor Takeda Ventures]...  to advance the clinical development of OrphoMed’s lead candidate, ORP-101, for the treatment of irritable bowel syndrome with diarrhea (IBS-D). [company press release, May 24, 17].

Ortel Corp (Alhambra, CA)

Lucent Buys Ortel
(Feb 8) Lucent Technologies is paying nearly $3B in stock to acquire Ortel Corp a leading developer of optical components used to upgrade cable TV networks for Internet and telephone service. The deal announced Monday will help Lucent, a leading developer of optical technology for telephone networks, to meet demand for equipment that enables high-volume, two-way communications over cable systems, which were originally designed to broadcast TV programming in only one direction.
Ortel had some SBIR help and became one of the few companies to graduate by growing past 500 employees. Most companies go nowhere near such growth because the government rarely picks companies for awards that have that kind of growth potential. Instead, the mission agencies who have a the lion's share of SBIR pick compliant contract R&D houses for limited scope projects.
New Products Power Ortel
(Dec 17)Ortel (Alhambra, CA) rolled out four new fiber optic solutions for the communications industry, including the industry's highest-power linear 1310nm laser module, the highest optical launch power 1550nm transmitter, a video overlay receiver for fiber-to-the-home (FTTH) applications and a new broadband photodiode module. It also announced a deal with Lucent announced an exclusive agreement with Lucent Technologies (NYSE:LU - news) Microelectronics Group for next-generation uncooled 980 nanometer (nm) pump laser modules used in metro optical network applications. Result: market cap up another 12% to $1.1B, up from $100M two months ago.
Is It Ortel or Is It Something Bigger?. It's a buying panic with the NASDAQ Composite up 82% for the past 12 months. 82% in a broad index? Fantasyland. What's your criterion for a bubble? The huge tech-stock demand "boils down to a very simple concept of the flow of funds" Mr. O'Kelly said. "We continue to see a tidal wave of funds flowing furiously into the technology sector. There is new money, money playing catch-up, institutional money and retail money. It reflects the desire by a very broad investor base to own the highflying, high-octane names." Tech stocks, with their promise of hefty earnings growth, are the rare group that can ignore the threat of rising market interest rates, said Michael Clark, head of U.S. stock trading at Credit Suisse First Boston, [ES Browning, WallStreet Journal, Dec 17]

Ortel Up A Third (Dec 13) Ortel (Alhambra, CA) shot up 33% Friday on a recommendation Instead of sending electrons down copper wire, you put photons down glass. There are a number of layers. The most obvious layer is the physical glass that gets put down along the ground, or along railroad tracks, or highways. This is produced by Corning and Lucent, the two major producers of optical fiber. The next layer is putting those photons over the optical fiber. Those are companies like JDS Uniphase, SDL,Ortel. [Jeffrey Bartash, CBS MarketWatch]

Ortel Skyrockets (Jun 21) Up 41% for the day and more than doubled since April 13, its low, is Ortel (Alhambra, CA). But it still has another 50% to go from here to reach its 12-month high of $20. It lost $6M ($5M from "discontinued operations") for its fiscal year as opposed to a $2M profit the previous year. Ortel had a little SBIR, five Phase 2s from 1988 to 1996, not a significant factor in its rise to a market cap of $160M. If DOD had taken a hypothetical equity for its SBIR "investment", the return would be good but not spectacular because the percentage contribution to capital would have been so small. Five Phase 2s cannot explain the rise from 60 to 400 employees in a decade. For other firms, the best example probably being Cree Research, that gain would be spectacular and enough to justify a whole wad of SBIR to similar firms (not a wad of SBIR to every claimant of good research).

Ortel (Alhambra, CA) saw a 14% drop in sales and a consequent $1.1M loss for the quarter. In a statement worthy of a government bureau it said, The third-quarter revenues of its core broadband products, which represented 71 percent of total revenues for the third quarter and 67 percent for the nine-month period, were negatively impacted by a slower-than-expected ramp-up of major product enhancements. The stock price took a hit of 28% in one day. Ortel makes advanced solutions to original equipment manufacturers for the transmission of video, voice and data. Ortel was a minor user of SBIR before going public in 1995.

Extremely Cost-Effective Prices (Apr 2) When Ortel (Alhambra, CA) announced new lower prices on 980 nm pump lasers, Honeywell gushed how it will "continue to utilize Ortel's advanced lasers, now at extremely cost-effective prices". Ortel credited its "working aggressively over the past several years" with DARPA ManTech money in a consortium including Honeywell. Maybe SDL's (San Jose, CA) heavy breathing in such lasers helped spur the price cut to 20% less than prevailing prices. Was it government sponsored R&D or was it market competition that brought on the miracle? Market competitors don't reduce prices because they can; they reduce prices because their market position is threatened.

Make a Profit, Take a Dive (Feb 27) Profits at Ortel (Alhambra. CA) were $2.1M for the quarter. Up from $1.4M same quarter in 1995. Great news for any SBIR company? No-o-o. Ortel led the down-pack on NASDAQ, falling 39%. The pundits said that was well below expectations and Ortel hinted that the next quarter wouldn't be so hot either. Is there justice? Depends on your concept of justice. Ortel is a shining star for SBIR, with profits and market capitalization that only a handful of SBIR companies can claim. But real-world NASDAQ is a tougher league than technology-push happyfuturepabulum of SBIR where the winners and the government conspire to pretend all is well. Government would do well to push more companies to risk what Ortel risked. After all, Ortel has already returned in corporate income taxes more than all the SBIR it ever got. How many multiple SBIR winners can make that claim?

Some Cable, Some Hype the company is displaying the industry's most sought after HFC solutions for CATV OEMs and systems integrators at the Western Cable Show, Dec 11-13, at the Anaheim Convention Center, booth number 4282, says the Ortel Corp (Alhambra, CA) press release. The words ringing from the Ortel booth will clash from the leftover words from the National SBIR Conference (mid Nov) at the adjoining Hilton. One hypes a product; the other hypes government handouts. Which is likely to create the most wealth in the long run? What's more if Ortel had brought the germ of its cable idea to the 1996 DOD Service (A, N, AF) SBIR booths for an SBIR citing the commercial payoff, it would have gotten a polite brushoff unless the early development directly served an existing military technology "need". Yes, the entire game is in the word "need". 

Ortel Big Day Ortel (Alhambra, CA) jumped to 4th highest gainer for the NASDAQ day (Nov 28) with a 27% rise in stock price after reporting nice earnings growth to $2.1M. Lots of SBIR companies would rejoice at sales of $2.1M for a quarter.

Ortel in China At Booth 41/42 in Beijing PT/EXPO COMM last week was Ortel (Alhambra, CA) Ortel revealed its Mirror Cell line of wireless and repeater products meant for selling in Asia.

Ortel Buys Into China For $2.4M Ortel Corp (Alhambra, CA) acquired an interest in a Chinese enterprise, Photon Technology, which already distributes Ortel products. Ortel is the creature of CalTech's Amnon Yariv. It had some inconsequential SBIR money before going public in 1995. Since then it has maintained its nice profit margins. Unfortunately, the news frightened some people as the stock dropped 17% last week. 

OrthoAccel Technologies (Houston, TX)

OrthoAccel Technologies  (Houston, TX; no SBIR, founded 2007) raised $5M cash [Joe Martin,Houston Business Journal, Mar 11, 16]    notable for developing AcceleDent, a device which uses "micropulses" to accelerate tooth movement when used in conjunction with dental braces. The product was released in the European and Australian markets in 2009,[1] South Korea in 2012,[2] and the United States since 2012 [wikipedia]  raised at least $20M through 2015 including   $750K award from the Texas Emerging Technology Fund in 2008  [company website]

OrthoAccel Technologies (Houston, TX;  no SBIR) said  it has received clearance from regulators to distribute to the Canadian market. ....  [Its] AcceleDent has already been cleared by [FDA] to speed up tooth movement for individuals with braces or clear aligners. [Bayan Raji, Houston Business Journal, Mar 4, 13]

Ortho Kinematics (Austin, TX)

Medical diagnostics company Ortho Kinematics (Austin, TX; no SBIR) [spine diagnostics company focused on revolutionizing spine motion analysis] received $728,608 of a planned $4 million financing involving 21 investors. ... moved to Texas in 2009.  [Christopher Calnan,Austin Business Journal, Dec 7, 15]

Ortho Kinematics (Austin, TX; no SBIR) medical diagnostics company focused on spinal imaging, has received $9.5 million from investors - part of a proposed $10.6 million round ...  reported previously that it is attempting to commercialize its vertebral motion analysis technology that can capture video X-ray-type images of the spine while in motion.  The latest funding is on top of nearly $10 million the company received from investors in 2014.  [Chad Swiatecki,  Austin Business Journal, Apr 14, 15]

Medical [spine] diagnostics company Ortho Kinematics (Austin, TX; no SBIR) received a $1.8 million funding as part of a planned $10.6 million round of financing. [Christopher Calnan, Austin Business Journal, Feb 23, 15]   partly funded by Texas Emerging Technology Fund [company website]

Ortho Kinematics (Austin, TX; no SBIR) raised $465,000 of a planned $750,000 financing a diagnostic technology company   [Christopher Calnan, Austin Business Journal, Sep 2, 14]  focused on spine imaging informatics  [company website]

Biomedical startup Ortho Kinematics (Austin, TX; no SBIR; five employees) has raised $2 million to expand a clinical study of its spine diagnostics technology. The 4-year-old company is developing noninvasive technology that provides imaging of patient spines, even in motion. ...  to expand the clinical studies, seek regulatory approval to market the system and hire key sales personnel. ...  moved its headquarters to Austin from San Francisco last year after receiving a $1.5 million grant from the Texas Emerging Technology Fund and an additional $2 million from venture capital firms  [Lori Hawkins, Austin American Statesman, Dec 8, 10]

Ortho Kinematics (Austin, TX; no SBIR)  has completed a $3.5 million funding round, the company announced ... recently moved to Austin, is commercializing its vertebral motion analyzer technology, the KineGraph VMA, which is designed to measure the quantity and quality of intervertebral motion, providing spine surgeons a painless and noninvasive way to assess spine function. [Austin Business Journal, Nov 12, 09]

Oryx Technology(Fremont, CA)

Oryx Lands a Deal(Feb 25) Little Oryx Technology (Fremont, CA) got a boost when a licensee of its electronic protection material announced a big contract with a Japanese firm. Oryx calls itself a technology management company with a proprietary portfolio of high technology products in surge protection and specialized materials. Hoover's calls it a products firm with half its sales to Pitney Bowes. It had a BMDO Phase 2 in 1997 to take a concept from the proof-of-principle stage through to a full process protocol that will allow one to fabricate a high volume (up to 50,000 devices/hr), low cost (1-2cent/device) surge suppressor based on the concept of cutting a "microgap" into a circuit trace on a printed circuit array pattern.. Oryx stock has shot up from 0.34 last Labor Day to 2.2 yesterday when it was up 17% (that's only 5/16). The low price seems well justified by the five straight years of losses totalling $18M but no long term debt. Another Irvine Sensors story of a technology of the permanent future? Besides the BMDO Phase 2 for this obviously commercializable protection, Oryx had three other Phase 2s for other materials technologies, two NASA and one Army before BMDO. SBIR, though SBIR was always a minor played in Oryx's erratic revenues since 1994.

Osazda Energy

The Department of Energy will award $128M to support 75 research projects that seek to advance the development of solar technologies. Most money went to academic and large businessses. Several awards went to former SBIR winners: Energy Materials (Norcross GA one SBIR) won a $4M Solar project award to create new methods to deposit layers of material to make the cell, develop a high-speed process ; Leading Edge Crystal Technologies (Gloucester, MA; one SBIR) won $2.5M to develop a floating-silicon method for producing high-quality single crystalline wafers ; Sunvapor (Livermore, CA ; one SBIR) won $2.5M to show how using enormous tanks that normally store liquefied petroleum gas can be used to accumulate and store solar-generated steam ; Brayton Energy (Hampton,NH; $3M SBIR) won $700K to partner w Oak Ridge Lab to examine examine creep behavior—the tendency to deform under mechanical stress—in thin-sheet nickel alloys; Ceramic Tubular Products (Lynchburg, VA; $3.2M SBIR) won $1.9M to develop silicon carbide composite receiver tubes for molten chloride salt and liquid sodium receivers; Echogen Power Systems, (Akron, OH; $300K SBIR) won $4.4M to develop a large-scale, low-cost, single-shaft compressor for supercritical carbon dioxide (sCO2) power cycles; Osazda Energy (Albuquerque, NM; one SBIR) won $1M to develop a cost-effective metal paste that strengthens the metal connections in solar cells; Scion Plasma (East Lansing, MI; $200K SBIR) won $1M to develop a tool that rapidly deposits transparent conductive oxide onto heterojunction silicon with intrinsic thin layer (HIT) solar cells; Swift Coat (Peoria, AZ; one SBIR) won $1M to make and scale multilayer, anti-reflective and anti-soiling coatings for solar glass [Jane Edwards, govconwire, Nov 7, 19]

Oscient Pharmaceuticals

At least five Massachusetts biotechs — Dynogen Pharmaceuticals , Epix Pharmaceuticals, Oscient Pharmaceuticals, Biopure  and Altus — have more or less ceased operations since the stock market meltdown in September 2008.  [Julie Donnelly, Mass High Tech, Mar 5, 10]

A bankruptcy court judge has approved a deal for Cornerstone Therapeutics to acquire the commercial rights to the antibiotic Factive from bankrupt Oscient Pharmaceuticals for $5M cash. [Mass High Tech, Sep 4, 09]

Oscient Pharmaceuticals filed for Chapter 11 bankruptcy protection yesterday  [Mass High Tech, Jul 14, 09]

following a difficult second half of sorts, Oscient Pharmaceuticals (Waltham, MA; $1.3M SBIR in 2004) reports that it is cutting staff levels by 32 percent and is considering a potential sale of the company ... Ranked as the sixth-fastest growing company in Massachusetts for 2008 by the Boston Business Journal, Oscient saw its stock value plummet from a 52-week high of $2.84 to about 19 cents as of yesterday’s close.   [Mass High Tech, Feb 12, 09] Its peak price in Y2K was 396.

Oscient Pharmaceuticals (Waltham, MA; $2.3M SBIR) said it has filed a patent infringement lawsuit against Lupin Pharmaceuticals, which is seeking to market a generic version of one of Oscient's drugs.  [Chris Reidy, Boston Globe, Jan 15]

Oscient Pharmaceuticals (Waltham, MA; $2.3M SBIR) received a warning letter from the NASDAQ that the biotech company’s market value dropped below $15 million for 10 days straight, failing to meet the exchange’s minimum eligibility requirement for market listing.[Mass High Tech, Oct 6, 08]

The stock of Oscient Pharmaceuticals (Waltham, MA; $2.3M SBIR) [down 24% ]is plunging as Wall Street is disappointed by the company's first-quarter revenue forecast.  [Boston Globe, Apr 17, 08]

Oscient Pharmaceuticals< up 20% [Oct 19, 07]

Oscient Pharmaceuticals down 11% as it talked disappointing revenue but not profits. [Oct 10, 07]

Oscient Pharmaceuticals down 10% [Aug 3, 07]

Oscient Pharmaceuticals dropped 18% after it upped its ongoing convertible senior bond offering[Apr 18, 07]

Oscient Pharmaceuticals (at least $2.3M SBIR) did an 8-to-1 common stock reverse split. [Nov 16, 06]

Oscilla Power (Seattle, WA)

Oscilla Power, an eight-person (Seattle, WA; no SBIR) startup has figured out a way to apply reverse magnetostriction to cheap iron-based metal alloys to generate electricity. The process is driven by the energy from ocean waves. And the devices have the added benefit of not having moving parts.  ... has spent the last four years demonstrating that its concept, which would be attached to ocean buoys, would be a cost-effective way to generate energy from waves. .... aimed at utility-size projects, Shendure said, and the idea is to prove it can compete with other green energy systems like solar and wind power in both power generation and cost effectiveness.  [Emily Parkhurst, Puget Sound Business Journal, Jan 23, 14] That old bugaboo of sweet technology -- cost.

Osiris Therapeutics

British medical device manufacturing company Smith & Nephew plc plans to acquire Osiris Therapeutics (Columbia, MD; $1M SBIR) for $660.5 million [cash]. ... Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud. [Washington Business Journal, Mar 12, 19]

Osiris Therapeutics (Baltimore, MD; $1M SBIR) will pay a $1.5 million fine to the U.S. Securities and Exchange Commission as part of a settlement over allegations that executives engaged in "wide-ranging fraud" to artificially inflate the company’s sales.   [Holden Wilen, Baltimore Business Journal, Nov 3, 17]

Osiris Therapeutics stock received a delisting notice from the Nasdaq Stock Exchange and will be suspended from trading   [Holden Wilen, Baltimore Business Journal, Mar 13, 17]

Osiris Thera down 26% [Mar 13, 17]

Osiris Therapeutics  isn't making any promises that it will meet the latest deadline handed down by the Nasdaq Stock Exchange to get current with its financial reporting. .... [it has] until March 10 to become current with its financial filings  [Holden Wilen, Baltimore Business Journal, Dec 5, 16]

Osiris Thera up 23% [Nov 10, 16]

Osiris Pharma up 24% [Nov 8, 16]

Osiris Therapeutics (Columbia, MD; $1M  SBIR) has to request a hearing before a Nasdaq hearings panel or else it could get delisted.  [Holden Wilen,  Baltimore Business Journal, Sep 20, 16]  As previously disclosed, the Company is working diligently to complete its previously announced restatements of prior period financial statements and transition to a new independent registered public accounting firm for the 2015 audit so that it is in a position to bring its SEC filings up to date. [company press release Sep 19, 16]

Osiris Thera down 11% [Sep 9, 16]

Osiris Thera down 12% [May 31, 16]

Osiris Thera down 12% [Mar 23,16]

Osiris Thera down 11% [Mar 9,16]

Osiris Thera down 13% [Feb 4, 16]

Osiris Thera down 17% [Jan 15, 16]

Osiris Pharma down 22%  [Nov 17, 15]

Osiris Thera down 20%  [Nov 6, 15]

Osiris Thera  down 10% [Oct 29, 15]

Osiris Thera down 10% [Aug 5,15]

Osiris Thera  up 13% [Jul 16,15]

Osiris Thera up 12% [May 9, 14]

Osiris Pharma up 33% [Nov 1, 13] took a smaller loss in the third quarter as its revenue climbed. [AP, Nov 1]

Osiris Pharma  down 17% [Oct 21, 13]

Osiris Thera up 12% [Oct 2, 13]

OsirisThera down 12% [Aug 15, 13]

Osisris Thera down 12% [Aug 14, 13]

Osiris Therapeutics ($1M SBIR) up 138% [Aug 13, 13] said data from a study showed that its Grafix wound-care product proved "overwhelmingly" effective in treating diabetic foot ulcers, paving the way for increased reimbursement from insurers that will boost sales of the therapy. Shares jumped [immediately] to their highest in more than six years, doubling the value of the company to about $800 million.  [Reuters, Aug 13, 13]

Osiris Thera up 35% [Mar 6, 13] after the company reported a jump in revenue from new surgical repair products. [AP, Mar 6]

Osiris Thera down 17%  [Jun 27, 12]

Osiris Thera up 10%  [Jun 18, 12]

Osiris Thera< up 14%  [Jun 15, 12]

Osiris Thera up 14%  [Jun 14, 12]

Osiris Thera  up 12% [May 24, 12]

Osiris Thera  up 15% [May 21, 12]

Osiris Thera   down 13% [Feb 9, 12]

Osiris down 14% [Aug 10, 11]

Osiris Thera  up 10% [Dec 9, 10]

Osiris Thera up 13% [Jun 24, 10]

Osiris Pharma down 13% [May 7, 10]

Osiris Therapeutics gained 5% after winning orphan-drug designation from the FDA for the company's main product, stem-cell therapy Prochymal, as a treatment of type-1 diabetes. [Wall Street Journal, May 6]

Osiris Therapeutics< which is having trouble advancing its latest stem cell therapies, has put more money in the bank from an older technology in the marketplace. ... said that it had achieved a $15 million milestone payment related to its sale of the Osteocel business to NuVasive  ... after NuVasive reached $35 million in cumulative sales of Osteocel which is used to regenerate bone in various orthopedic situations. [Tucker Echols, Baltimore Business Journal, Nov 3, 09]

Osiris Therapeutics down 34% [Sep 8, 09]   after the company said preliminary data on its highly anticipated stem-cell therapy, Prochymal, failed to meet its main goal in two key trials. Prochymal is the company's main drug, and approval is being sought for multiple applications. [Wall Street Journal, Sep 9]

Osiris Therapeutics said interim data from a Phase II clinical trial of its stem-cell-based treatment showed no significant improvement in lung function.  [Wall St Journal, Jun 25,09]

Osiris Thera up 13% [Jun 1, 09]

Osiris Therapeutics discontinued enrollment in a clinical trial for Prochymal, a Crohn's disease treatment, due to a suspected flaw in the trial's design. The Baltimore stem-cell researcher fell 21%  [Wall Street Journal, Mar 28]

New highs made by Cubist Pharma and Osiris Therapeutics [Dec 2, 08]

a first-ever deal to bring treatments to market based on adult stem cells, Genzyme  has entered into a deal with Osiris Therapeutics, which will see Genzyme investing at least $130 million in Osiris — in a deal worth a potential $1.25 billion  [Mass High Tech, Nov 4, 08]

Osiris up 10% [Oct 28, 08]

Osiris down 13% [Oct 23, 08]

Osiris down 10% [Oct 22, 08]

Osiris Thera up 13% [Oct 16, 08]

Osiris Thera down 10% [Oct 15, 08]

Osiris Thera down 10% [Oct 2, 08]

Osiris Thera up 15% [Sep 18, 08]

Osiris Therapeutics said it has reclaimed sole worldwide rights to cardiovascular indications for Prochymal and ended its development and commercialization agreement with Boston Scientific Corporation in order to provide Osiris with the flexibility to enter more strategically beneficial relationships. [Chris Reidy, Boston Globe, Jan 8, 08]

Cleveland BioLabs down 59% [Jan 4, 08] as DOD picks Osiris, up 10%, for $225M contract for stem cell therapy.

Osiris Therapeutics up 16% [AP, Nov 27, 07] after it said that one-year data on its stem-cell treatment candidate for knee surgery, called Chondrogen, showed positive results.

Osiris Therapeutics up 16% after announcing encouraging results from its effort to help the hundreds of thousands who die each year because their scarred hearts can no longer pump blood efficiently [, Mar 26, 07]

Osiris Therapeutics dropped 10% after a clinical trial of its stem cell therapy did not make enough replacement cartilage for damaged knees.  

Osiris Therapeutics up 13%. [Dec 4, 06]

Osiris Therapeutics up 15% after good news form a clinical trial of a stem cell therapy. It also had recently raised another $20M. SBIRs totaling $1M in the 1990s. [Nov 10, 06] 

OSI Pharmaceuticals

A Long Island drug company, OSI Pharmaceuticals  (Uniondale, NY; $2.4M SBIR), was seen as a sign of the region's promise when it developed a cancer drug, Tarceva, that was approved by the Food and Drug Administration in 2004. But the company was later acquired by Astellas Pharma Inc. and earlier this year announced plans to shutter its last remaining Long Island facility.  [Will James, Wall Street Journal, Aug 5, 13]

OSI Pharmaceuticals, (Melville, NY; $1.4M SBIR) 8.4%  after saying Tarceva, a lung-cancer treatment sold with Swiss drug maker Roche, extended survival after patients got chemotherapy.  [Wall Street Journal, Jul 14]

Oso Biopharmaceuticals Manufacturing (Albuquerque, NM)

Investors who backed Albany Molecular Research are seeing a major payoff  - doubled in six months.  ...  after on July 1 announced it completed a $110 million acquisition of Oso Biopharmaceuticals Manufacturing  (Albuquerque, NM; no SBIR).   ...  it nearly imploded a few years ago. Between 2009 and 2012, the company's stock fell from $20 a share to near $2.  [David Robinson, Albany Business Review, Jul 8, 14]

Oso Biopharmaceuticals Manufacturing (Albuquerque, NM; no SBIR,350 employees ) entered into a definitive agreement to be acquired by Albany Molecular Research for $110 million in cash. ...   OsoBio’s forecasted full year 2014 revenue is between $58 million and $60 million  [Dan Mayfield, Albuquerque Business First, Jun 2, 14]

Osprey Medical (Minnetonka, MN)

Osprey Medical (Minnetonka, MN; no SBIR) raised $17.5 million for its device that makes a heart procedure safer for patients with chronic kidney disease. [Amirah Al Idrus, Fierce Biotech, Aug 9, 17]

Osprey Medical [Minnetomka, MN; no SBIR) closed on $16.3 million in [private placement] funding as it prepares to launch its product next year.  ...  makes AVERT, a system that protects patients' [who also suffer from kidney disease] kidneys during cardiology procedures. ...  went public in Australia three years ago, raising $20 million. It banked another $14 million through a private placement in 2013.  [Katharine Grayson, Minneapolis / St. Paul Business Journal, Mar 23, 15]

Osprey Medical (Minnetonka, MN; no SBIE)  raised $14 million to launch medical technology that protects patients' kidneys during cardiology procedures. ...  also will use the funding to conduct clinical trials. ....  filed to go public in Australia and completed its $20 million initial public offering last year.  [Katharine Grayson, Minneapolis / St. Paul Business Journal , Oct 16, 13]


BioAdvance, operator of the Biotechnology Greenhouse Corp. of Southeastern Pennsylvania, said it made commitments of $2.4 million to seven new life science companies:  RMH Sciences  (Philadelphia, PA; no SBIR) which is developing antibacterial agents for the treatment of resistant gram negative and gram positive infections; Ossianix  (no SBIR), which is developing single domain antibodies based on the shark VNAR structure to treat immunological, inflammatory, musculoskeletal, neurologic, and other disorders; Merganser Biotech (Newtown Square, PA; no SBIR) which is developing hepcidin peptides for the treatment of hemoglobinopathies such as sickle cell anemia and diseases of iron overload; Anakim Biologics (Exton, PA; no SBIR) which is developing efficiencies and improvements in biologics manufacturing; Enzium (Philadelphia, PA; no SBIR) which is developing highly sensitive biosensor methodologies for the testing of proteases and other enzymes; Imiplex (Newtown, PA; two SBIRs) which is developing the TriPol platform, engineered from proteins, designed to provide a flexible system for constructing diverse nanostructures; Cool-Bio (Wayne, PA; no SBIR) which is developing platelet-inhibiting technology geared specifically to activation during the cooling process of cardiac bypass.  [John George, Philadelphia Business Journal, Jun 20, 12]

OSSIO (Woburn, MA)

OSSIO (Woburn, MA; no SBIR), an orthopedic fixation company, announced that its OSSIOfiber™ Bone Pin Family has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA). This first of its kind technology features a proprietary bio-integrative material to provide stability and secure bone fixation during the healing process, leaving no permanent hardware behind. [company press release, Jan 7, 19]

Osteotech (Eatontown, NJ)

Osteotech (Eatontown, NJ; $200K SBIR) soared 63% after Medtronic said it will buy the , company for about $123 million. ... a provider of human bone and bone-connective tissue used in transplants, has been embroiled in a proxy fight with a dissident shareholder. But Medtronic will pay a 65% premium to Monday's closing price. [Wall Street Journal, Aug 18]

Ostendo Technologies (Carlsbad, CA)

Venture Capital investments in San Diego 3Q2016.    Ostendo Technologies (Carlsbad, CA; one SBIR)  $42 million;  Tealium ( San Diego; no SBIR)  $35 million ; Singlera Genomics   (San Diego, CA; no SBIR) $20 million;  Avelas Biosciences     (San Diego, CA; no SBIR)  $20 million ;  Fortis Therapeutics     (San Diego, CA; no SBIR) $18 million ; Histogen   (San Diego, CA; no SBIR) $16 million ; Medsphere Systems  (Carlsbad, CA; no SBIR) $15 million;  CellSavers  (San Diego, CA; no SBIR) $15 million;  Progenity  (San Diego, CA; no SBIR) $12 million; AristaMD  (San Diego, CA; no SBIR)  $11 million.   [Bruce Bigelow,, Oct 11, 16] 

Ostendo Technologies (Carlsbad, CA; one SBIR) has been awarded a $58.3 million government contract to provide the Air Force with a synthetic-holographic 3D workstation prototype, the Defense Department announced. [Nathan Max,, Aug 24, 12]

Ostendo Technologies CA; one SBIR) has been awarded a $58.3 million [four year] government contract to provide the Air Force with a synthetic-holographic 3D workstation prototype, the Defense Department announced.  [Nathan Marx,, Aug 22, 12]

Osterhout Design Group (San Francisco, CA)

NASA has chosen a virtual and augmented eyeglass platform developed by Osterhout Design Group (San Francisco, CA; no SBIR, founded 1999) to test for possible deployment in space. ... after a year long process of evaluating wearable computing platforms for use by astronauts doing maintenance and other electronic procedures, said [NASA]    [Patrick Hoge, San Francisco Business Times, Mar 12, 15]

OtoNexus Medical Technologies (Seattle, WA)

OtoNexus Medical Technologies (Seattle, WA; no SBIR, founded 2010) is building to sell.  ...  looking for a "short-term exit," CEO Caitlin Cameron said ...  the company's recent achievements include a grant from the National Institutes for Health for about $1.2 million and a grant for an undisclosed amount from the Philadelphia Pediatric Medical Device Consortium, which is a joint partnership between the Food and Drug Administration and the Children's Hospital of Philadelphia. [Coral Garnick, Puget Sound Business Journal, Jun 1, 16]

Otonomy (San Diego,CA)

Otonomy (San Diego, CA; no SBIR) down 83% [Aug 30, 17] revealed that a drug it has been developing for Meniere’s disease, a condition defined by a fluid imbalance in the inner ear, failed badly in Phase 3 testing. ...  The results were so devastating that Otonomy has decided to immediately stop all ongoing tests of Otividex ... The company went public in 2014 in a $100 million IPO   [Ben Fidler,, Aug 30, 17]

Otonomy (San Diego, CA; no SBIR, founded 2008) said that it has raised $100 million in an initial public stock offering. ....  A developer of drugs for middle- and inner-ear diseases, Otonomy's products currently in development include AuriPro, a sustained-release form of the antibiotic ciprofloxacin that's designed to reduce complications in children undergoing ear tube placement surgery.  [Bradley Fikes,, Aug 13, 14]

Otonomy  (San Diego, CA; no SBIR) which has raised $144 million from investors since the biotech was founded in 2008, plans to raise as much as $86 million in an IPO [Alex Lash,, Jul 17, 14]

Otonomy (San Diego, CA; no SBIR, 35 employees) developer of drugs for ear diseases, has raised $49 million from venture capital investors. ... primarily go to three medications that are in different stages of clinical development. .... Last September, the company announced that it had raised $45.9 million.  ... is preparing to file for FDA marketing approval for OTO-201, which is designed for children undergoing ear-tube placement.  [Bradley Fikes,, May 1, 14]

Otonomy (San Diego, CA; no SBIR) a biotech developing therapies for middle and inner ear disorders, has raised $45.9 million in venture funding, the company said .... for late-stage clinical trials of the products. [Bradley Fikes,, Sep 5, 13]

Otonomy (San Diego, CA; no SBIR) has collected an initial round of $10.5 million in venture capital. ...  [has] clearance to start its first clinical trial in people with Meniere’s disease [of the inner ear].  [Luke Timmerman,, Jun 22, 10]

OtoSense (Cambridge, MA)

OtoSense (Cambridge, MA; no SBIR) sound-recognition technology startup, is planning to raise $1.45 million in investor funding, according to a regulatory filing. ...  advanced sound-recognition technology can identify a wide range of sounds including doorbells, dogs barking, alarm clocks, microwave beeps, telephone rings, smoke alarms and more. The technology is embedded into a mobile app for those who are deaf and hard of hearing.  ...  Orange, a European company whose 2013 revenues were about $53 billion, plans to release a home surveillance system later this year with OtoSense's sound-recognition technology integrated into the system's sensors that monitor the house and communicate with a mobile app.  [Sara Castellanos, Boston Business Journal, Feb 10, 15]

Ottomatika (Pittsburgh,PA)

Ottomatika (Pittsburgh, PA; no SBIR) raised $2.6 million from investors, ....  develops technology for advanced driving assistance and autonomous driving features.  ....   created a practical self-driving car that navigated 33 miles of Pittsburgh roadway in September 2013 ...The car, a Cadillac SRX bought off a local lot, was outfitted with sensors, radar, lidar and infrared cameras, and software. [Patty Tascarella,  Pittsburgh Business Times, Nov 19, 14]  

Outset Medical (San Jose, CA)

Outset Medical (San Jose, CA; no SBIR) that makes dialysis equipment it says is far smaller and easier to use than the products of its rivals, closed a dual-stage $91 million equity and debt financing round. ...  "Our plan is to ramp up commercialization pretty rapidly in the next couple of years," [CEO Leslie] Trigg said.   ...  The market for such devices is estimated at $13 billion annually, says investor Warburg Pincus.  [Chris Rauber, San Francisco Business Times, Jun 9, 15]

Medical tech startup Outset Medical (San Jose, CA; no SBIR, founded 2010) raised $60 million in a Series B round to create miniature dialysis machines that one day could be used at home, the company disclosed  [Gina Hall, Silicon Valley Business Journal, May 22, 15]

OvaScience (Boston, MA)

Struggling women’s fertility company Ovascience (founded 2013), which trades at less than $1 a share, will [reverse] merge [with $30M] with Millendo Therapeutics  (Ann Arbor, MI; no SBIR). The combined company will be 80 percent owned by Millendo shareholders and focus on drugs for rare endocrine disorders. [Ben Fidler, Aug 10, 18] 

Semprius& (Durham, NC; $500K SBIR) startup that claims to have developed the world’s most efficient solar panel made a prestigious roster of the most important emerging technologies in the world.- the annual list compiled by [MIT] Technology Review, [on] criterion for emerging technologies: their potential to change the world   ....  has raised $44 million from venture capitalists and Siemens  [John Murawski, Raleigh News & Observer, May 2, 12]  The other nine technologies are:  egg stem cells by OvaScience  (Boston, MA; no SBIR) ;  A camera that lets images be adjusted after the shot by Lytro (Mountain View, CA; no SBIR); solar powered micro-grids by Mera Gao Power (Reusa, India); 3-D transistors by Intel; a faster Fourier transform by MIT; nanopore DNA sequencing by Oxford Nanopore
(Oxford, England); crowd-funding by Kickstarter (New York City); high speed materials discovery by  Wildcat Discovery Technologies (San Diego, CA; no SBIR); and Timeline interface by Facebook.

OvaScience (Cambridge, MA; no SBIR) specializing in fertility treatments, announced that it has completed a $37 million Series B financing.  [Chris Reidy, Boston Globe, Apr 4, 12]

OvaScience  (Boston, MA; no SBIR, founded 2011)  reproductive medicine startup, said a new study has confirmed its potential treatment for infertility.  .... [co-ounnder Dr. Michelle] Dipp expects the company’s product, which will be a mix of a service and the energy-rich mitochondria isolated from the egg stem cell, to initially be used by women who failed IVF a couple times, but eventually by all patients. Following the clinical trial, the company plans launch a product in 2013.   .[Lori Valigra, Mass High Tech, Feb 27, 12]

Ovid Therapeutics (New York, NY )

Ovid Therapeutics (New York, NY; no SBIR) raised $75 million in an IPO, continuing a recent flurry of biotech offerings—among them BioHaven Pharmaceuticals (New Haven, CT; no SBIR) and UroGene Pharma (New York, NY; no SBIR) —that have all met or exceeded their share price projections.  [Ben Fidler,, May 5, 17]

Oxalo Therapeutics (Chicago, IL)

$75K Platinum [MassChallenge] Winner: Oxalo Therapeutics (Chicago, IL; $2.3M SBIR, founded 2017) developing a novel drug to prevent kidney stones using breakthroughs in microbiome research. [BostInno, Oct 17, 18]

biotech Oxalo Therapeutics (Chicago, IL; no SBIR), University of Chicago biotechnology startup is closer to developing a first-of-its-kind drug to prevent kidney stones thanks to $2.3 million from [NIH]. [Stephanie Goldberg, Crain's Chicago Business, Sep 25, 18]

Oxford Performance Materials (South Windsor, CT)

Oxford Performance Materials (South Windsor, CT; no SBIR), which has benefited from Connecticut's support four times since 2001, was celebrated Wednesday by the governor, legislators and Department of Economic and Community Development Commissioner Catherine Smith as the first recipient of the Small Business Express program.  The state has set aside $100 million to lend and give to companies headquartered in Connecticut with fewer than 50 employees who need to buy equipment or have expansion plans that require more employees than current revenue can support. ...focusing on custom-made implants for head and jaw surgeries, which is a much higher margin product than its former line of raw materials for implants. It's not yet turning a profit.   [Mara Lee, Hartford Courant, Jan 18, 12]

Oxis International (Tampa, FL)

Promising anti-cancer immunotherapy technologies developed by a pair of star researchers at the University of Minnesota have been licensed and put on a fast track to commercialization by a veteran biotech entrepreneur Oxis International  (Tampa, FL; no SBIR) .... Vallera’s drug candidate is comprised of antibodies that seek out proteins present on the surfaces of most B-cell lymphoma and leukemia cells and delivers a payload of diphtheria toxin. When OXS-1550 binds to the cancer cells, they internalize the drug and are killed due to the action of the toxic payload.  After the drug demonstrated success in a Phase 1 human clinical trial with B-cell lymphoma/leukemia patients, Oxis launched a Phase 1/Phase 2 trial earlier this year at the Masonic Cancer Center in Minneapolis.  [Don Jacobson, Twin Cities Business, Sep 7, 16]

Oxygen Biotherapeutics (Durham, NC)

drug developer Oxygen Biotherapeutics (Morrisville, NC; no SBIR), which has gone through ups and downs in recent months, [changed] its name to Tenax Therapeutics. ...  About a week ago, the company halted trials testing Oxycyte in humans because it had difficulty enrolling patients.  [Jason deBruyn, Triangle Business Journal, Sep 16, 14] 

Oxygen Biotherapeutics (Morrisville, NC; no SBIR, 12 employees) released results from a clinical trial showing that its lead product under development did not have adverse effects in two series of animal trials.  ....  wants to develop a treatment for traumatic brain injury whereby its product Oxycyte would help deliver oxygen to the brain. ...  part of a $2.1 million grant from the U.S. Army.   [Jason deBruyn, Triangle Business Journal, Sep 23, 13]

Oxygen Biotherapeutics, (Durham, NC; no SBIR, 21 employees) developing products to treat various ailments and injuries by increasing the delivery of oxygen to damaged tissue, filed plans late Friday to raise as much as $75 million by selling more shares. ... has outgrown its space  [Alan Wolf, Raleigh News & Observer, Mar 30, 10]  up 23% [Mar 29]

Oxygen Biotherapeutics (Durham, NC; no SBIR)is in line to receive $6 million from a private placement of securities because the Durham drug development company has advanced its lead drug into clinical trials. [Frank Vinluan, Triangle Business Journal, Sep 8, 09]

<Oyster Point Pharma (Princeton, NJ)

Oyster Point Pharma (Princeton, NJ; no SBIR), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced the pricing of its [IPO] to raise $80M [company press release, Oct 30, 19]

helping small high-tech companies get from idea to market